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Abstract 
Cell growth, the addition of mass and volume, is required for the 
development and homeostasis of all organisms. In mammalian cells, cell growth 
and size homeostasis usually requires an instructive signal in the form of a 
growth factor with loss of this signal resulting in cell atrophy. 
The primary Schwann cell has proven a powerful system to study cell 
growth in vitro – underlining the requirement of growth factors for mammalian 
cells biogenesis. Using this system, IGF-1 was identified as a Schwann cell 
growth factor that drives cell volume addition. In contrast, NRG-1 has no effect 
on Schwann cell volume, but does drive mitochondrial biogenesis - highlighting 
that cell growth can be non-uniform, diverging from the simple coordinate 
addition of volume and organelles.  
In this thesis, I demonstrate that the addition of mass and volume can be 
uncoupled during cell growth. IGF-1 drives coordinate addition of cell mass and 
volume, whereas sustained Raf/MEK/ERK activation drives addition of protein 
mass and specific organelles in the absence of an increase in cell volume. 
Furthermore, the addition of volume can be uncoupled from mass 
accumulation, downstream of IGF-1. This demonstrates that factors other than 
protein mass limit volume addition. 
To investigate the regulation of cell volume I took two approaches: 
Firstly, a cellular approach - comparing plasma membrane dynamics in growing 
and growth factor-starved cells. I show that membrane turnover is extremely 
fast with the whole membrane internalised ~ three times an hour. Moreover, this 
rapid and ATP-dependent rate is maintained in starved, autophagic cells - 
indicating that it is an essential cellular process. The speed of membrane 
turnover however, precluded using this approach to identify how cells deliver 
membrane to the cell surface to drive plasma membrane expansion. Secondly, 
a biochemical approach - to identify important signalling pathways. I identify a 
critical role for de novo lipogenesis for both the addition and maintenance of cell 
volume and SREBP-2 as an essential transcription factor mediating this 
process.  
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Chapter 1: Introduction 
1.1 Introduction to Cell Growth 
 The development and homeostasis of multicellular organisms depends 
on the proper control of cell size and number, which is orchestrated through the 
coordination and regulation of cell growth, cell division and cell survival (Conlon 
and Raff, 1999). Deregulation of any one of these processes can prevent the 
development of a proportionally sized and functional adult as well as cause 
disease, including cancers.  
Mammalian cells usually require instructive signals to grow, divide and 
survive; growth factors are required to drive cell growth, mitogens drive cell 
division and survival factors promote cell survival (Conlon and Raff, 1999). 
Although a single factor may promote more than one of these processes, cell 
growth, division and survival are distinct and can be- and often are- 
independently regulated (Conlon and Raff, 1999, Zetterberg et al., 1984). In 
multicellular organisms such independent control helps provide the flexibility 
necessary to produce the multiple specialised cell types with different sizes, 
numbers and lifetimes the organism needs. In addition, given that cells in 
multicellular organisms are bathed in a nutrient rich environment permissive for 
cell growth, division and survival, the requirement for instructive signals 
prevents uncoordinated cellular and organ growth. In contrast to multicellular 
organisms, unicellular yeast do not require intercellular coordination of growth, 
division and survival. So it is perhaps unsurprising that the regulation of these 
processes in yeast appears to be simpler; the presence of appropriate nutrient 
conditions is sufficient to promote cell growth and division (Grewal and Edgar, 
2003). Whereas the mechanisms and regulation of mammalian cell division and 
survival have been and continue to be heavily researched, the field of cell 
growth remains relatively understudied.  
Cell growth is the addition of mass and/or volume and occurs through the 
addition of cytosol and organelles. Growth must occur in a specific and tightly 
regulated manner to ensure each cell and each cell type in a multicellular 
organism develops and maintains the machinery it requires to function. Growth 
factors drive the addition of mass and volume by activating pathways that 
promote nutrient uptake and stimulate macromolecular synthesis, whilst 
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inhibiting the bulk degradation of cell components by autophagy (Conlon and 
Raff, 1999, Lum et al., 2005a, Rathmell et al., 2000, Wullschleger et al., 2006).  
 
1.2 Schwann Cell Model System 
 The rat primary Schwann cell system used in these studies has several 
properties that make it a powerful system in which to study cell growth (Conlon 
and Raff, 2003, Conlon et al., 2001, Echave et al., 2007, Echave et al., 2009). 
Schwann cells can be cultured indefinitely as primary cells, maintaining genetic 
stability and primary checkpoints- including normal growth control (Mathon et 
al., 2001). This is in contrast to many mammalian cell culture systems, which 
tend to use transformed, immortalised or cancer cell lines that exhibit 
deregulated cell growth, survival and cell-cycle progression.  
Linked to this, as mammalian cells Schwann cells are dependent on 
instructive signals in the form of growth factors, mitogens and survival factors to 
grow, divide and survive, respectively. Schwann cells produce an autocrine 
survival factor that has no effect on division or cell growth (Cheng et al., 1998). 
This, in combination with the fact that defined serum-free Schwann cell culture 
conditions have been developed, means it is possible to maintain Schwann 
cells in conditions free from added growth factors, mitogens and survival 
factors. Such conditions provide a clean background against which to study the 
effects of adding specific extracellular factors or genetic changes on, for 
example, cell growth. 
If cells are dividing it is difficult to dissect the specific effects a factor has 
on cell growth. First, because the growth promoting effects of a factor will be 
spread over an increasing number of cells and, second, because cell 
populations dividing in vitro are asynchronous and differences in cell 
metabolism and biogenesis can be affected by cell cycle stage (Bryan et al., 
2010, Son et al., 2012, Tzur et al., 2009). The second point is particularly 
problematic if the cell cycle distribution between the two populations being 
compared is different. As certain extracellular factors/ genetic changes can be 
both mitogenic and growth promoting, a simple strategy can be used so that the 
effects on cell growth can be studied independently of any effect on cell 
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division; the Schwann cells are cell cycle arrested using the reversible DNA 
polymerase α inhibitor aphidicolin. This induces a G1/S cell cycle arrest, but cell 
growth continues (Collins et al., 2012, Conlon et al., 2001, Conlon and Raff, 
2003, Costa et al., 1992, Echave et al., 2009, Ikegami et al., 1978). 
 
1.3 Cell Growth vs Proliferation 
 As already touched upon, cell growth and proliferation are distinct and 
separable processes. Cell growth is the addition of mass and volume, whereas 
proliferation is the progression through the cell cycle and division to create two 
daughter cells. There are similarities between the regulation of growth and 
proliferation. In mammalian cells, both usually require an instructive signal in 
the form of an extracellular growth factor or mitogen, respectively, and certain 
extracellular factors can act both as a mitogen and a growth factor (Zetterberg 
et al., 1984). Moreover growth and proliferation are often coupled, such as cells 
dividing exponentially in vitro, or in transit amplifying populations in vivo where 
the aim is to produce large numbers of approximately identical cells. However 
the two processes can be separated and are frequently differentially regulated; 
a cell can divide in the absence of growth, as occurs in early zygotic divisions, 
and grow (add mass and volume) in the absence of cell division, as occurs 
during the post-mitotic growth of neurons and muscle (Conlon and Raff, 1999).  
 Furthermore, whereas proliferation is an all or nothing event- a cell is 
either in or out of the cell cycle- the processes that drive cell growth are 
continually active in all cells. Any cell, whether it is adding mass or volume or 
maintaining cell size, undergoes continuous biosynthesis to replace damaged 
macromolecules and organelles and in order to adapt to changing intra- and 
extra- cellular environments and carry out cell-type specific functions. 
Biogenesis is therefore a necessary function in all living cells. In contrast cells 
can- and often will- survive in the absence of proliferation, as evidenced by the 
numerous post-mitotic or quiescent cells in adult mammals in vivo.  
The separation of cell growth and proliferation has been highlighted 
using the Schwann cell experimental system described in Section 1.2. First, 
studies by Conlon et al demonstrated that distinct extracellular factors drive 
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Schwann cell growth (addition of cell volume) and proliferation (Conlon et al., 
2001). They showed that Insulin Like Growth Factor-1 (IGF-1) is a Schwann cell 
growth factor that, alone, has no effect on cell cycle progression. In contrast 
neuregulin (NRG1) is a mitogen, but cannot drive cell volume addition. This 
means that, in the absence of a growth factor such as IGF-1, cells treated with 
NRG1 become progressively smaller as they divide without having added 
volume during the cell cycle (Conlon et al., 2001).  
Subsequent studies showed that the separation of Schwann cell growth 
and proliferation is achieved, at least in part, through differential use of distinct 
signalling pathways. Proliferation depends on signalling through the ERK 
pathway and growth depends on signalling through the PI3K/ Akt pathway 
(Echave et al., 2009). These effects correlate with sustained signalling through 
the two pathways; whereas both IGF-1 and NRG1 transiently activate ERK and 
PI3K/Akt/mTOR signalling to similar and robust levels, proliferation is 
associated with sustained signalling through the ERK pathway and cell volume 
addition with sustained signalling through the PI3K/Akt/mTOR pathway (Echave 
et al., 2009). The importance of these pathways in cell growth will be 
highlighted throughout this Introduction and described specifically in Section 
1.7. However it is worthwhile to note at this point that the PI3K/ Akt/ mTORC1 
pathway has been shown to be important for cell growth in most, if not all, 
systems in which it has been studied (Bohni et al., 1999, Echave et al., 2009, 
Gao and Pan, 2001, Kwon et al., 2001, Leevers et al., 1996, Montagne et al., 
1999, Porstmann et al., 2008, Ruvinsky et al., 2005, Shima et al., 1998, 
Wullschleger et al., 2006).  
A further example that cell growth and proliferation are independently 
regulated can be highlighted using the Schwann cell; although loss of the 
retinoblastoma protein (Rb) drives both Schwann cell growth and proliferation, 
the two processes can be uncoupled. Whereas blocking E2F-dependent 
transcription, which is the best-characterised Rb effector, is sufficient to prevent 
cell cycle progression, it is not sufficient to block cell growth- thus demonstrating 
they are independently regulated (Collins et al., 2012).  
Although cell growth and division are independent processes it is clear 
that proliferation cannot be indefinitely separated from cell growth. At some 
point a cell dividing in the absence of additive growth will become too small and/ 
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or contain insufficient functioning organelles to continue to divide. In this way, 
division may become dependent on growth. In line with this, haematopoietic 
cells that have been growth factor and mitogen starved for a number of weeks 
in vitro will take several days to re-enter the cell cycle after re-stimulation with 
their growth factor and mitogen, interleukin-3 (IL-3), perhaps suggesting they 
need to reach a minimum size/ biogenic capacity for cell cycle progression (Lum 
et al., 2005a). 	  
To summarise: growth (addition of mass and volume) and proliferation 
(progression through the cell cycle) are distinct and separable processes, 
although they may often be coupled. In the Schwann cell at least, the 
separation of growth and proliferation is achieved in part through differential use 
of distinct signalling pathways; ERK drives proliferation and PI3K/ Akt drives 
addition of cell volume. Finally, one of the most striking differences between 
growth and proliferation is that whereas a cell is either in or out of the cell cycle 
and can survive in either context, the biogenic processes that drive cell growth 
must be continuously active in all cells.  
 
1.4 Cell Growth: How is Cell Size Determined? 
Organism size is determined by the balance between the rates of cell 
growth, division and survival (Conlon and Raff, 1999). These are separable 
processes that can be independently regulated, as already discussed. 
However, during the development of multicellular organisms they must be co-
ordinately regulated in order to produce a correctly proportioned adult and this 
appears to be achieved, in part, through the autonomous control of tissue and 
organ size (Conlon and Raff, 1999, Wolpert, 2010). This can include both organ 
intrinsic and extrinsic (systemic) size controls. Murine thymus glands and 
salamander eyes and limbs are examples of organ intrinsic control; if additional 
of these organs are transplanted into donor animals, each will grow to its 
normal adult size (Metcalf, 1963, Potter and Xu, 2001). In contrast, the spleen 
appears to be an example of extrinsic control of organ size; when the equivalent 
experiment is performed with foetal spleens, the total spleen mass will equal 
that of one normal size adult spleen (Metcalf, 1964). The mechanism that exert 
organ size control are poorly understood, however recently the extracellular 
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ligand regulated Salvador Warts Hippo pathway has emerged as an important 
regulator of tissue and organ size in both Drosophila and mammals (Heallen et 
al., 2011, Lee et al., 2010, Pan, 2010, Song et al., 2010). The canonical target 
negatively regulated by this kinase cascade is the transcriptional co-activator 
Yorkie (Yki), in Drosophila, and Yes-associated protein (YAP) or transcriptional 
co-activator with PDZ-binding motif (TAZ), in mammals; phosphorylation by the 
upstream kinase Warts (Drosophila), or Lats1/2 (Mammals) excludes Yki/ YAP/ 
TAZ from the nucleus and can result in their ubiquitination and degradation 
(Pan, 2010). These co-activators promote the expression of genes regulating 
proliferation, e.g. cyclin E, apoptosis, e.g. DIAP1, and growth, e.g. the miRNA 
bantam, to control tissue and organ size (Pan, 2010). This thesis focuses on the 
mechanisms directly regulating cell growth and cell size, however it is important 
to remember that in vivo growth control, including growth factor availability, can 
be determined by the surrounding tissue as well as systemic delivery of 
extracellular factors and nutrients.  
1.4.1 Proliferating cell populations 
Cell size is determined by growth vs. division 
The mean cell size of proliferating cell populations is determined by the 
balance between the rates of cell growth and cell division (Figure 1.1). If one of 
either of these rates is altered the mean cell size of the population will shift to a 
new steady state size that represents the new balance between growth rate and 
cell cycle time. This provides a simple mechanism to vary cell size, which is 
able to produce the multiple cell types of different sizes observed in vivo.  
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The ability to vary cell size by changing the balance between cell cycle 
time and growth rate has been demonstrated in vitro using the Schwann cell. In 
this system, increasing the concentration of the mitogen NRG1 whilst 
maintaining a constant concentration of the growth factor IGF-1 (and thus a 
constant growth rate) drives increasing rates of cell cycle progression and, as a 
result, a decrease in the mean cell size in the population (Conlon et al., 2001). 
In vivo, the developing Drosophila epidermis provides a similar example, 
demonstrating the physiological relevance of this mechanism. In this tissue, 
temporally regulated signalling from mitogens (ecdysone and, later, the 
Epidermal Growth Factor Receptor) and growth factors (insulin) means this 
tissue undergoes an initial period of cell growth in the absence of cell division, 
followed by a reciprocal period of division in the absence of growth before, 
finally, the two processes become coupled (Ninov et al., 2009). As a result cell 
size changes as the epidermis develops.  
Moreover, multiple genetic studies have demonstrated that cell growth 
does not usually depend on cell-cycle progression. Movement through the cell 
cycle in eukaryotic cells is driven by cyclin-dependent kinases (CDKs), which 
are regulated by a number of positive (e.g. cyclins) and negative (e.g. CDK 
inhibitory kinases) signals. This controls the ordered transition from one cell 
cycle phase to the next (G1 to S to G2 to M phase). Numerous studies have 
provided examples where the cell cycle is arrested- as a result of disruption to 
cell cycle machinery- but cell growth continues (Johnston et al., 1977, 
Jorgensen and Tyers, 2004, Neufeld et al., 1998). In the budding yeast 
Saccharomyces cerevisiae, for example, the Cln cyclins (Cln1, 2 and 3) are 
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major regulators of the G1-S phase transition and loss of these genes blocks 
cell cycle progression (Cross, 1990, Nash et al., 1988, Richardson et al., 1989). 
However, cell growth continues. Similarly, in the Drosophila wing, loss of dE2F- 
a transcription factor that drives entry into S phase from G1- or overexpression 
of the dE2F inhibitor dRBP (drosophila retinoblastoma protein) blocks cell cycle 
progression but not cell growth (Neufeld et al., 1998). In both examples, 
because cell growth continued in the absence of cell division, cell size 
increased. Similarly, accelerating rates of cell division by disrupting negative 
regulators of the cell cycle does not necessarily accelerate growth rate. 
Dominant mutations in the Cln cyclins in S. cerevisiae, or overexpression of 
dE2F in the Drosophila wing decrease cell size by enhancing rates of cell cycle 
progression without significantly affecting cell growth rates (Hadwiger et al., 
1989, Neufeld et al., 1998, Sudbery et al., 1980).  
Nonetheless, parts of the cell cycle machinery can regulate both cell 
cycle progression and growth, which may be a way to couple the two processes 
during the proliferative expansion of certain tissues in vivo, when large numbers 
of homogenous cells need to be produced (Fero et al., 1996, Kiyokawa et al., 
1996, Nakayama et al., 1996). Mice that have lost the cell-cycle inhibitor P27 (a 
CDK inhibitor), for example, are significantly larger than their wild type 
counterparts as a result of excessive proliferation, coupled with enhanced cell 
growth. The effect is dose dependent as heterozygous mice are sized midway 
between the wild type and knockout mice and, similarly, the organs most 
affected by the loss are those that express P27 most highly. It is not clear 
whether cell autonomous growth and division rates are elevated in the absence 
of P27, or whether cell growth and division simply persists for longer. The above 
example notwithstanding, like cell cycle rates, cell growth can be accelerated 
without a corresponding acceleration in proliferation. In the Drosophila wing 
disc, for example, overexpression of the critical regulators of cell growth dAkt or 
dMyc increases cell and organ size without affecting cell cycle progression 
(Edgar, 1999, Johnston et al., 1999, Verdu et al., 1999).  
Interestingly, although cell growth does not usually require cell cycle 
progression, growth rates can be affected by cell cycle position. Studies in 
fission yeast (Schizosaccharomyces Pombe), budding yeast (S. cerevisiae) and 
mammalian cells have demonstrated that growth rate varies with cell cycle 
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phase (Bryan et al., 2010, Goranov and Amon, 2010, Son et al., 2012, Tzur et 
al., 2009). In mammalian transformed lymphoblasts and IL3-dependent B cells 
(FL5.12 cell line), G1 growth rates are initially slow and then accelerate rapidly, 
before slowing during S phase and again at the G2-M transition (Son et al., 
2012, Tzur et al., 2009).  
So, although the rates of cell growth and division can be independently 
regulated, in some situations the two processes are interdependent. Linked to 
this, a highly controversial area of research in the cell growth and proliferation 
field has been whether there is control of cell size at division in any one dividing 
cell population. This is the so-called ‘Cell Size Checkpoint’ debate. 
The ‘Cell Size Checkpoint’ debate 
If there is a ‘Cell Size Checkpoint’, it is adaptable and therefore does not 
appear to be intrinsically determined. This is because, as described above, 
changing mitogen and/ or growth factor concentration in mammalian cells can 
change cell size. Similarly, increasing nutrient availability- the primary 
determinant of yeast growth and division rates- increases yeast cell size 
(Jorgensen and Tyers, 2004).  
The requirement for a ‘Cell Size Checkpoint’ centres around whether the 
independent regulation of cell growth and cell division is sufficient to maintain 
the control of cell size in proliferating populations, or whether a mechanism 
must be invoked to ensure a cell only divides when it has reached a certain 
threshold size. Essentially, whether cell growth (growth rate and/ or cell size) 
must regulate cell-cycle progression to control cell size at division. To explain 
this further: consider a steady state proliferating population. It has a constant 
mean cell size. To maintain this stationary state each cell must approximately 
double its mass and volume before dividing. However, there is inevitably 
variability in cell size about the mean across the population. This means there 
are some smaller cells and some larger cells. The theoretical requirement, or 
not, for a Cell Size Checkpoint rests on whether cell growth rates are size 
dependent (so-called ‘exponential’ growth). Specifically, whether larger cells 
grow faster than smaller cells. If they do and there is no control over cell size at 
division then, because there is variation in cell size within a population, the 
largest cells would become ever larger than the smallest cells because they 
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would grow at increasingly faster rates. This would cause cell sizes in the 
population to become increasingly divergent. Therefore, if cell growth rates are 
cell size dependent then maintenance of a constant mean cell size and size 
distribution in the population requires a cell intrinsic ‘Cell Size Checkpoint’ that 
ensures a cell divides when, and only when, it reaches a specified size. In this 
way cells that are smaller at the start of G1 will more than double their mass 
before dividing, whereas cells that are larger would less than double their mass. 
In contrast, if cell growth rates are cell size independent (so-called ‘linear’ 
growth rates) then the mean and variance in cell size of the population can be 
maintained without the need for a size checkpoint. This is because, on average, 
every cell will add the same amount of mass and volume per unit time. So 
across each cell cycle, smaller cells will usually more than double in size and 
larger cells will usually less than double in size. Over time, the size of any larger 
or smaller cell will converge to the population mean, thus maintaining the 
constant mean and distribution of cell sizes in the population- without the need 
for an intrinsic cell size checkpoint (Figure 1.2).  
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The reasoning for larger cells having higher growth rates than smaller 
cells is that larger cells are likely to contain more biosynthetic machinery (e.g. 
ribosomes) and, as a result, carry out higher rates of synthesis and subsequent 
accumulation of mass. Indeed, there is evidence from a number of systems that 
ribosome number and the rate of protein synthesis correlates with cell size 
(Conlon and Raff, 2003, Dolznig et al., 2004, Elliott and McLaughlin, 1978, 
Moore, 1988, Popolo et al., 1982, Zetterberg and Killander, 1965b). However, 
larger cells may also contain more degradative machinery and therefore higher 
rates of degradation might balance the increased rate of synthesis (Conlon and 
Raff, 2003, Dolznig et al., 2004). The mechanistic relationship between 
synthesis, degradation and cell growth rate will be discussed in more detail in 
Section 1.4.3. This Section focuses on the evidence for and against size 
dependent cell growth rates and the existence of a Cell Size Checkpoint.  
There is evidence of size dependent growth rates and a Cell Size 
Checkpoint in yeast (Di Talia et al., 2007, Godin et al., 2010, Johnston et al., 
1977, Jorgensen et al., 2002, Jorgensen et al., 2004, Jorgensen and Tyers, 
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2004, Moore, 1988, Nurse, 1991, Popolo et al., 1982). Studies that have 
quantified cell growth rates at the single cell level- measuring the increase in 
buoyant mass or accumulation of a fluorescent marker of cell protein content- 
have demonstrated that growth rates increase as cell size increases in S. 
cerevisiae (Di Talia et al., 2007, Godin et al., 2010).  
A Cell Size Checkpoint has two key features: a critical size threshold and 
a mechanism to sense when the critical size is reached. In S. cerivisiae, the 
size threshold exists at the end of G1, prior to the onset of S phase (at the 
‘Start’, or ‘Restriction point’, where the cell commits to cell cycle entry) 
(Johnston et al., 1977). The threshold appears to be set- at least in part- by 
nutrient driven ribosome biogenesis, which negatively regulates progression 
through Start (Figure 1.3) (Jorgensen et al., 2002, Jorgensen et al., 2004, 
Jorgensen and Tyers, 2004). In rich nutrient conditions, where rates of 
ribosome biogenesis are high, there is a strong repression of Start and cells 
must reach a larger cell size before this repression is overcome and they pass 
through Start (Jorgensen and Tyers, 2004). Disrupting signalling between 
nutrients and ribosome biogenesis renders cell size insensitive to changes in 
carbon (nutrient) availability, demonstrating this mechanism is essential to 
determine the correct nutrient regulated size threshold (Jorgensen et al., 2004, 
Jorgensen and Tyers, 2004). It remains to be elucidated how ribosome 
biogenesis negatively regulates Start. 
What proxy of cell size do yeast measure to know when the critical size 
threshold has been reached? If cells are treated with sublethal doses of the 
protein synthesis inhibitor cycloheximide they grow to a bigger size and 
accumulate more ribosomes before they pass the threshold (‘Start’). This may 
suggest they ‘monitor’ the rate of protein translation (or a consequence of 
protein translation, e.g. accumulation of a cell cycle regulator) to control entry 
through Start (Figure 1.3) (Jorgensen and Tyers, 2004, Moore, 1988, Popolo et 
al., 1982).  
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Recently, a distinct Cell Size Checkpoint Mechanism based on a 
geometric measure (cell length) has been described in the fission yeast, 
Schizosaccharomyces Pombe. These rod-shaped cells grow by distal extension 
and, in wild type nutrient rich conditions, divide when they have grown to a 
length of 14µm. This cell size threshold is controlled by a spatial gradient of the 
mitotic inhibitor Pom1 kinase that extends from the cell tips, where Pom1 is 
localised, to the middle of the cell, where the mitotic targets of Pom1 are found 
(Figure 1.4) (Martin, 2009, Martin and Berthelot-Grosjean, 2009, Moseley et al., 
2009, Pan and Chang, 2009). When the cell has elongated such that Pom1 
concentration at the centre reaches a critical low, Pom1’s target, the kinase 
Cdr2, is no longer inhibited. Active Cdr2 inhibits Wee1 and thus releases the 
cyclin-dependent kinase Cdk1 from inhibition by Wee1. Cdk1 then drives mitotic 
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entry (Figure 1.4 B). It is not yet understood how Pom1 inhibits Cdr2- whether 
Pom1 phosphorylation inhibits Cdr2 activity, or whether Pom1 regulates Cdr2 
localisation and interaction with Wee1 (Martin, 2009, Martin and Berthelot-
Grosjean, 2009, Moseley et al., 2009, Pan and Chang, 2009). This cell length 
checkpoint mechanism does not exclude the possibility that there is also a link 
to ribosome/ protein synthesis rates in S. pombe. 
 
Whilst there is clear evidence for cell size dependent growth rates and a 
Cell Size Checkpoint in yeast, in mammalian cells the issue remains 
controversial (Conlon et al., 2001, Dolznig et al., 2004, Echave et al., 2007, 
Fantes and Nurse, 1977, Godin et al., 2010, Tzur et al., 2009). Early work 
suggested that the rate of cell growth increased across G1 (Anderson et al., 
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1969, Elliott and McLaughlin, 1978, Killande.D and Zetterbe.A, 1965a, 
Killande.D and Zetterbe.A, 1965b, Zetterberg and Killander, 1965a). Although 
this might reflect size dependent growth rates, it is also possible that growth 
rates are simply regulated by cell cycle stage, independent of cell size. Recent 
studies from the Manalis and Kirschner groups have demonstrated, using 
independent methods, that the growth rate of mouse haematopoietic cells 
appears to be size dependent (Godin et al., 2010, Son et al., 2012, Tzur et al., 
2009). The Manalis group quantified the buoyant mass of single cells of 
different sizes over time and found cell growth rate increased with cell size, i.e. 
growth was exponential (Godin et al., 2010, Son et al., 2012). The Kirschner 
group derived lymphoblast growth rate as a function of cell size from cell 
populations using a mathematical model proposed by Collins and Richmond in 
1962 (Tzur et al., 2009). So, whereas the Manalis group quantified the growth 
rate of single cells, the Kirschner group used the size behaviour of cell 
populations to determine the relationship between cell size and growth rate. 
Both groups reached the same conclusion: cell growth rate increased with cell 
size.  
If mammalian growth rates are size dependent, as suggested by these 
studies, this implies there must be a Cell Size Checkpoint. Interestingly, several 
studies have shown that the variation in cell size (volume or mass) in cell 
populations decreases just prior to the onset of S phase, suggesting that the 
size of the cells entering S phase is regulated- consistent with a Cell Size 
Checkpoint (Killande.D and Zetterbe.A, 1965a, Killande.D and Zetterbe.A, 
1965b, Son et al., 2012). Most interestingly, the recent findings of Son et al 
suggest a possible mechanism by which cells sense when the critical size 
threshold is reached. They find that the variation in growth rate (increase in 
mass per unit time) in both mouse lymphoblasts and IL-2 dependent B cells 
(FL5.12 cell line) constricts to an even greater degree than cell size before cells 
enter S phase (Son et al., 2012). This suggests the cells might monitor growth 
rate (or a consequence of growth rate) as a proxy of cell size to regulate entry 
into S phase, implying that the mechanism may be similar to that in S. 
cerevisiae, which appears to monitor protein synthesis rate (Jorgensen and 
Tyers, 2004, Moore, 1988, Popolo et al., 1982).  
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However, in contrast to haematopoietic cells, evidence suggests 
Schwann cell growth rates are independent of cell size (Conlon and Raff, 2003). 
Conlon and Raff used Schwann cells that were cell cycle arrested in early S 
phase using the DNA polymerase α inhibitor aphidicolin to study rates of cell 
growth independent of cell division and in the absence of confounding effects of 
cell cycle stage on growth rates. They found that the increase in cell volume 
and protein mass of cells growing in the presence of serum was independent of 
cell size: cell volume and protein mass increased linearly over a five-fold 
increase in cell volume measured across 5 days in continuous culture. As 
shown in Figure 1.2, if growth rates are size independent- as suggested by this 
study- there is no need for a Cell Size Checkpoint to maintain constant mean 
cell size in proliferating populations.  
It is possible that in some cell types cell growth rate is size dependent, 
e.g. lymphoblasts, and in other cell types it is not, e.g. Schwann cells. It may be 
relevant that the lymphoblasts and B cells in which size dependent growth rates 
were quantified were transformed or immortalised, whereas the Schwann cells 
are primary cells. It is also possible that the findings of the Schwann cell study 
reflect the cell cycle stage at which the cells were arrested. Given that the cells 
are arrested at the onset of S phase and that Son et al propose that growth 
rates of cells of different sizes converge at the G1-S transition (i.e. growth rates 
become somewhat uncoupled from cell size), it is interesting to speculate 
whether the lack of correlation between Schwann cell size and the rate of mass 
and volume addition was because the cells were arrested at a point where rates 
of cell growth are largely uncoupled from cell size. Further work is required to 
clarify the relationship between cell size and growth rates in mammalian cells.  
The existence of a mammalian Cell Size Checkpoint has also been 
investigated using an alternative approach that is not based on quantifying the 
relationship between growth rate and cell size. Such studies used so-called 
‘Switch’ experiments, where cells are switched between a condition where 
growth and division rates were slower and cells were smaller and a condition 
where growth and division rates were faster and cells were larger (the increase 
in growth rate was greater than the increase in division rate and hence cell size 
increased) (Conlon and Raff, 2003, Dolznig et al., 2004, Echave et al., 2007). If 
a Cell Size Checkpoint exists, the constraints of such a checkpoint mean the 
 	   36	  
new size should be achieved in one cell cycle. This means that when cells are 
switched up from the ‘slow’ to the ‘fast’ condition, the first cell cycle in the ‘fast’ 
condition should be elongated as the cells have to more than double their size 
to reach the new larger size threshold. Conversely, when cells are switched 
down from the ‘fast’ to the ‘slow’ condition, the first cell cycle in the ‘slow’ 
condition should be shortened as cells reach the size threshold before they 
have doubled in size. In contrast, if there is no Cell Size Checkpoint, in both 
cases, the cell growth and division rates should rapidly switch to those of the 
new condition and cell size will gradually adjust to the new mean size over a 
number of cell cycles. Figure 1.5 shows the difference between cell behaviour 
in a switch down if there is (Figure 1.5 A) and is not (Figure 1.5 B) a Cell Size 
Checkpoint. 
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However, these studies have also yielded conflicting findings. In the 
Schwann cell, consistent with the Schwann cell growth rate study, there is no 
evidence to support a Cell Size Checkpoint (Conlon and Raff, 2003, Echave et 
al., 2007). When cells are switched up or down their growth and proliferation 
rates rapidly change in response to changes in the strength of the growth factor 
and mitogenic signals, whereas cell size takes several cell divisions to adjust to 
the new mean size (Echave et al., 2007). In contrast, Dolznig et al found that, 
when erythroblasts are switched down, the duration of the first cell cycle in the 
new condition is shortened and so cell size is rapidly reduced within one cell 
cycle- suggesting the existence of a Cell Size Checkpoint (Dolznig et al., 2004). 
It must be noted that the difference in cell size between the ‘slow’ and ‘fast’ 
growth conditions were smaller in this study than in the Schwann cell studies 
and could be adjusted across one cell cycle with or without the existence of a 
Cell Size Checkpoint. In addition, Dolznig et al used inhibitors to slow rate of 
cell cycle progression and transformed cells to increase the rate of cell cycle 
progression. These factors may have influenced the findings of this paper. 
Based on these growth rate and switch studies, it remains unclear whether 
mammalian cell growth rates are size dependent and whether, or not, there is a 
mammalian Cell Size Checkpoint. 
 To summarise: Mean cell size in proliferating cell populations is 
determined by the balance between rates of cell growth and division, which can 
be independently controlled. It is not clear whether steady state proliferating 
mammalian cell populations also require an intrinsic ‘Cell Size Checkpoint’ that 
regulates cell size at division in order to maintain a constant mean cell size and 
size variance in the population. There is evidence to suggest a checkpoint 
exists in proliferating yeast populations.  
1.4.2 Non-Dividing cell populations 
Determining cell size 
Although many cell types undergo extensive post mitotic growth (the 
most notable examples being skeletal muscle, neurons and myelinating 
Schwann cells) sooner or later non-dividing mammalian cells attain a final cell 
size. This size is often maintained for long periods of time, sometimes even for 
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the remainder of the organism’s lifetime. The question is, how does a cell ‘know’ 
when to stop growing- in other words, how is final cell size determined?  
 The mechanisms regulating this are largely poorly understood, however 
in some cell types, it has been shown that the amount of growth factor signal a 
cell receives determines final cell size. This is nicely demonstrated during the 
development of the peripheral nervous system. Myelinating Schwann cells 
associate with axons in a 1:1 ratio and ensheath the axon in multiple layers of 
myelin membrane, forming the myelin sheath. The thickness of the sheath, and 
therefore the radial growth, of the Schwann cell is determined by the amount of 
growth factor (NRG1 Type III) expressed on the cell surface of the ensheathed 
axon (Michailov et al., 2004, Taveggia et al., 2005). Larger calibre axons 
produce more NRG1 Type III and, as a result, are surrounded by a thicker 
myelin sheath and therefore a larger Schwann cell (Figure 1.6). This is an 
adaptive response because larger axons require a thicker myelin sheath for 
efficient axonal signal transduction. Proving that it is the amount of growth 
factor that determines final Schwann cell size, experimentally manipulating 
NRG1 Type III signalling during myelination is sufficient to change the final size 
of the myelin sheath and the Schwann cell in vitro and in vivo (Garratt et al., 
2000a, Garratt et al., 2000b, La Marca et al., 2011, Michailov et al., 2004, 
Taveggia et al., 2005). It seems to be the amount of axonal NRG1 Type III and 
not the availability of the receptor on the Schwann cell that is limiting in vivo, 
because mice heterozygous for neuronal NRG1 display hypomyelination, 
whereas mice heterozygous for the ErbB2 subunit of the NRG1 receptor, the 
heterodimeric ErbB2/ErbB3 receptor, in the Schwann cell have normal 
myelination (Michailov et al., 2004). NRG1 signalling and therefore Schwann 
cell size is further modified by the activity of BACE1 and TACE, two proteases 
that activate and inactivate, respectively, NRG1 by cleaving distinct sites in the 
extracellular domain of the growth factor (Hu et al., 2008, Hu et al., 2006, La 
Marca et al., 2011). 
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The mechanism by which NRG1 Type III controls Schwann cell size is 
not fully understood, however evidence suggests it is achieved in part by the 
dual regulation of both positive and negative regulators of the biogenic PI3K/ 
Akt/ mTORC1 pathway. So, NRG1 Type III not only activates this pathway, but 
also stabilises the lipid phosphatase PTEN (phosphatase and tensin homolog 
deleted on chromosome 10), a negative regulator of Akt activation, by 
stabilising the PTEN scaffold Dlg1 (discs like homolog 1) (Figure 1.6) (Cotter et 
al., 2010, Macklin, 2010, Maurel and Salzer, 2000). Both the positive (Akt/ 
mTORC1) and negative (Dlg1/PTEN) signals are critical for attaining the correct 
final Schwann cell size (Goebbels et al., 2010, Sherman et al., 2012). 
Figure 1.6 The level of NRG1 Type III growth factor signalling determines 
myelinating Schwann cell size through positive and negative regulation of 
the biogenic Akt pathway
NRG1 Type III expressed by axons determines the thickness of the myelin sheath and,
consequently, final Schwann cell size. This is achieved, at least in part, because the 
NRG1 regulates both activation and attenuation of Akt signalling, which is necesary for
myelination. The schematic shows how the level of axonally expressed NRG1 Type III
regulates the thickness of the myelin sheath:
A) Small calibre axons express low levels of NRG1 Type III resulting in relatively low
level myelination and, consequently, a smaller Schwann cell.
B) Large calibre axons express high levels of NRG1 Type III resulting in more extensive
myelination and a larger Schwann cell. Signalling pathways involved in the control of 
myelination downstream of NRG1 Type III are depicted.  
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Presumably growth is attenuated and final cell size attained when the activity of 
PTEN becomes strong enough to suppress Akt activation (Macklin, 2010). 
Interestingly, Akt/ mTORC1 may not be the only effector downstream of PTEN 
that drives cell growth as expression of constitutively active Akt in Schwann 
cells does not drive hypermyelination, whereas loss of PTEN does (Flores et al., 
2008, Goebbels et al., 2010). How a stronger NRG1 signal drives greater and/ 
or more sustained growth before the inhibitory effect of PTEN blocks further 
growth is not clear.  
This is not the only reported example of a growth factor determining final 
cell size. Nerve Growth Factor (NGF) controls sympathetic neuron size. These 
neurons extend, often very long, axons to innervate their target tissue. Although 
it is target innervation that inhibits further axonal extension, it is the level of 
target derived nerve growth factor (NGF) that determines the extent of axon and 
dendrite branching and therefore final neuron size (Glebova and Ginty, 2004, 
Purves et al., 1988, Snider, 1988, Voyvodic, 1989). This can be demonstrated 
in vivo, as manipulating NGF levels results in a corresponding change in 
neuronal size (Purves et al., 1988).  
It remains to be seen whether growth factor determination of cell size is a 
widespread phenomenon- certainly other signals could also determine final cell 
size. For example, analogous to the limiting growth factor hypothesis described 
above, competition for limiting nutrients may also determine cell size. Nutrient 
dependent regulation of cell growth will be discussed further in Sections 1.8. In 
addition, extrinsic mechanical forces exerted on a cell can also determine cell 
size. This may occur in the form of compressive and extensive forces from 
surrounding tissue; these forces inhibit and promote chondrocyte growth, 
respectively (Villemure and Stokes, 2009). In addition, shear forces from fluid 
flow can also negatively regulate cell growth, as is the case in kidney epithelium 
(Boehlke et al., 2010). In kidney epithelial cells shear stress, sensed by the 
primary cilia (ubiquitous mechanosensory organelles). This activates AMP-
Activated Protein Kinase (AMPK), which inhibits mTORC1 and, as a result, 
inhibits further cell growth and therefore determines final cell size. In the kidney 
fluid flow rate is determined by tubule geometry and is important for maintaining 
efficient filtration of the blood. Therefore, the authors speculate that having cell 
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growth (and therefore tubule geometry) determined by shear stress, i.e. fluid 
flow rate, helps ensure optimal blood filtration.   
Growth factors, nutrient levels and extracellular mechanical forces are all 
examples of how cell extrinsic factors can determine final cell size. However 
final cell size can also be determined by cell intrinsic mechanisms. For example, 
cell ploidy is directly correlated with cell size in all organisms where it has been 
studied (Fankhauser, 1945, Henery et al., 1992, Flemming et al., 2000, Nurse, 
1985). In some cases this relationship is causal; manipulating ploidy in murine 
embryonic cells, salamander larval cells and the hyopdermis of the nematode 
Caenorhabditis elegans induces a corresponding change in cell size, for 
example. Increasing ploidy is not universally sufficient to increase cell size, 
however. In the naturally polyploid cells of the Drosophila muscle wall and 
nematode hypodermis for example, endoreplication is necessary but not 
sufficient to drive cell growth (Demontis and Perrimon, 2009).  
Maintaining cell size 
It is clear that several factors can determine and influence final cell size 
in non-dividing cells. Ultimately final cell size is attained and maintained when 
the rates at which the cell is accumulating/ synthesising material equals the rate 
at which material is degraded/ lost. This means the signal(s) that determine cell 
size must, directly or indirectly, regulate the rates of these processes so that 
they become equal. Irrespective of whether growth factors determine final cell 
size, both cell growth and maintaining mammalian cell size usually require the 
presence of a growth factor signal. One of the primary reasons for this is that 
growth factor activated pathways are required to maintain sufficient nutrient 
uptake to sustain cell metabolism. In the absence of a growth factor signal, cells 
undergo autophagy to provide the energy and substrates to prolong survival 
and, as a result, atrophy (Conlon and Raff, 1999, Echave et al., 2007, Edinger 
and Thompson, 2002, Franklin and Johnson, 1998, Kirkland and Franklin, 2007, 
Lum et al., 2005a, Vander Heiden et al., 2001). 
 It is not clear if the growth factor signal to maintain cell size must be as 
strong as it was during the preceding period of additive growth- given that 
maintaining hyperactive growth factor signalling can cause cell hypertrophy in a 
number of systems (Adams and McCue, 1998, Barton-Davis et al., 1998, Flores 
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et al., 2008, Goebbels et al., 2010, Lupu et al., 2001, Musaro et al., 2001, 
Musaro et al., 1999, Porstmann et al., 2008, Purves et al., 1988, Walenkamp 
and Wit, 2007). Furthermore, in some cases the signal to maintain cell size 
seems to be distinct from the signal that drives the preceding cell growth. In 
myelinating Schwann cells, for example, disrupting NRG1/ ErbB signalling (the 
signal that determines cell size) in the adult after myelination is complete and 
Schwann cells have attained their final size has no effect on myelin sheath 
thickness and Schwann cell size (Atanasoski et al., 2006, Fricker and Bennett, 
2011, Fricker et al., 2011, Garratt et al., 2000a, Garratt et al., 2000b, Michailov 
et al., 2004). Moreover, inhibition of PI3K in myelinated cultures in vitro does 
not induce demyelination, suggesting the intracellular signalling pathways that 
regulate myelin sheath growth and size homeostasis may also be distinct 
(Maurel and Salzer, 2000). What signal maintains cell size homeostasis in the 
adult Schwann cell is not clear.  
 In a subset of Drosophila neurons (class IV dendritic arborisation 
neurons), signals important for maintenance of dendrite size have been 
elucidated (Emoto et al., 2006, Parrish et al., 2007). In these cells the kinase 
Hippo (Hpo) regulates both cell growth and subsequent cell size homeostasis, 
but through distinct downstream effectors (inhibition of the transcriptional co-
activator Yorkie and activation of the Polycomb repressor complex, 
respectively) (Emoto et al., 2006, Parrish et al., 2007). Hippo signalling 
negatively regulates growth and, consistent with this, loss of Hippo during 
development is associated with increased branching and crossing of dendrites 
in these cells (Emoto et al., 2006, Pan, 2007). However, in the mature neuron 
dendrites are not maintained if Hippo signalling is lost (Emoto et al., 2006, 
Parrish et al., 2007). Interestingly, loss of Hippo signalling has no effect on axon 
maintenance in these same neurons, indicating it cannot be the only pathway 
that regulates size maintenance (Emoto et al., 2006). Further studies in other 
cell types are required to determine, first, whether distinct signalling pathways 
are commonly used for cell growth vs size maintenance and, second, whether 
Hippo/Warts signalling (and it’s homologues in other systems) is a common 
regulatory mechanism for cell size maintenance and what other signalling 
pathways also regulate size homeostasis in different contexts.  
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Changing cell size 
Although many non-dividing adult cells can maintain cell size 
homeostasis for long periods of time, this does not mean they are no longer 
receptive to physiological growth stimuli. Skeletal and cardiac muscle cells 
remain incredibly plastic throughout life and grow/ atrophy in response to stimuli 
such as mechanical load and innervation. In skeletal muscle there is some 
understanding of how these signals regulate protein synthesis and degradation 
to regulate cell growth/ atrophy. Reduced mechanical load, i.e. inactivity, or 
denervation leads to skeletal muscle atrophy, primarily through an increase in 
proteasome dependent protein degradation (Bodine et al., 2001a, Jagoe and 
Goldberg, 2001, Medina et al., 1995). Although mechanical load (resistance 
exercise) drives muscle hypertrophy, interestingly, during exercise protein 
synthesis is depressed and there is net loss of mass (Dreyer et al., 2006, 
Williamson et al., 2006). After exercise both protein synthesis and protein 
degradation rates increase, but the increase in synthesis is greater and more 
prolonged than the increase in degradation and therefore muscle mass 
increases (Biolo et al., 1995). Muscle hypertrophy and atrophy (and protein 
synthesis and degradation) are correlated with activation of IGF-1/ PI3K/ Akt 
and mTORC1 signalling in the muscle (Baar and Esser, 1999, Dreyer et al., 
2006, Williamson et al., 2006, Sacheck et al., 2004, Sandri et al., 2004, Stitt et 
al., 2004, Gulve and Dice, 1989, Zdanowicz et al., 1995). Forced activation of 
this pathway drives hypertrophy and prevents atrophy (Barton-Davis et al., 
1998, Bodine et al., 2001b, Glass, 2003, Lai et al., 2004, Musaro et al., 2001, 
Rommel et al., 2001). Akt inhibits protein degradation through inhibition of the 
ubiquitin ligase (Atrogin-1) that labels proteins for proteasome mediated 
degradation (Sacheck et al., 2004, Sandri et al., 2004, Stitt et al., 2004).  
The regenerative capacity of the peripheral nervous system (PNS) after 
injury is another very good example of cells that retain the capacity to grow 
throughout life. Following nerve injury and separation of the axon from its target, 
cell growth is reactivated to drive axon extension to re-innervate the target and 
achieve functional recovery. This regenerative growth depends on the activity of 
the kinase mTORC1 (Section 1.7). Axonal outgrowth is enhanced when 
mTORC1 activity is increased and, reciprocally, is partially blocked if mTORC1 
is inhibited (Abe et al., 2010). Most interestingly, the lack of regenerative 
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capacity in the central nervous system (CNS) seems to be, in part, due to the 
inability to reactivate mTORC1 in neurons after injury; in fact, forced activation 
of mTORC1 in CNS neurons after injury promoted regenerative growth (Liu et 
al., 2010, Park et al., 2008). Interestingly, the findings of Abe et al also highlight 
the importance of appropriate inactivation of regenerative growth- as continued 
mTORC1 hyperactivity drives axonal hypertrophy and incorrect target 
innervation in vivo (Abe et al., 2010). These examples highlight that although 
adult cells may have reached and maintain cell size homeostasis, sometimes 
for long periods of time, many remain receptive and responsive to growth 
stimuli.  
1.4.3 Cell size, growth rates and the underlying rates of synthesis and 
degradation 
 How do growth factors drive growth and set cell size? Cell growth occurs 
when rates of synthesis exceed rates of degradation of cell material. As 
described in Section 1.4.1, cell growth rates may be cell size dependent or 
independent. These two modes of cell growth will require different regulation of 
synthetic and degradative rates- although it is not understood how this is 
achieved, it is possible to model possible mechanisms (Figure 1.7).  
If cell growth rates are cell size independent the simplest situation would 
be for a growth stimulus, e.g. a growth factor, to ‘set’ a rate of synthesis and a 
rate of degradation that do not change with cell size (Figure 1.7 A i). However, 
experimental evidence suggests that, at least for cell protein, this model is 
unlikely. Conlon & Raff found that although the rate of cell volume addition 
during Schwann cell growth is cell size (volume) independent, rates of both 
protein synthesis and protein degradation increase as cell size increases 
(Conlon and Raff, 2003). For this to give a size independent growth rate, the 
rate of synthesis and degradation must increase by the same absolute amount 
per unit increase in cell size.  
If cell growth rates are positively size dependent, so larger cells grow 
faster than smaller cells, the rate of synthesis must increase faster than the rate 
of degradation as cell size increases. Demonstrated in Figure 1.7 are growth 
rates that increase linearly with cell size, which was the relationship Godin et al 
observed for E. coli, S. cerevsiae and mammalian lymphoblasts (Godin et al., 
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2010). However other relationships are possible- growth rates may increase 
exponentially with increases in cell size, for example. Several mechanisms are 
possible to achieve the linear, size dependent growth rate shown in Figure 1.7. 
Rates of degradation may remain unchanged, whilst rates of synthesis increase 
with cell size (Figure 1.7 B i). Alternatively, both may increase but the increase 
in synthetic rate is greater than the increase in degradation rate (Figure 1.7 B ii). 
An interesting third possible mechanism is that the fold-change in each rate per 
unit increase in cell size is equivalent (Figure 1.7 B iii). In this case, because the 
rate of synthesis exceeds the rate of degradation at any size, an equivalent 
fold-change in both rates means the rate of synthesis increases by a greater 
absolute amount than the rate of degradation. This means that as cell size 
increases, the difference between the rate of synthesis and degradation, i.e. the 
growth rate, increases. 
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Interestingly, there is evidence to suggest that protein synthesis and 
degradation are coupled downstream of growth factor (NGF) signals in 
sympathetic neurons (Franklin and Johnson, 1998, Kirkland and Franklin, 
2007). In the presence of NGF, suppressing protein synthesis using mild doses 
of the protein synthesis inhibitor cycloheximide led to a corresponding decrease 
in the rate of protein degradation (Kirkland and Franklin, 2007). As a result, 
neurite outgrowth continued and did not slow. The authors proposed that this 
coupling mechanism helps ensure cell growth can be maintained at a constant 
rate in spite of natural stochastic fluctuations that are likely to occur in the 
absolute rate of both these processes.   
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Figure  1.7  Cell  growth  rates  are  determined  by  the  underlying  rates  of  
synthesis  and  degradation
Cell  growth  rates  are  determined  by  the  underlying  rates  of  synthesis  vs  degradation.  Shown  
are  possible  mechanisms  to  ensure  a:
A)  Size  independent  growth  rate.
B)  Linear  and  positively  size  dependent  growth  rate.
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1.5 Cell Size: Macromolecule Addition, Water Uptake & 
Organelle Biogenesis 
 The size of the cell, in other words its mass and volume, is determined 
by the amount of organelles and cytosol contained within the plasma 
membrane. Breaking this down further, cell size is largely the sum of the water 
and macromolecules that constitute the cytosol, organelles and plasma 
membrane. Therefore, to understand the control of cell growth and cell size, it is 
necessary to understand how biogenic stimuli regulate macromolecular and 
water accumulation and organelle biogenesis. 
1.5.1 Macromolecule Addition: Protein  
Cellular Protein 
 Proteins are fundamental cell macromolecules. They comprise more than 
50% of the dry mass of the cell and are essential as structural elements within 
the cell (e.g. cytoskeletal actin), as well as being major signalling molecules and 
effectors for most cell functions (as enzymes- kinases, phosphatases, 
hydrolases and so on) (Alberts, 2002). The cell can acquire the amino acid 
monomers for protein synthesis by uptake of exogenous amino acids via amino 
acid transporters in the plasma membrane (Palacin et al., 1998). Of the 20 
amino acids, 9 are essential in human cells and therefore can only be obtained 
in this way. The remaining 11 amino acids can be obtained by uptake or 
synthesised de novo from Tricarboxylic Acid (TCA) cycle intermediates in the 
mitochondria. In addition, amino acids released when intracellular proteins are 
degraded can be recycled in de novo protein synthesis. Amino acids can also 
be oxidised to generate cellular energy- the mechanism/ pathway by which this 
catabolism occurs varies depending on the amino acid (Alberts, 2002).  
Protein Synthesis and Degradation 
Ribosomes translate mRNA into protein by catalysing the successive 
addition of amino acids, via the formation of high-energy peptide bonds, to form 
a polypeptide chain. The translation of most mRNAs requires at least 9 
eukaryotic initiation factors and involves the formation of an initiation complex at 
the 5’-cap of the mRNA (Jackson et al., 2010). This complex ‘scans’ the 5’-UTR 
of the mRNA until it reaches an initiation codon, at which point the remaining 
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ribosomal subunit joins the complex and translation begins. The translation of a 
fraction of mRNAs, at least in some conditions, is mediated not via this 
‘scanning’ mechanism (Jackson et al., 2010). Instead, Internal Ribosome Entry 
Sites (IRES), sequences within the mRNA, directly recruit the ribosome, 
bypassing the 5’-cap. Translation elongation requires two elongation factors 
(eEF1 and eEF2) that mediate the codon-by-codon movement of the ribosome 
along the mRNA (Jackson et al., 2010).  
 Protein degradation occurs by one of two mechanisms: ubiquitin-
dependent proteasomal degradation, or lysosomal degradation. A large 
proportion of nascent proteins are rapidly degraded by the proteasome because 
they have not been properly synthesised, including truncated polypeptide 
chains and misfolded proteins (Buchberger et al., 2010). The double-membrane 
bound lysosomes contain a variety of hydrolytic enzymes to catalyse the 
breakdown of cell components- including proteases, which hydrolyse proteins 
into their constituent amino acids. Lysosomes catalyse the degradation of bulk 
cellular components downstream of the autophagy pathway (Mizushima, 2007). 
In addition, certain proteins are selectively taken up and degraded by the 
lysosome (Dice, 1990). 
Regulation of Protein Biogenesis & Cell Growth 
Given that proteins are major structural, signalling and enzymatic 
components of the cell they are, unsurprisingly, essential for cell growth. As 
described in Section 1.4.2 ‘Changing cell size’, dynamic control of protein 
synthesis and degradation rates downstream of growth and atrophy signals 
(e.g. IGF-1 and denervation, respectively) appear to underly the remarkable 
plasticity in skeletal muscle size (Medina et al., 1995, Sandri et al., 2004, Stitt et 
al., 2004, Lecker et al., 1999, Davis and Fiorotto, 2009, Kimball, 2002, 
Williamson et al., 2006). Moreover, cells and organisms with mutations in genes 
involved in protein synthesis display reduced cell growth (Grewal et al., 2005, 
Jorgensen et al., 2002, Jorgensen et al., 2004, Oliver et al., 2004). Simply 
blocking protein synthesis is somewhat of a sledgehammer approach to 
demonstrate the importance of protein biogenesis in cell growth, however it is 
effective. Protein synthesis requires a large investment of cellular energy and 
biosynthetic resources, which is due in large part to ribosome biogenesis. This 
in itself requires the coordination of all three RNA polymerases, the synthesis of 
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79 ribosomal proteins and the sum action of more than 200 proteins (Rudra and 
Warner, 2004). Rapidly proliferating HeLa cells produce ~7500 ribosomes a 
minute, which is estimated to require the synthesis of ~300,000 proteins, and 
yeast rDNA transcription is thought to constitute 60% of the total transcription in 
the cell (Warner, 1999, Mayer and Grummt, 2006).  
With the above points in mind, it is perhaps unsurprising that global protein 
synthesis is tightly regulated by the factors that regulate cell growth and 
biogenesis. This is partly achieved by regulating the rate of ribosome 
biogenesis, which is closely coupled to the rate of protein synthesis in order to 
prevent waste of cell energy and substrates (amino acids, nucleotides e.t.c) 
(van Riggelen et al., 2010, Wullschleger et al., 2006, Hardie, 2011). It is also 
achieved through the regulation of protein translation rates, which occurs 
primarily at the level of translation initiation (Jackson et al., 2010). It must be 
noted that, in addition to the mechanisms described here that concern how 
global protein turnover is regulated, individual proteins are also subject to 
specific control of their transcription, translation and degradation rates.  
Growth factors promote protein synthesis both by increasing nutrient uptake, 
and therefore amino acid availability, and by positively regulating ribosome 
biogenesis and translation initiation. One of the major effectors of growth factor 
activated protein synthesis is mTORC1. As already described, mTORC1 is a 
central regulator of cell growth and, as such, regulates many aspects of 
biogenesis and bioenergetics (Porstmann et al., 2009, Wullschleger et al., 
2006). Protein synthesis is regulated at multiple levels by mTORC1, or its 
homologues in other organisms. Quantifying the rate of 35S-Methionine 
incorporation into nascent protein in the presence and absence of mTORC1 
inhibition demonstrated that loss of signalling through this pathway reduces 
protein synthesis, although the kinetics of this can vary in different cell types 
(Herbert et al., 2000, Wang et al., 2000, Hsieh et al., 2012, Thoreen et al., 
2012, Thoreen et al., 2009). At the transcriptional level mTORC1 activates all 
three RNA polymerases, which are required for ribosome biogenesis (Mayer 
and Grummt, 2006, Claypool et al., 2004, Grewal et al., 2007, Guertin et al., 
2006, Hannan et al., 2003, Mayer et al., 2004). At the translational level; 
inhibiting mTORC1 appears to supress the translation of almost all mRNAs. A 
subset of mRNAs are especially sensitive to mTORC1 inhibition- namely those 
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containing pyrimidine rich 5’-TOP, or TOP-like sequences (Hsieh et al., 2012, 
Thoreen et al., 2012). These genes mainly encode proteins involved in protein 
synthesis, including ribosomal genes, and their enhanced downregulation is 
likely to amplify the suppression of protein synthesis upon mTORC1 inhibition. It 
was thought that mTORC1 dependent control of translation was mediated by 
the p70 S6 Kinases (S6K), however subsequent studies did not support this 
and, recently it was shown that mTORC1 controls translation initiation via 
negative regulation of 4EBP1, an inhibitor of cap-dependent translation (Hsieh 
et al., 2012, Jefferies et al., 1997, Pende et al., 2004, Thoreen et al., 2012) 
A number of other metabolic/ biogenic stimuli in addition to growth factors 
regulate mTORC1 activity, including amino acid availability; amino acid 
deprivation inhibits mTORC1 activation (Kim et al., 2002, Nicklin et al., 2009). 
This is dominant to growth factor regulation, which presumably ensures that 
translation does not begin when it cannot be completed due to lack of 
substrates and conserves a large amount of cellular resources through the 
particular suppression of ribosome biogenesis. In addition, amino acid 
deprivation also inhibits protein synthesis independent of mTORC1, by 
activating GCN2, an inhibitory kinase of the translation initiation factor eIF2α. 
Both these mechanisms are described in more detail in Sections 1.8 & 1.9, 
where nutrient regulation of cell growth is discussed.  
In addition to mTORC1, other growth factor activated signalling pathways 
also regulate protein synthesis to promote cell growth (James and Zomerdijk, 
2004, Roux et al., 2007, van Riggelen et al., 2010). Of particular importance, 
Myc dependent cell growth is characterised by an increase in protein synthesis 
associated with an increase in rRNA, ribosome and nucleolar density (Grewal et 
al., 2005, Iritani and Eisenman, 1999, Johnston et al., 1999, Kim et al., 2000, 
Pierce et al., 2004, Schreiber-Agus et al., 1997, Schuhmacher et al., 1999, Wu 
and Johnston, 2010). 
As well as increasing protein synthesis, growth factors can also promote 
protein accumulation by suppressing protein degradation. IGF-1 drives muscle 
growth in part by suppressing Atrogin-1 mediated proteasome dependent 
degradation, downstream of PI3K/ Akt, as described in Section 1.4.2 ‘Changing 
Cell Size’ (Sacheck et al., 2004, Sandri et al., 2004, Stitt et al., 2004). Although 
many of the biogenic effects of PI3K/ Akt are mediated by mTORC1, this 
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function is mTORC1 independent. Enhanced proteasomal degradation 
underlies muscle atrophy and Atrogin-1 knockout mice exhibit decreased 
atrophy after denervation, therefore suppression of this degradative pathway is 
likely to be an important mechanism for IGF-1/ Akt mediated muscle growth 
(Sandri et al., 2004, Stitt et al., 2004, Bodine et al., 2001a).  
Although growth factors may suppress protein degradation rates, this 
does not preclude that (limited) protein degradation is necessary during cell 
growth- for example to clear effete proteins and organelles, preventing them 
accumulating and potentially inhibiting functional growth. Indeed, in skeletal 
muscle, inhibiting autophagy and therefore bulk degradation leads to muscle 
atrophy (Masiero and Sandri, 2010). The role of protein degradation in cell 
growth has been best studied in neuronal cells and remains controversial. 
Some studies found that proteasomal degradation was required for neurite 
outgrowth and/ or axonal extension, whereas other studies found that inhibiting 
proteasome dependent degradation enhanced these processes (Inoue et al., 
2004, Kavakebi et al., 2005, Laser et al., 2003, Song et al., 2009, Verma et al., 
2005). The conflicting findings of these studies may be explained by differences 
in type of neuron and/ or growth conditions, as well as the differentiation state of 
the cell during the study. This may indicate that cells have different 
requirements for degradative machinery during different stages and types of cell 
growth.  
In summary: proteins are a major cellular macromolecule, playing 
essential structural and functional roles within the cell. As such, protein function 
is inevitably necessary for cell growth. Protein turnover is dynamically controlled 
downstream of positive and negative growth stimuli, two of the most notable 
being growth factors and amino acid deprivation, respectively. The kinase 
mTORC1 regulates protein biogenesis downstream of both these stimuli, 
although mTORC1 independent pathways are also significant. The importance 
of protein turnover in cell growth is particularly apparent in skeletal muscle, 
where the control of protein turnover is a significant determinant in the growth/ 
atrophy of this tissue in response to positive/ negative extracellular stimuli.   
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1.5.2 Macromolecule Addition: Lipid 
Cellular Lipids 
 Lipids are a critical cell component and have numerous functions; they 
are the primary constituents of all biological membranes, they are the cell’s 
major energy storage molecule, they are the basis of certain post-translational 
protein modifications and, finally, a number of lipids are signalling molecules. 
Numerous classes of lipids are found in the cell and each performs specific 
functions. Phospholipids form the basis of cell membranes and cholesterol, 
glycolipids, sphingolipids and ether lipids are all also important membrane 
lipids. Triacylgycerols (TAGs) and sterol esters are the main lipid storage 
molecules and other lipids, as well as derivatives of the aforementioned lipids, 
act as signalling molecules. Across these classes more than 1000 lipid species 
are found within the cell (Sleight, 1987). The basic building blocks of all higher 
order lipids are fatty acids and/ or sterols. 
Lipid metabolism is very dynamic- the acyl groups of triacylglycerols and 
phospholipids are highly labile and undergo continual turnover and remodelling. 
There is also constant so-called ‘futile cycling’ of TAGs into free fatty acids and 
glycerol and back again (Watt and Steinberg, 2008). Compared to protein, 
where there is distinct degradative machinery, lipid breakdown is less defined- 
lipases facilitate remodelling, as well as complete breakdown, of lipid species. 
There is some evidence that the rates of phosphatidylcholine (PC) synthesis 
and degradation are coupled to maintain correct cellular levels of PC (Walkey et 
al., 1994, Baburina and Jackowski, 1999). There is also evidence that the 
turnover of different lipids can be coupled- namely PC and cholesterol, the two 
major components of the plasma membrane (Kellner-Weibel et al., 1998, 
Shiratori et al., 1994). This may facilitate the maintenance of correct membrane 
lipid composition, which is vital for proper membrane function. Changes in 
composition alter the physical properties of the membrane, e.g. fluidity, and this 
can, amongst other things, affect the organisation and function of membrane 
proteins (Spector and Yorek, 1985). 
Several organelles play a direct role in cell lipid metabolism. Fatty acid 
and sterol synthesis occurs in the cytoplasm via substrates from the 
mitochondria and the peroxisomes. Then, the smooth endoplasmic reticulum, 
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lipid droplets and cis-Golgi are all sites of synthesis and modification of one or 
more higher order lipids. Breakdown and remodelling of phospholipids can 
occur in the cell membranes they are part of and triacylglycerols are broken 
down on lipid droplets and in the lysosome. The fatty acid precursors of higher 
order lipids are oxidised in the mitochondria and/ or peroxisomes, depending on 
the fatty acid. 
Uptake of exogenous lipids 
 In vivo, most mammalian cells acquire most of their lipids from uptake of 
exogenous lipids from the circulation. In the absence of sufficient exogenous 
lipid, cells carry out de novo fatty acid and sterol synthesis to provide the 
precursors for higher order lipogenesis however, in most adult cell types the 
rate of de novo lipogenesis is low. Notable exceptions are adipocytes and 
hepatocytes, which convert excess carbohydrate from the diet into storage 
lipids via de novo fatty acid and sterol synthesis, and steroid-hormone 
producing cells, such as the testis. 
Lipoproteins and free fatty acids bound to albumin are the primary 
circulating lipids (Shen et al., 1977, Spector et al., 1980). Circulating free fatty 
acids are taken up both by passive diffusion across the membrane and 
facilitated protein-mediated transport. Once inside the cell free fatty acids are 
converted with the addition of a CoA molecule and can enter metabolic and 
signalling pathways. Lipoproteins have a neutral lipid core, containing varying 
amounts of TAGs and cholesteryl esters (depending on the type of lipoprotein) 
and this is surrounded by a monolayer of phospholipid and cholesterol studded 
with apolipoproteins (Shen et al., 1977). TAGs are primarily found in Very Low-
Density Lipoproteins (vLDL); cell surface lipoprotein lipases hydrolyse the TAGs 
at the extracellular side of the plasma membrane and a small proportion of the 
released fatty acids are taken up by the cell directly- the remainder become 
bound to albumin and continue to circulate (Goldberg et al., 2009). Cholesterol 
is mainly found circulating as Low-Density Lipoproteins (LDL) that are 
recognised by cell-surface LDL receptors (LDLR), internalised by endocytosis 
and delivered to the lysosome where they are hydrolysed by lysosomal lipases 
to release free cholesterol and fatty acids that can be used by the cell (Jeon 
and Blacklow, 2005). 
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De novo fatty acid and sterol synthesis 
The carbon backbone for de novo fatty acid and sterol synthesis comes 
from cytoplasmic acetyl-CoA, which is derived primarily from mitochondrial 
citrate, a tricarboxylic acid cycle intermediate (Lynen, 1966). Fatty acid and 
sterol synthesis also requires reducing power, in the form of nicotinamide 
adenine dinucleotide phosphate (NADPH), and ATP. Citrate transporters export 
citrate from the mitochondria to the cytosol where it is hydrolysed to acetyl-CoA 
and oxaloacetate by the enzyme ATP-Citrate Lyase (ACLY). The cytosolic 
acetyl-CoA can then be used for fatty acid or sterol synthesis. 
During the synthesis of fatty acids, acetyl-CoA is carboxylated to 
malonyl-CoA by the enzyme acetyl-CoA carboxylase (ACC); this is the 
committed step of fatty acid synthesis. One molecule of malonyl-CoA and one 
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molecule of acetyl-CoA then react in a condensation reaction catalysed by the 
enzyme Fatty Acid Synthase (FASN), yielding a four-carbon product. This then 
undergoes successive rounds of addition of the 2-carbon malonyl-CoA 
molecules via FASN mediated condensation reactions to yield the 16-carbon 
straight chain saturated (i.e. no double bonds in the carbon backbone) fatty acid 
palmitate (Figure 1.8) (Wakil et al., 1983). Desaturation of fatty acids occurs by 
desaturase enzymes. 
In cholesterol synthesis one molecule of acetyl-CoA reacts in a 
condensation reaction with one molecule of acetoacetyl-CoA (synthesised from 
acetyl-CoA by the action of the enzyme thiolase) in a condensation reaction 
catalysed by the enzyme HMG-CoA synthase 1 (HMGCS1). This produces 3-
hydroxy-3-methylglutaryl-CoA (HMGCoA), which is then reduced to mevalonate 
by the action of HMGCoA reductase (HMGCoR). In a series of three reactions, 
6 molecules of mevalonate react to produce one molecule of lanosterol and this 
is then converted to cholesterol in a series of 19 reactions (Figure 1.8) (Rudney 
and Sexton, 1986). HMGCoR is the rate-limiting enzyme for cholesterol 
biosynthesis. 
Regulation of de novo fatty acid and sterol synthesis 
The SREBPs are basic helix-loop-helix-leucine zipper (bHLH-Zip) 
transcription factors (Bengoechea-Alonso and Ericsson, 2007). Two genes 
encode three isoforms of the protein; the SREBF1 gene encodes SREBP-1a 
and -1c (also known in rat as adipocyte determination and differentiation factor 
1, or ADD1) that differ in their first exon as a result of alternative transcriptional 
start sites and the SREBF2 gene encodes SREBP-2 (Bengoechea-Alonso and 
Ericsson, 2007, Hua et al., 1996, Eberle et al., 2004, Yokoyama et al., 1993). 
The three proteins share a high degree of homology and a common domain 
structure- an N-terminal transactivation domain followed by a DNA binding 
domain, two transmembrane domains and a C-terminal regulatory region- and 
all bind as homodimers to sterol regulatory elements (SRE) and certain E-boxes 
in the promoters of target genes (Figure 1.9) (Amemiya-Kudo et al., 2002, 
Shimano, 2001, Sato et al., 1994). 
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The SREBPs regulate the genes involved in de novo fatty acid and 
cholesterol synthesis. In many cell types, SREBP-1c primarily regulates the 
genes involved in fatty acid synthesis (e.g. FASN & ACC), SREBP-2 primarily 
regulates the genes involved in cholesterol synthesis (e.g. HMGCoR) and 
SREBP-1a regulates both subsets (Amemiya-Kudo et al., 2002, Horton et al., 
2002, Horton et al., 2003b, Shimano et al., 1997a, Horton et al., 2003a). 
SREBP-1c and -2 are also SREBP targets as they contain SREs in their 
promoters (Horton et al., 2003a). There appears to be differences in SREBP-1 
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isoform expression in vivo and in vitro. In vivo most tissues seem to express 
higher levels of SREBP-1c compared to SREBP-1a (Shimomura et al., 1997b, 
de Preux et al., 2007). In contrast, in vitro SREBP-1a appears to be the major 
expressed isoform- in cells derived from a variety of tissues including those 
assayed in vivo (Shimomura et al., 1997b). The reason for this is not clear. 
In addition to their well-characterised role driving de novo fatty acid and 
sterol synthesis, the SREBPs also regulate wider cell metabolism, seemingly to 
facilitate lipogenesis. The SREBPs promote the expression of glucose-6-
phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the oxidative 
branch of the pentose phosphate pathway, for example, which produces 
NADPH to provide the reducing power for processes including de novo 
lipogenesis (Duvel et al., 2010, Liang et al., 2002, Shimano et al., 1999). 
Furthermore, the SREBPs promote the synthesis of the major cell membrane 
phospholipid, phosphatidylcholine (PC), by activating gene expression of both 
pathways the cell uses to synthesise PC (as well as by providing the substrates 
for PC synthesis via de novo fatty acid synthesis) (Ridgway and Lagace, 2003, 
Walker et al., 2011, Kast et al., 2001). Interestingly, the SREBPs also drive 
expression of the LDL receptor, which, by facilitating uptake of exogenous lipid 
(namely cholesterol), reduces the need for the cell to carry out the metabolically 
expensive SREBP driven process of de novo lipogenesis (Horton et al., 2002). 
Aside from metabolic targets, the cell cycle inhibitor p21 is also a direct SREBP 
transcriptional target; moreover overexpression of SREBP-1 can drive cell cycle 
arrest and senescence in different cell types (Inoue et al., 2005, Kim et al., 
2010, Nakakuki et al., 2007). 
Although the SREBPs are sensitive to distinct, although sometimes 
overlapping, upstream regulation, they are processed via essentially identical 
pathways to give the mature active protein. All three SREBP isoforms are 
synthesised as inactive precursors that localise to the endoplasmic reticulum 
(ER) membrane where they are found in complex with SREBP cleavage 
activating protein (SCAP) via an interaction between the C-termini of both 
proteins (Sakai et al., 1997). Forming a complex with SCAP is necessary for the 
ER-to-Golgi translocation of SREBP in COPII coated vesicles (DeBose-Boyd et 
al., 1999, Matsuda et al., 2001, Sakai et al., 1998, Sun et al., 2005). In the Golgi 
SREBP undergoes two successive proteolytic cleavages catalysed by the site-1 
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and site-2 proteases (S1P and S2P), two resident Golgi membrane proteins 
(DeBose-Boyd et al., 1999, Duncan et al., 1997, Duncan et al., 1998). This 
releases the mature active N-terminal region of the SREBP protein (mSREBP, 
~490 amino acids), which then translocates to the nucleus, binds to the 
promoter of target genes and activates transcription (Figure 1.10). It is thought 
that having a precursor pool translated and held in the ER allows the cell to 
respond rapidly to a requirement for fatty acid and sterol synthesis through 
rapid activation of the SREBPs. 
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Figure 1.10 Sterol-dependent processing of the inactive ER-bound 
precursor SREBP proteins to generate the mature active transcription 
factor
Schematic of the sterol-dependent regulation of the SREBP proteins.
A) In high sterol conditions cholesterol binds to SCAP, which changes the conformation of the 
protein and facilitates the binding of oxysterol-bound INSIG to the SREBP-SCAP complex. As a 
result, the SREBP-SCAP is retained in the ER. 
B) In low sterol conditions, where cholesterol is not associated to SCAP and oxysterols are not 
bound to INSIG, INSIG cannot bind to SCAP. This allows the SREBP-SCAP complex to interact 
and become incorporated in COPII vesicles that carry the complex to the Golgi. In the Golgi 
S1P and S2P proteases cleave the full-length precursor SREBP protein to release the mature 
N-terminal SREBP protein (mSREBP) that can then translocate to the nucleus and regulate the 
transcription of target genes.
SCAP
60
 	   61	  
There is careful feedback control on SREBP processing (and therefore 
activation) by the products of de novo fatty acid and sterol synthesis, which 
likely helps conserve cellular resources as de novo lipogenesis is metabolically 
costly (Hannah et al., 2001, Takeuchi et al., 2010, Walker et al., 2011, 
Shimomura et al., 1997a). The feedback inhibition mechanism is best 
understood for sterol dependent regulation of SREBP processing. When sterol 
levels in the cell rise, the level of sterols in the ER membrane increases. 
Cholesterol binds to the sterol-sensing domain of SCAP, which induces a 
conformational change in the protein and allows oxysterol bound Insulin-
Induced Gene 1 or 2 (INSIG1 or 2) to bind to the SREBP-SCAP complex 
(Motamed et al., 2011, Radhakrishnan et al., 2007, Radhakrishnan et al., 2004, 
Yabe et al., 2002, Yang et al., 2002). This prevents the export of SCAP/ SREBP 
to the Golgi, the proteolytic steps that generate the mature, active nuclear 
SREBP protein and therefore activation of de novo lipogenesis (including sterol 
synthesis) (Espenshade et al., 2002, Goldstein et al., 2006, Sun et al., 2005, 
Sun et al., 2007, Yabe et al., 2002, Yang et al., 2002).  
Conversely, when sterol levels are low INSIGs cannot bind to SCAP and 
subsequent translocation and processing of SREBP is facilitated (Gong et al., 
2006, Yabe et al., 2002, Yang et al., 2002). Moreover, the stability of the 
INSIGs is decreased when they are not bound to SCAP and so INSIG levels in 
the ER fall, which further helps to sustain the ER-to-Golgi transport of the 
SREBP-SCAP complex. Interestingly, whereas SREBP-2 seems to be sterol 
regulated in all cell types where it has been studied, both in vitro and in vivo, 
there are cell type and/ or in vitro to in vivo differences in the sterol sensitivity of 
SREBP-1. In HeLa cells, primary fibroblasts and primary endothelial cells in 
vitro, SREBP-1 processing increases upon sterol deprivation. However, in 
mouse and hamster liver in vivo sterol deprivation actually leads to a decline in 
SREBP-1 levels, concomitant with the increase in SREBP-2 (Du et al., 2006, 
Sheng et al., 1995, Shimomura et al., 1997b, Wang et al., 1994, Zhou et al., 
2004). The reason for this is not clear- it may reflect coordination between 
levels of fatty acids and sterols so that sterol synthesis is preferentially activated 
over and above fatty acid synthesis when sterol levels fall. 
Unsaturated fatty acids and phosphatidylcholine (PC) also regulate 
SREBP processing. Unsaturated fatty acids block nuclear SREBP accumulation 
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at least in part by increasing the stability of INSIG1 (Hannah et al., 2001, Lee et 
al., 2008, Yabe et al., 2002, Yellaturu et al., 2009a). Phosphatidylcholine (PC) 
depletion activates processing of SREBP-1, but not SREBP-2 (Walker et al., 
2011). How this specificity is achieved is not known.  
Once in the nucleus, DNA binding stimulates GSK3 dependent 
phosphorylation, FbW7 mediated ubiquitination and rapid proteasome 
dependent degradation of the SREBP- thus attenuating SREBP activity (Hirano 
et al., 2001, Punga et al., 2006, Sundqvist et al., 2005, Sundqvist and Ericsson, 
2003). SREBP activity requires coactivators and recruitment of the coactivator 
p300/CBP helps stabilise SREBP by acetylation (Giandomenico et al., 2003). 
Therefore the balance between activity dependent phosphorylation, 
ubiquitination and p300/ CBP dependent acetylation will help determine SREBP 
stability and therefore net activity, i.e. expression of target genes.  
Lipogenesis in cell growth 
 As cells grow and increase in volume and mass it is inevitable that they 
use lipids for membrane biogenesis. This is highlighted dramatically during 
Schwann cell myelination- in rodents, Schwann cell myelin membrane surface 
expands by up to ~10,000 fold in the first 10 weeks of postnatal life (Webster, 
1971). Unsurprisingly, this requires SREBP dependent lipogenesis and 
expression of the SREBPs and their downstream lipogenic targets peaks in the 
myelinating Schwann cell during active myelination (Verheijen et al., 2009, 
Leblanc et al., 2005).  
As would be expected, lipogenesis has been shown to be necessary for 
growth in a number of systems. Lipogenesis is necessary for the growth of 
several rapidly growing and proliferating tumour cell model systems (Bauer et 
al., 2005, Brusselmans et al., 2005, Hatzivassiliou et al., 2005, Kim et al., 2010, 
Kuhajda et al., 2000, Menendez and Lupu, 2007, Porstmann et al., 2005, 
Porstmann et al., 2008). In addition, organ and cell size is reduced in 
Drosophila lacking dSREBP and, as a result, de novo lipogenesis (Porstmann 
et al., 2008). In fact, driving constitutive SREBP activity is sufficient to drive the 
growth of certain cell types in vivo; transgenic mice overexpressing nuclear 
SREBP-1a or -1c in the liver, or -1a in adipocytes develop marked hypertrophy 
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of the respective tissues (Horton et al., 2003b, Kotzka et al., 2012, Shimano et 
al., 1997a).  
 Consistent with a role for lipogenesis in cell growth, growth factor and 
growth factor activated signalling pathways positively regulate both lipoprotein 
uptake and de novo lipogenesis (Duvel et al., 2010, Li et al., 2010, Peterson et 
al., 2011, Porstmann et al., 2005, Porstmann et al., 2008, Smith et al., 2008, 
Yellaturu et al., 2009a, Du et al., 2006, Luu et al., 2012, Demoulin et al., 2004, 
Hegarty et al., 2005, Zhou et al., 2004). This is most well described for the 
insulin/ IGF-1 and the downstream PI3K/ Akt/ mTORC1 pathway. In fact, 
constitutively active Akt is sufficient to drive addition of cell volume in human 
retinal epithelial cells, dependent on the SREBPs and de novo lipogenesis 
(Porstmann et al., 2005).  The mechanism(s) by which these signals activate 
SREBP dependent transcription and de novo lipogenesis is not always 
completely understood, however it is clear they activate SREBP maturation 
from the precursor form, as well as alter the stability and transcriptional activity 
of the mature proteins (Duvel et al., 2010, Li et al., 2010, Peterson et al., 2011, 
Porstmann et al., 2005, Porstmann et al., 2008, Smith et al., 2008, Yellaturu et 
al., 2009a, Du et al., 2006, Luu et al., 2012, Yellaturu et al., 2009b, Hegarty et 
al., 2005).  
The best understood example of extracellular factor driven SREBP 
maturation seems to be the action of insulin on SREBP-1c in hepatocytes. In 
these cells insulin drives two PI3K/ Akt dependent mechanisms: first, 
phosphorylation of the SREBP-1c precursor and, second, downregulation of the 
liver specific isoform of INSIG (INSIG2a). Both of these events enhance the 
interaction between the SREBP-1c/ SCAP complex and COPII and therefore 
increases the rate of ER-to-Golgi transport and subsequent cleavage and 
activation of SREBP-1c (Yellaturu et al., 2009a, Yellaturu et al., 2009b, Yecies 
et al., 2011). Although similar mechanisms may operate in other cell types, 
INSIG2A is a liver specific INSIG isoform. This highlights another key point- it 
seems the SREBPs exhibit cell type specific responses to growth factor/ Akt 
activation. For example, Akt appears to drive SREBP-2 processing in some cell 
types and not others (Chinese Hamster Ovary (CHO) cells and HepG2 
hepatocytes vs. human retinal epithelial cells, respectively) (Du et al., 2006, Luu 
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et al., 2012, Porstmann et al., 2005, Porstmann et al., 2008). What underlies 
these differences is not clear.  
In addition to the PI3K/Akt pathway, insulin and IGF-1 also activate 
MAPK ERK signalling and insulin can drive ERK dependent phosphorylation on 
SREBP-1a and -2, which increases SREBP transcriptional activity (Kotzka et 
al., 2004, Kotzka et al., 2000, Roth et al., 2000). This occurs, at least in part, 
because the phosphorylation inhibits SREBP sumoylation; sumoylation 
promotes recruitment of a HDAC3 co-repressor complex to the SREBP and 
subsequent repression of SREBP dependent transcription (Arito et al., 2008, 
Hirano et al., 2003). 
Recently, a particularly novel mechanism of SREBP-1 regulation has 
been discovered downstream of mTORC1; mTORC1 regulates hepatic SREBP 
nuclear localisation and activity by phosphorylating and blocking the nuclear 
accumulation of the multifunctional protein, lipin1 (Peterson et al., 2011). 
Nuclear lipin1 excludes SREBP from the nucleus thus blocking its activity. It will 
be interesting to determine whether this mechanism is universal, or specific to 
hepatocytes, which have a particularly dynamic function in organism lipid 
metabolism and homeostasis. 
1.5.3 Water Uptake 
Approximately 70% of a cell’s weight is water (Luby-Phelps, 2000); some 
of this exists as free water and the rest is in hydration complexes with 
intracellular ions and organic molecules. Water is not just the medium in which 
cytoplasmic contents are held and reactions carried out- it is also a participant 
in many cellular reactions. It is required for hydrolytic reactions, including the 
catabolic degradation of macromolecules, and is produced in condensation 
reactions, including the anabolic synthesis of protein, carbohydrates and lipids. 
Water is taken up and lost by mammalian cells, according to the osmotic 
pressure gradient across the plasma membrane, both as a result of passive 
diffusion across the plasma membrane and facilitated transport through water 
channels, otherwise known as aquaporins (King et al., 2004, Verkman, 2011). 
So far 13 aquaporins have been identified in humans (Verkman, 2011).  
 The regulation of cell volume is critical for cell function and survival. 
Water movement into and out of the cell has the capacity to dramatically 
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change cell volume in a short space of time and so it is unsurprising that it is 
tightly regulated. Cell shrinking and swelling caused by inappropriate water 
movement affects, among other things, membrane integrity (by disrupting 
cell:cell junctions and membrane structure) and cytosolic protein function (by 
affecting the concentration and proximity of proteins in the cytosol) (Lang, 
2007).  
 The relationship between cell volume and cell water content has been 
studied primarily with respect to how water movement is regulated to maintain a 
constant cell volume. To avoid shrinking or swelling a cell must maintain 
osmotic equilibrium across the plasma membrane. This is an active process 
because extracellular and intracellular osmolarity both undergo constant 
fluctuations. For some cells these fluctuations are very large; in the kidney 
medulla, for example, extracellular osmolarity can fluctuate approximately 4-fold 
away from isotonicity (~300mmol/L to 1400mmol/L) in a matter of hours (Lang, 
2007, Lang et al., 1998). Most cell types experience milder fluctuations in intra- 
and extra- cellular osmolarity. When intra- or extra- cellular osmolarity changes 
it creates an osmotic pressure gradient across the plasma membrane. This 
drives a net movement of water across the membrane to restore the osmotic 
equilibrium across the membrane, which causes the cell to shrink/ swell 
according to whether the cell had become hypo-/ hyper- tonic to the 
surrounding medium. ‘Sensors’ detect this change and trigger the cell to adjust 
its intracellular osmolarity to reverse the osmotic gradient and subsequent 
change in cell volume (so-called Regulatory Volume Increase/ Decrease) 
(Lang, 2007). The ‘sensors’ that detect the change in cell volume are not clear, 
although numerous, not necessarily mutually exclusive, models have been 
proposed and they all have a certain amount of supporting evidence. The 
proposed mechanisms include detection of changes in membrane tension, 
cytosolic pH (swelling acidifies the cytosol) and macromolecular crowding 
(changes in the properties and behaviour of molecules at high concentrations) 
(Burg, 2000, Lang, 2007, Lang et al., 1998). The cell adjusts its intracellular 
osmolarity through movement of ions into/ out of the cytoplasm, primarily 
through regulating plasma membrane ion channels, and the uptake and 
synthesis/ release and degradation of organic osmolytes, as appropriate (Burg 
and Ferraris, 2008, Lang, 2007). Whilst it is clear that water movement across 
the plasma membrane is carefully regulated to control cell volume, how water 
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uptake is controlled as cells add volume during cell growth- and how this relates 
to the biogenic aspects of cell growth- is not clear. 
1.5.4 Organelle Biogenesis and Uniform and Non-Uniform Cell Growth 
Cell mass and volume represents the sum of the cell organelles and 
cytosol. Unsurprisingly, given the energetic and biosynthetic investment 
required, organelle biogenesis is a carefully regulated process, according to the 
needs of the cell. It is also complex, requiring the coordinated synthesis and 
localisation of multiple component molecules.  
There is a basal rate of organelle biogenesis in all cells to replace certain 
organelles or organelle sub-structures that have worn out and been degraded, 
usually by autophagy. Turnover can also be an integral part of a structure’s 
function. This is perhaps best demonstrated by the plasma membrane. The 
plasma membrane forms the barrier between the intra- and extra- cellular 
environments, protecting the integrity of the cytosol. However, as the interface 
between these two environments, it is also necessarily the site of 
communication and substance exchange between them (Conner and Schmid, 
2003). This means the plasma membrane has essential roles in cell signalling, 
nutrient uptake, cell surface homeostasis, migration, adhesion and, where 
appropriate, cell surface polarisation (Conner and Schmid, 2003). As a result, 
the plasma membrane is incredibly dynamic, constantly turning over in order to 
perform each of these functions.  As with all cellular structures, the size of the 
plasma membrane will depend on the balance between the rates of 
accumulation and loss of material. 
Cell organelle content can also rapidly change in response to specific 
stimuli. Given that growth factors drive cell growth, it is unsurprising to find that 
growth factor activated signalling pathways drive organelle biogenesis. In the 
Schwann cell, activation of both the PI3K and ERK signalling pathways is 
required for IGF-1 and NRG1 dependent mitochondrial biogenesis, mediated by 
the transcription factor, estrogen-related receptor alpha (ERRα) (Echave et al., 
2009). Similarly, mTORC1 has been shown to drive mitochondrial gene 
expression by promoting the formation and activity of a transcription factor 
complex containing the transcription factor Yin-Yang 1 (YY1) and the 
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transcriptional co-activator peroxisome-proliferator-activated receptor co-
activator alpha (PGC1-α) (Cunningham et al., 2007). 
There are examples where there is coordinated addition of cell mass, 
volume and organelles during cell growth. In steady state proliferating cell 
populations described in Section 1.4.1, for example, each cell will roughly 
double its mass, volume and organelle content across each cell cycle before 
dividing to produce two daughter cells with an approximately equivalent 
composition to the starting mother cell. However, considering the diversity in 
cell size, morphology and organelle content across different cell types in vivo, 
as well as across the lifetime of individual cell types, it is clear that non-uniform 
cell growth is a frequent event- where one or more parts of the cell, be it 
molecule or organelle, grows at a different rate to the rest of the cell. Differential 
cell growth ensures cells are adapted to their specific function. Adipocytes, for 
example, develop large lipid droplets that occupy a large proportion of the 
cytosol, which means they are effective lipid storage sites. In contrast, skeletal 
muscle cells have few small lipid droplets but have extensive mitochondria, 
which enable the cells to produce large amounts of ATP to drive muscle 
function. Moreover, an increase or decrease in muscle use leads to a 
corresponding change in the amount of mitochondria per cell, demonstrating 
how morphological changes (growth) can allow a cell to adapt to environmental 
changes.  
Non-uniform cell growth is particularly well demonstrated by examples of 
differential organelle biogenesis within a single cell type. B cells, for example, 
pass through two distinct phases of organelle biogenesis after they are 
activated in an immune response. Initially there is an increase in cell volume, 
accompanied by a large increase in cytosolic ribosome density and 
mitochondrial size, as well as partial expansion of the endoplasmic reticulum 
(ER) (Shohat et al., 1973). This is followed by a disproportionate expansion of 
the ER compared to cell volume such that the ER fills the majority of the cytosol 
(Kirk et al., 2010, Shohat et al., 1973). During this time, cytosolic ribosome 
numbers fall, ribosomes become associated with the expanding ER and there is 
no further increase in mitochondrial size (Kirk et al., 2010, Shohat et al., 1973). 
The expansion of the ER is required for the mature plasma cell to synthesise 
and secrete large amounts of immunoglobulins and is a clear example where 
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differential organelle biogenesis is critical for the cell to perform its function 
(Federovitch et al., 2005, Rush et al., 1991). 
Distinct growth stimuli appear to be able to control differential organelle 
biogenesis, for example. In the Schwann cell, IGF-1 drives a proportional 
increase in cell and mitochondrial volume. In contrast, IGF-1 and NRG1 
synergise to increase mitochondrial volume, whilst cell volume is equivalent to 
in the presence of IGF-1 alone- and therefore mitochondrial density increases 
(Echave et al., 2009). This example is especially noteworthy because NRG1, as 
described in Section 1.3, was not classically described as a Schwann cell 
growth factor because it does not induce cell volume addition. However the 
mitochondrial finding clearly demonstrates that NRG1 has biogenic capabilities 
and therefore could be described as a growth factor. This is particularly 
interesting because it highlights that cell growth needs to be considered in a 
more sophisticated manner than simply the addition of cell volume.  
 
1.6 Growth Factor Regulation of Cell Growth 
 The emphasis on growth factors throughout this Introduction will have 
highlighted their key features. Namely; growth factors are required for 
mammalian cell growth (the addition of cell mass and volume), can determine 
final cell size and are also required to maintain cell size homeostasis. Cell 
growth control is the control of the rates of accumulation and loss of intracellular 
contents. Therefore, unsurprisingly, growth factors regulate cell growth by 
promoting accumulation (by driving expression of nutrient transporters and 
anabolic pathways, i.e. the uptake and synthesis of material) and suppressing 
bulk loss (by suppressing catabolic pathways such as autophagy) (Conlon et 
al., 2001, Edinger and Thompson, 2002, Vander Heiden et al., 2001, Luu et al., 
2012, Sacheck et al., 2004, Stitt et al., 2004).  
Many growth factors act through Receptor Tyrosine Kinases (RTKs), 
including IGF-1, NGF and the NRGs that have been used to describe growth 
factor functions in preceding sections. RTKs are integral plasma membrane 
proteins with an extracellular ligand binding domain, a transmembrane domain 
and a cytoplasmic domain (Lemmon and Schlessinger, 2010). Binding of the 
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extracellular growth factor to its cognate receptor drives a structural change in 
the receptor, inducing autophosphorylation on one or more tyrosine residues in 
the intracellular domain of the protein. This facilitates the recruitment of adapter 
proteins that bind to the activated intracellular domain of the receptor and lead 
to activation of the downstream signalling pathways.  
IGF-1 and its homologues are perhaps the best-characterised growth 
factors- driving growth in diverse organisms, from Drosophila to mammals 
(Laron, 2004, Chen et al., 1996, Lupu et al., 2001). Indeed, Growth Hormone 
(GH), which regulates much of post-natal developmental growth in mammals, 
does so in large part through stimulating production of IGF-1 (Conlon and Raff, 
1999). The IGF-1 Receptor (IGF1R) is a heterotetrameric protein consisting on 
two α and two β chains, that form the extracellular ligand (IGF-1) binding and 
transmembrane and intracellular kinase domains of the oligomer, respectively 
(Manning and Cantley, 2007, Tognon and Sorensen, 2012). Binding of IGF-1 to 
the receptor results in the transphosporylation of tyrosine residues in the 
activation loop of the receptor, followed by further phosphorylation of specific 
tyrosine residues in the intracellular domain of the protein. This phosphorylation 
allows the binding of adapter proteins and the activation of downstream 
signalling pathways (Figure 1.11). For example, PI3K is recruited to the IGF1R 
via the insulin receptor substrate adapter proteins (IRS1-4), as well as through 
direct binding to the C-terminal domain of the receptor. This recruits PI3K to the 
plasma membrane where it can phosphorylate phosphatidylinositol (4,5)-
bisphosphate (PIP2) to generate PI(3,4,5)P3 (PIP3), resulting in activation of Akt 
and downstream signalling (Manning and Cantley, 2007). ERK signalling is also 
activated downstream of IGF-1. In the canonical pathway, this is via recruitment 
of src homology 2 containing transforming protein (Shc), growth factor receptor 
bound protein-2 (Grb2) and the Ras guanine exchange factor, Sons of 
sevenless (SOS), which can then activate the membrane anchored small GTP-
ase Ras and, downstream of this, the MAPK ERK cascade. Activated Ras can 
also activate PI3K that has been recruited to the IGF1R, via PI3Ks catalytic 
subunit. 
Loss of IGF-1 signalling during development leads to impaired growth 
and dwarfism and, reciprocally, high levels of circulating IGF-1 contribute to 
excess growth and resulting gigantism (Laron, 2004, Lupu et al., 2001, 
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Walenkamp and Wit, 2007). The primary intracellular signalling pathway IGF-1 
(as well as other growth factors) activates to drive cell growth is the PI3K/ Akt/ 
mTORC1 pathway (Demoulin et al., 2004, Hegarty et al., 2005, Zhou et al., 
2004, Rommel et al., 2001, Sacheck et al., 2004, Macklin, 2010). The role of 
PI3K/Akt, mTORC1 and other growth factor activated signalling pathways is 
discussed in the following Section. 
 
1.7 Signalling Pathways Regulating Cell Growth 
1.7.1 PI3K/ Akt Dependent Cell Growth 
In vitro and in vivo studies in every system studied show that signalling 
through this pathway drives cell growth and hyper-/ hypo- activation of Akt 
drives cell hyper-/ hypo- trophy in a number of different models (Chan et al., 
2011, Collins et al., 2012, Echave et al., 2009, Flores et al., 2008, Lai et al., 
2004, Leevers et al., 1996, Maurel and Salzer, 2000, Peng et al., 2003, 
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Porstmann et al., 2005, Porstmann et al., 2008). In addition to cell growth, the 
PI3K/ Akt pathway also promotes cell survival, proliferation and migration 
(Manning and Cantley, 2007, Kockel et al., 2010).  
Akt (also known as protein kinase B, PKB) binds to the PIP3 generated 
by PI3K activity via its pleckstrin homology (PH) domain (Figure 1.12) (Manning 
and Cantley, 2007). Once at the plasma membrane Akt is activated by 
phosphorylation at two sites, by distinct kinases; PDK1 (phosphatidylinositol-
dependent kinase-1) on threonine 308 and mTORC2 on serine 473 (Alessi et 
al., 1997, Sarbassov et al., 2005b). PI3K signalling is antagonised by the lipid 
phosphatase PTEN that dephosphorylates PIP3 to PIP2  (Song et al., 2012). Akt 
is an AGC family serine-threonine kinase and there are 3 mammalian isoforms 
of the protein, encoded by different genes (Akt1, Akt2, Akt3). As already 
described, mTORC1 is the major downstream effector of Akt in promoting cell 
growth. Activated mTORC1 activates a negative feedback loop to attenuate 
IGF-1/ PI3K signalling by phosphorylating (directly and indirectly) insulin 
receptor substrate-1 (IRS-1), which promotes its degradation (Manning and 
Cantley, 2007). In addition, the mTORC1 effector S6 Kinase (S6K) can 
phosphorylate and inhibit the Rictor subunit of the mTORC2 complex (Dibble et 
al., 2009, Julien et al., 2010). It seems likely these negative feedback loops help 
prevent hyperactivation of the PI3K pathway in response to growth factor 
stimulation. 
Akt promotes nutrient uptake by increasing the cell surface expression 
and/ or activity of glucose, amino acid, transferrin and lipoprotein receptors 
(Edinger and Thompson, 2002, Elstrom et al., 2004, Manning and Cantley, 
2007, Plas et al., 2001, Wieman et al., 2007). Once inside the cell, these 
nutrients are used in Akt driven metabolism; for example for de novo biogenesis 
or proteins and lipids from nutrient-derived mitochondrial precursors (as 
described in Sections 1.5.1 & 1.5.2) (Elstrom et al., 2004, Hagiwara et al., 2012, 
Manning and Cantley, 2007, Porstmann et al., 2008, Wise et al., 2008).  
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The mTORC1 pathway is a critical downstream effector of Akt induced 
cell growth and signalling through this pathway will be discussed in more detail 
in the following Section. However, Akt also regulates mTORC1-independent 
targets to drive cell growth (Berwick et al., 2002, Chan et al., 2011, Luu et al., 
2012, Porstmann et al., 2008, Sandri et al., 2004, Stitt et al., 2004, Wieman et 
al., 2007, Yecies et al., 2011). These include the FOXO transcription factors 
and the kinase glycogen synthase kinase 3 (GSK3β), which are both inhibited 
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by Akt phosphorylation and both have roles in Akt dependent cell growth and 
metabolism (Manning and Cantley, 2007, Porstmann et al., 2008, Sandri et al., 
2004, Stitt et al., 2004, Sundqvist et al., 2005). Inhibition of FOXO1, for 
example, is required for the Akt dependent inhibition of Atrogin-1 and, as a 
result, proteasomal degradation (Sandri et al., 2004, Stitt et al., 2004).  
Both mTORC1 dependent and independent effects are apparent across 
all the metabolic pathways regulated by Akt- often converging on the regulation 
on the same protein. For example, in the haematopoietic FL5.12 cell line, Akt 
promotes mTORC1-independent expression of the Glut1 glucose transporter at 
the cell surface (Wieman et al., 2007). However, mTORC1 potentiates the 
activity of the transporter (Wieman et al., 2007). Similarly, as described in 
Section 1.5.2, Akt drives mTORC1-dependent processing and activation of the 
master regulators of lipogenesis, the SREBPs, but mTORC1-independent 
stabilisation of the active SREBPs (Luu et al., 2012, Porstmann et al., 2008). 
Moreover, mTORC1 is not sufficient to drive hepatic lipogenesis in vivo in the 
absence of Akt (Wan et al., 2011, Yecies et al., 2011). This appears to be, at 
least in part, because Akt is required to downregulate the negative regulator of 
SREBP processing and activation, INSIG2A (Yecies et al., 2011). 
 Interestingly, there are findings that suggest PI3K/ Akt is required for 
biogenesis even under conditions where the pathway is not activated i.e. 
signalling is at basal/ control levels. In the Schwann cell, for example, loss of Rb 
drives cell growth in the absence of PI3K/ Akt/ mTORC1 activation (Collins et 
al., 2012). However, inhibiting PI3K blocks Rb dependent cell volume addition 
(Collins et al., 2012). Similarly, expression of Myc in immortalised human 
fibroblasts does not activate Akt, however Akt is required for Myc to drive rRNA 
transcription (Chan et al., 2011). This suggests basal flux through the PI3K/ Akt 
pathway may be required for cell growth and biogenesis, even where the 
pathway itself is not the driving force. 
1.7.2 mTORC1 Signalling  
 The mTOR kinase is found in two distinct multi-subunit complexes in the 
cell, mTORC1 and mTORC2 (Laplante and Sabatini, 2012, Zhou and Huang, 
2010). Both complexes contain the mTOR kinase, but differ in other subunits- 
most notably Raptor and Rictor, present in mTORC1 and 2, respectively. 
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Studies using the inhibitor Rapamycin that directly inhibits mTORC1 but not 
mTORC2 (via interaction with Raptor), as well siRNA mediated silencing and 
knock-outs of complex specific subunits have demonstrated that the two 
complexes have distinct regulatory inputs and functions (Laplante and Sabatini, 
2012, Zhou and Huang, 2010). In contrast to mTORC1, mTORC2 is not 
considered a major regulator of cell growth and biogenesis- although the 
complex is one of the kinases that phosphorylates and activates Akt at the 
plasma membrane (Sarbassov et al., 2005a, Wullschleger et al., 2006, Zhou 
and Huang, 2010). Confirming that mTORC1 is a critical mediator of PI3K/ Akt 
dependent cell growth, inhibiting mTORC1 blocks PI3K/ Akt mediated cell 
growth in numerous systems (Goebbels et al., 2010, Meikle et al., 2008, 
Narayanan et al., 2009, Porstmann et al., 2005, Zhou et al., 2009).  
mTORC1 is activated by the GTP-bound form of the small GTPase 
Rheb. This is inhibited by the TSC1/TSC2 complex, which acts as a Rheb 
GTPase-activating protein (GAP) (Huang and Manning, 2008). Numerous 
upstream signals converge to regulate mTORC1, highlighting that it is a central 
node in cellular signalling (Sengupta et al., 2010), These include growth factors, 
amino acid availability and cellular energy and oxygen levels. Many of these act 
by regulating the activity of the TSC1/ TSC2 complex. Extracellular factors 
primarily regulate mTORC1 signalling via Akt, which phosphorylates and 
inactivates two negative regulators of mTORC1, PRAS40 and TSC2 (Inoki et 
al., 2002, Oshiro et al., 2007, Potter et al., 2002, Sancak et al., 2007, Vander 
Haar et al., 2007). ERK can also inhibit TSC2 as well as phosphorylate the 
Raptor subunit of mTORC1, potentiating the activity of the complex (Carriere et 
al., 2008, Carriere et al., 2011, Ma et al., 2005, Rolfe et al., 2005, Winter et al., 
2011). Amino acid availability regulates mTORC1 activation by controlling the 
localisation of the complex and therefore the interaction with its activator, Rheb 
(Discussed in more detail in Sections 1.8 and 1.9) (Inoki et al., 2003a, Kim et 
al., 2008a, Sancak et al., 2010, Sancak et al., 2008, Kim et al., 2012, Zoncu et 
al., 2011). Amino acid availability is dominant to growth factor signalling, which 
likely ensures protein synthesis is not activated when substrates are limiting. 
Cellular energy deprivation (also discussed in more detail in Section 1.9) and 
hypoxia also inhibit mTORC1 (Sengupta et al., 2010). Within the mTORC1 
complex; phosphatidic acid can stabilise the complex by binding to Raptor and 
there is mutual inhibition between the mTOR subunit and a recently discovered 
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subunit Deptor- although the physiological significance of this interaction is not 
yet fully understood (Foster, 2009, Peterson et al., 2009).   
mTORC1 promotes cell growth and biogenesis via a number of 
mechanisms, as has been detailed through this Introduction. The roles of 
mTORC1 in protein synthesis and lipogenesis have been described in detail in 
Sections 1.5.1 and 1.5.2. mTORC1 also promotes the synthesis of ATP, 
NADPH and precursors for such macromolecular synthesis by promoting 
nutrient uptake, activating the pentose phosphate pathway, increasing glycolytic 
flux and promoting mitochondrial gene expression (Cunningham et al., 2007, 
Duvel et al., 2010, Edinger and Thompson, 2002, Grewal et al., 2007, Laplante 
and Sabatini, 2010, Mayer and Grummt, 2006, Peterson et al., 2011, 
Porstmann et al., 2008, Schieke et al., 2006, Thoreen et al., 2012, Wullschleger 
et al., 2006). For example, mTORC1 has been shown to promote glucose 
uptake and glycolysis study in mouse embryonic fibroblasts (MEFs) in vitro via 
activation of the transcription factor hypoxia inducible factor 1α (HIF1α) and the 
pentose phosphate pathway via activation of the SREBPs (Duvel et al., 2010). 
In addition to these biosynthetic and bioenergetics functions, mTORC1 further 
promotes an anabolic phenotype by suppressing bulk degradation by 
autophagy (Jung et al., 2010, Kim et al., 2011). This is mediated, at least in 
part, by direct phosphorylation of Ulk1, a kinase that drives autophagy initiation 
(Kim et al., 2011). The fact mTORC1 regulates multiple aspects of cell 
metabolism can provide a way to coordinate biogenesis downstream of positive 
and negative metabolic stimuli. 
The S6 kinases (S6K1/2) and 4EBP proteins (4EBP1/2) are the best 
known mTORC1 substrates and are activated and inhibited, respectively, by 
mTORC1 phosphorylation (Fingar et al., 2002, Sengupta et al., 2010). These 
substrates mediate the effects of mTORC1 on protein synthesis. S6K promotes 
mRNA processing, translation elongation and ribosome biogenesis through 
regulation of the mRNA processing protein SKAR, eukaryotic elongations 
factors and the ribosomal protein S6, respectively (Laplante and Sabatini, 
2012). Inhibition of 4EBP1 promotes cap-dependent translation initiation (Hsieh 
et al., 2012, Thoreen et al., 2012). Consistent with an important role for S6K 
and 4EBP downstream of mTORC1, disrupting signalling through each can 
inhibit and promotes cell growth, respectively (Miron et al., 2001, Sarbassov et 
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al., 2005a). Some functions of mTORC1 are known to be independent of these 
effectors; for example, mTORC1 phosphorylates and inhibits Ulk1, a component 
of the autophagy machinery, to inhibit autophagy and lipin1 to regulate SREBP 
activity and the de novo lipogenic pathway (Kim et al., 2011, Peterson et al., 
2011). 
1.7.3 ERK1/2 Dependent Cell Growth 
 The Raf/ MEK/ ERK MAP kinase (MAPK) cascade has been implicated 
in the regulation of diverse cellular processes including proliferation, 
differentiation, survival and migration. Raf kinase is activated by the small 
GTPase Ras downstream of extracellular factor receptors, including Receptor 
Tyrosine Kinases and G-Protein Coupled Receptors (Mendoza et al., 2011). 
Activated Raf phosphorylates and activates the MAPK kinases MEK1/2, which 
in turn phosphorylate and activate the MAPKs ERK1/2. Activated ERK 
phosphorylates and regulates a number of cytosolic (e.g. p90 ribosomal S6 
kinase (RSK)) and nuclear (e.g. c-Fos) targets and there is evidence to suggest 
the two ERKs (ERK1 and ERK2) have distinct cellular functions (Lloyd, 2006, 
Yoon and Seger, 2006). 
 The cellular response to ERK in a number of systems seems to depend 
on the kinetics and strength of the ERK signal (Marshall, 1995). For example, in 
the neuronal PC12 cell line sustained and strong ERK activation drives 
differentiation, whereas transient ERK signalling is associated with proliferation 
(Marshall, 1995). In contrast, in differentiated myelinating Schwann cells in vitro 
and in vivo, sustained and strong ERK signalling drives dedifferentiation, 
whereas lower levels are required for differentiation (Harrisingh et al., 2004, 
Napoli et al., 2012, Newbern et al., 2011). 
 As mentioned above, ERK signalling can activate mTORC1 in some 
situations. ERK and its target RSK can both directly phosphorylate and inhibit 
TSC2 and phosphorylate the mTORC1 subunit Raptor, potentiating mTORC1 
activity, including driving protein synthesis (Carriere et al., 2008, Carriere et al., 
2011, Ma et al., 2005, Rolfe et al., 2005, Winter et al., 2011). In addition, ERK 
has been shown to directly regulate factors that drive rRNA transcription and 
cap-dependent translation initiation, suggesting it can promote protein synthesis 
independent of effects on mTORC1- although this effect may be modest 
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(James and Zomerdijk, 2004, Roux et al., 2007). Indeed, overexpression of 
MEK1 in cardiac myocytes in vitro and in vivo can drive hypertrophy, which has 
been associated with increased protein synthesis in vitro (Bueno et al., 2000, 
Ueyama et al., 2000). This data demonstrates that, in some systems, ERK does 
have a role driving cell growth.  
Like Akt, ERK can also promote lipogenesis. ERK mediated 
phosphorylation enhances SREBP transcriptional activity and therefore 
lipogenic gene expression, as described in Section 1.5.2 (Arito et al., 2008, 
Kotzka et al., 2004, Kotzka et al., 2000, Roth et al., 2000). Moreover, liver 
hypertrophy driven by overexpression of mature SREBP-1a in this tissue is 
prevented by mutation of the MAPK phosphorylation sites in the protein, 
suggesting a physiological role for ERK in SREBP mediated lipogenesis in the 
liver (Kotzka et al., 2012). 
 Interestingly, Raf/ MEK/ ERK and Akt signalling have been shown to 
regulate distinct and independent aspects of sensory axon outgrowth in vitro- 
whereas hyperactivation of Raf1 drives axonal elongation, hyperactivated Akt 
increases axon calibre and branching (Markus et al., 2002). This suggests that, 
in this context, they regulate at least some distinct targets. One possible ERK 
regulated, Akt independent target is the transcription factor serum response 
factor (SRF). In vitro, overexpression of SRF is sufficient to drive axon 
outgrowth and this requires MEK, but not PI3K (Wickramasinghe et al., 2008). 
Although it is not clear which SRF targets are important for axon outgrowth, 
given that axon elongation is going to require cytoskeletal remodelling and 
extension, one attractive candidate is actin, which is induced by SRF in this 
system (Wickramasinghe et al., 2008). Finally, studies in the Schwann cell 
demonstrate that ERK is required for mitochondrial biogenesis downstream of 
synergistic IGF-1 and NRG-1 signalling- demonstrating that ERK can have a 
functional role in organelle biogenesis (Echave et al., 2009). 
1.7.4 Myc Dependent Cell Growth 
Aside from PI3K/ Akt and mTORC1, Myc can also play an important role 
in regulating cell growth in a number of systems. Myc dependent cell growth is 
associated with increased protein biogenesis; including increased rRNA levels, 
ribosome and nucleolar density, protein synthesis and cell protein content 
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(Chan et al., 2011, Grewal et al., 2005, Iritani and Eisenman, 1999, Johnston et 
al., 1999, Kim et al., 2000, Pierce et al., 2004, Saucedo and Edgar, 2002, 
Schreiber-Agus et al., 1997, Schuhmacher et al., 1999, Wu and Johnston, 
2010). Myc also drives glycolysis, mitochondrial biogenesis and activity and 
glutamine metabolism- apparently switching mitochondrial metabolism to being 
increasingly dependent on glutamine-derived carbon, as opposed to glucose-
derived carbon (Fan et al., 2010, Gao et al., 2009, Graves et al., 2012, Kim et 
al., 2008b, Li et al., 2005, Morrish et al., 2008, Osthus et al., 2000, Wise et al., 
2008). These have been shown to be important for Myc dependent survival and 
proliferation- although their role in Myc dependent cell growth per se has not 
been investigated, given their function in cell bioenergetics and biosynthesis, it 
would not be surprising if they were required. 
Like the PI3K/ Akt pathway, Myc can be activated downstream of 
extracellular factor receptor signalling. In Drosophila, two negative regulators of 
dMyc have been specifically linked to regulation of cell growth- the TRIM-NHL 
proteins, Brat and MeiP26 (Betschinger et al., 2006, Frank et al., 2002, Herranz 
et al., 2010, Neumuller et al., 2008). Loss of either of these proteins increases 
dMyc levels and cell size, associated with an increase in nucleolar size- 
analogous to dMyc overexpression (Betschinger et al., 2006, Herranz et al., 
2010, Neumuller et al., 2008). Interestingly, miRNAs have been implicated in 
MeiP26 regulation of dMyc, the first studies associating this relatively new field 
with regulation of cell growth (Herranz et al., 2010). 
Interestingly and importantly, dMyc and PI3K dependent cell growth 
appear to be driven, in part, by distinct mechanisms. In Drosophila fat cells, 
overexpression of PI3K and dMyc drive equivalent increases in cell volume 
(Grewal et al., 2005). However, only dMyc drives a significant increase in 
nucleolar size and rRNA levels, suggesting dMyc drives significantly higher 
rates of protein synthesis than PI3K (Grewal et al., 2005). It is important to note 
that this does not mean PI3K does not also upregulate protein synthesis in this 
system- as described in Section 1.7.1, enhanced protein biogenesis is a well 
characterised effect of PI3K/ Akt/ mTORC1 signalling. However it does suggest 
that in Drosophila fat cells, there may be a greater role for protein synthesis in 
dMyc dependent cell growth and other aspects of biogenesis, e.g. lipogenesis, 
have significant roles in PI3K dependent cell growth.  
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1.7.5 Other Signalling Pathways 
 As discussed in Section 1.7.3, the transcription factor SRF may mediate 
Raf driven axonal outgrowth. SRF has also been shown to be involved in 
cardiac muscle growth (Zhang et al., 2001a, Zhang et al., 2001b). During 
development, SRF is required for cardiac muscle growth and, in the adult, 
overexpression of SRF in cardiac muscle drives pathological hypertrophy 
(Zhang et al., 2001a, Zhang et al., 2001b). SRF also regulates skeletal muscle 
growth and maintenance during development and in the adult but, interestingly, 
SRF does not appear to directly regulate cell growth in this context- it regulates 
secretion of interleukin-4 (IL-4), which then acts to drive muscle growth (Charvet 
et al., 2006, Guerci et al., 2012). 
 Another signalling pathway that has been shown to regulate growth in a 
number of cell types is the calcineurin pathway. Calcineurin is a calcium 
activated serine/ threonine phosphatase. The primary substrates of calcineurin 
are the nuclear factor of activated T-cell proteins (NFATs) that, once 
dephosphorylated, translocate to the nucleus and act as transcriptional 
coactivators within a number of different transcriptional complexes (Hogan et 
al., 2003). Section 1.4.2 ‘Determining Cell Size’ has already described that 
NRG1 driven Schwann cell myelination involves the PI3K/ Akt pathway. In 
addition, and also important for myelination, NRG1 signalling activates 
calcineurin-NFAT signalling via a phospholipase C (PLC) dependent increase in 
intracellular calcium, independent of PI3K (Kao et al., 2009). Loss of calcineurin 
in Schwann cells leads to hypomyelination (Kao et al., 2009). Calcineurin is also 
required for NGF-dependent axonal outgrowth, by both NFAT dependent and 
independent mechanisms (the latter by regulating NGF receptor endocytosis 
and therefore signalling dynamics), as well as pathological cardiac hypertrophy 
(Bourajjaj et al., 2008, Graef et al., 2003, Molkentin et al., 1998, Wilkins et al., 
2004).  
 Finally, the retinoblastoma protein (Rb) is a well-known tumour 
suppressor and its role regulating the cell cycle in this context has been 
extensively studied (Giacinti and Giordano, 2006). However, more recently it 
has been shown that Rb also specifically regulates cell growth (Collins et al., 
2012). Most interestingly, Rb dependent growth is independent of the classic 
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Rb targets important for cell-cycle regulation, the E2F transcription factors, as 
well as PI3K/ Akt/ mTORC1, MEK/ ERK and c-Myc activation.  
 These examples demonstrate that diverse signalling pathways can be 
involved in regulating cell growth in different contexts and show that they can 
act in parallel with, independent of or in a different context to the classic PI3K/ 
Akt pathway. However, many of these pathways remain poorly understood. 
1.7.6 Crosstalk Between Signalling Pathways  
As will have become clear throughout this introduction, particularly in the 
formative parts of this Section 1.7, numerous pathways can converge on 
common upstream regulators of biogenesis (e.g. mTORC1) or downstream 
cellular processes (e.g. lipogenesis). The effects of multiple signals can be 
additive- for example Akt and ERK can phosphorylate TSC2 on distinct sites to 
drive additive activation of mTORC1, as assayed by phosphorylation of the 
mTORC1 target, S6 kinase (S6K) (Winter et al., 2011). Distinct pathways can 
also synergise to drive a novel growth output- in Schwann cells loss of Rb, 
which drives strong short-term growth, can synergise with Ras, which drives 
weak sustained growth, to drive strong and sustained cell growth (Collins et al., 
2012). In other cases a pathway may be required for the activation of another- 
such as the case in human fibroblasts where Akt is required for Myc to drive 
rRNA transcription, although Akt itself is not activated (Chan et al., 2011). There 
are also situations where signalling pathways can antagonise one another- 
PI3K and ERK signalling can negatively, as well as positively, regulate each 
other (Mendoza et al., 2011).  
 
1.8 Nutrient Regulation of Cell Growth and Cell Size 
In addition to growth factors, nutrients are critical for cell growth and 
maintenance. Not only as the substrates for biogenesis, but also as direct 
regulators of growth factor activated signalling pathways and biogenesis 
(Metallo and Vander Heiden, 2010, Wellen and Thompson, 2012, Wullschleger 
et al., 2006). This means there is strong interdependence on combined nutrient 
and growth factor availability to maintain cellular biogenesis: growth factors are 
necessary for nutrient uptake and metabolism and, reciprocally, nutrients are 
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required to promote growth factor signalling (Barata et al., 2004, Edinger and 
Thompson, 2002, Plas et al., 2001, Rathmell et al., 2000, Vander Heiden et al., 
2001, Wieman et al., 2007). Coupling cell growth to nutrient availability likely 
ensures growth only occurs when the substrates are available to fuel this 
energetically demanding process (Edgar, 2006, Guthrie and Brown, 1968, 
Winick and Noble, 1966). 
Nutrients regulate biogenesis both at the systemic and cellular level. In 
mammals, circulating nutrient levels are kept within narrow physiological limits; 
this is achieved through the regulation of tissue metabolism to store/ mobilise 
nutrients from/ into systemic circulation as required (Berg, 2002). The 
metabolism of the liver, skeletal muscle and adipose tissues are particularly 
dynamic in response to whole body feeding/ fasting and they play a critical role 
in the regulation of circulating nutrient levels. Feeding causes blood glucose 
levels to rise, which stimulates the release of insulin. Insulin promotes glucose 
and fatty acid uptake by tissues, through activation of PI3K/Akt signalling. A 
certain amount of excess glucose is taken up by the liver and skeletal muscle 
and stored as glycogen and any remainder is converted to triacylglycerols 
(TAGs) and stored primarily in adipose tissue. Initial starvation, e.g. overnight, 
causes blood glucose levels to fall, which inhibits insulin release and stimulates 
glucagon release. This drives the breakdown and release of previously stored 
glycogen as glucose to maintain circulating blood glucose levels. Under these 
conditions many tissues switch to using circulating fatty acids as an energy 
source, which preserves circulating glucose for tissues that cannot utilize fatty 
acids, such as the brain. The feedback control of systemic nutrient levels and 
the plasticity of the metabolism of certain tissues helps ensure a constant 
supply of nutrients to all tissues to maintain cell size and growth, as appropriate, 
in the face of fluctuating nutrient intake by the organism.  
At the cellular level, nutrient regulation of growth factor signalling is 
perhaps best understood for the regulation of mTORC1 by amino acids (Kim et 
al., 2002, Nicklin et al., 2009). Removal of amino acids (in particular the 
essential branched chain amino acid leucine) rapidly inactivates mTORC1 (Kim 
et al., 2002). Amino acids regulate mTORC1 localisation and therefore access 
to its activator, the small GTPase Rheb (Inoki et al., 2003a, Kim et al., 2008a, 
Sancak et al., 2010, Sancak et al., 2008, Kim et al., 2012, Zoncu et al., 2011). 
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Specifically; amino acid signalling from inside the lysosome drives nucleotide 
loading of the Rag GTPases, which form part of the Ragulator/Rag complex, via 
a v-ATPase that physically interacts with this complex (Zoncu et al., 2011). 
When activated, the Rag GTPases recruit mTORC1, via its subunit Raptor, to 
the lysosome membrane. This allows mTORC1 to interact with Rheb, which is 
also localised on this membrane (Kim et al., 2008a, Sancak et al., 2010, 
Sancak et al., 2008). Targeting mTORC1 to the lysosomal membrane by 
addition of a lysosome localisation motif to the protein overcomes amino acid 
dependent regulation (Sancak et al., 2010). In the absence of amino acids, the 
binding protein SH3BP4 binds the inactive Rag GTPase complex and impairs 
conversion of the complex to the active form, which further ensures mTORC1 
remains inactive (Kim et al., 2012). As they control mTORC1 localisation, amino 
acids are dominant to the numerous other factors that regulate mTORC1, 
including growth factors and cellular energy status (AMPK). 	  
Amino acids further regulate protein synthesis downstream of mTORC1- 
highlighting the importance of preventing activity of biogenic pathways when the 
necessary substrates are unavailable. This regulation is via the eiF2α kinase, 
GCN2. In both yeast and mammalian cells, amino acid starvation activates 
GCN2, which phosphorylates the translation initiation factor eiF2α on serine 51. 
This phosphorylation reduces the activity of eiF2α and therefore inhibits 
translation initiation and protein synthesis (Sonenberg and Hinnebusch, 2009). 
In yeast GCN2 is activated by the binding of uncharged tRNAs, which would be 
present in the cell upon amino acid shortage (Dong et al., 2000). It is likely 
mammalian GCN2 is activated by a similar mechanism, as the tRNA binding 
domains of GCN2 are conserved and critical for mammalian GCN2 function 
(Sood et al., 2000). Importantly, although the translation of most mRNAs is 
suppressed upon GCN2 activation, the translation of the transcription factor 
ATF4 is increased; ATF4 promotes expression of genes involved in amino acid 
import and synthesis, as well as other stress responses to cope with the amino 
acid shortage, and, thus, aims to relieve the amino acid shortage in the cell 
(Harding et al., 2000, Harding et al., 2003, Chen et al., 2004).  
Most interestingly, although this aspect of GCN2 activity specifically 
targets the protein synthesis machinery, long-term leucine deprivation 
suppresses lipogenesis in the liver, in a GCN2 dependent manner. Leucine 
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starvation inhibits lipid synthesis through downsregulation of SREBP-1c, a 
master regulator of lipid synthesis, in the livers of Gcn+/+ mice, but not in the 
livers of Gcn-/- mice (Guo and Cavener, 2007).  Again, this likely highlights the 
importance of appropriate coordination of multiple aspects of biogenesis. 
 Recent evidence has also shown that nutrients can control growth factor 
signalling by direct post-translational modifications of proteins. In B cells 
dependent on the growth factor IL-3, glucose is necessary to promote the cell 
surface expression of the IL-3 receptor (IL3R) (Wellen et al., 2010). In the 
absence of glucose, amino acid uptake is reduced and cells atrophy- even in 
the continued presence of IL-3. It transpires that glucose is required as the 
substrate of the hexosamine pathway that provides the moiety for the N-
glycosylation and subsequent cell surface expression of IL3R. As most growth 
factor receptors are N-glycosylated and this is known to affect their surface 
expression, this could be a universal phenomenon (Metallo and Vander Heiden, 
2010). Nutrient dependent post-translational modifications do not seem to be 
limited to glucose dependent glycosylation. Zhao et al found that nutrient 
dependent acetylation in the liver regulated the activity of enzymes involved in a 
range of metabolic pathways, including glycolysis and fatty acid synthesis (Zhao 
et al., 2010). Protein acetylation depends on the availability of acetyl-CoA, 
which depends on nutrient availability. Ultimately, nutrient availability is 
necessary even to provide the ATP for protein phosphorylation, which is 
necessary for a vast array of cellular functions including growth factor signalling 
and biogenesis (Wellen and Thompson, 2012). 
 
1.9 Growth Factor and/ or Nutrient Withdrawal; the Effects on 
Cell Growth and Metabolism 
 As nutrient and growth factor signalling are interdependent, the effects of 
growth factor and nutrient withdrawal overlap. As a direct effect of losing growth 
factor signalling, growth factor activated anabolic pathways are repressed and 
this helps conserve cellular energy and metabolites. In addition, catabolic 
pathways- namely autophagy- that are suppressed by growth factor signalling 
are activated. This appears to provide substrates to fuel necessary biogenesis 
and prolong cell survival. In line with this, Yu et al showed that mTORC1 is 
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reactivated in rat kidney cells upon protracted serum (nutrient and growth 
factor) starvation, which the authors hypothesise is due to the result of the 
replenishment of intracellular amino acids by autophagy (Yu et al., 2010). 
Despite this, because starvation and catabolism causes cellular atrophy, it will 
ultimately lead to cell and organism death (Edinger and Thompson, 2002, Lum 
et al., 2005a, Rathmell et al., 2000, Vander Heiden et al., 2001).  
The cell also activates a number of adaptive responses to cope with the 
effects of growth factor and nutrient withdrawal. Depletion of cellular energy, as 
can occur downstream of starvation, increases the AMP/ADP: ATP ratio in the 
cell. This activates the heterotrimeric kinase AMPK (AMP-activated protein 
kinase), a highly conserved eukaryotic sensor of cellular energy status (Hardie, 
2011). AMPK suppresses most anabolic pathways- acting to acutely regulate 
metabolic enzymes via phosphorylation, as well as mediating longer-term 
transcriptional changes (Mihaylova and Shaw, 2011, Hardie, 2011). Using lipid 
metabolism as an example; AMPK phosphorylates and inhibits HMGCoR and 
ACC to repress de novo fatty acid and sterol synthesis, as well as 
phosphorylating and inactivating SREBP-1 to inhibit expression of these, and 
other, lipid synthesis genes (Carling et al., 1987, Li et al., 2011, Sato et al., 
1993). AMPK also inhibits mTORC1 by phosphorylating and activating the 
mTORC1 inhibitor TSC2, as well as by direct phosphorylation of the Raptor 
subunit of the mTORC1 complex (Inoki et al., 2003b, Gwinn et al., 2008). This 
further suppresses anabolism and activates catabolism, as already described. 
Although most anabolic processes are blocked, AMPK drives 
mitochondrial biogenesis, through the activation of the transcriptional co-
activator peroxisome proliferator-activated receptor γ co-activator 1α (PGC1-α) 
(Zong et al., 2002). This increases the cells capacity for oxidative 
phosphorylation and helps restore the energy balance within the cell. 
Interestingly, AMPK also promotes the surface expression of nutrient 
transporters and nutrient uptake (Bonen et al., 2007, Chen et al., 2008, Kurth-
Kraczek et al., 1999). However, if AMPK is activated under starvation 
conditions, this cannot be sufficient to maintain adequate nutrient uptake in 
growth factor deprived cells because cells atrophy (Edinger and Thompson, 
2002, Lum et al., 2005a, Rathmell et al., 2000, Vander Heiden et al., 2001). 
Indeed, AMPK also activates catabolic pathways to provide cell metabolites- 
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activating autophagy by direct phosphorylation and activation of Ulk1, a 
component of the autophagic machinery, as well as indirectly via inhibition of 
mTORC1 (Egan et al., 2011, Kim et al., 2011).  
During development, the growth of certain tissues is protected from the 
effects of nutrient deprivation. So called ‘organ-sparing’ preserves the growth 
and maintenance of the CNS at the expense of other organs. Starvation, 
unsurprisingly, attenuates net growth of developing Drosophila larvae. 
However, CNS growth is maintained. Whereas most tissues depend on nutrient 
dependent signals to drive cell growth, the growth of neural progenitor cells (the 
cell lineage that forms the brain tissue) is regulated by a nutrient independent 
extracellular factor, Jelly belly (Jeb) (Cheng et al., 2011). Jeb drives 
downstream activation of the critical growth-promoting PI3K pathway, thus 
liberating neural lineages from growth restriction upon nutrient deprivation 
(Cheng et al., 2011). Interestingly, this only occurs after Drosophila larvae have 
passed a nutrient-dependent ‘critical weight gain’ threshold and neuroblasts 
have begun to grow and divide (Sousa-Nunes et al., 2011). Presumably this 
ensures growth is restricted until the animal has acquired enough resources to 
complete development even if subsequent starvation occurs. 
 
1.10 Cell Growth and Disease 
 Carefully regulated and coordinated cell growth is required for the 
development and maintenance of a functional organism; loss of proper growth 
control results in disease. At the most basic level this is seen when systemic 
growth factor signalling is misregulated during development; too much Growth 
Hormone (GH) drives acromegaly/ gigantism, whereas too little GH or the 
inability to respond to GH or IGF-1, the primary mediator of the effects of GH, 
leads to growth retardation and dwarfism (Walenkamp and Wit, 2007).  
 Improper cell growth disrupts normal cell and tissue function. Highlighting 
this, recent evidence suggests Autistic Spectrum Disorders (ASD) may result 
from hypertrophic neuronal growth that disrupts neuronal wiring and 
connectivity. A subset of ASD sufferers have inactivating mutations in negative 
regulators of mTORC1 and, at the age of onset, a considerable proportion of 
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autism sufferers have significantly larger brains than age-matched controls 
(Butler et al., 2005, Courchesne et al., 2007, Wiznitzer, 2004). Moreover, this 
enlargement is associated with areas of the brain involved in social and 
emotional processing- the functions affected in autistic individuals (Courchesne 
et al., 2007). Consistent with a causative role for impaired mTORC1 signalling 
in ASDs, mice lacking PTEN or TSC1 (two negative regulators of mTORC1 
activity) in specific subsets of neurons develop neuronal hypertrophy and 
display impaired social interactions, reminiscent of the type found in ASD 
patients (Kwon et al., 2006, Meikle et al., 2008, Meikle et al., 2007, Tsai et al., 
2012). Importantly, blocking mTORC1 activity with rapamycin reversed both the 
hypertrophy and a number of the behavioural phenotypes- demonstrating a 
causative role for mTORC1 and, potentially, hypertrophy in the ASD-related 
phenotypes (Meikle et al., 2008, Tsai et al., 2012, Zhou et al., 2009).  
 ASDs may represent a disorder caused by subtle changes in cell growth 
and subsequent organ disorganisation. However a more overt example of 
diseases associated with overgrowth are cancers. The formation of a tumour 
cell mass requires deregulated cell growth, in addition to deregulated 
proliferative and survival controls. As a result, tumour cell metabolism is geared 
towards macromolecular synthesis and biogenesis; most tumours display 
biogenic and bioenergetic characteristics of rapidly growing and proliferating 
cells (DeBerardinis et al., 2007, Vander Heiden et al., 2009). This includes high 
rates of aerobic glycolysis (Warburg effect), glutaminolysis and nutrient import, 
which all help drive high rates of de novo fatty acid, protein and nucleotide 
synthesis (Deberardinis et al., 2008b, Vander Heiden et al., 2009, Warburg, 
1956, Menendez and Lupu, 2007).  
Whereas normal cells usually require growth factor signalling to drive 
biogenesis, tumour cells are largely liberated from this regulatory control by 
mutations that result in activation of the key growth regulating pathways Akt, 
mTORC1 and/ or Myc (Lum et al., 2005a, Meyer and Penn, 2008, Shaw and 
Cantley, 2006, Wullschleger et al., 2006). Indeed, inherited mutations in 
negative regulators of growth such as PTEN and TSC1/2 predispose to tumour 
development (Bonneau and Longy, 2000, Inoki et al., 2005, Sampson, 2003). It 
must be noted that these pathways also regulate other processes that 
contribute to tumourigenesis, e.g. cell survival and cell cycle progression, which 
 	   87	  
means it is difficult to prove that the deregulated growth has a causative role in 
the cancer (Meyer and Penn, 2008, Vivanco and Sawyers, 2002). In support of 
this causation however is evidence that targeting tumour cell metabolism and 
biogenesis, such as by blocking fatty acid synthesis, can reduce the growth of 
numerous tumour cells (Bauer et al., 2005, Brusselmans et al., 2005, 
Hatzivassiliou et al., 2005, Menendez and Lupu, 2007, Kuhajda et al., 2000). 
Furthermore, as described earlier, recent findings from our lab showed that 
oncogenic Ras and loss of the tumour suppressor Rb, two pathways 
deregulated in most cancers, synergise to strong and sustained cell growth in 
both primary Schwann cells and fibroblasts in vitro (Collins et al., 2012, Hahn 
and Weinberg, 2002). Interestingly, Rb does not activate PI3K/ Akt signalling, 
which suggests other cooperating pathways may also be required to drive the 
prolific cell growth characteristic of many tumours. 
One example of cell overgrowth that is particularly interesting with 
respect to disease is cardiac hypertrophy. This is because, depending on the 
hypertrophic stimulus, it can be physiological or pathological. Exercise and 
pregnancy drive physiological hypertrophy, characterised by increased myocyte 
size, which includes a proportional increase in the expression of myofibril 
proteins and mitochondrial biogenesis, and efficient vascularisation of the 
enlarged muscle tissue. In contrast, hypertension and myocardial infarction are 
examples of stimuli that cause pathological hypertrophy, where there is a lack 
of coordination between the biogenic processes described for physiological 
hypertrophy and disproportionate expansion of certain regions of cardiac 
muscle, leading to impaired cardiac function (Ojamaa, 2010, Schaub et al., 
1997). These examples demonstrate that hypertrophy can be beneficial in adult 
organisms, but highlight that this must be properly coordinated- otherwise tissue 
function is compromised and disease results. 
Most interestingly, distinct signalling pathways drive physiological and 
pathological hypertrophy. Activation of IGF-1 and PI3K/ Akt signalling in the 
heart can drive physiological hypertrophy and loss of signalling through this 
pathway prevents exercise induced physiological hypertrophy (DeBosch et al., 
2006, DeBosch and Muslin, 2008, Dorn and Force, 2005, Kehat and Molkentin, 
2010, Kim et al., 2008c, McMullen et al., 2003, Shioi et al., 2000). However, 
disruption of IGF-1/ PI3K/ Akt signalling does not prevent pathological 
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hypertrophy induced by pressure overload, suggesting that this might be 
mediated by distinct signalling pathways (DeBosch et al., 2006, McMullen et al., 
2003). Indeed, the calcineurin-NFAT pathway appears to be important in this 
regard- transgenic mice that overexpress calcineurin or NFAT3 in the heart 
develop pathological hypertrophy and, reciprocally, loss of calcineurin-NFAT 
signalling blocks pathological hypertrophy (Bourajjaj et al., 2008, Bueno et al., 
2002, Molkentin et al., 1998, Wilkins et al., 2004). Interestingly, although SRF is 
required for cardiac muscle growth during development, transgenic mice 
overexpressing SRF in cardiac myocytes develop pathological hypertrophy 
(Zhang et al., 2001a, Zhang et al., 2001b). Again, this highlights that activation 
of biogenic signalling pathways must be properly controlled in order to prevent 
disease.  
 From these examples it is clear that disrupted cell growth underlies a 
range of diverse diseases and can be caused by inappropriate changes in 
systemic signalling as well as cell intrinsic genetic changes. By understanding 
the mechanisms that underlie normal cell growth control it should be possible to 
determine how this control becomes deregulated during disease and, 
potentially, develop therapeutics to target this deregulation. Reciprocally, 
understanding the mechanisms underlying diseases resulting from deregulated 
growth can give an insight into normal cell growth control- particularly in high 
penetrance inherited genetic disorders. 
 
1.11 Summary 
 Cell growth, the addition of mass and/ or volume, is critical for the 
development and homeostasis of all organisms. Loss of cell growth control, 
leading either to hyper- or hypo- trophy, causes disease. Mammalian cell 
growth and size maintenance usually requires an instructive growth factor 
signal, which drives nutrient uptake, promotes anabolism and suppresses bulk 
degradation. In the absence of such a signal cells atrophy, because they cannot 
utilise sufficient extracellular nutrients to maintain cell metabolism. 
 Cell growth is distinct and separable from cell proliferation, which is 
simply progression through the cell cycle. In dividing cell populations, cell size is 
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determined by the balance between growth and division. In non-dividing 
populations, where there is no cell division to limit cell size, another signal must 
determine final cell size- in some tissues this is the level of growth factor signal 
a cell receives. In addition to growth factors, signals such as extracellular 
nutrient availability and mechanical forces can also regulate cell growth and cell 
size.  The PI3K/ Akt/ mTORC1 pathway appears to be a central and regulator of 
cell growth downstream of diverse biogenic stimuli.  
Cell growth may be uniform (i.e. the coordinate addition of cell mass, 
volume and organelle content), however it can also be non-uniform, resulting in 
the disproportionate expansion of one part of the cell, e.g. an organelle, 
compared to the rest. In every case, growth is closely coupled to the needs of 
the cell; presumably to prevent waste of cellular resources. 
Finally, the primary Schwann cell is a powerful model system in which to 
study cell growth. Schwann cells can be cultured indefinitely as primary cells 
that maintain intact checkpoints, including normal growth control. Moreover, 
Schwann cells produce their own survival factor that has no effect on cell 
growth or division, which means the cells survive in conditions free from added 
extracellular factors. This provides a clean background against which to study 
the effects of adding specific factors on cell growth. 
 
1.12 Thesis Aims 
Cell growth, the addition of cell mass and volume, is regulated by growth factor 
activated signalling pathways. Studies in the Schwann cell have identified that 
organelle (mitochondrial) biogenesis can be differentially regulated downstream 
of distinct extracellular factors (IGF-1 and NRG1) and uncoupled from cell 
volume addition, dependent on activation of the PI3K and ERK signalling 
pathways. The objectives of this thesis work were to use the in vitro Schwann 
cell system to investigate: 
1. The regulation of cell growth and biogenesis downstream of the PI3K/Akt 
and ERK signalling pathways. 
2. The cellular changes and signalling required for cell volume addition 
during cell growth.  
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Chapter 2: Materials and Methods 
Plastic ware was purchased from Falcon, reagents from Sigma and tissue 
culture dishes from Nunc, unless otherwise specified. All kits were used 
according to manufacturers instructions, unless otherwise specified. Solutions 
were made up with MilliQ deionised water (ddH2O). 
2.1 Cell Culture 
Primary Schwann Cells 
Primary Schwann cells were purified from the sciatic and brachial nerves of 
postnatal day 7 Sprague Dawley rats, according to the method of Cheng et al 
(Cheng et al., 1995). This method yields cultures of >99.9% purity by 
immunfluorescence for cell markers. Cells were maintained in culture in low-
glucose (1g/l), no glutamine DMEM plus phenol red (Lonza) supplemented with 
3% charcoal stripped foetal calf serum (FCS) (Biosera), glutamine (4mM) 
(Gibco), Kanomycin (100µg/ml), gentamycin (2µg/ml) (Gibco), forskolin (1µM) 
(Ascent Scientific) and GGF on Poly-L-Lysine (PLL) (2.4µg/ml) coated dishes. 
Medium with these supplements is hereafter described as complete medium. 
Cells were cultured at 37°c in 10% CO2 and 95% humidity. Cells were 
passaged on reaching ~80% confluency. 
NSΔRafER Cells 
NSΔRafER cells were generated by the co-culture of primary Schwann cells 
with a producer line expressing ΔRafER retrovirus, pre-treated with mitomycin C 
(Lloyd et al., 1997). After several days cultures were transferred to selective 
medium containing G418 (0.4mg/ml) (Gibco). Drug resistant colonies were 
pooled and expanded. Activation of the RafER construct was achieved by the 
addition of tamoxifen (Tmx) in ethanol (100nM) (VWR) (Harrisingh et al., 2004). 
Cells were cultured in low-glucose no glutamine DMEM minus phenol red 
(Gibco), with supplements and in conditions as described above.  
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Generation of ER.mSREBP1a and ER.mSREBP2 expressing Schwann 
cells by retroviral transduction 
Phoenix amphotropic packaging cells were used to produce the retrovirus titre 
required to infect the NS cells. Phoenix cells were seeded onto 100mm dishes 
in 10% FCS containing high glucose (4500mg/l) DMEM at a density of 5x106 
cells per dish. The following morning the cells were medium changed in 4ml 
fresh medium and transfected as follows: 6.2µg DNA + 5.5µl attractene 
(QIAGEN) + plain DMEM to a total volume of 1860µl was mixed in a 2ml 
eppendorf and incubated at room temperature for 15 minutes before being 
added directly to the cells. After 4 hours the cells were medium changed into 
10ml of fresh medium and left for 24 hours and then media changed into 6ml 
fresh medium (the smaller volume concentrates the virus). After a further 24 
hours the 6ml of media, containing the virus, was collected into a falcon and the 
cells given 6ml fresh medium. After filtering the virus-containing medium 
through a 0.45µm filter (Millipore), polybrene was added to a final concentration 
of 4µg/ml. This virus was used immediately to infect normal or NSΔRafER 
Schwann cells (seeded the previous day onto 100mm dishes at a density of 
5x105 cells per dish) as follows: the Schwann cell medium was aspirated and 
replaced with the prepared virus solution and the cells incubated with the virus 
for 3 hours at 37°c. The Schwann cells were then media changed back into 
normal Schwann cell culture medium and left overnight. The virus collection/ 
infection was repeated over the next two days so that in total 3 infections were 
carried out. This was to ensure maximal retroviral transduction efficiency. After 
the final infection, successfully transduced cells were selected by antibiotic 
selection. All constructs used in this thesis contain the puromycin resistant gene 
therefore cells were incubated in normal medium containing the addition of 0.5-
1µg/ml puromycin. Selection was continued until parallel plates of cells infected 
with a non-puromycin resistant construct and undergoing the same puromycin 
selection were dead, approximately 3 days. Cells were then cultured in normal 
Schwann cell medium, as described in section 2.1. 
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Protocol for Cell Cycle Arrest and Transfer to Defined Growth Factor-Free 
Conditions 
Cells were seeded onto PLL, fibronectin (10µg/ml) and laminin (50ug/ml) coated 
dishes in complete medium for 24 hours prior to being treated with the DNA 
polymerase α inhibitor aphidicolin (1µg/ml) in complete medium for 24 hours. 
Cells were then switched into defined factor-free medium plus aphidicolin for a 
further 24 hours. Two types of defined factor-free medium were used, as 
described in the results chapter: 
1. Minimal Medium: DMEM containing transferrin (100µg/ml), bovine serum 
albumin (BSA) (100µg/ml) (Gibco), putrescine (16.1µg/ml) and selenium 
(39ng/ml). In certain experiments delipidated BSA (Sigma) was used to 
make the Minimal Medium, as specified in the Results chapter. 
2.  SATO: DMEM containing transferrin (100µg/ml), BSA (100µg/ml), 
putrescine (16.1µg/ml), selenium (39ng/ml), thyroxine (50ng/ml), 
triiodothyrine (50ng/ml) and progesterone (60ng/ml). 
After this treatment cells were switched to medium containing +/- extracellular 
factors, as specified in individual experiments. Extracellular factors used in this 
study were: complete medium, defined medium, IGF-1 (100ng/ml) (Autogen 
Bioclear) in defined medium, Tmx in defined medium (to activate the RafER 
construct; ethanol was added (v:v) to control cells). At the concentration used, 
IGF-1 is saturating for cell volume addition (Conlon et al., 2001). 
Exogenous Fatty Acids and Cholesterol 
A chemically defined mix of fatty acids and cholesterol (Chemically defined lipid 
concentrate, Gibco) was added, in dilutions as described in the results, in 
defined medium plus aphidicolin in a 30 minute pre-incubation prior to the 
addition of extracellular factors in the experimental protocol described above. 
Inhibitors 
Inhibitors were added in defined medium plus aphidicolin in a 30 minute pre-
incubation prior to the addition of extracellular factors in the experimental 
protocol described above. The exception is chloroquine. Chloroquine was 
added 7 hours prior to the end-point assay being performed, which in all cases 
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is after any extracellular factors were added. See Table 2.1.1 for list of 
inhibitors. 
Inhibitor Function Concentration Company 
Rapamycin Inhibits mTORC1 0.15µg/ml Sigma 
ZSTK474 Inhibits class I PI3K’s 500nM Alexis Biochem 
PD184532 Inhibits MEK 0.75µM Axon 
NaN3 Inhibits aerobic 
respiration to deplete 
cellular ATP 
20mM Sigma 
NaN3/NaF Inhibits aerobic 
respiration/ glycolysis 
to deplete cellular ATP 
5µg/ml/126µg/ml Sigma 
Chloroquine Inhibits lysosome 
acidification to inhibit 
lysosome function 
25µM Sigma 
Cerulenin Inhibits fatty acid 
synthase and 
HMGCoA Reductase 
to inhibit de novo fatty 
acid and sterol 
synthesis 
7.5µg/ml Cayman 
Chemicals 
Simvastatin Inhibits HMGCoA 
Reductase to inhibit de 
novo sterol synthesis 
5µM Sigma 
C75 Inhibits fatty acid 
synthase to inhibit de 
novo fatty acid 
synthesis 
3µg/ml Sigma 
Table 2.1.1 Inhibitors 
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Transient transfection of cells with siRNA 
Cells were plated onto PLL and fibronectin coated 6-well dishes (150,000 cells 
per well) in complete medium. The following day cells were transfected with 
siRNA duplexes as follows: FlexiTube siRNA (Qiagen) stock solutions (20µM in 
ddH2O) were diluted in plain DMEM to generate siRNA working solutions of 
0.4µM (SREBP-2 siRNA oligo’s) or 0.8µM (SREBP-1 siRNA oligo’s). Then, 
siRNA/lipid complexes were prepared by sequentially adding 88µl plain DMEM 
+ 12µl siRNA working solution + 6µl HiPerfect (Qiagen) (volumes shown are for 
a single well). Complexes were left to form at room temperature for 15 minutes. 
In this time, cells were medium changed with 2.3ml fresh complete medium and 
then the total volume (106µl) of siRNA/lipid complex was added dropwise to the 
cells and incubated overnight for 18 hours. After this time, cells were medium 
changed into Minimal Medium plus aphidicolin and left for 24 hours before 
being changed into Minimal Medium plus aphidicolin +/- extracellular factors, as 
specified in the results. After a further 24 hours, cell volume was assayed using 
the Coulter Counter. Knockdown was verified by RT-qPCR.  
 
2.2 Cell Size Measurements 
Coulter Counter: Cell Volume  
Cells cultured in 6-well dishes were gently washed 1x with PBS (PAA) and 
removed from the dish in 500µl pre-warmed trypsin-EDTA. Trypsin activity was 
quenched with the addition of 1500µl medium containing 3% FCS and the total 
volume was transferred to 6ml Isoton II (Beckman Coulter) in an acuvette cup 
(Beckman Coulter) and the volume of >5000 cells was measured using a 
Multisizer 4 Coulter Counter (Beckman Coulter) and data analysed in the 
accompanying software. Each condition within an experiment was measured in 
duplicate or triplicate. 
Quantitative Phase Microscopy (QPM): Cell Dry Mass and Cell Volume 
Cells were cultured on PLL, fibronectin and laminin coated glass-bottomed 
dishes (Mattek, P35G-1.0-14-C). Imaging was performed on a Quantitative 
Phase Microscope (QPM) custom built from a Nikon Eclipse TE2000-E 
 	   95	  
microscope (Nikon). The imaging process is a Diffractive Phase Microscope 
Method. The microscope stage was contained within a 37°c heated 
environmental chamber supplied with a humidified gas mixture (90% air/ 10% 
CO2). Samples were imaged in conditioned medium filtered using a 0.2µm filter 
to remove interfering cellular debris. Samples were carried to the microscope in 
a heated chamber to avoid cooling of the cell culture medium and were placed 
on the microscope stage 20 minutes before imaging to allow motion within the 
culture medium created during the transfer to settle.  
Images were taken in MetaMorph (Molecular Devices) and analysed within 
MatLab (MathWorks) using algorithms developed by Seungeun Oh (Kirschner 
Lab, Harvard Medical School). Background reference images were taken in the 
absence of a sample in the specimen holder. Reference images were taken 
intermittently through the imaging process to account for drift or alterations in 
the imaging apparatus over time. The interferometric data (cellular dry mass) 
was retrieved by comparison of the sample image to the reference image using 
QPM image processing. Cellular dry mass was calculated using this information 
and the refractive index of the imaging medium (conditioned medium as 
described above), which was measured using a refractometer. 
Cell volume was quantified from the difference in apparent cell dry mass when 
images are taken in 2 different media with differing and known refractive 
indices. To do this, after imaging in conditioned media as described above 
media was replaced with pre-warmed conditioned medium containing 10% ficoll 
and re-imaged. The presence of ficoll increased the density and therefore the 
refractive index of the medium. The refractive indices of the two media were 
measured using a refractometer. See Popescu et al 2006 for the principles of QPM. 
Cell Protein Content 
Bichonic Acid (BCA) Assay 
In the BCA assay the reduction of a copper containing substrate (by peptide 
bonds and the amino acids cysteine, tryptophan and tyrosine) produces a 
colorimetric change, the intensity of which can be quantified by measuring 
absorbance at 560nm in a spectrophotometer. The amount of copper reduced 
and therefore intensity of colour is proportional to the protein concentration in 
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the measured solution. To calculate the protein concentration of cell lysates, 
absorbance was compared to the absorbance of bovine serum albumin (BSA) 
standards of known concentrations quantified in parallel. 
Cells cultured in 6-well dishes were gently washed 1x with PBS and lysed in 
300µl radio-immunoprecipitation assay (RIPA) buffer (Table 2.4.5) + 0.05% 
sodium dodecyl sulphate (SDS) (BioRad) on ice, rotating for 30 minutes. 
Lysates were then transferred to labelled eppendorfs on ice. Lysate protein 
concentration was determined using a modified BCA Assay (Pierce), as follows: 
25µl of sample was transferred to a well of a 96-well plate and, to this, 200µl of 
working BCA reagent (50:1 solution of reagents A:B) was added. After 
incubating the plate for 30 minutes at 60°c, protein concentration was 
determined by absorbance at 560nm using a Versamax spectrophotometer and 
SoftMax Pro Software (Molecular Devices) and comparison to the absorbance 
of bovine serum albumin (BSA) (Pierce) standards made in RIPA+0.05% SDS. 
Each well of the 6-well dish was lysed in 300ul lysis buffer, therefore: 
Protein per well (mg) = lysate protein concentration (mg/ml) x 0.3   
To calculate the amount of protein per cell, protein per well was normalised to 
the cell number per well of parallel 6-well cell culture plates. Cell number per 
well was quantified using a Z2 Coulter Counter (Beckman Coulter), as follows: 
Cells were gently washed 1x with phosphate-buffered saline (PBS) and 
removed from the dish with 500µl trypsin-EDTA. Trypsin activity was quenched 
with the addition of 500µl medium containing 3% FCS and the total volume 
transferred to 6ml Isoton II (Beckman Coulter) in an acuvette cup (Beckman 
Coulter). Each condition was assayed in triplicate. 
Total Cell Protein (Alexa647-Succinimidyl Ester) 
Cells were cultured on 13mm glass coverslips. Stocks of 10mg/ml Alexafluor-
conjugated Succinimidyl Ester (Molecular Probes) were made up in dimethyl 
sulfoxide (DMSO) and stored at -20°c for up to 12 months. Coverslips were 
fixed in 4% PFA/PBS for 15 minutes at room temperature. After washing 2x in 
PBS cells were permeabilised in 100% ice-cold methanol for 10 minutes at 
room temperature before being washed a further 2 x in PBS and incubated in 
the dark at room temperature for 30 minutes in a 40ng/ml solution in PBS of 
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Alexafluor-conjugated Succinimidyl Ester to label cell primary amines. After this 
time, coverslips were washed 6x in PBS before being mounted on glass slides 
in mounting medium. 
Succinimidyl esters react with primary amines, therefore labelling the N-
terminus of amino acids, peptides and proteins and the R-group of lysines. The 
amount of cell-bound Alexa647-succinimidyl ester was taken as an indicator of 
cell protein content and was quantified as the total cell fluorescence intensity 
measured from widefield microscopy images taken using either widefield 
microscope described in section 2.6. 
 
2.3 Molecular Biology 
RNA extraction 
After aspirating the cell culture medium and without washing the cells, 1ml Tri 
reagent was added directly to cells cultured on 10cm dishes. Cells were lysed 
by pipetting the sample up and down several times, avoiding bubbles. The 
homogenised samples were then transferred to 1.5ml eppendorfs, snap frozen 
in liquid nitrogen and stored at -80°c until use.  
After thawing at room temperature, the homogenised samples were incubated 
at room temperature for 5 minutes to allow complete dissociation of 
nucleoprotein complexes. Then 200µl chloroform (VWR) was added to each 
sample in the eppendorf and the eppendorf shaken vigourously by hand for 15 
seconds. The samples were then incubated at room temperature for 10 minutes 
before being centrifuged at 13000 RPM for 15 minutes at 4°c in a tabletop 
centrifuge (Biofuge). The mixture separates into a lower, pink phenol-chloroform 
phase and an upper aqueous phase that contains the RNA. The upper aqueous 
phase was removed (~400µl), transferred to a new tube and 500µl 100% 
isopropanol (VWR) added before incubating the samples at room temperature 
for 10 minutes. The samples were then centrifuged again at 13000 RPM for 10 
minutes at 4°c. The supernatant was then removed from the tubes, leaving the 
RNA pellet, which was then washed by adding 600µl 75% ethanol and 
incubating at room temperature for 10 minutes. The samples were then 
vortexed briefly before being centrifuged at 7500g for 5 minutes at 4°c to re-
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pellet the RNA. After aspirating the supernatant the RNA was left to air-dry and 
then resuspended in 12µl RNAse-free water. The concentration of RNA was 
determined using a nanodrop spectrophotometer (Thermoscientific) at OD260. 
RNA was stored at -80°c until use. 
Complementary DNA (cDNA) synthesis 
To produce cDNA for quantitative RT-PCR, 500ng-1µg of RNA was reverse 
transcribed using the SuperScriptTM II Reverse First-Strand Synthesis System 
(Invitrogen). Samples containing RNA, 1µl random hexamers and 1µl of dNTPs 
(10mM each dNTP) were made up to a total volume of 12µl using sterile, 
distilled water and then incubated at 65°c for 5 minutes and then rapidly chilled 
on ice for >1 minute. Then, 8ul of the Stock II Reaction mix (4µl 5x First-Strand 
Buffer, 2µl 0.1M Dithiotheitol (DTT), 0.5µl RNAseOUTTM (40U/µl), 0.5µl 
SuperScriptTM II Reverse Transcriptase (200U), 1µl H2O) was added to each 
sample and mixed by pipetting up and down gently several times. The reactions 
were then incubated at 25°c for 10 minutes, then 42°c for 50 minutes. The 
reactions were then terminated by heating to 70°c for 15 minutes before being 
chilled on ice. Finally, the RNA in the sample was removed by addition of 0.5µl 
E. coli RNAseH (2U/µl) and incubation at 37°c for 20 minutes. 
Quantitative Polymerase Chain Reaction (QPCR) 
Quantitative PCR was performed using the MESA BLUE qPCR MasterMix Plus 
for SYBR® kit (Eurogentec) and Opticon2 DNA engine (MJ Research).  
Relative transcript levels of target genes were normalised to B2M. The gene 
specific primers used to amplify target gene transcripts in this thesis are 
described in Table 2.3.1. For most reactions, gene specific primers were 
designed using the Roche Applied Science Assay Design Centre (Roche 
Applied Science), or, where specified, taken from published data.  
To perform the qPCR: A master mix of 0.75µl primer stock solution (containing 
10mM each of the forward and reverse primers in ddH2O), 10µl 2x MESA Blue 
MasterMix and 7.5µl ddH2O was made for η x reactions for each gene to be 
assayed in the experiment and mixed gently but thoroughly by pipetting. This 
18µl volume of master mix was added to a well of the PCR plate, followed by 
2µl cDNA template or ‘No Template ddH2O’ control. All reactions were 
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performed in duplicate. The basic cycling parameters used for the qPCR are 
outlined in Table 2.3.2, although optimal annealing (A), extension (E) and 
primer dimer melting temperatures (TM) were determined empirically for each 
primer pair (Table 2.3.1). At the end of 40 cycles of amplification a dissociation 
curve was generated by measuring SYBR green fluorescence at 0.2°c intervals 
between 55°c and 95°c to check only one amplicon was detected by the PCR 
reaction. Relative quantitation of mRNA levels was made using the ΔΔCT 
method. This is an approximation method and assumes the normaliser gene 
and target gene are amplified with equivalent efficiencies (the proportion of 
cDNA strands amplified in every cycle).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	   100	  
Gene Primer Source qPCR 
notes 
B2M F: 5’ –TGACCGTGATCTTTCTGGTG- 3’ 
R: 5’ –ATTTGAGGTGGGTGGAACTG- 3’ 
Roche 
Applied 
Science, 
ProbeFinder 
A 58°c,  
E 72°c, 
TM 77°c 
FASN F: 5’ –GGCCACCTCAGTCCTGTTAT- 3’ 
R: 5’ –AGGGTCCAGCTAGAGGGTACA- 3’ 
Roche 
Applied 
Science, 
ProbeFinder 
A 58°c,  
E 72°c, 
TM 77°c 
HMGCoA 
Reductase 
F: 5’ –GACCTTTCTAGAGCGAGTGCAT- 3’ 
R: 5’ –GCTATATTCTCCCTTACTTCATCCTG- 3’ 
Roche 
Applied 
Science, 
ProbeFinder 
A 58°c,  
E 72°c, 
TM 77°c 
SREBP-2 F: 5’ -CGCTCGCATTTCACTGAAGTAG- 3’ 
R: 5’ -GGCATAGAAGACGGCCTTCAC- 3’ 
(de Preux et 
al., 2007) 
A 60°c,  
E 72°c, 
TM 77°c 
SREBP-1a F: 5’ –CGAGGTGTGCGAAATGGAC- 3’ 
R: 5’ –GAAGCATGTCTGATGTCGGTCA- 3’ 
(de Preux et 
al., 2007) 
A 58°c,  
E 72°c, 
TM 77°c 
SREBP-1c F: 5’ –ACGGAGCCATGGATTGCACA-­‐	  3’ 
R: 5’ -CAAATAGGCCAGGGAAGTC- 3’ 
(de Preux et 
al., 2007) 
A 60°c,  
E 72°c, 
TM 77°c 
Table 2.3.1 Gene specific primers. 
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Stage Condition Number of Cycles 
Hot Start 95°c, 10 minutes 1 
Denaturation 95°c, 15 seconds 40 
 
 
Annealing 58°c, 20 seconds 
Extension 72°c, 25 seconds 
Melt Primer Dimers 77°c, 1 second 
Table 2.3.2 Basic cycling conditions used for qPCR. 
E. coli transformation by ‘heat shock’ 
Aliquots containing 50µl of competent E. coli (DH5α strain) in 1.5ml eppendorf 
tubes were thawed on ice. The DNA to be transformed into the bacteria was 
then added directly to the thawed vials; typically this was ~20ng maxi prep 
DNA. After flicking several times to mix the DNA and bacteria the tubes were 
incubated on ice for 30-45 minutes before being heat-shocked at 42°c for 45 
seconds and then immediately chilled on ice for 2-3 minutes. After this, 1ml of 
SOC medium (Invitrogen) was added to each tube and the tubes were 
incubated, shaking, at 37°c for 45 minutes. The bacteria were then pelleted by 
centrifugation at 6000 RPM for 2 minutes in a tabletop centrifuge and, after 
removing 750µl using a P1000 Gilson pipette, resuspended in the remaining 
250µl of the supernatant. Usually, 50µl of this transformed bacterial suspension 
was spread onto LB agar plates and incubated overnight at 37°c.  
The LB agar plates were made by melting LB Broth agar (10g tryptone, 5g 
yeast extract, 5g NaCl, 1ml IN NaOH, 15g agar or agarose, to a final volume of 
1 liter in water), then leaving the melted agar until cooled to below 35°c before 
adding the appropriate antibiotic for selection (in all cases in this thesis, 
ampicillin to a final concentration of 100µg/ml) and pouring onto 10cm dishes 
(Sterilin). Plates were left to air dry in a sterile environment before use. 
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Growing up bacterial colonies and harvesting bacterial cultures using 
DNA maxi preps 
Single bacterial colonies from the LB agar plates described above were picked 
and added to 4ml LB broth (10g tryptone, 5g yeast extract, 5g NaCl, 1ml IN 
NaOH, to a final volume of 1 litre in water) containing the antibiotic ampicillin 
(100µg/ml) for selection in a 5ml tube (Sterilin), loosely fastened, and incubated 
for ~8 hours, shaking, at 37°c. After this time, 1ml of this starter culture was 
used to inoculate 100ml LB broth containing the antibiotic ampicillin (100µg/ml) 
for selection and left overnight, shaking, at 37°c. 
The bacteria from the overnight cultures were pelleted by centrifugation at 4000 
RPM for 20 minutes at 4°c (Beckman Coulter, Model J-6M). Plasmid purification 
was carried out using the EndoFree Plasmid Maxi Kit (QIAGEN) according to 
the manufacturers instructions, except that the final DNA pellet was 
resuspended in 100µl sterile ddH2O. The concentration of DNA was determined 
using a nanodrop spectrophotometer (Thermoscientific) from Abs260/280. DNA 
was stored at -20°c. 
DNA sequencing 
DNA was sequenced externally by Source Bioscience. Samples were sent as 
follows: 15µl DNA (100ng/µl) and primers (3.2pmol/µl). 
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DNA plasmid constructs used in the thesis 
The DNA constructs used in this thesis are as follows: 
Plasmid Vector Description Source Published 
pBabe-
puroERTM-
mSREBP1a 
pBabe-
puroERTM 
Retroviral 
expression 
vector 
Schulze 
lab 
(London 
Research 
Institute) 
N/A 
pBabe-
puroERTM-
mSREBP2 
pBabe-
puroERTM 
Retroviral 
expression 
vector 
Schulze 
lab 
(London 
Research 
Institute) 
N/A 
pBIRD-GFP pBIRD Retroviral 
expression 
vector 
Raff lab 
(LMCB, 
UCL) 
(Tang et al., 
2001) 
Table 2.3.3 DNA constructs used in the thesis 
 
2.4 Western Blotting 
Preparation of Protein Extracts from Whole Cell Lysates 
Cells were washed gently 1x in ice-cold PBS, scraped in 1ml ice-cold PBS 
using a rubber bung and transferred to a 2ml eppendorf, all on ice. Cells were 
pelleted by centrifugation at 4°c for 5 minutes at 7000 RPM in a tabletop 
centrifuge and, after aspirating the supernatant, the cell pellet was snap-frozen 
in liquid nitrogen. Cell pellets were stored at -80°c before lysis. Cell pellets were 
lysed in RIPA buffer (Table 2.4.5) and protein concentration of the lysate was 
determined using the microplate BCA assay (Pierce, according to 
manufacturers instructions. After taking samples for the BCA assay, sample 
buffer (4x) was immediately added to the lysates to a final dilution of 1x. After 
the BCA assay, the protein concentration of the sample buffer containing 
 	   104	  
lysates was adjusted using 1x sample buffer and lysates were boiled for 5 
minutes at 95°c.  
Preparation of Protein Extracts from Nuclear and Cytoplasmic Fractions 
Cells were washed gently 1x in ice-cold PBS, scraped in 1ml ice-cold PBS + 
protease inhibitors (Table 2.4.1) using a rubber bung and transferred to a 1.5ml 
eppendorf, all on ice. Cells were pelleted by centrifugation at 4°c for 5 minutes 
at 3000 RPM in a tabletop centrifuge (Biofuge) and, after aspirating the 
supernatant, the cell pellet was washed once with 500µl Buffer A (Table 2.4.2) 
and the centrifugation repeated. After aspirating the supernatant the cell pellet 
was resuspended in 4x pelleted cell volumes of Lysis Buffer (Buffer A + 0.5% 
NP40) and incubated on ice for 10 minutes. The suspension was flicked gently 
every 3 minutes during the incubation period to gently mix the contents. After 
centrifugation at 4°c for 10 minutes at 6000 RPM in a tabletop centrifuge the 
supernatant (cytoplasmic fraction) was transferred to a fresh eppendorf on ice 
and frozen at -80°c. The nuclear pellet was washed in 250µl of Buffer A and the 
centrifugation repeated. After aspirating the supernatant the nuclear pellet was 
resuspended in 1.5x pelleted cell volumes of Buffer C (Table 2.4.3) and 
incubated on ice for 15 minutes. The suspension was flicked gently every 5 
minutes during the incubation period to gently mix the contents. After 
centrifugation at 4°c for 30 minutes at 13000 RPM in a tabletop centrifuge the 
supernatant (cytoplasmic fraction) was transferred to a fresh eppendorf on ice 
and frozen at -80°c. Before running an SDS-PAGE, sample buffer (4x) was 
added to the lysates to a final dilution of 1x and boiled for 5 minutes at 95°c.  
 
 
 
 
 
 
 	   105	  
Reagent Source Final Concentration 
PBS Internal 1x 
β-glycerophosphate Sigma 6.48mg/ml 
Orthovanadate Sigma 1mM 
DTT Sigma 0.5mM 
Phenylmethanesulfonylfluoride 
(PMSF) 
Sigma 0.5mM 
Table 2.4.1 PBS + protease inhibitors. 
Reagent Source Final Concentration 
Hepes pH 7.9 Sigma 10mM 
Magnesium chloride Sigma 1.5mM 
Potassium chloride Sigma 10mM 
Protease inhibitor cocktail Sigma 1:50 
β-glycerophosphate Sigma 6.48mg/ml 
Orthovanadate Sigma 1mM 
DTT Sigma 0.5mM 
Phenylmethanesulfonylfluoride 
(PMSF) 
Sigma 0.5mM 
Table 2.4.2 Buffer A. 
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Reagent Source Final Concentration 
Hepes pH 7.9 Sigma 20mM 
Glycerol Sigma 25% 
Sodium chloride Sigma 0.5M 
Magnesium chloride Sigma 15mM 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma 0.2mM 
Protease inhibitor cocktail Sigma 1:50 
β-glycerophosphate Sigma 6.48mg/ml 
Orthovanadate Sigma 1mM 
DTT Sigma 0.5mM 
Phenylmethanesulfonylfluoride 
(PMSF) 
Sigma 0.5mM 
Table 2.4.3 Buffer C. 
SDS-PAGE 
Proteins were separated by SDS-PAGE, at room temperature (Table 2.4.4 for 
gel recipes). Proteins <30kDa were detected using 15% gels, 30-120kDa 
proteins using 10% gels and >120kDa proteins using 5% gels. PageRuler Plus 
Prestained protein ladder (Fermentas) was used for determination of protein 
molecular weights. 
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 Running Gel Stacking Gel 
30% Acrylamide/ 0.8% Bis  See text 17% 
1M Tris (pH8.8) 37% n/a 
1M Tris (pH 6.8) n/a 12% 
20% SDS 0.10% 0.10% 
10% Ammonium persulfate (APS) 0.040% 0.060% 
TEMED 0.047% 0.12% 
Table 2.4.4 SDS-PAGE gel recipes, showing final concentrations (to 2s.f.). 
Protein Transfer and Immunoblotting 
Proteins were transferred to a PVDF membrane (Immobilon) by wet transfer 
(Table 2.4.5), at 25V (0.5-1 Amp) for 2 hours at 4°c. Membranes were blocked 
for 1 hour at room temperature in 5% milk/TBS-T (Table 2.4.5) and incubated 
overnight at 4°c in primary antibody in block solution, rotating (Table 2.4.6). The 
following day, the membrane was washed for 3x 10 minutes in TBS-T and then 
incubated in secondary antibody in block solution (Table 2.4.6) for 2 hours at 
room temperature, rotating. After washing for 3x 10 minutes in TBS-T and 1x 5 
minutes in TBS, membranes were developed using ECL/ ECL+ developing 
reagent (GE Healthcare, Table 2.4.6) and exposed using the ImageQuant LAS 
4000 mini CCD camera system (GE Lifesciences). Where membranes required 
stripping and reprobing; membranes were incubated rocking for 1 hour in 1x 
stripping buffer (Table 2.4.5), then washed for 3x 5 minutes in TBS-T and 
reblocked for 1 hour in 5% milk/TBS-T, all at room temperature, before being 
incubated in primary antibody, as before.  
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Solution Recipe 
RIPA Lysis Buffer 100mM NaCl, 1% TritonX-100, 0.5% 
sodium deoxycholate, 0.1% SDS, 
50mM Tris pH7.5, 1mM EGTA, 20mM 
NaF, 100µg/ml 
phenylmethanesulfonylfluoride 
(PMSF), 15µg/ml aprotinin, 1mM 
Na3VO4 
Sample Buffer (4x) 200mM Tris pH6.8, 400mM DTT, 8% 
SDS, 0.2-0.4% Bromphenol Blue, 
40% glycerol 
Running Buffer (10x) 50mM Tris, 500mM Glycine, 0.1% 
SDS 
Transfer Buffer (1x), for 10% and 
15% gels 
20% Methanol, 40mM Tris, 300mM 
glycine 
Transfer Buffer (1x), for 5% gels 10% Methanol, 0.1% SDS, 40mM 
Tris, 300mM glycine 
TBS-T (20x) 200mM Tris base pH8, 3M NaCl, 
0.02% Tween-20 
TBS (20x) 200mM Tris base pH8, 3M NaCl 
5% Milk/ TBS-T Skimmed milk powder in 1x TBS-T 
Stripping Buffer (1x) 200mM glycine pH 2.5, 0.4% SDS 
Table 2.4.5 Solutions used for protein extraction and Western blotting. 
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Antibody Source Dilution Secondary 
Antibody 
Develop 
Using 
Mw  
(kDa) 
pERK1/2 Sigma (M5670) 1:5000 α-mouse HRP ECL 42/44 
ERK1/2 Sigma (M8159) 1:10000 α-rabbit HRP ECL 42/44 
pS6K 
(thr389) 
Cell Signalling 
Technology 
(CST) (9205S) 
1:1000 α-rabbit HRP ECL+ 76 
pAkt 
(ser473) 
CST (193H12) 1:2000 α-rabbit HRP ECL+ 60 
ERα (MC-
20) 
Santa Cruz (sc-
542) 
1:1000 α-rabbit HRP ECL+ N/A 
SREBP1 
(2A4) 
Neomarkers 
(MS-1207) 
1:500 α-mouse HRP ECL+ 125/68 
SREBP2 Abcam 
(ab30682) 
1:500 α-rabbit HRP ECL+ 125/68 
mSin3a 
(AK-11) 
Santa Cruz (sc-
767) 
1:1000 α-rabbit HRP ECL 150 
GAPDH Millipore 
(MAB374) 
1:1000 α-mouse HRP ECL 36 
Vinculin Sigma (V9131) 1:1000 α-mouse HRP ECL 116 
β-tubulin Sigma (T4026) 1:2000 α-mouse HRP ECL 55 
α-rabbit 
HRP 
GE Healthcare 1:2000 n/a n/a n/a 
α-mouse 
HRP 
GE Healthcare 1:2000 n/a n/a n/a 
Table 2.4.6 Antibodies used for Western blotting. 
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2.5 Immunofluorescence and Fluorescent Labelling of 
Subcellular Components  
Immunofluorescence 
Cells were cultured on 13mm glass coverslips and fixed in 4% PFA (TAAB) in 
PBS for 15 minutes at room temperature. After washing 2x in PBS cells were 
permeabilised in dilutions of TritonX-100 (BioRad) in PBS, or ice-cold Methanol 
(VWR) at room temperature before blocking and incubating overnight at 4°c in 
primary antibody diluted in fresh blocking reagent, as described in Table 2.5.1. 
The following day, coverslips were washed 6x in PBS and incubated at room 
temperature for 1 hour in 3% BSA/PBS containing Alexafluor-conjugated 
secondary antibody (1:500) (Molecular Probes) plus Hoescht (1:5000). 
Coverslips were then washed 5x in PBS, 1x in ddH2O and mounted on glass 
slides (VWR) in Fluoromount G mounting medium (Southern Biotech).  
Imaging of fixed cell slides was performed depending on the cellular parameter 
subsequently quantified, as follows (detailed imaging protocols are described in 
section 2.6): 
1. Organelle volume: Leica SPE confocal microscope.  
2. Organelle number, area and fluorescence intensity: Zeiss Axioskop 2 
widefield microscope.  
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Antibody Source Dilution Permeabilise Blocking 
solution 
Secondary 
Antibody 
α-TGN38 Sigma 
(T9826) 
1:500 0.2% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-rabbit 
Alexa Fluor 
488 
α-fibrillarin Abcam 
(ab4566) 
1:500 0.2% TritonX-
100/PBS, 10 
minutes 
3% 
BSA/PBS 
α-mouse 
Alexa Fluor 
488 
α-GM130 BD 
Transducti-
on (610822) 
1:100 0.2% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-mouse 
Alexa Fluor 
488 
α-catalase Gift from 
Prof. C. 
Danpure, 
UCL 
1:500 0.3% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-guinea 
pig  
Alexa Fluor 
555 
α-LC3B Nanotools 
(0231-100) 
1:250 Ice-cold 
methanol, 5 
minutes 
3% 
BSA/PBS 
α-mouse 
Alexa Fluor 
488 
α-KDEL Stressgen 1:1000 0.2% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-mouse 
Alexa Fluor 
488 
α-ERα 
(MC-20) 
Santa Cruz 
(sc-542) 
1:50 0.5% TritonX-
100/PBS, 5 
minutes 
10% 
BSA/ 
0.1% 
Tween-
20/ PBS 
α-rabbit 
Alexa Fluor 
488 
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α-SREBP1 
(2A4) 
Neomarkers 
(MS-1207) 
1:150 0.1% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-mouse 
Alexa Fluor 
488 
α-SREBP2 Abcam 
(ab30682) 
1:150 0.1% TritonX-
100/PBS, 5 
minutes 
3% 
BSA/PBS 
α-rabbit 
Alexa Fluor 
488 
Table 2.5.1 Antibodies used for immunofluorescence. 
 
Fluorescent Labelling of Subcellular Compartments 
Nucleus (Hoescht)  
Cells were cultured on 13mm glass coverslips and fixed in 4% PFA/PBS for 15 
minutes at room temperature. After washing 2x in PBS cells were permeabilised 
in 0.2% Tween-20/PBS for 5 minutes at room temperature, washed 2 x in PBS, 
1 x in PBS plus Hoescht (1:10000) for 20 seconds, then a further 2 x in PBS 
before being mounted on glass slides in FluoromountG mounting medium. 
Imaging of fixed cell slides was performed using a Leica SPE confocal 
microscope, as described in section 2.6. 
Mitochondria (Mitotracker Green) 
Cells were cultured on 13mm glass coverslips. Stocks of 1mM Mitotracker 
Green (Molecular Probes) were prepared in DMSO and stored at -20°c for up to 
1 year. Working stocks were prepared by diluting the stocks to 50µM in DMSO 
and stored at -20°c for 1-2 months. Mitotracker was used at a final 
concentration of 100nM, by adding working stock directly to the medium of cells 
growing on coverslips. The cells were then incubated in the dark for 1 hour at 
37°c, before being washed 2 x in PBS and fixed in 4% PFA/PBS at room 
temperature for 15 minutes. After permeabilisation in ice-cold acetone for 5 
minutes at room temperature, the coverslips were washed 5 x in PBS and 1 x in 
H2O, before being mounted on glass slides in ProLong Gold mounting medium 
(Invitrogen). 
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Imaging of fixed cell slides was performed using a Leica SPE confocal 
microscope, as described in section 2.6. 
Lipid Droplets (Oil Red O) 
Oil Red O stock solutions were made fresh for each experiment. The day 
preceding the experiment, Oil Red O powder was dissolved at a concentration 
of 5mg/ml in 100% isopropanol in a 37°c water bath for 1 hour, vortexing every 
10 minutes, then passed through a 0.2µm filter and left at 4°c overnight. On the 
day of the experiment, the working solution was made by diluting the stock 
solution to a final concentration of 60% isopropanol, heating to 37°c and then 
leaving to cool at room temperature for 30 minutes before use.   
Cells to be stained were cultured on 13mm glass coverslips and fixed in 4% 
PFA/PBS for 15 minutes at room temperature. Coverslips were then washed 1 x 
in H2O and 1 x in 60% isopropanol for 20 seconds each before being incubated 
at room temperature with the working Oil Red O solution for 20 minutes. 
Coverslips were washed free of Oil Red O by rinsing 1 x in 60% isopropanol, 
then washing 3 x in H2O, the middle wash containing Hoescht (1:10000) to stain 
the nuclei, before being mounted on glass slides in mounting medium. 
Imaging of fixed cell slides was performed using a Zeiss Axioskop 2 widefield 
microscope, as described in section 2.6. 
Plasma Membrane (Cell Mask and FM1-43) 
1. Cell Mask: 
Cells were cultured on 13mm glass coverslips. Staining solutions were prepared 
by diluting Cell Mask Orange stock solution (1:20000, final concentration 
2.5µg/ml) (Molecular Probes) in warm conditioned medium. To label the cells, 
the coverslips were removed from the incubator, the culture medium aspirated 
and replaced with 500ul per well of the staining solution and the cells incubated 
in the stain solution for 5 minutes at 37°c. The stain solution was then removed, 
the coverslips washed 3 x with PBS and fixed in 4% PFA/PBS for 15 minutes at 
room temperature. After washing 2 x in PBS coverslips were mounted on glass 
slides in ProLong Gold mounting medium. 
 	   114	  
Imaging of fixed cell slides was performed using a Leica SP5 confocal 
microscope, as described in section 2.6. 
2. FM1-43: 
Cells were cultured on glass-bottomed dishes (Mattek, P35G-1.0-14-C). Stocks 
of 1mM FM1-43 (Molecular Probes) were prepared in ddH2O and stored at -
20°c. For prepare solutions for staining; FM1-43 stocks were diluted in warm 
conditioned medium, using medium that lacks phenol Red, at various 
concentrations (Surface Area=5µg/ml, 0-9 mins Endocytosis=2.5µg/ml, 0-
60mins Endocytosis=10µg/ml, 0-60mins endocytosis with azide=2.5µg/ml). 
Cells were labelled live, whilst on the microscope stage (section 2.6). To label 
the cells, culture medium was removed from the cell culture dishes with a 
P1000 Gilson pipette and replaced with the FM1-43 staining solution, initially for 
1 minute representing the time=0mins labelling. This was taken to represent 
labelling of the plasma membrane only. To image, the stain solution was 
removed with a P1000 Gilson pipette and replaced with imaging medium (plain 
DMEM lacking phenol Red) and the cells rapidly imaged.  
For cell surface area experiments cell populations were seeded and treated in 
parallel and at each timepoint a single population was FM1-43 labelled and 
imaged, as for time=0mins above. Plasma membrane growth rates were 
calculated as follows: 
Growth rate hr-1 (relative to size at t=0hrs): 
 = Total cell fluorescencetime=t – Total cell fluorescencetime=0 
  t * Total cell fluorescencetime=0 
And: 
Growth rate min-1 = Growth rate hr-1  
            60 
For plasma membrane endocytosis and recycling experiments, sequential 
labelling then imaging was repeated as necessary to quantify membrane 
internalisation over time.  
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Imaging was performed using spinning disc confocal microscopy as described 
in section 2.6. 
 
2.6 Fluorescence Microscopy 
Widefield Microscopy 
Coverslips mounted on glass slides were imaged using either: 
1. NIKON Eclipse Ti, with accompanying NIS elements software (Nikon). 
Images were taken using a 20x objective (0.8x NA) 
2. Zeiss Axioskop 2 (Zeiss), with OpenLab software (Perkin Elmer). Images 
were taken using a 25x objective (0.8x NA) 
Images were taken ensuring no saturation of pixel intensity. 
Confocal Microscopy 
Fixed Cell  
Coverslips mounted on glass slides were imaged using either: 
1. Leica TCS SPE Confocal Microscope, with accompanying Leica LAS AF 
software. Images were taken using a 63x (1.3 Numerical Aperture (NA)) or 
40x (1.15x NA) objective, with a 1.5x zoom. Images were taken at 
1024x1024 pixels therefore xy pixels had a 113.79nm (63x objective) or 
179.21nm (40x objective) diameter. Optical sections were taken at 252nM 
intervals. Images were collected at 600Hz, with a 2 x frame average.  
2. Leica TCS SP5 Confocal Microscope, with accompanying Leica LAS AF 
software. Images were taken using a 40x objective (1.3 NA), with 1.7 zoom. 
Images were taken at 1024x1024 pixels therefore xy pixels had a 222.8nm 
diameter. Optical sections were taken at 305nm intervals.  Images were 
collected at 700Hz, with a 2x frame average. 
For SPE and SP5 based imaging, fluorescence was excited and emission 
wavelengths collected as described in Table 2.6.1. Stacks of images were 
taken through the depth of the cell, ensuring no saturation of pixel intensity. 
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Live Cell 
Spinning disc confocal microscopy was performed using a Perkin Elmer 
Ultraview Vox Confocal Imaging System with a Nikon Eclipse Ti microscope 
and using Volocity software. Cells growing on glass-bottomed dishes were 
placed on the microscope stage in a chamber supplied with a humidified gas 
mixture (90% air/ 10% CO2) within a heated environmental chamber, set at 
37°c, which also contained the body of the microscope and objective lens. 
Imaging was performed using a 40x or 20x objective and collected using a 
Hamamatsu C9100-13 CCD camera. Images were taken at 512x512 pixels 
therefore xy pixels had a 2.7µm diameter. Optical sections were taken at 0.5µm 
intervals. Differential Interference Microscopy (DIC) images were taken at the 
plane of best focus at the start of the experiment. 
Fluorescent Marker Laser (nm) 
Hoescht 405 
Alexa Fluor 488 488 
Alexa Fluor 555 532 
Oil Red O 532 
Mitotracker Green 488 
Cell Mask Orange 532 
Tetramethylrhodamine 
Dextran (10k Mw) 
532 
Table 2.6.1 Wavelengths used to excite/ emission spectra wavelengths 
collected for fluorescence microscopy. 
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2.7 Image Quantification after Fluorescence Microscopy 
Cell Surface Area (Cell Mask Orange) 
Cell surface area was quantified from image stacks taken through the depth of 
Cell Mask Orange labelled cells using a Leica SP5 confocal microscope. 
Image stacks were opened in ImageJ, Autothresholded from the brightest slice 
and made into binary images. Cell surface area was quantified as the sum of 
the cell surface area in the XYZ and XZY planes as follows: Cell surface area in 
the XYZ plane was taken as 2 x the thresholded cell area in the maximal 
projection of the image stack and in the XZY plane as the thresholded cell 
perimeter per slice of the image stack x interslice distance (z-spacing = 252nm). 
Cell area from maximal projections and cell perimeter per slice of image stacks 
were measured using the Analyse particles function, with the area and 
perimeter measurement functions activated within ‘Set Measurements’, 
respectively. Particles less than 10 pixels in size were excluded from 
measurements. This eliminated inclusion of background staining in the 
quantification.  
Organelle Volume  
Image stacks taken using fluorescence confocal microscopy (section 2.5) were 
opened in ImageJ (National Institute of Health), a region of interest (ROI) drawn 
around the organelle to be measured and the stack Autothresholded based on 
the brightest slice. The area of thresholded pixels in each slice was measured 
using the Analyse Particles function, with a minimal particle size of 10 pixels. 
This successfully excluded background staining from analyses. To obtain the 
volume of the organelle, the total area of pixel staining was multiplied by pixel 
depth. Organelle volume per unit of cell volume was calculated as the mean 
organelle volume/ mean cell volume measured using the CoulterCounter in a 
set of parallel experiments (section 2.2).  
Organelle Area 
Images taken using widefield microscopy (section 2.6) were opened in ImageJ. 
The ‘Subtract Background’ function was used to remove background, with a 
rolling ball radius of 50 pixels and no smoothing. Images were thresholded and 
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made binary. The threshold level was constant per experiment, but varied 
between experiments and the appropriate threshold was determined 
subjectively by eye. The Create Selection function was used to automatically 
outline the thresholded area and the contained area was then quantified using 
the Measurement function. 
Organelle Number 
Maximal projections of image stacks taken using fluorescence confocal 
microscopy (section 2.6) were generated in ImageJ and converted to 8-bit. The 
maximal projections were thresholded so minimal thresholded pixel 
intensity=100. The number of particles (organelles) was counted using the 
Analyse Particles function, with a minimal particle size of 10 pixels to exclude 
background staining. Organelle number per unit of cell volume was calculated 
as the mean organelle number/ mean cell volume measured using the 
CoulterCounter in a set of parallel experiments (section 2.2). 
Where appropriate, mean cell volume was taken from CoulterCounter 
measurements and mean cell protein was taken from BCA measurements of 
parallel cell cultures and used to calculate mean organelle number per unit of 
cell volume/ protein. 
Fluorescence Intensity 
Image stacks taken using standard fluorescence confocal microscopy, spinning 
disc confocal microscopy or single images taken using widefield microscopy 
(section 2.6) were opened in ImageJ. For the confocal images, the Sum of Slice 
function was used for each stack to generate a single image whose pixel values 
represented the sum of pixel intensities at that location through the depth of the 
slice from the confocal images. Total fluorescence (corresponding to the plasma 
membrane and internalised plasma membrane for FM1-43 staining (section 2.5) 
or the amount of internalised fluorescent dextran (section 2.11) was determined 
per cell by quantifying the sum of pixel intensities within an ROI containing the 
cell of interest, corrected for background fluorescence by subtracting from each 
pixel within the ROI the mean non-cellular pixel value, i.e. background pixel 
value. The mean background pixel value was taken as the mean pixel value of 
two randomly drawn ROIs in regions of the image containing no cells, but as 
close to the cell being quantified as possible. 
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2.8 Transmission Electron Microscopy (TEM) 
Cell Preparation and Imaging 
After washing 2x in PBS, cells grown on 13mm glass coverslips were fixed in 
2% PFA (EM Grade)/2% gluteraldehyde (TAAB, EM Grade) in 0.1M cacodylate 
for 30 minutes at room temperature. Post-fixation, cells were osmicated in the 
dark for 1 hour at 4°c in a 1:1 solution of 2% osmium tetroxide (TAAB): 3% 
potassium ferricyanide, washed 3 x in 0.1M cacodylate then incubated in 1% 
tannic acid/ 0.05M cacodylate for 40 minutes at room temperature, before 
washing a further 2 x in 0.05M cacodylate and 1 x in ddH2O. The cells were 
then dehydrated in successive washes of 70% ethanol, 90% ethanol (3 minutes 
each) and 2 x 100% ethanol, (10 minutes each). Coverslips were embedded in 
EPON (Table 2.8.1) by first passing through a transition solvent of 1:1 
polypropylene oxide (Fisher Scientific): EPON for 1 hour at room temperature, 
followed by 2 x 1 hour incubations at room temperature in 100% EPON at which 
point the coverslips were mounted cell side down on pre-polymerised EPON 
stubs and baked overnight at 60°c. The coverslips were removed from the cell 
embedded EPON stubs by freezing in liquid Nitrogen before ultrathin sections 
were cut from the EPON stubs and mounted on Formvar (Agar Scientific) 
coated grids. A systematic random sampling method was used in sectioning to 
ensure a representative sample population was obtained that would be suitable 
for stereological analysis. This involved taking sections every approximately 
250nm, from a randomised starting height within the top of the EPON stub. To 
improve the contrast of images, sections were stained with lead citrate before 
imaging. Sections were inverted onto lead citrate droplets (in the presence of 
NaOH crystals to prevent moisture absorption by the droplets) and left for 15 
minutes at room temperature, before being washed 5x in ddH2O and left to air 
dry. 
Imaging was performed on a Tecnai Spirit Transmission Electron Microscope 
(TEM) with iTem software (Olympus). Images were taken at 3860x2524 pixels 
and 16500 magnification. Sections were imaged at random to obtain a set of 
images for analysis that was representative of the cell population through the 
depth of the cell. 
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Reagent Final Concentration Source 
Epon 812  48% TAAB 
Dodecenyl succinic anhydride 
(DDSA) (Distilled Grade) 
19% TAAB 
Methyl nadic anhydride (MNA) 33% TAAB 
2,4,6-tris(Dimethylaminomethyl) 
phenol (DMP-30) 
2% TAAB 
Table 2.8.1 EPON recipe. 
Stereological Analysis of Transmission Electron Microscopy Images 
Electron microscopy images were analysed within ImageJ. According to the 
principle of Delesse, area fraction is equivalent to volume fraction. Therefore 
organelle volume per cell was calculated as the organelle area per unit cell area 
x mean cell volume. Organelle and cell areas were estimated by tracing their 
respective perimeters within each image using the freehand draw tool in ImageJ 
and quantifying the contained areas. Lipid droplet number per cell was 
calculated using a modification of the method of Weibel and Gomez (Weibel, 
1962), as follows: 
 Number per unit volume= K*(number per unit area3/2) 
     β*volume fraction1/2 
Where K is an arbitrary constant taken as 1 if the size distribution of the object 
is minimal, as is the case here, and β is the width to length ratio of the object, 
which I have taken as 1 as lipid droplets are approximately spherical. 
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2.9 Measuring De Novo Lipid Synthesis 
Cells were seeded onto PLL, fibronectin (10µg/ml) and treated as described in 
section 2.1 ‘Protocol for Cell Cycle Arrest and Transfer to Defined Growth 
Factor-Free Conditions’, using Minimal Medium. After treatment as indicated in 
the results for 4 hours, cells were incubated with 2.5µCi/well [2-14C] pyruvate 
(250µM final concentration) (Perkin Elmer) for a further 4 hours. After washing 
2x with PBS, cells were lysed in 1ml 0.5% TritonX-100/PBS. Lipids were 
extracted by successive addition of 2ml methanol, 2ml chloroform (VWR) and 
1ml water, vortexing for 3-5 minutes between each addition. Phase separation 
was achieved by centrifuging the samples for 15 minutes at room temperature 
and 1500g. The lower organic phase was transferred to a scintillation vial and 
allowed to air dry at room temperature overnight. The lipids were dissolved in 
5ml Ultima Gold LSC Cocktail (Perkin Elmer) and counts per minute quantified 
using a scintillation counter. Counts were normalised to the cell number of 6-
well dishes seeded and cultured in parallel. 	  
 
2.10 Endocytosis and Recycling of Cell Surface Protein (Cell 
Surface Protein Biotinylation) 
Total Cell Surface Protein Endocytosis and Recycling 
Biotin labelling solution was prepared immediately before the assay, as follows: 
0.5mg/ml EZ-Link Sulfo-NHS-SS-Biotin (Pierce) was dissolved in ice-cold 
PBS/1mM MgCl2/0.5mM CaCl2 (PBS++), by rotating at 4°c for 15 minutes. 
Cells cultured on 13mm glass coverslips were washed 2 x in ice-cold PBS++ to 
halt cell metabolism, including endocytosis and recycling, and incubated for 12 
minutes on ice in biotin labelling medium, rotating gently. After this time, the 
labelling medium was aspirated and any remaining free biotin was quenched by 
3 x 5 minute washes, on ice and rotating, in ice-cold Quenching Buffer (1mg/ml 
BSA/PBS++). After the final wash in Quenching Buffer, cells were washed 2 x 
on ice in ice-cold PBS++.  
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Endocytosis: 
To perform the endocytosis assay the biotin labelled cells/coverslips were 
washed quickly 2 x in pre-warmed 37°c plain DMEM to rapidly warm them to 
37°c so endocytosis would resume and the coverslips inverted onto 70ul of 
conditioned medium and incubated at 37°c. At specified times, coverslips were 
placed in ice-cold PBS++. At the end of the assay remaining cell surface biotin 
was cleaved by washing the cells 1 x in ice-cold Cleavage Buffer (Table 2.9.1) 
and then incubating the cells on ice and rotating for 2 x 15 minutes in ice-cold 
Cleavage Buffer. After aspirating the final Cleavage Buffer wash, remaining 
Cleavage Buffer was removed by washing the cells thoroughly 5 x in ice-cold 
PBS++. Subsequently, cells were fixed in 4% PFA/PBS for 20 minutes, washed 
2 x in PBS and then permeabilised for 10 minutes in 0.2% TritonX-100, all at 
room temperature. Following fixation and permeabilisation, internalised and 
intracellular biotin was detected by incubating the cells/coverslips for 1 hour in 
1:250 Alexa488-Streptavidin (Molecular Probes) at room temperature. After 
labelling, coverslips were washed 5x in PBS, 1x in ddH2O and mounted on 
glass slides in FluoromountG mounting medium.  
Recycling: 
As for the endocytosis assay described above, the biotin labelled 
cells/coverslips were washed quickly 2 x in pre-warmed 37°c plain DMEM to 
rapidly warm them to 37°c so endocytosis would resume and the coverslips 
inverted onto 70ul of conditioned medium and incubated at 37°c for 45 minutes 
to allow internalisation and filling of the recycling path. After this time, coverslips 
were placed in ice-cold PBS++ and remaining cell surface biotin was cleaved by 
washing the cells 1 x in ice-cold Cleavage Buffer (Table 2.9.1) and then 
incubating the cells on ice and rotating for 2 x 15 minutes in ice-cold Cleavage 
Buffer. After aspirating the final Cleavage Buffer wash, remaining Cleavage 
Buffer was removed by washing the cells thoroughly 5 x in ice-cold PBS++. To 
perform the recycling assay, the coverslips were then washed quickly 2 x in pre-
warmed 37°c plain DMEM to rapidly warm them to 37°c so trafficking would 
resume and the coverslips inverted onto 70ul of conditioned medium containing 
50mM glutathione (pH adjusted back to 7-7.4 using sodium hydroxide (BDH)) 
and incubated at 37°c (the glutathione cleaved biotin that was returned to the 
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cell surface by recycling, preventing re-internalisation of the biotin by 
endocytosis). At specified times, coverslips were placed in ice-cold PBS++. At 
the end of the assay, any remaining cell surface biotin was cleaved using the 
protocol already described. Cells were then fixed and intracellular biotin labelled 
with Alexa488-Streptavidin as described for the endocytosis assay above. 
 
Reagent Final Concentration Source 
Glutathione  50mM Sigma 
EDTA 10mM Sigma 
NaCl 75mM Sigma 
BSA 1% Sigma 
NaOH 750mM BDH 
ddH2O N/A MilliQ 
Table 2.9.1 Cleavage buffer recipe. 
Analysis: 
Intracellular biotin was imaged using fluorescence widefield microscopy (Zeiss 
Axioskop 2) and quantified as total intracellular fluorescence per cell as 
described (sections 2.6 & 2.7). The mean fluorescence intensity per cell of cells 
after 0 minutes of endocytosis (Coverslips biotin labelled but not returned to 
37°c before cell surface biotin was cleaved, i.e. cells where endocytosis and 
recycling of cell surface biotinylated proteins has not occurred) was subtracted 
from the mean intensity per cell at each timepoint, to control for uncleaved cell 
surface biotin.  
 
2.11 Endocytosis and Recycling of Cell Surface Lipid (FM1-43) 
The lipophilic styryl dye FM1-43 was used as a marker of plasma membrane 
endocytosis and recycling. Labelling was carried out and single cells imaged as 
described (sections 2.5 & 2.6). Fluorescence intensity was quantified as 
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described (section 2.7). Internalised membrane at time=t was quantified as 
follows: 
Internalised   =  Total cell    –  Total cell  
membranetime=t   fluorescencetime=t  fluorescencetime=0 
Endocytosis rates (min-1) were calculated from linear regression analysis on the 
internalised membrane across 0-9 minutes uptake. The rate at which FM1-43 
accumulates in the cell is after endocytosis (min-1), i.e. the rate when endocytic 
and recycling rates are in equilibrium representing the proportion of internalised 
membrane not recycled back to the cell surface, was calculated from linear 
regression analysis on the internalised membrane across 10-60 minutes 
uptake. Recycling rates (min-1) were calculated by subtracting the rate of FM1-
43 accumulation (10-60 minutes) from the rate of endocytosis. Rate analyses 
were performed on the mean data across all experiments performed. 
 
2.12 Endocytosis and Recycling of Fluid-Phase (Fluorophore-
Conjugated Dextran) 
Microscopy Based Assay 
Cells cultured on 13mm glass coverslips were inverted onto 70µl of 
tetramethylrhodamine dextran 10k Mw (2mg/ml) (Molecular Probes) in 
conditioned medium and incubated at 37°c. At specified times, coverslips were 
placed in ice-cold Ca2+ and Mg2+ free PBS (PAA) on ice and washed gently 10x 
with ice-cold Ca2+ and Mg2+ PBS. Subsequently, cells were fixed in 4% 
PFA/PBS on ice for 30 minutes, washed 3 x in PBS, the middle wash containing 
Hoescht (1:10000) to stain the nuclei and mounted on glass slides in mounting 
medium. 
Internalised dextran was imaged using fluorescence confocal microscopy and 
quantified as total intracellular fluorescence per cell as described (sections 2.6 
& 2.7). The mean fluorescence intensity per cell of control coverslips incubated 
for the length of the timecourse inverted onto 70ul of pre-chilled 
tetramethylrhodamine dextran 10k Mw (2mg/ml) in conditioned medium and on 
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ice was subtracted from the mean intensity per cell at each timepoint, to control 
for marker that became associated with the plasma membrane. 
Rates of endocytosis and recycling of dextran were calculated from these 
values of total intracellular fluorescence per cell over time as described for FM1-
43. 
 
2.13 Statistical Analysis 
All statistical analyses were performed using Prism4 (Graphpad). Analyses 
were performed as described in figure legends in the Results. Where Two-Way 
ANOVA was carried out, post hoc Bonferroni tests were applied. Where One-
Way ANOVA was carried out, post hoc Newman-Keuls testing was performed 
when fewer than 5 comparisons were made and post hoc Tukey’s testing was 
performed when greater than or equal to 5 comparisons were made. 
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Chapter 3: Results 
Biogenesis Downstream of IGF-1 Stimulation or Raf/ MEK/ ERK 
Activation 
 Cell growth is classically associated with an increase in cell volume. This 
may involve a proportional increase in cell mass, organelle content and volume- 
as occurs in proliferating transit amplifying cell populations in vivo or when cells 
are proliferating exponentially in culture. These cells usually double their 
volume, mass and organelle content across the cell cycle before dividing to 
produce two daughter cells roughly equivalent to the starting mother cell. 
However, when the diversity in cell size, morphology and organelle content of 
different cell types in vivo is considered it is clear that non-uniform cell growth 
(where the addition of cell volume and organelle biogenesis occurs uncoupled) 
is also a frequent event. This is particularly well demonstrated by examples of 
differential organelle biogenesis within a single cell. For example, in an 
activated B cell the endoplasmic reticulum (ER) expands disproportionately to 
the accompanying increase in cell volume, which means ER density within the 
cell increases (Federovitch et al., 2005, Kirk et al., 2010, Rush et al., 1991). 
This is necessary for the mature B-cell to produce sufficient immunoglobulins 
during the immune response. The diversity in cell morphology across and within 
the development of different cell types shows that cell growth is distinctly more 
complex than the coordinate addition of cell mass and volume.  
 IGF-1 is classified as a Schwann cell growth factor because it drives 
addition of cell volume (Conlon et al., 2001, Echave et al., 2009). In contrast 
NRG-1 has not historically been considered as a growth factor because it 
cannot drive addition of Schwann cell volume (Conlon et al., 2001, Echave et 
al., 2009). However studies from our lab have shown that NRG-1 induces 
Schwann cell mitochondrial biogenesis, which increases mitochondrial volume 
in the cell (Echave et al., 2009); as NRG-1 does not drive an increase in cell 
volume, mitochondrial density increases. These results show that NRG-1 does 
have biogenic capabilities and therefore could be considered as a growth factor, 
even though it does not drive the addition of cell volume. 
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 As outlined in the introduction, major signalling pathways activated 
downstream of both IGF-1 and NRG-1 are the PI3K/ Akt and the Raf/ MEK/ 
ERK pathways (Echave et al., 2009). In the Schwann cell, both IGF-1 and NRG-
1 transiently activate equivalent and strong signalling through both ERK and Akt 
(Echave et al., 2009). However NRG-1 drives sustained ERK signalling 
whereas IGF-1 drives sustained Akt signalling (Echave et al., 2009). The ability 
of IGF-1 to drive addition of Schwann cell volume depends on the PI3K/ Akt 
pathway (Echave et al., 2009).  
 In light of the mitochondrial findings this thesis aimed to investigate 
biogenesis downstream of the PI3K/ Akt and ERK signalling pathways in further 
detail. To specifically activate ERK signalling; these studies used Schwann cells 
that stably express a tamoxifen (Tmx) inducible Raf kinase construct 
(NSΔRafER cells) (Samuels et al., 1993); application of Tmx (100nM) results in 
sustained Raf kinase activation. In this way it is possible to drive sustained and 
specific ERK signalling, without activation of PI3K/Akt (Samuels et al., 1993). 
The NSΔRafER cell system was used to compare the biogenic effects of ERK 
signalling to those of IGF-1 stimulation- a condition that drives PI3K/ Akt 
dependent addition of cell volume. 
 The basic experimental protocol used throughout was as follows: 
NSΔRafER cells were cell cycle arrested, using the DNA polymerase α inhibitor 
aphidicolin, in the presence of serum for 24hrs (Conlon and Raff, 2003, Conlon 
et al., 2001, Costa et al., 1992, Echave et al., 2009, Ikegami et al., 1978). The 
use of aphidicolin allowed the biogenic effects of Raf kinase or IGF-1 to be 
tested independently of effects each may have on cell cycle progression. This is 
important because if cells are dividing the biogenic effects are spread over an 
increasing number of cells and is difficult to follow. If cells are not dividing the 
biogenic effects are contained within single cells and can be more easily 
observed and quantified. Following this, cells were transferred to defined 
conditions (free from exogenous mitogens, growth factors and survival factors: 
Minimal Medium) plus aphidicolin for a further 24 hours. At this point, cells were 
treated with IGF-1 or the Raf kinase construct was activated using Tmx and 
assays conducted as indicated in the text, again in the presence of aphidicolin. 
Maintaining the cells in defined conditions free from exogenous mitogens, 
growth factors and survival factors (Minimal Medium) for 24 hours prior to Raf 
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kinase activation or IGF-1 stimulation provided a clean background against 
which the effects of these stimuli could be assayed. Variations in this protocol, 
both in cell type and/ or experimental conditions, are highlighted and described 
where they have been used. 
 
3.1 The Addition of Mass and Volume can be Uncoupled During Cell 
Growth 
 The addition of cell volume is one parameter, and the classical 
descriptor, of cell growth. It is generally considered that cell mass correlates 
with cell volume, and the two parameters have traditionally been used 
interchangeably. As has been demonstrated in previous studies, IGF-1 drives 
an increase in Schwann cell volume, as shown in Figure 3.1 and 3.3 A (Conlon 
et al., 2001, Echave et al., 2009). Cell volume was quantified in two ways in 
these studies. First using the Coulter Counter (Figure 3.1) (Materials & Methods 
2.2), which measures the volume of small particles by volume displacement as 
they pass through the instruments measuring aperture. The volume of 
trypsinised cells (because cells must be in suspension to pass through the 
coulter counter) was quantified after 24 hours IGF-1 stimulation or Raf kinase 
activation and compared to untreated control cells. Data previously published 
by the Lloyd lab showed the volumes quantified by this method are comparable 
to those of equivalent adherent cells quantified from confocal stacks of cells 
labelled with a fluorescent cytosolic dye, indicating that trypsinising cells does 
not significantly affect their volume and therefore that Coulter Counter 
measurements are a reliable quantitative measure of cell volume (Echave et al., 
2007). In the second approach, cell volume was measured using Quantitative 
Phase Microscopy (QPM) and were performed in collaboration with the 
Kirschner Lab, Harvard Medical School (Figure 3.2 & 3.3 A) (Materials & 
Methods 2.2). QPM can be used to quantify the phase-shift of the light waves of 
a beam of light as they pass through a material, e.g. a cell. Cell volume can be 
calculated from the difference in the extent of the phase-shift when a cell is 
measured in two different media that have different refractive indices (in this 
case, conditioned medium and conditioned medium + 10% ficoll to increase the 
refractive index). QPM was performed on living, adherent cells grown on glass 
bottomed cell culture dishes, again after 24hrs +/- treatment- a schematic of the 
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image processing steps can be seen in Figure 3.2. Both methods gave 
equivalent results; that is, IGF-1 drives an ~1.3-fold increase in cell volume over 
24 hours relative to control untreated cells whereas, and perhaps unsurprisingly 
given that NRG-1 does not drive addition of Schwann cell volume, sustained 
Raf kinase activation does not drive addition of Schwann cell volume (Figure 
3.1 & 3.3 A).  
In addition to cell volume, cell mass is also an important parameter of 
biogenesis and cell growth. QPM was used to quantify the dry organic mass of 
single cells; that is, the total mass of proteins, lipids, carbohydrates, nucleic 
acids and their derivatives, within the cell. Again, these experiments were 
performed in collaboration with the Kirschner Lab, Harvard Medical School. As 
for cell volume, the dry mass of living, adherent cells was quantified 24hrs +/- 
IGF-1 treatment or Raf kinase activation (Tmx treatment). As for cell volume, 
dry mass is calculated from the cell-induced phase-shift of the microscope light 
beam. Unlike cell volume, which uses the difference in cell-induced phase-shift 
between cells in media of two different refractive indices to calculate cell 
volume, cell dry mass can be calculated from the phase-shift induced by any 
one medium of known refractive index. Most surprisingly, in contrast to cell 
volume, Raf kinase was able to drive a comparable increase in cell mass to 
IGF-1; both IGF-1 stimulation and Raf kinase activation increased cell dry mass 
~1.5-fold over 24 hours (Figure 3.3 B).  
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Figure 3.1 IGF-1 drives an increase in cell volume
Aphidicolin arrested NSΔRafER cells were treated as indicated and cell volume was quantified 
using a Coulter Counter
A) Representative frequency distribution of cell volumes in the measured populations (μmᶟ) 
B) Quantification of mean cell volume (μmᶟ). Bar chart shows mean + standard error of the 
mean (SEM) of 8 experiments, performed in duplicate per condition per timepoint per 
experiment. Repeated Measures One-Way ANOVA p<0.05, select post hoc Tukey’s as
indicated on the graph.
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Raw Cell Image Background Selections
Background Subtracted Cell ROI
Figure 3.2 Image processing of raw Quantitative Phase Microscopy (QPM) 
images
Schematic showing the image processing of raw QPM data. Images were taken on a custom
built Quantitative Phase Microscope and analysed in MetaMorph. Background selections
were taken from non-cellular areas surrounding the cell of interest. These were used to 
remove tilts and background noise in the image, created by, for example, movement in the 
cell culture medium during image acquisition. Once this background had been subtracted the 
outline of the cell was carefully traced to generate the cell Region Of Interest (ROI). The cell 
induced phase shifts and, subsequently, cell dry masses and volumes were calculated from 
the cell ROI in the processed image. 
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Figure 3.3 Cell mass and volume can be uncoupled during cell growth
Aphidicolin arrested NSΔRafER cells were treated as indicated and cell volume and dry mass 
quantified by Quantitative Phase Microscopy (QPM): 
A) Mean cell volume (μmᶟ). Bar chart shows mean +SEM from >12 cells quantified per condition.
B) Mean cell dry mass (pg). Bar chart shows mean +SEM of 4 experiments, minimum 20 cells 
quantified per condition per experiment. One-Way ANOVA p<0.05, post hoc Newman-Keuls as 
indicated on the graph.
C) Mean dry mass per unit of cell volume (pg/μmᶟ). Bar chart shows mean +SEM from >12 cells 
quantified per condition. 
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To investigate this somewhat surprising finding further, and because a 
large proportion of cell dry mass is protein, the total protein mass per cell was 
quantified by two independent methods. First the standard Bicinchoninic Acid 
Assay (BCA) assay was used to measure the amount of protein per cell 
(Materials & Methods 2.2). The concentration of protein in cell lysates was 
measured using a modified BCA assay and normalized to the cell number in 
parallel cell culture dishes. The BCA is a colorimetric assay where the intensity 
of colour formation after the BCA reagent is added to a sample is proportional 
to the concentration of protein in the sample. The second approach to quantify 
protein per cell was to use a fluorophore-conjugated succinimidyl ester (S. 
Ester) to label fixed cell populations (Materials & Methods 2.2). The succinimidyl 
group reacts with primary amines, such as the N-terminus of proteins, peptides 
and amino acids and the R-group of lysines and therefore the amount of S. 
ester binding (fluorescence intensity per cell measured by microscopy) should 
reflect the amount of fixed protein, peptides and amino acids per cell. As can be 
seen in Figure 3.4 A, labeling resulted in staining throughout the cell with a 
clear increase in intensity in the central nuclear area of the cell, which would be 
predicted as this is the tallest part of the cell and contains the protein rich 
nucleus. To support the validity of using S. Ester labeling to quantify cell protein 
mass, the dry mass (by QPM) and then, after fixation, the protein mass (by S. 
Ester labeling) of the same cells were quantified and plotted against each other 
on a graph (Figure 3.4 B). Although dry mass is the sum of more than just cell 
protein content it would be expected that, within one cell population, there is a 
strong correlation between dry mass and protein per cell- because it would be 
predicted that the proportion of dry mass that is protein is relatively constant. As 
can be seen, the correlation between the QPM and S. Ester quantifications for 
individual cells is highly significant, supporting the use of the S. Ester technique 
to quantify cell protein content.  
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Figure 3.4 There is a strong correlation between cell dry mass, quantified by 
QPM, and protein mass, quantified by succinimidyl ester labelling
Aphidicolin arrested NSΔRafER cells (except where indicated below) were treated as indicated 
for 24hrs.
A) Representative widefield microscopy images after AlexaFlour647-succinimidyl ester labelling 
of fixed cells. Scale bar = 25μm.
B) Correlation between dry mass measured by QPM (pg) and the fluorescence intensity of the 
same cell quantified after subsequent succinimidyl ester labelling. Linear regression analysis, 
p<0.0001. Spearmans rank Correlation Coefficient, p<0.001. 
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As for cell volume and dry mass, the amount of protein per cell of 
NSΔRafER cells was quantified after 24hrs +/- IGF-1 or Tmx treatment (to 
activate Raf kinase). Both the BCA assay and S. ester labelling showed the 
same result; that is, in contrast to cell volume and consistent with the dry mass 
quantifications, activation of Raf kinase is at least as efficient as IGF-1 at driving 
an increase in protein mass. Compared to control (EtOH+/IGF-1-) cells, IGF-1 
and Raf kinase activation each drove a significant ~1.3-1.5-fold increase in 
protein mass over 24 hours (Figure 3.5 A & 3.6 A). The increase in protein 
mass seen with Raf kinase activation was not an artefact of Tmx treatment 
because treating Schwann cells lacking the Tmx inducible Raf kinase construct 
with an equivalent dose of Tmx, did not drive an increase in cell protein mass 
(Figure 3.5 C & 3.6 B). Interestingly, cell protein content, as assayed by the 
BCA assay, is significantly greater in Raf kinase activated cells compared to 
IGF-1 treated cells (Figure 3.5 A). The same trend is seen with S. ester labeling, 
although it is not significant (Figure 3.6 A). Whether this is due to a difference in 
sensitivity of the two assays is not clear. If the difference is real, it is particularly 
interesting because IGF-1 tends to drive a slightly greater increase in dry mass 
than Raf kinase (Figure 3.3 A and 3.12 B). The difference in Figure 3.3 A is not 
significant, however this may be due to the relatively low cell numbers in this 
assay- these assays were performed in a limited timeframe as part of a 
collaboration, precluding further investigation of the finding.  
 The increase in protein mass and total dry mass downstream of IGF-1 is 
approximately proportional to the increase in cell volume and therefore the 
mass: volume ratio of the cell, i.e. mass density, does not significantly change 
(Figure 3.3 C & 3.5 B). In contrast, Raf kinase activation drives an increase in 
mass in the absence of an increase in cell volume and therefore the mass: 
volume ratio of the cell increases ~1.5-fold compared to control untreated cells 
(Figure 3.3 C & 3.5 B).  
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Figure 3.5 IGF-1 and Raf kinase activation drive an increase in cell protein mass
Aphidicolin arrested NSΔRafER cells (except where indicated below) were treated as indicated 
for 24hrs before protein per cell was quantified using the BCA Assay. Bar charts show mean 
+SEM.
A) Mean amount of protein per cell (a.u.). Mean of 8 experiments, performed in duplicate. 
One-Way ANOVA p<0.0001, post hoc Tukey’s as indicated on the graph.
B) Mean amount of protein per unit cell volume (a.u.), experiments as in A). Repeated Measures 
One-Way ANOVA p<0.05, post hoc Tukey’s as indicated on the graph.
C) Mean amount of protein per cell (a.u.) of aphidicolin arrested NS cells treated as indicated for 
24hrs. Mean of 5 experiments, performed in duplicate. Repeated Measures One-Way ANOVA 
p<0.05, select post hoc Newman-Keuls as indicated on the graph.
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Figure 3.6 IGF-1 and Raf kinase activation drive an increase in cell protein 
mass
Aphidicolin arrested NSΔRafER cells (except where indicated below) were treated as indicated 
for 24hrs before protein per cell was quantified as fluorescence intensity per cell after 
AlexaFlour647-succinimidyl ester labelling of fixed cells. Bar charts show mean +SEM.
A) Mean fluorescence intensity per cell (a.u.) after succinimdyl ester labelling. 
B) Mean fluorescence intensity per cell (a.u.) of aphidicolin arrested NS cells treated as 
indicated for 24hrs. 
Mean of A) 6 and B) 3 experiments, minimum 50 cell quantified per experiment. Repeated 
Measures One-Way ANOVA, A) p<0.01 and B) p<0.001, select post hoc Newman-Keuls as 
indicated on the graphs.
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 In summary, the results shown here demonstrate that the addition of 
mass and volume can be uncoupled during cell growth. Whereas IGF-1 drives a 
proportional increase in cell mass and volume, sustained Raf kinase activation 
drives an increase in mass in the absence of an increase in cell volume. 
Therefore, whereas IGF-1 treated cells maintain a constant mass: volume ratio 
(density), the mass: volume ratio (density) of Raf kinase activated cells 
increases. These findings suggest that the addition of protein mass per se is 
insufficient to drive an increase in cell volume and therefore that another 
factor(s) must limit volume addition. In the context of this system, it raises the 
question of what other factor(s) IGF-1 regulates to drive cell volume addition. 
 
3.2 IGF-1 dependent Cell Volume Addition is PI3K and mTORC1 
Dependent, but MEK Independent 
 The level of phosphorylated Akt is an indicator of the activation state of 
the PI3K/ Akt pathway and the level of phosphorylated S6 Kinase (S6K) is an 
indicator of mTORC1 activation (mTORC1 is a major downstream effector of 
Akt). As described in the Introduction (Section 1.7), the PI3K/ Akt and mTORC1 
pathway are central regulators of cell growth and are activated downstream of 
IGF-1 (Engelman et al., 2006). The Raf/ MEK/ ERK signalling pathway also 
activates biogenic pathways (Section 1.7) and, as shown by the results above, 
cell growth (addition of mass). Although there is no evidence that Raf kinase 
activation can activate PI3K/ Akt, there is evidence that ERK signalling activates 
mTORC1, through phosphorylation and inhibition of the negative regulator of 
mTORC1, TSC2, as well as direct phosphorylation of the Raptor subunit of 
mTORC1 (Carriere et al., 2008, Carriere et al., 2011, Ma et al., 2005). To 
determine the activation state of these pathways after IGF-1 treatment or Raf 
kinase activation in Schwann cells, Western blot analysis was performed over a 
timecourse after IGF-1 or Tmx treatment (Figure 3.7).  
Consistent with published data, Western blot analysis showed that IGF-1 
drives sustained activation of the PI3K/ Akt/ mTORC1 pathway (Figure 3.7 A i 
pAkt (ser 473) and iii pS6K (thr 389)) (Echave et al., 2009). Activation persists 
at 24 hours after IGF-1 treatment, which is the endpoint for most growth/ size 
assays in this study. In contrast, and again consistent with published data, 
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Western blot analysis showed that IGF-1 only transiently activates ERK 
signalling; levels of pERK1/2 return to basal control levels within 1 hour of IGF-1 
treatment (Figure 3.7 A ii) pERK1/2) (Echave et al., 2009). 
Confirming the activity of the RafER construct, sustained activation of 
Raf kinase drove sustained activation of ERK signalling, as shown by Western 
blot (Figure 3.7 A ii pERK1/2, Tmx+/IGF-1-). This figure also demonstrates that 
a single dose of Tmx was sufficient to activate the Raf kinase construct and 
downstream ERK signalling for at least 24 hours. Raf kinase activation drove a 
possible transient activation of S6K, seen at 10 minutes and 1 hour post-Tmx 
treatment (Figure 3.7 A iii pS6K (thr 389)). This activation declined over time, 
returning almost to control levels by 6 hours post-Tmx treatment. There is some 
evidence that activated ERK can phosphorylate and activate mTORC1 and this 
may explain the levels of pS6K seen here (Carriere et al., 2008, Carriere et al., 
2011, Winter et al., 2011). Tmx treatment of normal Schwann cells lacking the 
Tmx-inducible Raf kinase construct showed that activation of these pathways 
was not an artefact of Tmx treatment (Figure 3.7 B). Raf kinase did not activate 
signalling through Akt (Figure 3.7 A i pAkt (ser 473)). 
The PI3K/ Akt/ mTORC1 pathway is a central regulator of cell growth that 
is critical for nutrient uptake, biogenesis and cell volume addition in numerous 
systems in vitro and in vivo (Bohni et al., 1999, Echave et al., 2009, Gao and 
Pan, 2001, Kwon et al., 2001, Leevers et al., 1996, Montagne et al., 1999, 
Porstmann et al., 2005, Porstmann et al., 2008, Ruvinsky et al., 2005, Shima et 
al., 1998, Wullschleger et al., 2006). Consistent with a central role for the PI3K/ 
Akt/ mTORC1 pathway in cell growth as described in the Introduction, published 
data from our lab has shown that addition of Schwann cell volume downstream 
of IGF-1 is dependent upon sustained signalling through the PI3K/ Akt/ 
mTORC1 pathway (Echave et al., 2009). To confirm this result in these studies, 
cells were treated with IGF-1 (or Tmx) +/- inhibitors against PI3K and mTORC1: 
ZSTK474 (500nM), an ATP-competitive inhibitor of class I PI3Ks and 
Rapamycin (0.15µg/µl), an allosteric inhibitor of mTORC1. Inhibitors were 
added to cells 30 minutes prior to IGF-1 or Tmx, to ensure any signalling 
through these pathways was blocked before the addition of the factors. Cell 
volume was quantified 24 hours later, using the Coulter Counter. Western blot 
analyses showed that ZSTK474 and Rapamycin effectively blocked signalling 
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through Akt and S6K respectively at the concentrations used in these assays 
(Figure 3.8 C, ZSTK474 & 3.9 C, Rapamycin). Use of either of these inhibitors 
significantly blocked IGF-1 dependent cell volume addition (Figure 3.8 
ZSTK474 & 3.9 Rapamycin) (Materials & Methods 2.1). There is no statistically 
significant effect of either inhibitor on the cell volume of control or Raf kinase 
activated cells, although the trend was for cell volume to be reduced in both 
conditions with either inhibitor (Figure 3.8 & 3.9). 
ERK signalling has previously been shown to be dispensible for IGF-1 
driven cell volume addition (Echave et al., 2009). To confirm this result, ERK 
signalling was blocked using PD184352 (0.75µM), an allosteric inhibitor of 
MEK1/2, the upstream activator of ERK1/2 (Materials & Methods 2.1). As for the 
PI3K and mTORC1 inhibitors, PD184352 cells were pre-treated with the 
inhibitor for 30 minutes before factors (IGF-1 or Tmx) were added and cell 
volume was quantified after a further 24 hours. As shown in Figure 3.10, 
inhibition of ERK signalling did not block IGF-1 dependent cell volume addition. 
Western blot analysis of pERK1/2 showed the inhibitor is active at the 
concentration used in the assays (Figure 3.10 C).  
 In conclusion, IGF-1 dependent cell volume addition depends on 
signalling through PI3K and mTORC1 but is refractory to inhibition of MEK. 
Correlating with these results, IGF-1 stimulation drives sustained activation of 
the PI3K/Akt/mTORC1 pathway but only transient activation of MEK/ERK 
signalling.  
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Figure 3.7 IGF-1 drives sustained signalling through the PI3K/Akt/mTORC1 
pathway and Raf kinase activity drives sustained pERK activation
A) Aphidicolin arrested NSΔRafER cells were treated as indicated and then cell lysates 
collected for western blot analysis of protein levels of: i) pAkt (ser473), ii) pS6K (thr389), 
iii) pERK. Akt or β -tubulin were used as a loading control.
B) Aphidicolin arrested NSΔRafER or NS cells were treated as indicated and then cell lysates 
collected for western blot analysis of pERK and pS6K (thr389) protein levels. β-tubulin was used 
as a loading control.
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Figure 3.8 IGF-1 dependent cell volume addition is PI3K dependent
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs (cell volume) or 1hr 
(western blot) +/-ZSTK474, an inhibitor of class I PI3Kinases before:
A) Cell volume was quantified using a Coulter Counter, shown as a representative frequency 
distribution of cell volumes in the measured populations (μmᶟ).
B) Cell volume was quantified using a Coulter Counter, shown as quantification of mean cell 
volume (μmᶟ). Bar chart shows mean +SEM of 4 experiments, each experiment performed in 
duplicate. Repeated measures two-way ANOVA, between growth conditions p<0.01, DMSO vs 
inhibitor p<0.01. Post hoc Bonferroni as shown on the graph.
C) Western blot analysis was performed on cell lysates to show the inhibitor was working.
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Figure 3.9 IGF-1 dependent cell volume addition is mTORC1 dependent
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs (cell volume) or 1hr 
(western blot) +/-Rapamycin, an inhibitor of mTORC1 before:
A) Cell volume was quantified using a Coulter Counter, shown as a representative frequency 
distribution of cell volumes in the measured populations (μmᶟ).
B) Cell volume was quantified using a Coulter Counter, shown as quantification of mean cell 
volume (μmᶟ). Bar chart shows mean +SEM of 3 experiments, each experiment performed in 
duplicate. Repeated measures two-way ANOVA, between growth conditions p<0.01, DMSO vs 
inhibitor p<0.01. Post hoc Bonferroni as shown on the graph.
C) Western blot analysis was performed on cell lysates to show the inhibitor was working.
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Figure 3.10 IGF-1 dependent cell volume addition is MEK independent
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs (cell volume) or 1hr 
(western blot) +/- PD184352, an inhibitor of MEK before:
A) Cell volume was quantified using a Coulter Counter, shown as a representative frequency 
distribution of cell volumes in the measured populations (μmᶟ).
B) Cell volume was quantified using a Coulter Counter, shown as quantification of mean cell 
volume (μmᶟ). Bar chart shows mean +SEM of 5 experiments, each experiment performed in 
duplicate. Repeated measures two-way ANOVA, between growth conditions p<0.01, DMSO vs 
inhibitor p>0.05. Post hoc Bonferroni as shown on the graph.
C) Western blot analysis was performed on cell lysates to show the inhibitor was working.
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3.3 Addition of Mass is PI3K, mTORC1 and MEK Dependent  
As demonstrated in the preceding Section IGF-1 and Raf kinase 
differentially activate distinct signalling pathways; namely signalling through Akt, 
mTORC1 and ERK. It was therefore important to determine whether IGF-1 and 
Raf kinase rely differentially on activity through each of these signalling 
pathways to drive addition of cell mass. To do this cells were treated with 
inhibitors against PI3K, mTORC1 and MEK for 24hrs +/- IGF-1 or Tmx (as for 
cell volume in the above section) and the amount of protein per cell quantified 
using S. Ester labelling, as described in Section 3.1.  
As for cell volume, IGF-1 dependent addition of protein mass required 
signalling through PI3K and mTORC1 (Figure 3.11 A & B, respectively), 
correlating with sustained activation of the PI3K/ Akt/ mTORC1 pathway. 
Interestingly and in contrast to the addition of cell volume, the addition of protein 
mass downstream of IGF-1 also required signalling through the MEK/ERK 
pathway. As shown in Figure 3.12, inhibition of MEK blocked IGF-1 dependent 
addition of protein mass, as assayed by two independent methods: S. Ester 
labelling and quantification of cell protein mass (Figure 3.12 A), as well as QPM 
quantification of cell dry mass (Figure 3.12 B) (QPM in collaboration with the 
Kirschner Lab, Harvard Medical School). This is despite the fact that IGF-1 only 
transiently activated ERK signalling, which may suggest that a basal flux of 
activity through this pathway is required for addition of protein.  
This result is particularly interesting because it demonstrates that cell 
volume can be added independently of cell mass during cell growth- because 
inhibiting MEK blocks IGF-1 induced addition of mass, but not volume. 
Therefore in the presence of the MEK inhibitor cells continue to add volume but 
do not add mass. Given that the results in Section 3.1 have already shown that 
cell mass can be added independently of cell volume during cell growth 
(downstream of specific Raf kinase activation), this means that both mass and 
volume can be independently regulated during cell growth.  
Unsurprisingly, given that activation of Raf kinase in this inducible system 
drives sustained and specific ERK signalling, addition of mass downstream of 
Raf kinase was also MEK dependent (Figure 3.12). Interestingly, although Raf 
kinase activation did not activate signalling through PI3K (as indicated by levels 
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of pAkt, Figure 3.7 A), addition of protein mass downstream of Raf kinase 
required PI3K (Figure 3.11 A). Addition of protein mass downstream of Raf 
kinase also required mTORC1 (Figure 3.11 B), which was only transiently 
activated following Raf kinase activation (Figure 3.7 A iii pS6K). These results 
suggests basal signalling through PI3K and mTORC1 may be required for the 
addition of protein mass.   
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Figure 3.11 Addition of mass is PI3K and mTORC1 dependent
Aphidicolin arrested NSΔRafER cells were treated +/- inhibitors as indicated for 24hrs before 
mean amount of protein per cell (a.u.) was quantified (as total fluorescence intensity per cell 
after AlexaFlour647-succinimidyl ester labelling of fixed cells).
A) +/- ZSTK474, an inhibitor of class I PI3Kinases.
B) +/- Rapamycin, an inhibitor of mTORC1.
Bar charts show mean +SEM of A), B) 4 experiments, minimum 50 cells quantified per condition 
per experimen . Repeated Measures Two-Way ANOVA A) and B) DMSO vs inhibitor p<0.001. 
Post hoc Bonferroni as indicated on the graphs.
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Figure 3.12 In contrast to cell volume, addition of mass is MEK dependent
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs +/-PD184352, an 
inhibitor of MEK, before:
A) Mean amount of protein per cell (a.u.) was quantified as total fluorescence intensity per cell 
after AlexaFlour647-succinimidyl ester labelling of fixed cells. Bar chart shows mean +SEM of 
4 experiments, minimum 50 cells quantified per condition per experiment. 
B) Mean dry mass per cell (pg) was quantified by QPM. Bar chart shows mean +SEM of 2 
experiments, minimum 20 cells quantified per condition per experiment. 
Repeated measures Two-Way ANOVA, A) DMSO vs inhibitor p<0.001, B) Between growth 
conditions p<0.05. Post hoc Bonferroni as indicated on the graph.
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To confirm the specificity of the inhibitors with respect to the pathways 
(PI3K, mTORC1 and ERK) assayed in these experiments, Western blot 
analyses were performed against markers of each pathway +/- each inhibitor. 
As expected, inhibiting PI3K (ZSTK474) or mTORC1 (Rapamycin) did not block 
ERK signalling (Figure 3.13 A pERK1/2). Similarly, inhibiting MEK (PD184352) 
did not significantly block signalling through PI3K downstream of IGF-1 (Figure 
3.13 B pAkt). However, the Western blot analysis suggested that inhibiting MEK 
reduced IGF-1 dependent S6K activation (Figure 3.13 A i pS6K). This requires 
further investigation, but it might suggest MEK/ ERK signalling contributes to 
mTORC1 activation downstream of IGF-1. If so, it would be interesting to 
determine if reduced signalling through mTORC1 contributes to the inhibition of 
IGF-1 dependent cell mass addition when MEK is inhibited (Figure 3.12). 
Moreover, given that the IGF-1 dependent addition of both mass and volume is 
prevented when mTORC1 signalling is blocked using Rapamycin (Figure 3.9, 
3.11 & 3.13), it is interesting to speculate whether a partial block through this 
pathway is sufficient to block addition of mass, whereas a complete block is 
required to inhibit volume addition. Inhibiting MEK did block the transient 
activation of mTORC1 downstream of Raf kinase (Figure 3.13 A i pS6K). This is 
as predicted because Raf should drive specific signalling through MEK/ ERK 
and therefore MEK/ ERK should mediate Raf kinase dependent activation of 
mTORC1. 
Both Rapamycin and ZSTK474 reduced signalling through mTORC1 to 
below the basal levels seen in control cells (Figure 3.13 A i pS6K (thr 389)). 
Although this might suggest non-specific inhibition of mTORC1 by ZSTK474, it 
is more likely that basal PI3K activity is required even for basal mTORC1 
activity. Indeed, ZSTK474 was chosen because it has very low levels of non-
specific mTORC1 inhibition compared to other PI3K inhibitors; in a different cell 
culture system, it was found that ZSTK474 inhibited PI3K at as little as 100nM 
whereas, in the same system, a 100µM concentration blocked only 40% of 
mTORC1 activity (Kong and Yamori, 2007). Given that 100nM was the 
concentration used in this study, it is unlikely that the inhibitor is acting directly 
on mTORC1.  
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Figure 3.13 Inhibitors used are specific, with respect to the analysed pathways
Aphidicolin arrested NSΔRafER cells were treated +/- inhibitors as indicated for 24hrs before cell 
lysates were collected and western blot analysis performed to confirm the specificity of the 
inhibitors used, with respect to the:
A) MEK (pERK) and mTORC1 (pS6K) pathways.
B) PI3K/Akt (pAkt) pathway.
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Basal signalling through mTORC1 is inhibited by both ZSTK474 and 
Rapamycin and both these inhibitors block Raf kinase dependent addition of 
protein mass- despite the fact Raf kinase activation did not activate signalling 
through PI3K (as indicated by levels of pAkt, Figure 3.7 A) and only transiently 
activated S6K (Figure 3.7 A iii pS6K). This is consistent with a hypothesis that a 
basal flux through mTORC1 is required for the addition of protein mass.   
In conclusion, as for cell volume, IGF-1 dependent addition of cell mass 
is PI3K and mTORC1 dependent. However, in contrast to cell volume, the 
addition of mass also requires signalling through MEK. Similarly, Raf kinase 
dependent addition of cell mass requires PI3K, mTORC1 and MEK. As Raf 
kinase drives addition of mass in the absence of an increase in cell volume and 
IGF-1 treatment can drive volume addition when the addition of protein mass is 
blocked (MEK inhibition), this means the addition of cell mass and volume can 
be separated and independently regulated. Unlike cell volume addition, the 
dependence on PI3K, mTORC1 and MEK to add cell mass does not correlate 
with activation of signalling through these pathways by IGF-1 and Raf kinase. 
This may suggest that a basal flux of signalling through these pathways is 
necessary for a cell to add mass upon receipt of a specific growth stimulus.  
 
Organelle Biogenesis Downstream of IGF-1 and Raf Kinase Activation: A 
Cell Biological Approach 
 The above results demonstrate that both Raf kinase activation and IGF-1 
treatment drive Schwann cell biogenesis, but in distinct ways; both cause 
addition of protein mass however only IGF-1 drives addition of cell volume. This 
suggests the addition of protein mass per se is insufficient to drive an increase 
in cell volume. If so, additional factors must limit cell volume addition. 
To begin to investigate what other factor(s) IGF-1 regulates to drive cell 
volume addition a cell biological approach was taken to compare biogenesis 
downstream of IGF-1 stimulation and Raf kinase activation. A combination of 
fluorescence and electron microscopy was used to compare organelle size and 
morphology 24 hours after IGF-1 stimulation or Raf kinase activation, i.e. the 
time at which cell volume and mass were assayed in the preceding sections.  
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3.4 IGF-1 Stimulation and Raf Kinase Activation Drive the Addition of 
Mitochondrial Volume and an Increase in Endoplasmic Reticulum (ER) 
Labelling 
The mitochondria are described as the powerhouse of the cell; they are 
the sites of aerobic respiration synthesising ATP for the cell’s bioenergetic 
requirements. In addition, the mitochondria provides the substrates for 
biosynthesis of fatty acids and amino acids to drive de novo lipogenesis and 
protein synthesis, respectively (DeBerardinis et al., 2008a, Deberardinis et al., 
2008b, Vander Heiden et al., 2009, Lynen, 1966). Indeed, growing evidence 
suggests this latter function is the primary function of mitochondria in rapidly 
growing cells where there is excess glucose (DeBerardinis et al., 2008a, 
Deberardinis et al., 2008b, Vander Heiden et al., 2009). The excess glucose 
provides sufficient fuel to drive glycolysis at a fast enough rate to produce much 
of the cells ATP requirement. This means mitochondrial resources can be 
diverted from ATP production to providing substrates for biosynthesis. Given 
that IGF-1 and Raf kinase are driving cell growth, i.e. biogenesis, it was 
interesting to investigate the mitochondrial load in these cells. 
To quantify the amount of mitochondria per cell the mitochondrial-specific 
fluorescent dye Mitotracker Green was used to label the mitochondria and the 
total volume of mitochondria per cell was determined from image stacks taken 
through the depth of the cell by fluorescence confocal microscopy (Materials & 
Methods 2.5-2.7) (Casley et al., 2002, Echave et al., 2009). Unlike many 
mitochondrial dyes the fluorescence of Mitotracker Green is reported to be 
relatively independent of mitochondrial membrane potential, which means 
labelling should be independent of mitochondrial activity and therefore reflect 
only the mitochondrial content of the labelled cells. Mitotracker Green (100nM) 
was added to the medium of live cells for 1hr at 37°c, 24 hours after IGF-1 
treatment or Raf kinase activation, and the cells were then fixed and processed 
for confocal microscopy. Using this technique it can be seen that both Raf 
kinase activation (Tmx+/IGF-1-) and IGF-1 stimulation (EtOH+/IGF-1+) drove 
an ~1.3- to 1.5-fold increase in mitochondrial volume per cell over 24 hours 
compared to control, untreated (EtOH+/IGF-1-) cells (Figure 3.14 A & B). To 
confirm the increase in mitochondria per cell downstream of Raf kinase 
activation was not an artefact of Tmx treatment, mitochondrial volume was also 
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quantified after treating normal Schwann cells lacking the Tmx inducible Raf 
kinase construct with Tmx or IGF-1. As shown in Figure 3.15, only IGF-1 drove 
an increase in mitochondrial volume in these cells, suggesting the increase in 
the amount of mitochondria after Raf kinase activation in the NSΔRafER cells 
was not an artefact of Tmx treatment. 
Consistent with the findings of Echave et al, the increase in mitochondrial 
volume was proportional to the increase in cell volume downstream of IGF-1 
and therefore mitochondrial density in the cell was unchanged compared to 
control (Echave et al., 2009). As Raf kinase increases mitochondrial volume per 
cell in the absence of an increase in cell volume, there was an ~1.5-fold 
increase in mitochondrial density per cell compared to control and IGF-1 
stimulated cells (Figure 3.14 B ii). This is also consistent with the finding that 
NRG-1, which drives sustained activation of the Raf/ MEK/ ERK signalling 
pathway, drives mitochondrial biogenesis (Echave et al., 2009).  
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Figure 3.14 IGF-1 stimulation and Raf kinase activation drive addition of 
mitochondrial volume
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs then stained with 
MitotrackerGreen to label mitochondria. Organelle volume was quantified from confocal 
microscopy image stacks.
A) Representative maximal projection images of labelled mitochondria. 
B) Mean total mitochondrial volume per cell (a.u.). Scale bar = 25μm.
C) Mean mitochondrial volume per unit of cell volume (a.u.). The cell volume of parallel cell 
cultures was quantified using a Coulter Counter.
Bar charts show mean +SEM of 6 experiments, minimum 35 cells quantified per condition per 
experiment. Repeated Measures One-Way ANOVA A) p,0.01 and B) p<0.001. Select post hoc 
Newman-Keuls as indicated. 
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Figure 3.15 Raf kinase dependent increase in mitochondrial volume is not an 
artefact of tamoxifen treatment
Aphidicolin arrested NS cells were treated as indicated for 24hrs then stained with Mitotracker 
Green to label mitochondria:
A) Representative maximal projection images of lab lled mitochondria. Scale bar = 25μm.
B) Mean total mitochondrial volume per cell (a.u.). Bar chart hows m an +SEM of 6 
experiments, minimum 35 cells quantified per condition per experiment. Repeated Measures 
One-Way ANOVA p<0.01. Select post hoc Newman-Keuls as indicated.
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Quantifying mitochondrial volume from light microscopy images may be 
problematic because the diameter of many mitochondria is less than 100nm 
and therefore below the resolution of the light microscope. This leads to an 
overestimation of mitochondrial volume per cell. More critically, the extent of 
overestimation may be different in different cell conditions if there is variation in 
mitochondrial diameter and/ or the proximity of mitochondria to one another 
within the cytoplasm between conditions. Therefore, to confirm the results 
obtained by light microscopy, mitochondrial volume was also quantified from 
electron microscopy (EM) images using stereology (Materials & Methods 2.8). 
Cells were treated for 24hrs +/- IGF-1 or Tmx, as for the Mitotracker assays, 
and then fixed and processed for Transmission Electron Microscopy. Briefly; 
cells were fixed, delipidated and dehydrated before being embedded in an 
EPON resin. The resin was then sectioned at 250nM intervals, starting from a 
random height within the sections. Each section contained slices from a number 
of cells and sections through the depth of the resin were chosen at random for 
imaging and subsequent analysis. These steps ensured a random sample of 
cell sections were analysed. Mitochondrial volume was quantified by calculating 
the mean proportion of the cell area occupied by mitochondria in the imaged 
cells (area fraction), which is equivalent to the mean proportion of the cell 
volume occupied by mitochondria (volume fraction) according to the principle of 
Delesse. The volume of mitochondria in µm3 was obtained by multiplying the 
volume fraction with the mean cell volume of parallel culture dishes.  
The EM results confirmed the light microscopy results. That is, both IGF-
1 stimulation and Raf kinase activation drove an ~1.5-fold increase in the total 
mitochondrial volume per cell (Figure 3.16 A & B i) and, because Raf kinase 
increases mitochondrial volume in the absence of an increase in cell volume, 
mitochondrial density per cell increased (Figure 3.16 B ii). IGF-1 drove a 
proportional increase in mitochondrial and cell volume and so mitochondrial 
density does not change relative to control untreated cells (Figure 3.16 B ii).  
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Figure 3.16 IGF-1 stimulation and Raf kinase activation drive the addition of 
mitochondrial volume
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs then fixed for 
transmission electron microscopy (TEM). Stereology was used to quantify mitochondrial volume 
and volume density per cell.
A) Representative TEM images showing sections taken from the mid-height of the cell. Scale 
bar =100nm. 
B) Mean total mitochondrial volume per cell (μmᶟ), 
C) Mean mitochondrial volume per unit of cell volume (μmᶟ/μmᶟ).
Bar charts show mean +SEM of 3 experiments, minimum 80 images quantified per condition per 
experiment. Repeated Measures One-Way ANOVA B) and C) p<0.05. Post hoc 
Newman-Keuls as indicated. 
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Another organelle central to biosynthesis is the endoplasmic reticulum 
(ER). The ER is composed of smooth (SER) and rough (RER) that function 
primarily in lipid and protein metabolism respectively. The SER is a major site of 
lipid synthesis as well as being involved in other aspects of metabolism 
including calcium homeostasis. The RER is the site of protein synthesis and 
primary modifications of integral membrane proteins and proteins destined for 
export and secretion. To label the ER and provide an indication of the relative 
size of this organelle in different conditions, cells were fixed after 24hrs +/- IGF-
1 treatment or Raf kinase activation and immunostained for fluorescence 
microscopy with an α–KDEL antibody (Materials & Methods 2.5). ‘KDEL’ is a 4 
amino acid ER retention signal contained in many resident ER proteins (e.g. 
grp94 (SER) and BiP (RER)) and therefore the amount of KDEL per cell should 
be an indicator of the amount of ER per cell; this technique cannot distinguish 
between the amount of SER and RER. Labelled cells were imaged using 
fluorescence widefield microscopy and fluorescence intensity per cell was 
quantified to indicate the amount of ER in the cell (Materials & Methods 2.6 & 
2.7). As can be seen in Figure 3.17 both Raf kinase activation (Tmx+/IGF-1-) 
and IGF-1 stimulation (EtOH+/IGF-1+) resulted in an ~1.5-fold increase in 
KDEL+ fluorescence per cell compared to control (EtOH+/IGF-1-) over 24hrs, 
suggesting an increase in the amount of ER in the cell.  
In conclusion, these results demonstrate that IGF-1 and Raf kinase drive 
an increase in the amount of mitochondria and ER in the cell. In other words, 
the increase in mass downstream of these stimuli is correlated with an increase 
in the mass of certain organelles. Given the central role both these organelles 
have in cellular biosynthesis, these findings are consistent with the increase in 
mass downstream of IGF-1 and Raf kinase activation. 
 
 
 
 
 
 
AB
EtOH+/IGF-1- Tmx+/IGF-1- EtOH+/IGF-1+
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
***
**
Average of 3 experiments
Repeated Measures Parametric ANOVA (p<0.001)
Newman-Keuls post-hoc significance tests as demonstrated on the graph
Figure 3.17 IGF-1 stimulation and Raf kinase activation drive an increase in the 
KDEL receptor, suggesting an increase in the size of the endoplasmic reticulum
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs, before anti-KDEL 
receptor immunofluorescence to label the endoplasmic reticulum (ER). Total fluorescence 
intensity was quantified from widefield microscopy images of labelled cells in ImageJ.
A) Representative widefield microscopy images of labelled ER. Scale bar = 25μm.
B) Mean fluorescence intensity per cell (a.u.). Bar chart shows mean +SEM of 3 experiments, 
minimum 30 cells quantified per condition per experiment. Repeated Measures One-Way 
ANOVA, p<0.001. Post hoc Newman-Keuls as indicated on the graph.
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3.5 The Nucleus and Trans-Golgi Network do not show Gross 
Morphological Changes after IGF-1 or Raf Kinase Activation  
It has been proposed that cells maintain a constant nuclear: cytoplasmic 
(N:C) ratio and this is a mechanism of cell size control (Umen, 2005). If so, it 
would be predicted that nuclear volume increases as cell volume increases to 
maintain a constant N:C ratio. However several studies suggest this is not the 
case. In budding yeast a constant N:C is not maintained as cells grow across 
the cell cycle (Jorgensen et al., 2007). In addition, although serum treatment 
drives an increase in both nuclear volume and cell volume in primary Schwann 
cells and fibroblasts, the increase in nuclear volume is not proportional to the 
increase in cell volume and so N:C decreases (Echave et al., 2007). It is not 
clear how nuclear size is related to function. It was therefore interesting to 
determine whether Raf kinase activation or IGF-1 stimulation affect nuclear 
volume. To quantify nuclear volume Hoescht was used to label the nuclei of 
fixed cells and nuclear volume was calculated from image stacks taken through 
the depth of the cell by fluorescence confocal microscopy (Materials & Methods 
2.5-2.7). As shown in Figure 3.18, neither Raf kinase activation (Tmx+/IGF-1-) 
or IGF-1 stimulation (EtOH+/IGF-1+) significantly changed nuclear volume 
compared to control (EtOH+/IGF-1-) over 24 hours. As it has previously been 
shown that serum drives an increase in Schwann cell nuclear volume (Echave 
et al., 2007), cells were also treated with medium containing serum (3% FCS 
(foetal calf serum)) to try to determine whether the lack of significant change in 
nuclear volume downstream of IGF-1 or Raf kinase was real or simply due to a 
detection problem. Consistent with previous findings, 3% FCS increased 
nuclear volume by ~1.25-fold compared to control (Figure 3.18). However, it is 
possible that IGF-1 and/ or Raf kinase drive a change in nuclear volume that is 
below the detection resolution of this technique.  
 
 
 
 
 
AB
EtOH+/IGF-1- Tmx+/IGF-1- EtOH+/IGF-1+
Nuclear Volume (um3)
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Mean +SEM
One-way  ANOVA (p<0.05), with post-hoc Newman Keuls
as indicated on graph
Average of 4 experiments
*
Figure 3.18 There is no significant change in nuclear volume after IGF-1 
stimulation or Raf kinase activation
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs before Hoescht 
staining to label the nuclei. Organelle volume was quantified from image stacks taken by 
confocal microscopy.
A) Representative maximal projection images of labelled nuclei. Scale bar = 25μm.
B) Mean total nuclear volume per cell (a.u.). Bar chart shows mean +SEM of 4 experiments, 
minimum 30 cells quantified per condition per experiment. Repeated Measures One-Way 
ANOVA, p<0.05. Post hoc Newman-Keuls as indicated on the graph.
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The Golgi apparatus receives proteins and lipids from the ER and 
modifies, sorts and packages them for delivery to their correct cellular location, 
or for secretion. The Golgi can be sub-divided into 4, approximately distinct, 
domains. The cis-Golgi is where cargo (proteins and lipids) are first received 
from the ER; cargo then moves more or less progressively through the medial, 
trans and, finally, the trans-Golgi network (TGN) and is appropriately modified, 
for example by glycosylation, as it moves. The TGN is primarily the sorting and 
distribution centre of the Golgi where, once correctly packaged, vesicles 
containing the modified cargo bud off and travel to the plasma membrane or 
other subcellular compartments. Given that IGF-1 and Raf kinase increase 
protein mass and possibly the amount of ER in the cell, it was interesting to 
determine whether there was a corresponding increase or change in Golgi 
architecture. Such a change might be necessary for processing an increased 
amount of nascent protein traffic, if this occurs, downstream of IGF-1 and Raf 
kinase activation, for example. To identify any changes in TGN architecture 
cells were fixed after 24hrs +/- Raf kinase activation or IGF-1 treatment and 
immunostained for fluorescence microscopy with an α–TGN38 antibody 
(Materials & Methods 2.5). TGN38 is an integral TGN membrane protein that 
has a role in formation of exocytic vesicles from the TGN and cycles between 
the TGN and plasma membrane- and it is regularly used as a marker of the 
TGN. Estimated TGN volume was quantified from image stacks taken through 
the cell by fluorescence confocal microscopy (Materials & Methods 2.6 & 2.7). 
As shown in Figure 3.19, although there is a trend for Raf kinase activation 
(Tmx+/IGF-1-) and IGF-1 stimulation (EtOH+/IGF-1+) to increase TGN volume 
compared to control (EtOH+/IGF-1-), this is not significant- potentially due to the 
relatively large variability in TGN size between cells in the same growth factor 
condition. It must be noted, as for the mitochondria, individual TGN vesicles and 
stacks can be smaller than the resolution of the light microscope; such 
differences in TGN volume will not be detected by this method.  
 In conclusion, neither nuclear and TGN volume are not significantly 
altered in IGF-1 treated or Raf kinase activated cells, compared to control; 
however, these results need to be interpreted with some caution.  
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Figure 3.19 IGF-1 stimulation and Raf kinase activation do not drive a significant 
change in trans-Golgi network (TGN) volume
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs, before anti-TGN38 
immunofluorescence to label the TGN. Organelle volume was quantified from image stacks 
taken by confocal microscopy.
A) Representative widefield microscopy images of labelled TGN. Scale bar = 25μm.
B) Mean TGN volume per cell (a.u.). Bar chart shows mean +SEM of 5 experiments, 
minimum 30 cells quantified per condition per experiment. Repeated Measures One-Way 
ANOVA, p>0.05. 
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3.6 The cis-Golgi and Organelles Associated with Lipid Metabolism 
Increase Downstream of IGF-1 
To continue to characterise the cellular and morphological effects of IGF-
1 and Raf kinase activation, the morphology, number and/ or volume of three 
other organelles- the cis-Golgi, lipid droplets and peroxisomes- were then 
analysed. As described above, the Golgi apparatus has four distinct domains. 
The cis-Golgi is the first of these and the site where proteins and lipids are 
received from the ER and begin to be further modified and processed. As 
before, cells were treated for 24hrs +/- Raf kinase activation or IGF-1 treatment 
before being fixed and immunostained for fluorescence microscopy. The cis-
Golgi was labelled using an α–GM130 antibody (Materials & Methods 2.5). 
GM130 facilitates membrane fusion events within the cis-Golgi and therefore 
helps maintain the organelle’s structure. Cis-Golgi volume was quantified from 
image stacks taken through the cell by fluorescence confocal microscopy 
(Materials & Methods 2.6 & 2.7). As shown in Figure 3.20, IGF-1 stimulation 
(EtOH+/IGF-1+), but not Raf kinase activation (Tmx+/IGF-1-) appeared to drive 
a significant change in cis-Golgi volume compared to control (EtOH+/IGF-1-) 
over 24 hours. Again, as for both the mitochondria and TGN, the diameter of 
cis-Golgi cisternae can be smaller than the resolution of the light microscope 
and therefore this method will not detect sub-resolution changes in cis-Golgi 
volume between the conditions tested. This means the quantified volumes may 
be under- or over- estimated for any condition and therefore, if the error is in a 
different direction or of a different magnitude between the three conditions 
(Control, Raf kinase or IGF-1), the IGF-1 specific difference may have been 
over- or under- estimated.  
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Figure 3.20 IGF-1 stimulation drives an increase in cis-Golgi volume
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs, before anti-GM130 
immunofluorescence to label the cis-Golgi. Organelle volume was quantified from image stacks 
taken by confocal microscopy.
A) Representative maximal projection images of labelled cis-Golgi. Scale bar = 25μm.
B) Mean total cis-Golgi volume per cell (a.u.). Bar chart shows mean +SEM of 4 experiments, 
minimum 30 cells quantified per condition per experiment. Friedman test p<0.05, post hoc 
Dunn’s test as indicated.
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Lipid droplets consist of a core of neutral lipids, primarily triacylglycerols 
(TAGs) and sterol esters, surrounded by a phospholipid monolayer containing 
many proteins that metabolise and transport lipids to/ from the lipid droplet 
surface (Walther and Farese, 2009). To label the lipid droplets, cells were fixed 
before being incubated with Oil Red O, which is a neutral lipid stain and 
therefore labels the lipid droplet core. Oil Red O emits red fluorescence and so 
the number of lipid droplets per cell was quantified in ImageJ from fluorescence 
widefield microscopy images of labelled fixed cells (Materials & Methods 2.5). 
The processed images used for quantification of lipid droplet number per cell 
are shown in Figure 3.21 A. As for the previous organelle analyses, cells were 
analysed 24 hours after IGF-1 or Tmx treatment. Quantification of the number of 
lipid droplets per cell (Figure 3.21 B) showed that IGF-1 stimulation 
(EtOH+/IGF-1+) but not Raf kinase activation (Tmx+/IGF-1-) resulted in a 2-fold 
increase in the number of lipid droplets per cell compared to control 
(EtOH+/IGF-1-). To confirm these results lipid droplets were identified and 
quantified by stereology from electron micrographs of sectioned cells (sections 
were ~250nm thick) (Materials & Methods 2.8). Two types of lipid droplets were 
identified by EM (Figure 3.22 A) and to distinguish between them for 
quantification purposes they were termed ‘Lipid Bodies’ and ‘Electron Dense 
Lipid Droplets’. Quantification of the number of lipid droplets per cell (by 
stereological analysis of electron micrographs, Materials & Methods 2.8) 
showed that over 24 hours IGF-1 stimulation caused a 2-fold increase in the 
number of Lipid Bodies per cell (Figure 3.22 B i). There was also a trend for the 
number of Electron Dense Lipid Droplets to increase specifically downstream of 
IGF-1, however this trend is not statistically significant. The number of lipid 
droplets per cell quantified by EM was greater than the number quantified by Oil 
Red O staining. This may be because Oil Red O staining is less sensitive at 
labelling lipid droplets than the direct identification of lipid droplets by EM. It 
may also be because, as noted from the EM images (data not shown), lipid 
droplets were often found clustered in the Schwann cells; if their proximity to 
one another is below the resolution of the light microscope they would be 
identified from Oil Red O staining as one larger droplet, when in fact they are a 
group of multiple droplets.  
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The size of lipid droplets is know to be highly heterogeneous and can 
range from <1-100µm in diameter, depending on cell type and cell state 
(Walther and Farese, 2009). To determine whether there was a difference in the 
size of individual lipid droplets between IGF-1, Raf kinase and control cells the 
mean volume per lipid droplet was also quantified from EM images using 
stereology. The results show there was no significant difference in the mean 
size of either type of lipid droplet between the three conditions (Figure 3.22 B ii). 
As shown in Figure 3.22 B iii, because the number of Lipid Bodies per cell 
increased specifically downstream of IGF-1 and there was no difference in the 
volume of individual droplets between conditions, the total volume of Lipid 
Bodies per cell increased 2-fold in the presence of IGF-1 over 24 hours, 
compared to Raf kinase activated (Tmx+/IGF-1-) or control (EtOH+/IGF-1-) 
cells. There was no significant difference in the total volume of Electron Dense 
Lipid Droplets per cell between the conditions. These results show that IGF-1 
stimulation, but not Raf kinase activation results in an increase in the number 
and total volume of lipid droplets per cell over 24hrs, compared to control 
untreated cells. 
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Figure 3.21 IGF-1 drives an increase in the number of lipid droplets per cell
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs then stained with Oil 
Red O to label the lipid droplets.
A) Representative maximal projections of Oil Red O staining. Scale bar = 25μm.
B) The mean number of lipid droplets per cell was quantified from images as shown in A) using 
ImageJ. Bar chart shows mean of 5 experiments, minimum of 20 cells quantified per condition 
per experiment. Repeated Measures One-Way ANOVA, p<0.05. Select post hoc 
Newman-Keuls as indicated on the graph. 
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Figure 3.22 IGF-1 drives an increase in the number and total volume of lipid droplets 
per cell
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs then fixed for 
transmission electron microscopy (TEM). Stereology was used to qua tify the number and 
volume of lipid droplets per cell.
A) Representative TEM images of the morphology of the two types of lipid droplets identified 
in Schwann cells. 
B) i) Mean number of lipid droplets per cell, ii) Mean volume of individual lipid droplets (μmᵌ) 
and iii) Mean total volume of lipid droplets per cell (μmᵌ).
Bar charts show mean +SEM of 3 experiments, minimum of 80 images quantified per 
condition per experiment. Repeated Measures Two-Way ANOVA B) and D) Between growth 
conditions p<0.01, Between lipid droplet types p<0.01 and C) Between growth conditions 
p>0.05, Between lipid droplet types p<0.05. Select post hoc Bonferroni as indicated on the 
graphs.
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Finally, to quantify the number of peroxisomes per cell, cells were fixed 
after 24hrs +/- Raf kinase activation or IGF-1 treatment and immunostained for 
fluorescence microscopy with an α–catalase antibody to label the peroxsiomes 
(Materials & Methods 2.5). Catalase is a peroxisomal matrix protein (also found 
in lower concentrations in the cytoplasm) involved in the redox function of the 
peroxisome. The number of peroxisomes per cell was quantified in ImageJ from 
maximal projection images taken by fluorescence confocal microscopy (Figure 
3.23 A & B i) (Materials & Methods 2.6 & 2.7). As for the number of lipid 
droplets per cell, IGF-1 (EtOH+/IGF-1+) but not Raf kinase activation 
(Tmx+/IGF-1-) caused a 2-fold increase in the number of peroxisomes per cell 
(Figure 3.23 B i). This increase is greater than the increase in cell volume 
downstream of IGF-1 and therefore the density of peroxisomes within the cell 
increased (Figure 3.23 B ii). This may indicate a central role for peroxisomes in 
IGF-1 dependent cell metabolism.  
Interestingly, the IGF-1 dependent increase in peroxisome number, like 
cell volume, depended on mTORC1; pre-treatment of the cells with rapamycin, 
an mTORC1 inhibitor, blocked the increase in peroxisome number after IGF-1 
stimulation (Figure 3.24). Consistent with a close link between peroxisome 
number and cell volume downstream of IGF-1, inhibiting MEK using PD184352- 
which did not block IGF-1 dependent cell volume addition- also did not block the 
IGF-1 dependent increase in peroxisome number (Figure 3.25). Interestingly, 
because MEK inhibition blocked IGF-1 dependent addition of cell mass, this 
result also suggests peroxisome number does not contribute significantly to cell 
mass. These findings cannot distinguish whether peroxisomes act upstream or 
downstream of IGF-1 dependent cell volume addition but they may suggest 
peroxisome number and cell volume are closely linked downstream of IGF-1.  
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Figure 3.23 IGF-1 drives an increase in peroxisome number per cell
Aphidicolin arrested NSΔRafER cells w re treated as indicated for 24hrs before anti-catalase 
staining to label the peroxisomes. 
A) Representative maximal projection images of labelled peroxisomes. Scale bar = 25μm. 
B) Mean number of peroxisomes per cell quantified from images as shown in A) in ImageJ.
C) Mean number of peroxisomes per μmᵌ cell volume.
B) and C) Bar charts showing mean +SEM of 3 experiments, minimum of 25 cells quantified per 
condition per experiment. Repeated Measures One-Way ANOVA B) p<0.001 and C) p<0.01. 
Select post hoc Newman-Keuls as indicated on the graph. 
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Figure 3.24 IGF-1 drives an mTORC1 dependent increase in peroxisome 
number per cell
Aphidicolin arrested NSΔRafER cells were treated as indicated +/- Rapamycin (to inhibit 
mTORC1) for 24hrs before anti-catalase staining to label the peroxisomes. 
A) Representative maximal projection images of labelled peroxisomes. Scale bar = 25μm. 
B) Mean number of peroxisomes per cell quantified from images as shown in A) in ImageJ. Bar 
chart shows mean +SEM of 3 experiments, minimum of 25 cells quantified per condition per 
experiment. Repeated Measures Two-Way ANOVA, interaction p<0.01. Post hoc Bonferroni as 
indicated on the graph.
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Figure 3.25 IGF-1 drives a MEK independent increase in peroxisome number 
per cell
Aphidicolin arrested NSΔRafER cells were treated as indicated +/- PD184352 (to inhibit MEK) 
for 24hrs before anti-catalase staining to label the peroxisomes. 
A) Representative maximal projection images of labelled peroxisomes. Scale bar = 25μm. 
B) Mean number of peroxisomes per cell quantified from images as shown in A) in ImageJ. Bar 
chart shows mean +SEM of 4 experiments, minimum of 25 cells quantified per condition per 
experiment. Repeated Measures Two-Way ANOVA Growth factors p<0.01, post hoc Bonferroni 
not shown.
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In conclusion: the results presented in this Section demonstrate that IGF-
1, but not Raf kinase, drives an increase in the number and total volume of lipid 
droplets, the number of peroxisomes and appears to increase the amount of 
cis-Golgi per cell, over 24hrs. These organelles all have roles in cell lipid 
metabolism. Given that IGF-1, but not Raf kinase, also drives an increase in cell 
volume, this may suggest that altered lipid metabolism has a role in IGF-1 
dependent cell volume addition. 
 
3.7 Chapter 3: Summary 
The findings described in this chapter can be summarised as follows: 
• The addition of cell mass and volume can be uncoupled during cell 
growth, demonstrating they are independently regulated processes: In 
the Schwann cell, IGF-1 drives coordinate addition of cell mass and 
volume, whereas Raf kinase activation drives an increase in cell mass in 
the absence of an increase in cell volume.  
• IGF-1 dependent addition of cell volume is PI3K and mTORC1 
dependent, but MEK independent- as previously published.  
• The addition of protein mass downstream of IGF-1 or Raf kinase is PI3K, 
mTORC1 and MEK dependent.  
• The finding that MEK is required for IGF-1 dependent addition of cell 
protein, but not volume demonstrates that cell volume can be added in 
the absence of an increase in cell protein mass during cell growth. This 
again highlights that mass and volume can be uncoupled during cell 
growth and therefore can be independently regulated. 
• Organelle size and/ or number does not necessarily correlate with cell 
mass or volume or the size and number of other organelles, but is likely 
regulated in response to specific signals. Mitochondrial volume and the 
amount of ER appear to increase downstream of both Raf kinase and 
IGF-1. In contrast, only IGF-1 drives an increase in the cis-Golgi, lipid 
droplets and number of peroxisomes in the cell, suggesting the addition 
of cell volume may be associated with specific changes in cell lipid 
metabolism. 
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3.8 Chapter 3: Discussion 
3.8.1 The Addition of Mass, Volume and Organelle Content can be Uncoupled 
During Cell Growth 
 The findings presented in this Chapter demonstrate that the addition of 
protein mass and volume are separable processes that can be independently 
regulated during cell growth. Given that it is often assumed that mass and 
volume increase co-ordinately during cell growth- and consequently that 
measures of mass and volume can be used interchangeably to describe 
growth- these results have important implications for the way we describe, study 
and think about cell growth. When describing cell growth we must be clear 
whether we are referring to cell mass (e.g. cell protein mass) or cell volume. 
Ideally, we would also describe how this relates to changes in cell organelle 
content. In addition, because they are separable and therefore can be 
independently regulated, to understand both the upstream signalling and the 
downstream effector mechanisms that control cell mass and volume, requires 
the addition of cell mass and volume to be studied in isolation. Given that this 
study has shown how mass and volume can be uncoupled downstream of IGF-
1 and Raf kinase in the Schwann cell, this model system is an ideal and 
tractable system in which to continue such studies. Importantly, this study 
demonstrates that the addition of volume is, in itself, a regulated process not 
necessarily driven simply by the synthesis of more ‘stuff’ (protein). Although 
intuitively it might be expected that cell protein mass and volume would co-vary 
as proteins synthesised during cell growth will take up space, i.e. volume, the 
results presented in this study demonstrate that this assumption does not hold 
true.  This raises two basic, yet important, biological questions: what drives the 
addition of cell volume in the absence of an increase in protein? And, 
reciprocally, how can the addition of protein mass not drive an increase in cell 
volume?  
Considering the first question: in the experiments presented in this 
Chapter, when MEK is inhibited in Schwann cells, IGF-1 can still drive a 
comparable addition of cell volume, even though the addition of cell protein 
mass is blocked. Although the use of an inhibitor is undoubtedly an artificial 
manipulation, the result nonetheless clearly demonstrates that it is possible to 
add volume in the absence of an increase in protein mass and, therefore, raises 
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the question: what drives the increase in cell volume? Both in terms of what is 
added to the cell to effect the increase and also what molecular mechanisms 
are required to drive the increase. It is also a second clear demonstration that 
the addition of protein is not the principle driver of cell volume addition- because 
volume can still be added when the addition of protein mass is prevented. One 
attractive candidate as a factor that is essential for the addition of cell volume is 
cell lipid. To add cell volume during cell growth it seems inevitable that lipids are 
required to fuel membrane biogenesis, including the increase in plasma 
membrane. This implies that there is a increase in lipid synthesis and the 
amount of lipid per cell. If this process continues to occur when MEK is 
inhibited, in the presence of IGF-1, this might be sufficient to drive expansion of 
membranous organelles, the plasma membrane and, as a result, cell volume. 
Certainly the results of these studies indicate a role for cell lipid metabolism in 
IGF-1 driven growth, as the cis-Golgi, lipid droplets and peroxisomes all 
increase specifically downstream of IGF-1- correlating with the increase in cell 
volume- and all three of these organelles have roles in cell lipid metabolism. 
Important membrane lipids are synthesised and/ or modified in the cis-Golgi 
and peroxisomes; sphingomyelins are synthesised and lipids are glycosylated 
in the cis-Golgi and ether phospholipids (plasmalogens) are synthesised in the 
peroxisomes (Colley, 1997, Jeckel et al., 1990). In addition, as a site of fatty 
acid oxidation, the peroxisomes are also involved in fatty acid breakdown and 
remodelling. Finally, lipid droplets are not simply storage sites for excess lipids 
as was once thought, but interact dynamically with organelles including the ER 
and plasma membrane to regulate cell lipid metabolism (Martin and Parton, 
2006, Walther and Farese, 2009). Strikingly, as for cell volume, the IGF-1 
dependent increase in peroxisomes was not blocked when MEK is inhibited. 
However, as for cell volume, it was blocked when mTORC1 was inhibited. 
These findings further correlate the addition of cell volume with, potentially, cell 
lipid metabolism (the addition of cis-Golgi and lipid droplets was not 
investigated after MEK or mTORC1 inhibition). A possible role for the 
peroxisomes in IGF-1 dependent cell growth will be discussed in more detail 
later in this Discussion.  
If lipogenesis is necessary for the addition of cell volume, it is important 
to address whether it is also sufficient to drive addition of cell volume, or 
whether other factors are also required. For example, activation of specific 
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biogenic pathways may be required to ensure synthesised lipids are assembled 
into functional membranes, such as the plasma membrane- in other words, that 
this process is specifically regulated.  The role of lipogenesis in IGF-1 mediated 
cell growth is explored in Chapter 5 of this thesis and the regulation of plasma 
membrane size is investigated further in Chapter 4. It may also be that the 
addition of cell volume requires the addition of other molecules, such as water. 
Water comprises 70% of the weight of the cell and net water movement into or 
out of the cell can result in rapid and significant changes to cell volume, 
therefore it seems highly plausible that regulation of water transport could have 
a role in the regulation of cell volume during cell growth (Luby-Phelps, 2000). 
These factors will be discussed in more detail at the end of Chapter 5. Based 
on the points raised in this section, it is tempting to speculate that, when MEK is 
inhibited, IGF-1 continues to drive the addition of cell volume because IGF-1 
continues to drive both the biogenesis of cell membranes (particularly the 
plasma membrane, which as the limiting membrane of the cell can restrict 
volume addition) and the uptake of water, which together drive the addition of 
cell volume.  
If the addition of lipids is sufficient to drive the membrane biogenesis that 
is necessary to increase cell volume, this implies that certain membranes and 
organelles can increase without increasing the total amount of protein in the 
cell- because it was possible to increase volume in the absence of an increase 
in total protein mass. It is possible, however, that although the total amount of 
protein in the cell did not increase in IGF-1 treated cells when MEK was 
inhibited, existing cell protein may have been redistributed to de novo 
membranes and/ or organelles and this may be required for the synthesis of 
these structures. This may be particularly important during mitochondrial 
biogenesis, as evidence from studies in S. cerevisiae suggests that the 
synthesis and assembly of certain mitochondrial membrane proteins and 
phospholipids are coupled (Gebert et al., 2011, Gohil and Greenberg, 2009). 
Moreover, this coupling is essential for the addition of either to mitochondrial 
membranes. This means that if the addition of either the lipids or the proteins is 
disrupted, mitochondrial membrane biogenesis is inhibited. This study did not 
address whether mitochondria still increase downstream of IGF-1 when MEK is 
inhibited, however previous findings from our lab have shown that mitochondrial 
gene transcription is blocked following inhibition of MEK, which suggests that 
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the increase in mitochondrial volume may be blocked (Echave et al., 2009). It 
would be useful to characterise in greater detail, using a combination of 
fluorescent imaging and electron microscopy, the composition and structure of 
IGF-1 treated cells where MEK/ ERK signalling has been inhibited. This could 
include, for example, quantification of mitochondrial volume. Such an analysis 
would help address the cellular changes that occur and therefore may be 
required for the addition of cell volume. As a final and brief point to consider 
when thinking about the regulation of cell protein in the presence of MEK 
inhibition, it is important to note that although total protein mass does not 
increase if MEK is inhibited, the turnover of proteins, e.g signalling proteins, is 
not necessarily blocked and this turnover may be required for the addition of 
cell volume, e.g. to regulate flux through important signalling pathways. 
To consider the second question: how can the addition of protein mass 
not drive the addition of cell volume? As shown by this study, activation of Raf 
kinase drives an increase in cell protein mass, and the density of specific 
organelles such as the mitochondria, without increasing cell volume. This 
means that increasing protein mass per se is insufficient to drive an increase in 
cell volume and demonstrates that the addition of cell volume is itself an 
independently regulated process. In other words, increases in cell volume are 
not simply a passive consequence of synthesising any macromolecule (protein), 
which then pushes out on the edges of the cell to increase cell volume either 
directly, or, in the case of soluble macromolecules such as cytosolic proteins, 
because water is drawn into the cell by osmosis as a result of increases in the 
concentration of soluble proteins in the cell (as will be discussed further below). 
One question raised by this finding is: where in the cell is the protein mass 
added such that it does not drive an increase in cell volume? Given that the 
amount of mitochondria and ER increase after Raf kinase activation, these 
organelles are likely to be the repository for a certain amount of the added 
protein. The mitochondria represent only 8.5% of the volume of the cell in Raf 
kinase activated cells, compared to 6.5% in control treated cells, explaining why 
this increase does not drive a significant increase in cell volume. The analyses 
performed in this study do not indicate what the increase in ER represents in 
terms of cell volume; if it is significant, then presumably other parts of the cell 
are reduced to compensate – perhaps, for example, cytosolic volume is 
reduced.  
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Interestingly, a microarray performed in our lab with the NSΔRafER 
Schwann cells used in this study demonstrated that Raf kinase induces large 
changes in gene expression and an increase in the amount of RNA in the cell, 
consistent with protein biogenesis (Unpublished observations and (Parrinello et 
al., 2008). Moreover, subsequent analyses of protein expression demonstrated 
that Raf kinase activation increases the expression of a number of secreted 
proteins (Napoli et al., 2012). Although secreted proteins are only present in the 
cell transiently- as they are synthesised on rough ER (RER), transported 
through the ER and Golgi systems and then transported to the plasma 
membrane in secretory vesicles- an increase in the synthesis of such proteins 
may also contribute to the increase in cell protein mass. Would this be expected 
to result in an increase in cell volume? Perhaps, if the volume of the ER and 
Golgi increased to cope with the increased secretory traffic. However, as 
described above, although the amount of ER does seem to increase, this does 
not result in an increase in cell volume. As this study found no significant 
increase in the amount of cis-Golgi or trans Golgi network (TGN) downstream of 
Raf kinase activation (although there was a trend for TGN volume to increase in 
Raf kinase activated cells, compared to control) this may suggest any increase 
in secretory traffic could be processed without an increase in the size of the 
Golgi. Alternatively, as considered in the results, it may be that Golgi volume 
does increase, but the light microscopy based assay used in this study was not 
sensitive enough to detect the increase, because the size of individual Golgi 
cisternae is below the resolution of the light microscope. 
Aside from the organelles, proteins can also be added to cytoskeletal 
structures- to the actin cortex, the microtubules and the nuclear lamina. These 
were not investigated in this study. As microtubule length has been shown to 
regulate cell length and cortical actin regulates cell shape and size, this 
suggests that if Raf kinase activation does increase the amount of cytoskeletal 
components, the resulting 3D-structures are more dense, as they do not 
significantly affect cell volume (Picone et al., 2010, Salbreux et al., 2012). It 
may be, for example, that there is an increase in the number of microtubules in 
the cell to facilitate an increase in secretory traffic to the plasma membrane.  
Finally, an interesting question to consider is whether Raf kinase drives 
an increase in the amount of soluble cytosolic proteins and/ or the size of the 
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cytosolic precursor amino acid pool. If so, this would be expected to increase 
intracellular osmolarity and therefore, in order to prevent this resulting in uptake 
of cell water and an increase in cell volume (assuming the increase would be 
detectable) Raf kinase activated cells would have to activate compensatory 
mechanisms to decrease intracellular osmolarity, i.e. by driving the loss of 
inorganic ions and organic osmolytes. An additional factor that also needs to be 
considered if Raf kinase drives an increase in the concentration of cytosolic 
proteins is that there is a hypothesis stating that cells sense ‘macromolecular 
crowding’ (changes in the behaviour of molecules at high concentrations) to 
regulate water uptake and, consequently, cell volume (Burg, 2000, Lang, 2007). 
If Raf kinase increases the concentration of soluble protein to the point where 
crowding would be predicted to be an issue, this suggests either the hypothesis 
is invalid (at least in these conditions), or mechanisms downstream of Raf 
kinase overcome the crowding.  
3.8.2 The Biological Implications of Uncoupling the Addition of Cell Mass, 
Volume and Organelle Content 
The findings presented in the Chapter have clearly shown that mass, 
volume and organelle biogenesis can be uncoupled. The mass and volume of 
the cell reflects the sum of the organelles and cytosol (and therefore the 
macromolecules and water) and hence, the differential regulation of cell mass 
and volume reflects the differential regulation of organelle and cytosolic content. 
Organelle biogenesis is metabolically expensive and is therefore tightly 
regulated according to need, which means that the uncoupling of cell mass and 
volume and, linked to this, differences in organelle content are likely to reflect 
differences in the needs, functions and/ or metabolic activity of a cell.  
In the Schwann cell, proliferation in vitro is absolutely dependent on ERK 
signalling and in vivo strong and sustained ERK signalling drives Schwann cell 
dedifferentiation and proliferation (Echave et al., 2009, Napoli et al., 2012). In 
contrast, as demonstrated in this study and in other studies both in vitro and in 
vivo, PI3K regulates Schwann cell size (volume) (Collins et al., 2012, Cotter et 
al., 2010, Echave et al., 2009, Macklin, 2010, Maurel and Salzer, 2000). In vivo, 
the addition of Schwann cell volume must be able to occur in the absence of 
cell division. This is because a significant amount of Schwann cell growth 
occurs when the cells are quiescent (although they remain poised to re-enter 
 	   181	  
the cell cycle, e.g. following nerve injury, to facilitate nerve regeneration) and 
therefore must occur without stimulating the mitogenic pathway. In the case of 
myelinating Schwann cells, for example, it is only once the cells are aligned with 
an axon and are quiescent that myelination occurs and the cell grows to its final 
size. Therefore it is advantageous, and likely even necessary, to have cell 
volume addition and cell proliferation regulated by distinct signalling pathways- 
the PI3K pathway and the ERK pathway, respectively. Although the growth and 
proliferative pathways may not be as distinct in many other cell types (where 
growth and proliferation is more frequently found coupled), their separation in 
the Schwann cell provides the opportunity to investigate biogenesis and cellular 
changes associated with each process independently.   
Although the Raf kinase system used in this thesis is artificial, it seems 
reasonable to assume that at least some of the cellular changes that occur after 
Raf kinase activation represent changes associated with preparation for cell 
proliferation. Most interesting in this regard is the increase in mitochondrial 
volume. This is reminiscent of the increase in mitochondria seen after 
stimulation with the mitogen NRG1, which also drives strong and sustained 
ERK signalling (Echave et al., 2009). It is interesting to speculate, as in Echave 
et al, that the increase in mitochondrial density is necessary to provide the ATP 
to fuel the energetically expensive process of proliferation. Considering the 
addition of Schwann cell volume: in vivo, like PI3K signalling, lipogenesis is 
required for Schwann cell myelination and for the cells to grow to their final size 
and in vitro, IGF-1 promotes lipogenesis in myelinating Schwann cell cultures 
(Collins et al., 2012, Liang et al., 2007, Verheijen et al., 2009). Therefore, 
following the discussion in the above Section 3.8.1, it is tempting to speculate 
that the IGF-1 driven increase in the amount of cis-Golgi, lipid droplets and 
peroxisomes is necessary for lipogenesis, which drives the addition of cell 
volume. In this regard, as stated in Section 3.8.1 and as will be discussed in 
further detail later in this Discussion, the peroxisomes are particularly interesting 
because their number correlates with the addition and inhibition of cell volume 
downstream of IGF-1. It also seems reasonable to hypothesise that the 
increase in mitochondria observed after IGF-1 treatment, as well as providing 
ATP to fuel cell growth, also provides biosynthetic precursors required to drive 
macromolecular synthesis required for volume addition, e.g. to drive 
lipogenesis. It does seem likely that cell proliferation will also require a certain 
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amount of lipogenesis, even in the absence of associated cell volume addition, 
in order to produce the necessary increase in plasma membrane. In this study, 
however, there was not evidence that Raf kinase activated de novo lipogenesis. 
This may be because the cells were cell-cycle arrested, circumventing the 
requirement for plasma membrane addition. It is also possible that the increase 
in plasma membrane required during cell division does not require, in the 
absence of cell volume addition, a significant increase in lipogenesis.  
The observations regarding cell organelle content described above 
suggest that at least some of the changes in organelle content observed 
downstream of Raf kinase activation and IGF-1 treatment in the Schwann cell 
could be consistent with the known function of each of these pathways in vivo. 
Examples of biogenic stimuli driving organelle biogenesis to control cell function 
have been directly studied in other cell types; ER expansion in the B cell is 
necessary for the production of immunoglobulins required to fight infection in an 
immune response, for example, and melanosome biogenesis in melanocytes 
protects cells against the mutagenic effects of ultraviolet radiation (UVR) 
(Federovitch et al., 2005, Rush et al., 1991, Schiaffino, 2010). Moreover, 
beyond the function of any one cell type, the ability to differentially regulate cell 
mass, volume and organelle content downstream of distinct signalling pathways 
must also help provide the flexibility to generate the diversity in cell size, 
morphology and organelle content across different cell types in vivo that is 
necessary for cells to carry out cell type specific functions efficiently. Differential 
cell growth can, for example, help drive the expansion of a large lipid droplet in 
adipocytes so that they can function effectively as an organism’s energy 
storage depot and can help drive specific expansion of the Golgi network in 
secretory cells so that they can efficiently modify the sufficient amounts of 
proteins and lipids for secretion (Koga and Ushiki, 2006, Zweytick et al., 2000).  
3.8.3 Regulating Cell Mass, Volume and Organelle Content 
Cells undergo continuous organelle and macromolecular turnover, as 
described in the Introduction, and the mass, volume and organelle content 
(size) of the cell is determined by the balance between the rate at which each of 
these components is accumulated/ synthesised and the rate at which each is 
lost/ degraded. This means that to understand how Raf kinase and IGF-1 drive 
an increase in cell mass, volume and/ or organelle content, it will be necessary 
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to understand how they regulate these opposing processes to drive net 
accumulation. This was not addressed in the current study. Given that both 
stimuli drive an increase in protein mass, the obvious starting point for such 
investigations would be to quantify the rates of protein synthesis and 
degradation downstream of Raf kinase and IGF-1. This could be done relatively 
easily using radiolabelled amino acids. In addition, because nucleolar size and 
cell ribosome number are closely coupled to the rate of protein synthesis 
(because ribosome biogenesis is metabolically costly), these could also be 
quantified as indicators of protein synthesis rates (Grewal et al., 2007, Grewal 
et al., 2005, Rudra and Warner, 2004, Warner, 1999, Wullschleger et al., 2006).  
Interestingly, there is evidence that protein synthesis and degradation is 
coupled downstream of growth factor signalling in sympathetic neurons 
(Franklin and Johnson, 1998, Kirkland and Franklin, 2007). In the presence of 
the growth factor NGF, neurite outgrowth was resistant to the inhibition of 
protein synthesis (protein synthesis was inhibited to varying extents using 
different concentrations of the protein synthesis inhibitor cycloheximide), 
because there was a corresponding inverse change in the rate of protein 
degradation 	   (Kirkland and Franklin, 2007). The authors propose this coupling 
helps ensure robust growth in the face of inevitable stochastic fluctuations in the 
rate of protein synthesis in vivo. It would be very interesting to use the Schwann 
cell system to determine if coupling is a general feature of cell growth control 
and to use the experimentally tractable Schwann cell system to address the 
molecular mechanism by which this occurs; for example, to determine whether 
there is direct crosstalk between the synthetic (ribosomes) and degradative 
(proteasomes and/ or lysosomes) machinery, or whether there is coordinated 
control of both by upstream growth factor activated signalling pathways. It 
would also be very interesting to determine whether coupling is limited to 
protein biogenesis, or if the synthesis and degradation of lipids, and even 
organelles, is also coupled. If so, coupling may be a universal mechanism 
regulating all aspects of cell growth. 
Considering the increase in protein mass induced by IGF-1 and Raf 
kinase activation a little further: although both stimuli increase cell protein mass, 
they may increase distinct subsets of proteins. In other words, the proteome of 
the cell may be very different following each stimulus. Such differences may be 
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significant to the distinct functions of the cell following IGF-1 treatment or Raf 
kinase activation. High throughput proteomic comparisons of the two conditions, 
as well as analyses of the proteins induced following each stimulus could be 
performed by SILAC combined with mass spectrometry analyses. These 
analyses may shed light on the mechanisms by which IGF-1 and Raf kinase 
increase cell protein mass, as well as any differences in these mechanisms 
between the two conditions and, therefore, could be important for 
understanding cell growth control downstream of these stimuli. 
Beyond considering macromolecular synthesis and degradation, it is 
important to understand how biogenic stimuli regulate organelle biogenesis, 
which is a largely poorly understood part of cell growth control. The finding that 
Raf kinase and IGF-1 regulate the size and/ or number of several organelles 
provides an ideal opportunity to study how growth factor activated signalling 
pathways activate the gene expression and biosynthetic programmes required 
to synthesise organelles. A study from our lab has already begun to address 
how growth factor activated signalling regulates Schwann cell mitochondrial 
biogenesis (Echave et al., 2009). In this study, Echave et al 2009 demonstrated 
that the transcription factor oestrogen-related receptor α (ERRα) is induced co-
operatively by the extracellular factors IGF-1 and NRG1 and that this is critical 
for the induction of mitochondrial gene expression downstream of these factors. 
Mitochondria are a good model organelle for studying growth factor activated 
organelle biogenesis because a number of transcription factors and co-
activators that regulate mitochondrial biogenesis have been identified, including 
ERRα and the transcriptional co-activator peroxisome proliferator-activated 
receptor γ co-activator α (PGC1α), which is considered to be a master regulator 
of mitochondrial biogenesis (Hock and Kralli, 2009, Ventura-Clapier et al., 
2008). This, together with the relative ease with which mitochondrial volume 
and mitochondrial DNA replication can be quantified, means it is straightforward 
to investigate the effects of specific biogenic stimuli on mitochondrial 
biogenesis. It would be very interesting to determine whether IGF-1 and Raf 
kinase increase mitochondrial volume via common transcriptional regulators, in 
addition to ERRα, as well as whether these signals converge only at these 
transcriptional regulators, or further upstream. As well as improving our 
understanding of mitochondrial biogenesis downstream of these stimuli, this will 
also provide information on how conserved the mechanisms driving 
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mitochondrial biogenesis are between distinct growth factor activated signalling 
pathways.  
3.8.4 Organelles Driving the Addition of Cell Mass and Volume 
 As has been touched upon in Sections 3.8.1 and 3.8.2, the relationship 
between the organelles and the mass and volume of the cell is complex, 
because the organelles do not just represent the mass and volume of the cell at 
any one point in time; many organelles are also the machinery required to drive 
future changes in cell mass and volume. Considering the findings of this study, 
the relationship between the mitochondria, ER and cell protein mass may 
represent a particularly noteworthy example of this. Raf kinase and IGF-1 both 
drive an increase in protein mass, mitochondrial volume and, seemingly, the 
amount of ER. The ER and mitochondria, as already discussed, are likely to 
represent part of the increase in protein mass. However, their functions are also 
likely to play an important role in driving the increase in cell protein, which will 
include contributing to the synthesis of more mitochondria and ER. This is 
because the mitochondria provide the ATP and biosynthetic precursors for 
macromolecular synthesis and the rough ER (RER) is where integral membrane 
proteins, secreted and ER and Golgi proteins are synthesised. Moreover, the 
RER expands in response to increased demand for protein (Federovitch et al., 
2005, Kirk et al., 2010, Schuck et al., 2009). However, it must be noted that this 
study did not distinguish between smooth ER (SER) and RER and so it is not 
actually possible to conclude whether it is the RER, the SER, or both that 
seems to increase downstream of Raf kinase activation. The two types of ER 
can be distinguished by electron microscopy and this could be exploited to 
perform such quantifications. It would be interesting to perform these analyses 
not just in terms of considering the addition of protein mass, but also 
considering the addition of cell volume downstream of IGF-1. This is because 
the SER is a primary site of lipid synthesis and so it would be very interesting to 
determine if the amount of SER increases specifically downstream of IGF-1, 
which would further link cell volume addition and cell lipid metabolism. 
As has been raised earlier in this Discussion, the findings of this study 
suggest there may be a specific role for peroxisomes in the addition of cell 
volume because, like cell volume, the number of peroxisomes increases 
downstream of IGF-1, but not Raf kinase activation. Furthermore, like cell 
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volume, this increase is not blocked by inhibition of MEK, but is blocked by 
inhibition of mTORC1. Although the role of peroxisomes in cell volume addition 
has not been investigated, the pathologies of several inherited peroxisome 
biogenesis disorders- namely those associated with impaired ether 
phospholipid synthesis- include hypomyelination and stunted growth, 
suggesting peroxisomes may function in cell growth, potentially including cell 
volume addition (Chrast et al., 2011, Wanders et al., 2010). The steps in 
peroxisome biogenesis are increasingly well understood- 34 peroxin (PEX) 
genes important in peroxisome biogenesis have been identified and 
characterised and this could be exploited to address whether peroxisomes have 
a functional role in cell volume regulation- particularly because knockout mice 
and cell lines exist for a number of these, which would facilitate loss-of-function 
studies (Lazarow, 2003, Liu et al., 2012). If peroxisomes have a role in cell 
volume regulation during cell growth, this finding would be important not only 
because it would be the first time this organelle has been directly associated 
with the regulation of cell growth, but also because the peroxisomes may then 
provide a novel therapeutic target for diseases of cell overgrowth, e.g. cancers. 
3.8.5 Signalling Pathways Driving Cell Growth 
The findings of this study suggest that PI3K and mTORC1 are necessary 
for the addition of Schwann cell volume and protein mass. This is consistent 
with findings in vivo, which show that loss of signalling through this pathway 
leads to hypomyelination and therefore reduced cell size in myelinating 
Schwann cells (Cotter et al., 2010, Macklin, 2010, Maurel and Salzer, 2000). In 
fact, the PI3K/ Akt/ mTORC1 pathway appears to be ubiquitously important in 
cell growth control; inhibition of this pathway prevents cell growth, and 
hyperactivation of the pathway can drive cell growth, across multiple diverse 
systems in vitro and in vivo (Chan et al., 2011, Collins et al., 2012, Echave et 
al., 2009, Flores et al., 2008, Lai et al., 2004, Leevers et al., 1996, Maurel and 
Salzer, 2000, Peng et al., 2003, Porstmann et al., 2005, Porstmann et al., 
2008). However, many of the studies in which activating PI3K/ Akt/ mTORC1 
signalling was shown to drive hypertrophy were performed in vivo, or in the 
presence of serum in vitro (Abe et al., 2010, Flores et al., 2008, Lai et al., 2004, 
Meikle et al., 2008, Peng et al., 2003, Porstmann et al., 2008, Zhou et al., 
2009). In both cases, this means extracellular factors were present that might 
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have cooperated with the hyperactivated signal to drive cell growth- in other 
words, the PI3K/ Akt/ mTORC1 pathway may not actually be sufficient to drive 
cell growth. The primary Schwann cell system used in this study can be 
exploited to address this issue, as- using expression constructs for different 
pathway components- the pathway can be activated in conditions free from 
potentially confounding extracellular growth factors. This approach has already 
been used to show that activating Akt (by overexpressing a tamoxifen inducible 
Akt construct) is sufficient to drive addition of Schwann cell volume, but it is not 
known if it can also drive addition of cell mass (Echave et al., 2009). Moreover, 
it is not known whether the addition of volume and/ or mass can be further 
narrowed down to mTORC1 downstream of Akt. It may be that, as has been 
found in mouse liver, Akt drives mTORC1-independent effects that are required 
for mTORC1-dependent biogenesis to manifest (Wan et al., 2011, Yecies et al., 
2011). Addressing these questions are important to determine the intrinsic roles 
of activated PI3K, Akt and mTORC1 in cell growth. 
After considering the specific functions of these upstream growth factor 
activated signalling molecules, the next question is: what signalling pathways 
are activated downstream of PI3K/ Akt, mTORC1, and also ERK, to drive 
biogenesis? Given that both IGF-1 and Raf kinase activation increase Schwann 
cell protein mass, it would be very interesting to determine whether there is a 
role for c-Myc. Myc is known to drive protein biogenesis, associated with an 
increase in rRNA levels, ribosome and nucleolar density and protein synthesis, 
and both ERK and Akt have been shown to stabilise the inherently unstable c-
Myc protein (Chan et al., 2011, Grewal et al., 2005, Iritani and Eisenman, 1999, 
Johnston et al., 1999, Kim et al., 2000, Pierce et al., 2004, Saucedo and Edgar, 
2002, Schreiber-Agus et al., 1997, Sears, 2004, Schuhmacher et al., 1999, Wu 
and Johnston, 2010). ERK can phosphorylate and stabilise c-Myc directly, 
whereas Akt phosphorylates and inhibits the kinase GSK3β, which 
phosphorylates c-Myc and, as a result, targets it for ubiquitination and 
degradation (Sears et al., 2000, Sears, 2004). Consistent with a potential role 
for c-Myc in the Schwann cell, levels of the c-Myc protein increase downstream 
of hyperactive Ras, which activates both PI3K/ Akt and ERK signalling (Collins 
et al., 2012). Interestingly, dMyc drives an increase in ribosomal density and 
nucleolar size in the Drosophila wing imaginal disc (Betschinger et al., 2006, 
Grewal et al., 2005). Given that ribosome number is meant to correlate tightly 
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with rates of protein synthesis, this may suggest protein density increases 
downstream of dMyc in these cells- reminiscent of effect of activating Raf 
kinase in this system. Therefore it is particularly interesting to speculate whether 
there is a specific role for c-Myc downstream of Raf kinase activation in the 
Schwann cell. 
Finally, this study did not investigate whether IGF-1 and sustained Raf 
kinase activation can synergise to drive biogenesis. Preliminary experiments 
suggest the two do not synergise on cell volume (data not shown). This is 
consistent with the finding that NRG1, which drives strong and sustained ERK 
signalling and does not drive addition of Schwann cell volume, does not 
enhance IGF-1 driven Schwann cell volume addition (Conlon et al., 2001). 
However, the two signals might co-operate to drive the addition of protein mass, 
i.e. the biogenic effect they both promote. This would be reminiscent of the 
finding that IGF-1 and NRG1 synergise to drive mitochondrial biogenesis in the 
Schwann cell, as well as the finding that IGF-1 and loss of the tumour 
suppressor protein Rb synergise to drive enhanced addition of cell mass and 
volume (Collins et al., 2012, Echave et al., 2009). Such synergistic and additive 
effects can help provide the flexibility to produce diverse cell growth in vivo, 
including differential organelle biogenesis, cell mass and volume, in response to 
activation of different combinations of signalling pathways. 
3.8.6 Conclusion   
The findings of this study demonstrate that both cell mass and volume 
can be separately and independently regulated. Ultimately, this means it is 
possible to independently regulate the addition of different organelles and 
cytosol, which allows cells to adapt to changes in the extracellular environment 
and to carry out different cellular functions. It is tempting to speculate, for 
example, that the increase in mitochondrial volume observed downstream of 
Raf kinase activation, increases the cells capacity to produce ATP and 
therefore prepares the cells for the energetically expensive process of cell 
proliferation, which is also induced by ERK signalling. From a physical 
perspective, it is perhaps surprising that both protein mass and volume can be 
added in the absence of the other. Whilst the findings presented in this Chapter 
have not provided definitive answers to how this is achieved, they have 
provided a number of relevant points of discussion- including the potential role 
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for lipids in the addition of cell volume, and where in the cell protein might be 
added such that it does not increase cell volume. A complete understanding of 
cell growth control will require understanding the mechanisms by which 
biogenic stimuli regulate both macromolecular synthesis and organelle 
biogenesis to drive cell growth. Given that this study has identified that Raf 
kinase activation and IGF-1 regulate both processes, these questions could be 
addressed in this tractable and powerful primary Schwann cell system. 
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Chapter 4: Results 
Plasma Membrane Growth and the Dynamics of Plasma 
Membrane Turnover  
It is inevitable that sustained cell volume addition will require expansion 
of the plasma membrane. The aim of the second part of this thesis was to study 
the mechanisms that regulate plasma membrane size and expansion during cell 
growth. The experimental conditions used in these studies differed slightly from 
those used in the preceding chapter. Namely, serum was used as a growth 
factor instead of IGF-1. Serum is more potent, promoting greater and more 
sustained growth; aphidicolin-arrested Schwann cells treated with serum (3% 
FCS) for 24hrs have ~2-fold greater increase in cell volume and protein mass 
than the equivalent cells treated with IGF-1 (Collins et al., 2012, Conlon et al., 
2001). Plasma membrane growth and dynamics in cells growing in the 
presence of serum were compared to cells that are growth factor deprived and, 
as a result, do not add mass or volume (Collins et al., 2012, Conlon and Raff, 
1999, Echave et al., 2007, Edinger and Thompson, 2002, Franklin and 
Johnson, 1998, Kirkland and Franklin, 2007, Lum et al., 2005a, Vander Heiden 
et al., 2001). Serum-treated versus growth factor-starved conditions represent 
the two extremes of cell growth and biogenesis. This meant they were more 
likely to provide a tractable system in which plasma membrane dynamics could 
be investigated. 
The basic experimental system is as described in Part 1. That is, cells 
were cell cycle arrested in the presence of serum (3% FCS) for 24hrs using the 
DNA polymerase α inhibitor aphidicolin. Then cells were transferred to defined 
conditions, in the absence of exogenous mitogens, growth factors and survival 
factors (SATO Medium), plus aphidicolin for a further 24 hours. At this point 
cells were treated with serum or maintained in SATO, still in the presence of 
aphidicolin, and assays conducted as indicated in the text. Using aphidicolin 
allowed the biogenic effects of serum to be investigated independently of 
effects on the cell cycle. As the effect of Raf kinase activation was not a focus of 
this research, these experiments used normal Schwann cells, i.e. lacking the 
Tmx-inducible Raf kinase construct. 
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4.1 Serum Drives Cell Growth: Cells in the Presence of Serum Add Mass, 
Volume and Plasma Membrane 
Serum is rich in extracellular factors, including growth factors. It also 
contains abundant nutrients, for example lipoproteins, that are the substrates 
for bioenergetics and biogenesis in the cell. The growth and biogenic 
capabilities of serum can be demonstrated by quantifying cell volume and 
protein mass over time after aphidicolin-arrested cells in defined conditions 
(SATO) are treated with medium containing 3% foetal calf serum (3% FCS). As 
shown in Figure 4.1 & 4.2, serum was able to drive an ~1.7-fold increase in cell 
volume over 24 hours as measured by Coulter Counter analysis. If the cell 
culture medium was not changed this increase plateaued between 24 and 36 
hours post-serum addition (Figure 4.1 A dotted line). Presumably this is 
because extracellular growth factors and nutrients in the serum were utilised by 
the cell and, as a result, were depleted from the extracellular medium. If the cell 
culture medium was replaced with fresh 3% FCS medium at 24 hours, cell 
volume addition continued (Figure 4.2 B). Previous findings from our lab and 
others have shown cells will not grow in the absence of extracellular growth 
factors and/or activation of biogenic pathways by genetic manipulation. 
Consistent with this, Schwann cells that remained in defined, growth factor free 
conditions did not add cell volume (Figure 4.1 & 4.2, SATO) (Collins et al., 
2012, Conlon and Raff, 1999, Echave et al., 2007, Edinger and Thompson, 
2002, Franklin and Johnson, 1998, Kirkland and Franklin, 2007, Lum et al., 
2005a, Vander Heiden et al., 2001). 
In addition to driving an increase in cell volume, serum was able to drive 
an ~1.5-fold increase in protein mass over 24 hours (Figure 4.3, ‘3% FCS’) 
(Conlon and Raff, 2003). In contrast, cells deprived of growth factors did not 
add protein mass (Figure 4.3, ‘SATO’). The amount of protein per cell was 
quantified using two approaches; first using the standard BCA assay (Figure 4.3 
A) and second by S. Ester labelling (Figure 4.3 B) (Both methods as described 
in Results 3.1 and Materials & Methods 2.2).  
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Figure 4.1 Serum drives the linear addition of cell volume
Aphidicolin arrested NS cells were treated as indicated before cell volume was quantified using 
a Coulter Counter. Graphs show mean +SEM.
A) Mean cell volume over time (μmᶟ), no media change at 24hrs.
B) Mean cell volume over time (μmᶟ), media change at 24hrs.
Graphs show mean +SEM of A) 7 and B) 4, performed in duplicate per timepoint per condition. 
Linear regression analysis A) 3% FCS p<0.05, SATO p>0.05 and B) 3% FCS p<0.05, 
SATO p<0.05. 
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Figure 4.2 Serum drives addition of cell volume
Aphidicolin arrested NS cells were treated as indicated before cell volume was quantified using 
a Coulter Counter.
A) Representative frequency distribution of cell volumes in the measured populations (μmᶟ).
B) Mean cell volume (μmᶟ). Bar chart showing mean +SEM of 7 experiments, performed in 
duplicate, and t-t st with Bonferroni correction for multiple hypothesis testing.
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Figure 4.3 Serum drives addition of cell protein mass
Aphidicolin arrested NS cells were treated as indicated before mean amount of protein per cell 
was quantified:
A) By the BCA assay ( .u.). B r chart shows mean +SEM of 7 experiments, performed in 
duplicate per timepoint per condition.
B) As fluorescence intensity per cell after AlexaFlour647-succinimidyl ester labelling of fixed 
cells (a.u.). Bar chart shows mean +SEM of 4 experiments, minimum of 50 cells quantified per 
condition per timepoint per experiment.
Repeated Measures Two-Way ANOVA A) SATO vs 3%FCS p<0.0001, Interaction p<0.01 and 
B) SATO vs 3%FCS p<0.01, Interaction p<0.05, post hoc Bonferroni as indicated on the graphs.
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To determine the effect of serum and growth factor starvation on plasma 
membrane size, two different approaches were used to quantify plasma 
membrane size as cells were growing in the presence of serum or shrinking due 
to growth factor starvation. In the first approach an amphipathic fixable 
fluorescent dye, Cell Mask Orange, was used to label the plasma membrane of 
live cell populations. The cells were then fixed and imaged by confocal 
fluorescence microscopy; images were taken at 252nm intervals through the 
depth of the cell. An outline of the cell surface was generated in silico from the 
image stacks and cell surface area was estimated from this outline (Materials & 
Methods 2.5 & 2.6) (Figure 4.4). The image of the cell surface created by this 
method is a simplification of the real cell surface as sub-light resolution 
membrane architecture and folds of the plasma membrane cannot be detected. 
This means such folds will not be quantified. This limitation is more acute in the 
Z-plane where the resolution of the light microscope is approximately twice the 
distance as it is in the XY-plane. As the morphology of cells in serum and SATO 
are very different, there may be a difference in the size of the experimental error 
associated with the cell surface area measurements between these conditions. 
To control for this, cell surface area was quantified at 2 hours, as well as 24 
hours, +/- serum treatment. After 2 hours cells in serum have already begun to 
take on a different morphology to those in SATO; however if the cells are 
changing surface area over the 24 hour assay one would predict these 
differences would be greater at 24 hours than 2 hours.  
There was no detectable difference in the cell surface area of the 
growing (3% FCS) and starved (SATO) cells 2 hours +/- serum addition and no 
difference in cell surface area compared to 0 hours (Figure 4.4 B). This 
suggested that the difference in cell morphology between serum treated and 
starved cells does not cause a detectable, artefactual difference in cell surface 
areas quantified by this method; at least whilst the cells are similar sizes. 
Across 24 hours, the surface area of cells growing (adding cell volume and 
protein mass) in the presence of serum increased ~1.5-fold, indicative of an 
increase in plasma membrane size (Figure 4.4 B). In contrast, the cells that 
remained in the absence of extracellular growth factors maintained a constant 
cell surface area (Figure 4.4 B), consistent with the inability of these cells to 
grow (add cell volume and protein mass).  
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Figure 4.4 Serum drives addition of plasma membrane
Aphidicolin arrested NS cells were treated as indicated before the plasma membrane dye 
CellMask Orange was used to label the cell surface of fixed cells. Cell surface area was 
quantified in ImageJ from image stacks of labelled cells taken by fluorescence confocal 
microscopy.
A) Representative images of CellMask Orange labelled cells used for quantification of: 
B) Mean cell surface area (μm²). Graphs shows mean +SEM of 3 experiments, minimum of 15 
cells quantified per timepoint per condition per experiment. Repeated Measures One-Way 
ANOVA p<0.01, post hoc Tukey’s as indicated on the graph.
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It is possible that the apparent change in surface area of the growing 
cells could be the result of the unfolding of plasma membrane ruffles rather than 
an increase in the actual amount of membrane. To address this possibility a 
second and more direct method was used to quantify plasma membrane size. 
The bulk of the plasma membrane, like all biological membranes, is composed 
of lipid. The fluorescent lipophilic probe FM1-43 inserts non-specifically into lipid 
membranes (i.e. insertion is unaffected by which lipid species make up the 
membrane) and once inserted into one leaflet of a lipid bilayer (e.g. the outer 
leaflet of the plasma membrane) it does not flip-flop into the other leaflet (Betz 
et al., 1996, Gaffield and Betz, 2006). Therefore, the size of the plasma 
membrane can be inferred as the total fluorescence intensity per cell after a 
brief labelling of the cells with FM1-43. It is the amphiphilic nature of the 
molecule that prevents FM1-43 flipping between the leaflets of the bilayer; it has 
two aliphatic hydrophobic tails that insert into the inner hydrophobic region of 
the membrane and a hydrophilic dicationic head that anchors in the membrane 
surface (Betz et al., 1996, Gaffield and Betz, 2006). Cell fluorescence intensity 
was quantified from spinning disc confocal images of live aphidicolin-arrested 
Schwann cell populations after briefly labelling the cells 10 and 24hrs +/- serum 
(3% FCS) treatment in FM1-43 containing medium (Materials & Methods 2.6 & 
2.7).  
As can be seen in Figure 4.5, consistent with the Cell Mask data, serum 
caused an increase in fluorescence intensity per cell over 24 hours, 
demonstrating that the size of the plasma membrane increased over this time. 
In contrast, and again consistent with the Cell Mask data, cells starved of serum 
appeared to maintain a constant plasma membrane size over the same time 
period; because the fluorescence intensity per cell remained unchanged. The 
FM1-43 results indicated plasma membrane size increased ~2.25-fold over 24 
hours in the presence of serum. This is greater than the increase quantified 
using the Cell mask approach (~1.5-fold). As already detailed, the Cell Mask 
assay simplifies the cell surface morphology and cannot account for sub-light 
microscopy resolution membrane structures or plasma membrane folds, which 
means the Cell mask quantification likely underestimates plasma membrane 
size per unit of cell surface. In contrast, FM1-43 will label both these structures 
and this may explain the larger increase in size quantified using this approach.    
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Figure 4.5 Serum drives addition of plasma membrane
Aphidicolin arrested NS cells were treated as indicated before the plasma membrane of live 
cells was briefly labelled using the fluorescent lipophilic dye FM1-43 and imaged using spinning 
disc fluorescence confocal microscopy. Total cell fluorescence intensity was taken to represent 
plasma membrane size, shown as plasma membrane size over time (a.u.). Graphs shows 
mean +SEM of 5 experiments. Minimum of 10 cells quantified per timepoint per condition per 
experiment. Repeated Measures Two-Way ANOVA (10 vs 24 hrs), interaction p<0.05, post hoc 
Bonferroni as indicated on the graph.
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Taken together the results described in this Section confirm that serum is 
a powerful Schwann cell growth factor that drives a significant increase in cell 
volume, protein mass and plasma membrane size over time. In the absence of 
serum and any growth factor stimulus Schwann cells do not add volume, 
protein mass or plasma membrane. 
 
4.2 Starved Cells Upregulate the Catabolic Process of Autophagy 
The results above show that Schwann cells are unable to add protein 
mass, volume or plasma membrane in the absence of serum or growth factors, 
suggesting that anabolic processes may be suppressed in these conditions. In 
fact, studies have shown that growth factor withdrawal usually has an even 
more dramatic effect on cell metabolism than simply suppression of anabolic 
processes; when extracellular factors are removed cells are unable to take up 
and utilise sufficient extracellular nutrients and become catabolic, undergoing 
autophagy to produce the nutrients to prolong survival (Edinger and Thompson, 
2002, Lum et al., 2005a, Lum et al., 2005b). 
A simple assay was used to determine whether autophagy is induced 
upon growth factor starvation in the Schwann cell: autophagosomes are cleared 
by fusion with, and degradation by, the lysosome and so the rate of autophagy 
can be inferred by the extent of autophagosome accumulation in the cell after 
lysosome function is inhibited. Therefore, chloroquine was used to inhibit the 
lysosome and autophagosome load per cell was quantified from 
immunofluorescence microscopy images of cell labelled with an 
autophagosome marker (α-LC3b) (Materials & Methods 2.5-2.7 & Figure 4.7 
A)). Autophagosome load was quantified as the amount of LC3b positive area 
per cell. As shown in Figure 4.6 & 4.7 B, chloroquine treatment induced a 
significant increase in the LC3b positive area per cell, both in cells that are in 
the presence of serum (3% FCS) or those in the absence of serum (SATO). 
This suggested Schwann cells undergo autophagy both in the presence or 
absence of serum. However the increase in the LC3b positive area, and 
therefore autophagic flux, was greatest in the serum-deprived cells (SATO); 
more than 3-fold greater than the increase seen in the presence of serum (3% 
FCS). Indeed, serum deprivation increased the autophagy rate to an even 
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greater extent than treatment with Rapamycin, an inducer of autophagy (Figure 
4.7 B). In the growth factor starved cells, mTORC1 activity was not evident- as 
would be predicted given the absence of growth factor signalling (Figure 4.6 B). 
These results show that the rate of autophagy is higher in serum starved 
(i.e. growth factor starved) cells than in growing (serum treated) cells or cells 
treated with an inducer of autophagy. This finding is consistent with studies in 
other cell types, which have shown that cells in the absence of growth factors 
cannot take up and utilise sufficient nutrients to maintain cell metabolism and 
instead undergo autophagy, using the products of this catabolism to drive 
necessary biosynthetic and bioenergetic reactions (Edinger and Thompson, 
2002, Lum et al., 2005a, Lum et al., 2005b). 
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Figure 4.6 Serum suppresses autophagy
Aphidicolin arrested NS cells were treated as indicated before:
A) Anti-LC3b staining to label the autophagosomes. Shown are representative widefield 
microscopy images of labelled autophagosomes. Scale bar = 25μm.
B) 10hrs +/- serum/ Rapamycin treatment, cell lysates were collected  for western blot analysis  
of protein levels of pS6K (thr389). β -tubulin were used as a loading control. 
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Figure 4.7 Serum suppresses autophagy
Aphidicolin arrested NS cells were treated as indicated before anti-LC3b staining to label the 
autophagosomes.
A) Schematic demonstrating the processing and analysis of raw images performed in ImageJ 
for quantification of:
B) Mean LC3b positive area per cell. Bar chart shows mean +SEM of 5 experiments. Minimum 
of 50 cells quantified per condition per experiment. Repeated Measures Two-Way ANOVA, 
interaction p<0.001, post hoc Bonferroni as indicated.
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4.3 Endocytosis and Recycling Rates of Membrane Lipids are Equivalent 
and Rapid in Starved and Growing Cells  
The plasma membrane is dynamic and membrane turnover is critical for 
regulation of extracellular signalling, uptake of nutrients and other substrates 
and maintaining the integrity of the barrier the plasma membrane forms 
between the intra- and the extra- cellular environment. Given its importance it is 
unsurprising that membrane turnover is a carefully regulated process. 
Membrane dynamics vary between cell types, although differences may also be 
skewed by the method of quantification as well as what membrane parameter, 
i.e. protein, lipid or fluid-phase, is quantified (Burgert and Thilo, 1983). 
The size of the plasma membrane is determined by the balance between 
the rate of membrane removal and membrane delivery. For the plasma 
membrane to grow there must be net delivery of membrane, which can be 
achieved by increasing the rate of membrane delivery, reducing the rate of 
membrane removal or both (Figure 4.8). It may even be achieved when 
membrane delivery and removal both increase or decrease, as long as the 
change in delivery relative to removal results in net delivery of membrane. For 
the plasma membrane to maintain a constant size the rate of membrane 
removal and delivery must be in equilibrium. Although the mechanisms by 
which plasma membrane size can be rapidly altered (for example upon stretch 
in alveolar or bladder epithelial cells) have been well studied, the mechanisms 
by which sustained expansion of the plasma membrane occurs during growth 
has not. Given that Schwann cells in the presence of serum add plasma 
membrane whereas starving cells maintain a constant plasma membrane size 
over 24hrs (Section 4.1, Figure 4.4 & 4.5), comparing these conditions seemed 
a tractable system in which to begin to investigate the mechanics of plasma 
membrane growth. 
The plasma membrane is removed and delivered by both vesicular and 
non-vesicular mechanisms (Figure 4.8). Proteins move primarily via the 
vesicular pathways and lipids via both vesicular and non-vesicular routes (Prinz, 
2010). Vesicular transport consists of a complex system of endocytic (removal) 
and exocytic (delivery) pathways. The exocytic pathways can be broadly 
divided into the exocytosis of de novo material (the secretory pathway), or 
material derived from previously endocytosed material (recycling exocytosis); 
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within these two categories multiple specific and overlapping pathways exist 
(Chieregatti and Meldolesi, 2005, Grant and Donaldson, 2009). This is true also 
for endocytic pathways (Conner and Schmid, 2003). As vesicular trafficking is a 
major mechanism of membrane removal (endocytosis) and delivery 
(exocytosis), these pathways were the focus of initial analyses. More 
specifically, the rates of endocytosis and recycling (of previously endocytosed 
material) were quantified. Although the terms ‘endocytosis’ and ‘recycling’ each 
encompass a range of specific pathways, global rates of endocytosis and 
recycling can be quantified using markers carried by (as far as is known) all 
pathways. As lipids are the major component of all cell membranes, the rates of 
endocytosis and recycling of membrane lipids were quantified first. 
Immediately after the addition of serum there will be a period of rapid 
endocytosis of activated nutrient and extracellular factor receptors. As this rapid 
rate of plasma membrane turnover is only transient it cannot represent the 
plasma membrane dynamics that contribute to long-term sustained serum-
driven plasma membrane growth. Therefore, the rates of plasma membrane 
endocytosis and recycling were quantified 10 hours +/- the addition of serum 
(3% FCS) when this transient increase in membrane turnover should have 
passed. The rate of plasma membrane lipid endocytosis and recycling was 
quantified using the lipophilic styryl dye FM1-43 used in Section 4.1 to quantify 
plasma membrane size. As already described, FM1-43 inserts non-specifically 
into lipid membranes and does not flip-flop between the leaflets of a bilayer. 
FM1-43 moves with the membrane it is inserted in, which means when the dye 
inserts into plasma membrane it will be endocytosed with that membrane. This 
can be quantified as the increase in fluorescence intensity, i.e. the amount of 
FM1-43, per cell. Importantly, FM1-43 is fluorescent only in a hydrophobic 
environment, e.g. lipid membranes, which means fluorescence intensity of a 
labelled cell should reflect only labelled membrane- any dye internalised within 
the lumen of endocytic vesicles should not fluoresce.  
 
 
 
 
Figure 4.8 Regulation of plasma membrane size
The size of the plasma membrane is determined by the balance between the processes that
deliver membrane (exocytosis and non-vesicular lipid delivery) and those that remove
membrane (endocytosis, vesicular secretion and non-vesicular lipid removal).
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The initial rate of increase in fluorescence per cell over time reflects the 
rate of lipid endocytosis. Then, as recycling of previously endocytosed material 
begins, the rate of accumulation of fluorescence slows to a lower rate that 
reflects the equilibrium between the rate of endocytosis and the rate of recycling 
(Figure 4.9). The rate of lipid recycling is calculated by subtracting the 
equilibrium rate from the initial rate of endocytosis. FM1-43 is frequently used to 
study the endocytosis and recycling of synaptic vesicle membrane and has also 
been used in other cell types (Bertrand et al., 2006, Gaffield and Betz, 2006, 
Hao and Maxfield, 2000). It is important to note one caveat of this technique; 
the FM1-43 inserted into the lipid membrane is in dynamic equilibrium with the 
surrounding medium and diffuses within the lipid leaflet it is inserted in. 
Therefore if labelled membrane destined for recycling passes through a 
membrane compartment that contains a lower concentration of FM1-43 before 
being recycled, some dye will exit the membrane destined to be recycled (data 
from (Griffiths et al., 1989) suggests this will be the case). This means the 
amount of FM1-43 leaving the cell in the recycled membrane will not equal the 
amount that entered the cell in the equivalent size of endocytosed membrane- it 
will be less and therefore the size of the recycled membrane will be 
underestimated (Hao and Maxfield, 2000). How significant this error is and 
whether the size of the error is different in the growing and starving cells was 
not investigated within these studies.  
For these assays, aphidicolin-arrested Schwann cells were incubated 
with FM1-43 containing medium 10 hours +/- serum treatment and the rate of 
plasma membrane lipid endocytosis and recycling determined from the increase 
in total cell fluorescence intensity of specific cells over time: the fluorescence 
intensity of a cell was quantified from live cell spinning disc confocal microscopy 
images taken through the cell’s depth, as it was for imaging FM1-43 labelled 
cells in the plasma membrane size assays (Materials & Methods 2.10).  
 
 
 
 
Figure 4.9 Accumulation of fluorescence intensity over time represents 
membrane endocytosis and recycling
When cells are continuously incubated in FM1-43 containing medium, FM1-43 is 
non-specifically incorporated into the plasma membrane. As incorporation is independent of
membrane lipid composition the cell fluorescence intensity represents the size of the lipid
membrane labelled with the probe. The FM1-43 will then move with the membrane as it is 
internalised by endocytosis and then recycled back to the plasma membrane. The initial rate of
increase in intracellular fluorescence intensity (total cell fluorescence intensity - total cell
fluorescence intensity at t=0mins, i.e. the fluorescence intensity of the labelled plasma
membrane) reflects the rate of lipid endocytosis. As recycling of previously endocytosed
membrane begins, the rate of accumulation of intracellular fluorescence slows to a new and
lower rate that represents the balance between the rate of endocytosis and the rate of recycling
exocytosis. The rate of recycling is calculated by subtracting the equilibrium rate from the rate  
of endocytosis.
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Plotting the accumulation of intracellular fluorescence intensity against 
time showed there was no significant difference in the accumulation of 
fluorescence intensity (representing cell surface derived plasma membrane 
lipid) between the starved and growing cells (Figure 4.10 A i). This is shown 
more clearly when the initial and secondary rates are plotted on separate 
graphs (Figure 4.10 A ii & iii, respectively) and when the endocytosis and 
recycling rates are calculated from the best fit lines (Figure 4.10 B). These 
results indicate that growth factor starved (SATO) and growing (3% FCS) cells 
endocytose and recycle plasma membrane lipids at equivalent rates (Figure 
4.10). From this data, measurable recycling began between 5 and 10 mins after 
endocytosis; demonstrated by the shift from the initial more rapid rate of 
increase in fluorescence intensity to the second lower rate (Figure 4.10 A i). 
This is consistent with findings in other cell types for the turnover of both 
membrane lipids and specific membrane proteins (Hao and Maxfield, 2000, 
Koval and Pagano, 1990, Maxfield and McGraw, 2004, Mayor et al., 1993, 
Scharschmidt et al., 1986). 
At 10 hours post-factor addition the growing cells have ~1.5-fold more 
plasma membrane than the starved cells, according to the FM1-43 data 
described in Section 4.1 (Figure 4.5). Therefore, because the starved and 
growing cells seemed to move equivalent amounts of membrane lipid, the 
starved cells endocytose and recycle a greater proportion of their membrane 
lipid than the growing cells (Figure 4.11). Expressing turnover relative to plasma 
membrane size showed that membrane turnover is rapid, as the equivalent of 
the total cell surface lipid is internalised once every ~15-20 minutes (Figure 
4.11). Although studies in other cell types give a wide range of values for the 
rate of membrane internalisation, these rates found certainly fall within the 
range found by other studies in a range of cell types (1-20 times per hour) 
(Burgert and Thilo, 1983, Hao and Maxfield, 2000). These results indicated that 
even in growth factor starved cells the highly energetic, ATP-dependent 
processes of membrane lipid trafficking were maintained at high rates- 
equivalent to those of cells growing in serum (3% FCS). This was somewhat 
surprising given that growth factor deprived cells were highly autophagic and 
unable to grow, suggesting they are nutrient deprived and catabolic, and 
therefore might be predicted to downregulate ATP-dependent processes such 
as membrane trafficking compared to anabolic, growing cells (3% FCS).  
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Figure 4.10 Endocytosis and recycling rates of membrane lipids are similar in 
starved and growing cells (serum-starved and serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs then incubated in FM1-43 
containing medium to label the plasma membrane and, over time, internalised plasma 
membrane. Labelled cells were imaged at timepoints as indicated using live cell spinning disc 
confocal microscopy. Endocytosis and recycling rates were calculated from the change in total 
cell fluorescence intensity over time. Graphs show mean +SEM.
A) Intracellular accumulation of FM1-43 derived fluorescence over time, i) 0-60 mins (the 
combined graph of ii) and iii)), ii) 0-9 mins, iii) 10-60 mins. Mean of ii) 7, iii) 8 experiments, 1 cell 
quantified per condition per experiment. Linear Regression Analysis and Two-Way ANOVA 
(Time: 0-9, or, 10-60 mins) of ii) and iii) all have minimum significance of p<0.01.
B) Bar charts to show endocytosis and recycling rates, calculated from the graphs shown in A). 
Two-Way ANOVA, endocytosis vs recycling p<0.01, post hoc Bonferroni as indicated.
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Figure 4.11 The whole plasma membrane turns over faster in starved cells 
compared to growing cells (serum-starved vs serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs then incubated in FM1-43 
containing medium to label the plasma membrane and, over time, internalised plasma 
membrane. Labelled cells were imaged at timepoints as indicated using live cell spinning disc 
confocal microscopy. Endocytosis and recycling rates were calculated from the change in 
total cell fluorescence intensity over time and normalised to plasma membrane size in each 
condition. 
Bar chart shows mean +SEM. Endocytosis and recycling rates were calculated from the 
graphs shown in 5.10, normalised to fluroescence intensity at 0mins for each cell quantified. 
Growth rate was calculated from data in figure 4.9. Two-Way ANOVA, endocytosis vs 
recycling p<0.001, SATO vs 3% FCS p<0.001, interaction p<0.01, post hoc Bonferroni as
indicated on the graph.
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To confirm that FM1-43 was being internalised in an ATP-dependent 
manner, consistent with internalisation via endocytosis, the assay was 
performed in the presence of inhibitors of respiration to block ATP production 
and subsequently deplete ATP within the cells. Inhibitors were added to the 
cells 30 minutes prior to the start of the assay to allow time for cellular ATP 
levels to become depleted*. Inhibition of oxidative phosphorylation using 
sodium azide completely blocked intracellular accumulation of FM1-43 
(fluorescence intensity) in the starving cells (SATO) and reduced the uptake of 
FM1-43 in the growing cells (3% FCS) (Figure 4.12 A). These results suggested 
the starving cells are more reliant on oxidative phosphorylation (aerobic 
respiration) to produce ATP than the growing cells, consistent with findings in 
other cell culture systems (DeBerardinis et al., 2008a, Gomes et al., 2011a, 
Lunt and Vander Heiden, 2011). Blocking both oxidative phosphorylation and 
glycolysis, by treating cells with sodium azide together with sodium fluoride (to 
inhibit glycolysis), blocked FM1-43 accumulation in both the starving (SATO) 
and growing (3% FCS) cells (Figure 4.12 B). The latter assay had to be 
performed over a shorter time period (0-9 minutes) as when both oxidative 
phosphorylation and glycolysis are blocked, the cells rapidly looked very sick, 
had extensive membrane blebs and died. The results of both assays show 
FM1-43 is internalised in an ATP-dependent manner, consistent with 
internalisation of the dye via endocytosis. 
In summary: the results presented in this Section demonstrate that the 
rate of ATP-dependent endocytosis and recycling of plasma membrane lipid is 
equivalent in starved (SATO) and growing (3% FCS) cells. Moreover this rate is 
very rapid, with the whole plasma membrane lipid content internalised once 
every 15-20 minutes. The rate of membrane turnover was more than 75x 
greater than the calculated rate of serum-induced plasma membrane growth. 
Moreover, the standard error on the calculated endocytic and recycling rates 
was 2- to 6-fold greater than the plasma membrane growth rate. This means 
that any shift in the balance between these rates which may be responsible for 
driving plasma membrane expansion in the growing cells would be too small to 
be detected using this assay (Figure 4.11 B). Therefore, the rapidity of 
membrane turnover precludes using this type of kinetic approach to determine 
the mechanism of plasma membrane growth.  
*Note	  added	  in	  proof	  –	  we	  now	  realise	  that,	  given	  that	  these	  are	  not	  specific	  inhibitors,	  these	  results	  must	  be	  interpreted	  with	  care.	  
We	  can	  say	  that	  these	  inhibitors	  block	  ATP	  and	  show	  that	  dye	  uptake	  is	  an	  active	  process.	  	  
AB
Figure 4.12 Intracellular accumulation of FM1-43 is ATP-dependent
Aphidicolin arrested NS cells were treated +/- serum as indicated for 9.5hrs then treated +/- 
inhibitor for 30mins before being incubated in FM1-43 containing medium to label the plasma 
membrane and, over time, internalised plasma membrane. Labelled cells were imaged at 
times as indicated using live cell spinning disc confocal microscopy. Graphs show intracellular 
accumulation of FM1-43 derived fluorescence over time, relative to plasma membrane size.
A) 0-60mins +/- sodium azide.
B) 0-9mins +/- sodium azide/sodium fluoride.
Graphs show mean +SEM of A) 4 and B) 5 experiments, 1 cell quantified per condition per 
experiment. Regression analysis, null hypothesis=regression curves are the same A) SATO vs 
SATO+azide p<0.0001, 3% FCS vs 3% FCS+azide p<0.01 B) SATO vs SATO+azide p<0.01, 
3% FCS vs 3% FCS+azide p<0.0001.
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4.4 Fluid-Phase Endocytosis and Recycling Rates are Similar in Starved 
and Growing Cells 
 It was somewhat surprising that ATP-dependent membrane lipid turnover 
was as rapid in the starved cells as in the growing cells, given that they are 
autophagic, slowly losing volume and predicted to be nutrient starved. To 
further investigate these findings, an alternative method was used to quantify 
plasma membrane trafficking; quantification of the rates of fluid-phase 
endocytosis and recycling. Fluid-phase represents the volume/ contents of 
trafficked vesicles. Fluid-phase endocytosis and recycling was quantified using 
fluorescently labelled 10kDa dextran, a classic fluid-phase marker. Similar to 
FM1-43, dextran should be non-specifically endocytosed and recycled with the 
contents of endocytic vesicles. The rates of fluid-phase endocytosis and 
recycling can be determined by quantifying the accumulation of dextran in cells 
over time, as they were for membrane lipid. These assays were performed 
10hrs +/- serum treatment (as before): Schwann cells grown on coverslips were 
incubated in cell culture medium containing fluorescently labelled dextran for 
various times before being fixed. Mean fluorescence intensity per cell at each 
timepoint, representing the amount of dextran accumulated within the cell within 
that time, was quantified from maximal projection fluorescence confocal 
microscopy images of labelled cells (Materials & Methods 2.6 & 2.11).  
As shown in Figure 4.13 A, fluorescently labelled dextran accumulated in 
the cells over time. Importantly, consistent with uptake being via endocytosis, 
accumulation of intracellular fluorescence was an active process because it was 
blocked when cells were kept at 4°c (Figure 4.13 B). Consistent with the 
membrane lipid turnover results, recycling of previously endocytosed material 
began to occur after 5-10mins (as demonstrated by the shift from the higher to 
lower rate of fluorescence intensity accumulation). Figure 4.14 A shows that 
endocytosis (the initial rate of fluorescence accumulation) was equivalent in 
starved and growing cells (SATO and 3% FCS, respectively). The second rate 
was slower in the growing cells, which suggests recycling occurs faster as the 
initial rates were equivalent. However, when the endocytosis and recycling 
rates were quantified, the difference was not significant (Figure 4.14 B).  
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Figure 4.13 Fluid-phase endocytosis and recycling rates are similar in starved 
and growing cells (serum-starved and serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs then incubated in fluorophore-
conjugated dextran containing medium. Intrac llular fluorescence intensity increases over time 
as dextran is endocytosed.
A) Representative maximal projection images of labelled cells over time, scale bar = 25μm. 
B) Dextran accumulation over 60mins at 37°c versus 4°c, to show uptake is an active process. 
Mean of 5 experiments, minimum 25 cells quantified per condition per timepoint per experiment. 
Bar chart shows mean +SEM. Repeated Measures Two-Way ANOVA, 37°c vs On Ice p<0.001,  
post hoc Bonferroni as indicated on the graph.
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Figure 4.14 Fluid-phase endocytosis and recycling rates are similar in starved 
and growing cells (serum-starved and serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs then incubated in fluorophore-
conjugated dextran containing medium, as in the previous fi ure. Endocytosis and recycling 
rates were calculated from the increase in intracellular fluorescence intensity over time. Graphs 
show mean +SEM.
A) Intracellular fluorescence intensity over time. Mean of 3 (0-10 mins), 5 (10-60 mins) 
experim nts, m imum 25 cells quantified per condition per timepoint per experiment. The linear 
regression analyses performed on this data were used to calculate:
B) Mean endocytosis and recycling rates in 3% FCS and SATO. Repeated Measures Two-Way 
ANOVA, Endocytosis vs Recycling p<0.001, post hoc Bonferroni as indicated on the graph.
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In conclusion, using this second approach to quantify membrane 
trafficking (quantifying the turnover of fluid phase) confirmed that starved and 
growing cells appeared to endocytose and recycle material at similar rates.  
 
4.5 Membrane Protein Endocytosis and Recycling Rates are Similar in 
Starved and Growing Cells  
Proteins, like lipids, are a critical component of cell membranes; they are 
necessary for all functions of the plasma membrane, from nutrient uptake to 
signalling and substrate adhesion. It is therefore unsurprising that the 
expression, localisation and turnover of plasma membrane proteins is carefully 
regulated. The mechanisms regulating the plasma membrane trafficking of 
many specific proteins have been well studied; especially those of extracellular 
factor and nutrient receptors, such as the epidermal growth factor receptor 
(EGFR) and transferrin receptor (TfnR), respectively. It is also known that 
different proteins have different trafficking kinetics and, in the case of receptors, 
are often regulated by ligand concentration and receptor activation. How the 
kinetics of individual proteins relates to the global rate of plasma membrane 
protein turnover is unclear.  
The results presented in Sections 4.3 and 4.4 indicate that both fluid-
phase and lipid turnover at the plasma membrane is similar in starved (SATO) 
and growing (3% FCS) Schwann cells. However, this does not mean the global 
rate of protein endocytosis and recycling at the plasma membrane are 
equivalent. It is possible that the behaviour of plasma membrane proteins may 
be uncoupled from that of the membrane lipid and fluid-phase. For example, in 
receptor mediated endocytosis (one of the major endocytic pathways) proteins 
are often clustered prior to being internalised, which increases the ratio of the 
protein: lipid in the endocytosed vesicle compared to the plasma membrane. 
Given that certain signalling pathways, such as mTORC1, activated 
downstream of serum (i.e. in the growing cells) are known to positively regulate 
this form of endocytosis (Galvez et al., 2007, Hennig et al., 2006, Pelkmans et 
al., 2005) it was interesting to determine how the global rate of plasma 
membrane protein endocytosis and recycling compare between the starving 
and growing cells. 
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Two simple assays were developed to track and quantify membrane 
protein endocytosis and recycling, respectively. These assays use the common 
technique of cell surface biotinylation where an amine-reactive biotin probe is 
used to label cell surface proteins. Cell surface biotinylation was performed on 
ice to prevent uptake of the biotin into the cell during labelling. To quantify total 
membrane protein endocytosis labelled, cells were then incubated at 37°c to 
allow trafficking, including endocytosis, to resume. As labelled proteins were 
endocytosed, biotin accumulated within the cells. At 0, 4, 8, 12 and 20 minutes 
after warming, cells were placed on ice to stop trafficking and remaining cell 
surface biotin was cleaved and removed. Cells were fixed, intracellular biotin 
was detected using Alexafluor488-Streptavidin and the amount of biotin per cell 
quantified as fluorescence intensity per cell from fluorescence widefield 
microscopy images (Materials & Methods 2.9). Turnover was quantified 
following 10 hours +/- serum treatment in aphidicolin-arrested Schwann cells, 
as for the membrane lipid and fluid-phase assays.  
As shown in Figure 4.15 A, label accumulated in distinct puncta over 
time, consistent with internalisation via endocytosis and trafficking within the 
vesicular endomembrane system. Similar to the membrane lipid and fluid-phase 
assays, when intracellular fluorescence intensity was plotted against time the 
initial rate of accumulation was taken to represent the rate of total protein 
endocytosis. As shown by the close correlation in intracellular fluorescence 
intensity between starved (SATO) and growing (3% FCS) cells over the first 12 
minutes of the assay (Figure 4.15 B), the starved and growing cells internalised 
membrane protein at a similar rate.  
Only proteins on the cell surface at the start of the assay are biotin 
labelled. This means that as the assay proceeds, the proportion of label 
distributed between the intracellular recycling membranes and the cell surface 
equilibrates, which means there will be no further increase in the amount of 
label inside the cell, as is seen in Figure 4.15 B. Moreover, intracellular intensity 
will fall (Figure 4.15 B) as endocytosed labelled proteins are degraded. 
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Figure 4.15 The rate of total membrane protein endocytosis is similar in starved 
and growing cells (serum-starved and serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs before cell surface biotinylation 
to label cell surface proteins. The kinetics of biotin internalisation after returning labelled cells to 
37°C was taken to represent the kinetics of cell surface protein internalisation.
A) Representative widefield microscopy images of intracellular biotin accumulation over time. 
Cells were fixed at various timepoints and intracellular biotin was detected using fluorophore-
conjugated streptavidin and used to quantify:
B) Fluorescence intensity over time. Graph shows mean +SEM of 7 experiments. Minimum of 
25 cells quantified per condition per timepoint per experiment. F-test comparison of the non-
linear regression analyses performed for 3% FCS and SATO, p>0.05.230
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To quantify the rate of total membrane protein recycling, a modified 
version of the endocytic assay was developed. Cells were labelled as for the 
endocytic assay and then returned to 37°c for 45 minutes to allow loading of the 
recycling compartment with labelled protein. The 45 minute timepoint was 
chosen because the membrane lipid and fluid-phase results show recycling 
begins before this time (beginning between 5 and 10 minutes after endocytosis, 
Figure 4.10 & 4.14). In addition, as there are both fast and slow recycling 
compartments, by loading the cells for 45 minutes the intention was to label 
both the slow and fast compartments so that the quantified rate of recycling is 
more reflective of the global rate of protein recycling. After 45 minutes, cells 
were placed on ice to prevent further trafficking and remaining cell surface 
biotin cleaved. The cells were then returned to 37°c to once again allow 
trafficking, including recycling, to resume. Cleavage buffer (reduced glutathione) 
was added to the cell culture medium when cells were returned to 37°c so that, 
as labelled proteins were recycled to the cell surface, their biotin label was 
cleaved and lost from the cells. At 0, 4, 8, 12 and 20 minutes after warming, 
cells were placed on ice to prevent further trafficking and any residual cell 
surface biotin was again cleaved and removed. Remaining intracellular biotin 
was labelled, imaged and quantified as for the endocytic assay.  
As shown in Figure 4.16 A, cells were heavily labelled at the start of the 
assay, with label concentrated in distinct puncta throughout the cell- consistent 
with localisation in the endomembrane system including recycling 
compartments. Over time label was lost from the cells. As for the endocytic 
assay, intracellular fluorescence intensity was taken to represent the amount of 
labelled protein in the cell. Therefore, the rate of loss of intensity over time 
represented the loss of labelled protein. This occurs by recycling, but is also 
likely to include loss resulting from degradation of labelled proteins. Plotting 
intracellular fluorescence intensity over time showed that the rate of loss of 
label was similar in the starved (SATO) and growing (3% FCS) cells, suggesting 
the total rate of loss (by recycling and/ or degradation) of endocytosed 
membrane protein was equivalent in the two conditions (Figure 4.16 B). These 
results, together with the results from the preceding sections, suggest that the 
global rates of endocytosis and recycling are similar for membrane lipid, protein 
and fluid-phase in growing (3% FCS) and starved (SATO) cells.  
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Figure 4.16 The rate of membrane protein recycling is similar in starved and 
growing cells (serum-starved and serum-treated cells)
Aphidicolin arrested NS cells were treated as indicated for 10hrs then cell surface biotinylated 
and returned to 37°c to load the recycling compartment with biotin labelled proteins before 
remaining cell surface biotin was removed. The subsequent loss of intracellular biotin after cells 
were again returned to 37°c was taken to represent the kinetics of cell surface protein recycling.
A) Representative widefield microscopy images of loss of intracellular biotin over time. Cells 
were fixed at various timepoints and intracellular biotin was detected using fluorophore-
conjugated streptavidin and used to quantify:
B) Fluorescence intensity over time. Graph shows mean +SEM of 4 experiments. Minimum of 
25 cells quantified per condition per timepoint per experiment. F-test comparison of the linear 
regression analyses performed for 3% FCS and SATO, p>0.05.232
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4.6 Chapter 4: Summary 
The findings described in this chapter can be summarised as follows: 
• Serum, a rich source of extracellular growth factors and nutrients, drives 
Schwann cell growth: Cells in the presence of serum add cell volume, 
protein mass and plasma membrane.  
In the absence of serum and extracellular growth factors, cells cannot 
add protein mass or plasma membrane and lose cell volume.  
As expected, starved cells display significantly higher rates of autophagy 
than growing cells. This is consistent with published data demonstrating 
that growth factor starved cells cannot maintain sufficient nutrient uptake 
to fuel metabolism and, as a result, catabolise intracellular contents by 
autophagy to provide the nutrients to prolong survival.  
• Despite these biogenic differences, cells growing in the presence of 
serum and cells that are growth factor starved maintain equivalent and 
highly rapid rates of ATP-dependent membrane lipid endocytosis and 
recycling. Moreover, because the starved cells have a smaller plasma 
membrane than the growing cells, the starved cells internalise a larger 
proportion of the cell surface per unit time than the growing cells. The 
equivalent of the whole lipid membrane is internalized approximately four 
times per hour, compared to approximately 2.5 times per hour. 
• The rates of fluid-phase and membrane protein endocytosis and 
recycling appear to be equivalent in starved and growing cells. This 
emphasizes the common kinetics of membrane trafficking in these 
biogenically distinct conditions. 
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4.7 Chapter 4: Discussion 
 The plasma membrane has the potential to both constrain and facilitate 
increases in cell volume. As cell volume is added during cell growth, it seems 
inevitable that the plasma membrane must expand, because the plasma 
membrane is the limiting membrane of the cell. The mechanisms driving this 
process are poorly understood and so this Chapter aimed to use the in vitro 
Schwann cell culture system to address the regulation of plasma membrane 
expansion during cell growth. These studies used a kinetic approach to 
compare the rates of plasma membrane endocytosis and recycling in cells 
which were growing and adding plasma membrane with those that were starved 
and maintaining a constant plasma membrane size in order to try to identify 
changes in the kinetics of membrane turnover that might be responsible for 
driving the expansion of the plasma membrane observed in the growing cells. 
As it transpired, the speed of membrane turnover precluded using this approach 
to identify the mechanism driving plasma membrane growth. This is because 
the speed of membrane turnover was so much greater than the rate of plasma 
membrane growth, which meant that- using the techniques available- the 
change in the balance between the rate at which membrane was added and 
membrane was removed that was responsible for driving plasma membrane 
growth was not detectable. Nonetheless, in addition to highlighting the speed of 
membrane turnover, these studies led to the striking observation that starved 
cells maintain a rate of cell surface endocytosis and recycling that is equivalent 
to the growing cells and is therefore incredibly rapid. The significance of these 
finding will be considered in the following Discussion. 
4.7.1 Plasma Membrane Growth 
Expansion and retraction of the plasma membrane can cause changes in 
cell surface area, however they cannot explain the persistent increase in 
plasma membrane required in proliferating cells, or during sustained membrane 
growth, such as in developing and elongating neurons and myelinating glia. 
These latter examples are two of the most dramatic examples of plasma 
membrane growth. A typical motor neuron axon with a 1µm diameter that is 
growing at 0.5mm a day must add ~1µm2 membrane a minute and the 
membrane of a myelinating Schwann cell can increase up to 10,000-fold in just 
10 weeks in rodents (Pfenninger, 2009, Webster, 1971). Consistent with this, 
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the FM1-43 data from this study indicates that serum drives an increase in the 
absolute amount of Schwann cell plasma membrane, and not just unfolding of 
existing membrane. 
It was not possible to use the kinetic approach employed in this study to 
understand the quantitative regulation of plasma membrane growth 
downstream of serum. This regulation remains poorly understood in all cases 
where changes in plasma membrane size have been studied. However, for 
systems where rapid changes in plasma membrane size are induced, the 
membrane trafficking pathways that are required to effect changes in plasma 
membrane size are better understood. Strikingly, the pathways involved differ 
depending on the system. For example, whereas Golgi-derived secretory 
membranes drive growth of axons and dendrites, membrane expansion at the 
latter stages of mitosis and during Drosophila spermatocyte cytokinesis 
depends on membrane recycling (Boucrot and Kirchhausen, 2007, Dyer et al., 
2007, Pfenninger, 2009, Prager-Khoutorsky and Spira, 2009, Ye et al., 2007). In 
Drosophila cellularisation, which divides the syncytial blastoderm into single 
membrane-enclosed cells, both Golgi-derived and recycling membranes are 
required (Lecuit and Wieschaus, 2000, Pelissier et al., 2003). Therefore plasma 
membrane size can be altered by distinct mechanisms in different cell types, in 
response to diverse stimuli. Studying the trafficking pathways responsible for 
driving plasma membrane growth may be more difficult in the Schwann cell 
growth model, as the increase in plasma membrane size during cell growth 
occurs more slowly over a longer period of time. In addition, the results of 
studies using inhibitor and/ or molecular approaches to block any one trafficking 
pathway to determine if this has an effect on plasma membrane growth are 
likely to be difficult to interpret, for two main reasons. First, because membrane 
trafficking has pleiotropic functions and so, for example, although endocytosis 
removes plasma membrane and therefore may be predicted to antagonise 
plasma membrane growth, endocytosis may also be required to drive plasma 
membrane growth because it is required for nutrient uptake and/ or efficient 
signalling through growth factor receptor activated signalling pathways. Second, 
there is some evidence that if one trafficking pathway is inhibited, others may 
be upregulated to compensate, therefore potentially leading to a false negative 
conclusion (Cupers et al., 1994). However, the studies of situations of rapid 
changes in plasma membrane size clearly show that a range of mechanisms 
 	   224	  
can be activated in different situations to drive changes in plasma membrane 
size. 
As the membrane turnover rates are equivalent in growing and starved 
cells, this suggests that growth factor activated signalling pathways do not 
affect the constitutive rate of plasma membrane turnover. However, reports 
using both inhibitor and silencing techniques have shown that growth factor 
activated signalling pathways, such as mTORC1 and integrins, can regulate the 
constitutive activity of different vesicular trafficking pathways. mTORC1, for 
example, promotes clathrin-mediated endocytosis (CME) and integrin signalling 
has been shown to promote caveolae-mediated endocytosis, but not CME, in 
HeLa cells (Galvez et al., 2007, Hennig et al., 2006, Pearse and Robinson, 
1990, Pelkmans et al., 2005). Given that inhibitors and genetic silencing 
techniques often block basal as well as stimulated flux through the relevant 
signalling pathways, it is possible that a basal flux through growth factor 
activated signalling pathways is maintained in the starved cells and that this is 
required to maintain membrane turnover. Quantifying the rates of trafficking 
through various endocytic and exocytic routes after inhibiting different growth 
factor activated signalling pathways, such as PI3K/ Akt, mTORC1 and/ or ERK, 
in the presence and absence of serum, could address whether any of these 
pathways have a role in regulating plasma membrane turnover in the Schwann 
cell. Interestingly, if mTORC1 activity does induce rapid and sustained CME 
downstream of serum, this implies there must be a corresponding upregulation 
of exocytic pathways/ downregulation of other endocytic pathways to 
compensate for the loss of plasma membrane caused by the increased rate of 
CME. A complementary approach, to address the regulation of trafficking 
pathways downstream of growth factor activated signalling, would be to 
determine whether these pathways regulate the expression, localisation and/ or 
activity of trafficking machinery, such as the Rab proteins- as this large family of 
small GTPases regulate diverse steps in vesicular transport (Somsel Rodman 
and Wandinger-Ness, 2000). For example, Rab4 and Rab11 have both been 
shown to regulate recycling exocytosis, a process that delivers membrane to 
the cell surface. Therefore it is interesting to speculate whether the activity of 
Rab4 and Rab11 could be promoted by growth factor activated signalling 
pathways to increase the rate of recycling exocytosis, to drive delivery of 
membrane to the cell surface and plasma membrane expansion. 
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In contrast to growth factors directly regulating plasma membrane 
expansion, an alternative hypothesis is that plasma membrane size increases 
as an indirect consequence of other aspects of growth factor induced cell 
growth. For example, it has been proposed that plasma membrane tension is 
maintained at a constant set point, with deviations from this set point driving 
compensatory changes in membrane area to return to the set point (Morris and 
Homann, 2001). If this is true, perhaps growth factor induced increases in cell 
volume push out on the plasma membrane and increase the membrane 
tension, thus inducing changes in the rates of plasma membrane trafficking to 
drive the increase in plasma membrane size, e.g. by inducing the release of 
membrane-bound vesicles to increase the rate of membrane delivery to the cell 
surface. If plasma membrane growth is regulated simply as an indirect 
consequence of increases in cell volume, then understanding the mechanisms 
driving plasma growth could potentially be addressed in any system where cell 
volume changes. In other words, initial mechanistic studies could be addressed 
in a system where cell volume changes more rapidly and extensively than 
during cell growth, e.g. as a result of changes in extracellular osmolarity.  Such 
a system is more experimentally tractable than a cell growth system where the 
changes in cell volume are smaller and longer term. Any findings from such 
studies could then be tested in a cell growth system. A limited number of 
studies have addressed how endocytosis and exocytosis rates change upon 
osmotic shock (Morris and Homann, 2001). However, they have not addressed 
the specific signalling pathways and vesicular pathways involved and therefore 
further mechanistic studies are required and could prove highly informative 
(Morris and Homann, 2001). 
This Discussion, so far, has considered the mechanisms of plasma 
membrane growth in terms of the pathways by which membrane is delivered 
and removed during changes in plasma membrane size. It has not addressed 
how membrane synthesis is coordinated with plasma membrane expansion. 
Although short term and/ or small increases in plasma membrane size may be 
provided by mobilisation of intracellular membrane stores, e.g. from endosomes 
(Dyer et al., 2007), sustained or large changes in plasma membrane area must 
be accompanied by membrane biogenesis. Consistent with this, phagocytosis 
in Human Embryonic Kidney 293 (HEK 293) cells leads to the induction of de 
novo cholesterol and phospholipid synthesis that matches the amount of 
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internalised membrane (Castoreno et al., 2005). Similarly, proper development 
of the extensive Schwann cell myelin sheath requires de novo lipogenesis and 
expression of the regulators of this process peak during myelination (Leblanc et 
al., 2005, Verheijen et al., 2009). Growth factor and growth factor activated 
signalling pathways are known to drive lipid uptake and de novo lipogenesis 
and it seems likely this is required to drive membrane biogenesis and may be 
sufficient to induce volume addition under these conditions- the role of 
lipogenesis in cell growth is investigated in Chapter 5 of this thesis (Duvel et al., 
2010, Li et al., 2010, Peterson et al., 2011, Porstmann et al., 2005, Porstmann 
et al., 2008, Smith et al., 2008, Yellaturu et al., 2009a, Du et al., 2006, Luu et 
al., 2012, Demoulin et al., 2004, Hegarty et al., 2005, Zhou et al., 2004). 
4.7.2 The Rapid Rate of Plasma Membrane Turnover 
 The most striking aspect of plasma membrane turnover is the speed at 
which it occurs. The plasma membrane is a remarkable structure. To be an 
effective barrier between the intra- and extra- cellular environments, plasma 
membrane integrity must be maintained at all times. Yet despite this, as the 
interface between these two environments, the plasma membrane must be 
dynamic; it is the only site of communication and substance exchange between 
the inside and outside of the cell.  
 This study found that the equivalent of the total cell surface lipid is 
internalised once every 15-20 minutes in both starved and growing cells. A 
limited number of studies have quantified membrane internalisation rates in 
other cell types and the results are in line with the findings of this study (ranging 
between 3-60 minutes, depending on the parameter and cell type quantified) 
(Burgert and Thilo, 1983, Griffiths et al., 1989, Hao and Maxfield, 2000, 
Steinman et al., 1976, Thilo and Vogel, 1980). Remarkably, because single 
membrane lipids can move by non-vesicular as well as vesicular routes, which 
would not be detected with the FM1-43 based assay used in this study, the 
quantification of membrane lipid internalisation made in this study is in fact quite 
likely an underestimate of the true rate (Prinz, 2010). The proportion of 
membrane lipid that moves via non-vesicular pathways is not well understood, 
however some studies have found that the movement of cholesterol and 
phosphatidylcholine to and from the plasma membrane is only minimally 
affected by inhibition of vesicular pathways (Hao et al., 2002, Kaplan and 
 	   227	  
Simoni, 1985, Prinz, 2010, Sleight and Pagano, 1983). This suggests the 
contribution of non-vesicular pathways to total membrane lipid addition/ removal 
may be significant, although it cannot be excluded that in these examples non-
vesicular pathways were upregulated to compensate for the inhibition to 
vesicular transport. 
 Rapid membrane lipid turnover may prove to be a robust and constitutive 
feature of cell biology, because it is maintained even in the starved cells in this 
study. Moreover, because this rapid rate is maintained in starved cells where 
other ATP-dependent processes will be downregulated to conserve cellular 
resources, this suggests that rapid membrane trafficking must be a critical and 
fundamental cellular process. Which aspect(s) of membrane function require 
the rapid rate of membrane turnover observed in these studies? Although the 
answer to this question remains unknown, it is possible to speculate on possible 
reasons a rapid rate of plasma membrane turnover may be required. It may be 
that membrane proteins and lipids undergo high rates of damage and therefore 
must be replaced at a high frequency. Although lipids can be remodelled in situ 
within membranes, it may be more efficient- particularly for those lipids in the 
outer leaflet of the membrane and therefore a distance from the cytosolic 
lipolytic and lipogenic enzymes- for the lipids to be internalised via endocytosis 
and then remodelled, for example replacing damaged fatty acids, or fatty acids 
that have undergone inappropriate oxidation, which would affect the packing 
and therefore liquidity of the plasma membrane. Another possibility is that the 
high rate of membrane turnover allows the cell to respond rapidly to changes in 
the intra-/ extra- cellular environment that require a change in membrane 
composition, i.e. because the machinery that replaces the membrane is already 
active, it is only the specific lipids/ proteins trafficked to/ from the plasma 
membrane that will need to be altered, upon the receipt of the relevant cellular 
signal. It has been postulated that the rapid ‘futile-cycling’ of triacylglycerols to 
free fatty acids and glycerol and back again, as well as the rapid glycolytic cycle 
observed in aerobic cells is, in part, also to provide the flexibility to respond to 
changes in the cellular environment (DeBerardinis et al., 2008a, Watt and 
Steinberg, 2008) and therefore this hypothesis is consistent with other aspects 
of cellular function. It is also highly plausible that at least some of the 
membrane functions that require a rapid rate of membrane turnover may differ 
between the starved and growing cells, because the metabolism of these cells 
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differs and several functions of membrane turnover are directly related to cell 
metabolism. For example, maintaining nutrient transporter mediated nutrient 
uptake requires membrane endocytosis and exocytosis. Growth factor 
signalling activates this process and so it will be active in the growing cells. In 
contrast, due to the absence of growth factor activated signalling, growth factor 
starved cells significantly downregulate nutrient transporter expression and 
internalisation (and therefore atrophy as they activate autophagy in order to 
provide the nutrients to drive cell metabolism), which suggests this function 
makes a significantly lower contribution to membrane turnover in the starved 
cells (Edinger and Thompson, 2002, Leto and Saltiel, 2012). It is not only 
nutrient transporter endocytosis and exocytosis that might be predicted to differ 
between the starved and growing cells. Many growth factor receptors, for 
example, are endocytosed upon ligand binding and this can be necessary to 
promote growth factor signalling (Pearse and Robinson, 1990).  
Given that the rate of certain functions of membrane turnover are likely to 
differ between the starved and growing cells, it might be predicted that the 
growth factor starved and growing cells are likely to traffic individual protein and/ 
or lipid components at very different rates. Somewhat surprisingly, preliminary 
studies investigating the rate of internalisation of specific proteins in the 
Schwann cell system suggest that the plasma membrane expression of the 
transferrin receptor, IGF-1 receptor and N-cadherin are similar in starved and 
growing cells, relative to total cell protein (data not shown). Although these 
experiments need to be repeated to verify and quantify the results, they are 
surprising. The transferrin receptor is a nutrient transporter that has been shown 
to be downregulated upon growth factor withdrawal in haematopoietic cells and 
there is no IGF-1 to bind and stimulate the endocytosis of the IGF-1 receptor in 
the growth factor starved cells (Edinger, 2007, Edinger and Thompson, 2002, 
Wieman et al., 2009, Wieman et al., 2007). Moreover, both the transferrin and 
IGF-1 receptors are classically endocytosed by CME, which is promoted by 
mTORC1 activity and mTORC1 signalling is activated only in the growing cells 
(Galvez et al., 2007, Hennig et al., 2006, Pelkmans et al., 2005). Therefore, it 
might have been predicted that the rate of internalisation of these proteins 
would be lower in the growth factor starved cells. Interestingly, one study has 
reported that when CME was inhibited by starvation, nutrient receptors were 
internalised via alternative pathways (Boucrot et al., 2010); the receptors 
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became localised in internalised tubules of plasma membrane that were not 
visible in the fed cells. Perhaps a similar process is maintaining the 
internalisation of the transferrin and IGF-1 receptors in the starved Schwann 
cell. 
Interestingly, membrane trafficking is not the only cellular process that 
appears to persist at a constitutive and rapid rate. A recent study compared the 
metabolism of rapidly growing and proliferating fibroblasts with those that were 
quiescent, in very low serum conditions (Lemons et al., 2010). This study found 
that several aspects of cell metabolism, including catabolic processes such as 
fatty acid and protein synthesis that might be expected to occur at a higher rate 
in the rapidly growing cells, were equivalent in the two conditions. However, the 
rates of degradation and secretion of lipids and proteins were higher in 
quiescent fibroblasts, compared to growing fibroblasts, resulting in no net 
growth. These findings of Lemons et al, together with the findings of this study, 
highlight the clear difference between the absolute rates of any cellular process 
and the rate of cell growth. Any biosynthetic process, e.g. lipid synthesis, may 
occur at a rapid rate. However, it will only result in net biogenesis and cell 
growth if the rate of the opposing process, in this case lipid degradation, is not 
equally as fast.  
4.7.3 The Rate of Plasma Membrane Trafficking is Equivalent in Starved and 
Growing Cells 
It was surprising that the rate of membrane lipid endocytosis and 
recycling is equivalent in starved and growing cells; membrane endocytosis and 
exocytosis is ATP-dependent and starved cells inhibit/ reduce the rate of ATP-
dependent processes that are not absolutely required, in order to conserve 
cellular energy and resources. Adaptive changes that can optimise cellular 
energy balance are observed in the starved Schwann cells in this study, which 
emphasises that these cells are energetically and biogenically challenged. 
Growth factor/ nutrient starved cells have been shown to rely more on 
mitochondrial oxidative phosphorylation to produce cellular ATP, than growing 
cells (DeBerardinis et al., 2008a, Gomes et al., 2011a, Gomes et al., 2011b, 
Gomes and Scorrano, 2011, Hardie, 2011). This is because oxidative 
phosphorylation is significantly more efficient than glycolysis at producing ATP. 
Consistent with increased reliance on the oxidative pathway, FM1-43 uptake 
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was blocked in the starved cells when oxidative phosphorylation was inhibited, 
whereas in the growing cells inhibition of both oxidative phosphorylation and 
glycolysis was required. In addition to increased dependence on oxidative 
phosphorylation, the starved cells also upregulate autophagy, which can 
provide the substrates to fuel necessary cell metabolism (Altman et al., 2009, 
Edinger and Thompson, 2002, Lum et al., 2005a, Rathmell et al., 2000, Yu et 
al., 2010). Together, these findings indicate the starved cells are undergoing 
adaptations to conserve cellular resources and optimise ATP productions. 
Therefore, the fact that ATP-dependent membrane turnover in these cells is 
maintained at an equivalent rate to in the growing cells, demonstrates that 
maintaining membrane turnover rates must be a critical cellular process- 
although the reason for this is not clear, as was discussed in Section 4.7.2.  
4.7.4 Conclusion 
The findings presented in this Chapter demonstrate that the turnover of 
the plasma membrane is incredibly dynamic and rapid in both starved and 
growing cells. As this ATP-dependent process is maintained at a rapid rate in 
starved cells that are undergoing adaptive changes to conserve cellular 
resources, it suggests the rapid rate is critical for cell function. This suggests 
there is a fundamental function of membrane turnover that is required in both 
starved and growing cells. This may be the replacement of effete membrane 
lipids and proteins or it may be that maintaining rapid turnover is required to 
enable rapid responses to changes in the extracellular environment, for 
example. However, given that aspects of cell metabolism, such as nutrient 
uptake and growth factor activated signalling, that differ between the starved 
and growing cells require membrane turnover, it is possible that certain 
functions of membrane turnover differ in importance between the two 
conditions. Strikingly, the equivalent rate of membrane turnover in starved and 
growing cells suggests that the global rate of membrane turnover is constitutive 
and unaffected by activation of growth factor activated signalling pathways. 
However, these pathways have previously been shown to regulate specific 
trafficking paths. This suggests either that the basal flux through these 
signalling pathways, which is maintained in the starved cells, is sufficient to 
maintain these trafficking pathways and/ or that regulation of these pathways 
has no impact on the global rate of trafficking. Understanding the relationship 
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between cell metabolism, bioenergetics and plasma membrane turnover and 
growth requires an understanding of the mechanisms regulating membrane 
trafficking in both starved and growing cells, as well as the critical functions of 
membrane turnover that require turnover rates to be maintained at such a rapid 
rate. 
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Chapter 5: Results 
The Role of Lipogenesis in Cell Volume Addition 
The results presented in Chapter 3 (‘Biogenesis Downstream of IGF-1 
Stimulation or Raf/ MEK/ ERK Activation’) demonstrated that IGF-1 and Raf 
kinase differentially regulate organelle size and morphology. Given that it is 
likely that lipids need to produced to add volume during cell growth (to facilitate 
the expansion of membranous organelles and the plasma membrane), it was 
interesting to note that organelles associated with lipid metabolism, namely the 
peroxisomes and lipid droplets, are specifically increased downstream of IGF-1. 
This suggested that addition of cell volume, even over the short (24 hour) time 
period of these assays, would require specific alterations in cell lipid 
metabolism.  
Several lines of evidence support this hypothesis: first, IGF-1 has been 
shown to drive lipogenesis through PI3K/ Akt dependent expression of the 
SREBPs, the master regulators of de novo lipogenesis (Du et al., 2006, Luu et 
al., 2012, Smith et al., 2008). Second, Akt has been shown to drive an 
mTORC1/ SREBP/ de novo lipogenesis dependent increase in cell volume in 
human epithelial cells (Porstmann et al., 2008). Finally and importantly, IGF-1 
dependent addition of Schwann cell volume is PI3K/ Ak/ mTORC1 dependent 
(Section 3.2) (Echave et al., 2009). Therefore, the remainder of these studies 
focused on investigating the role of lipogenesis in the regulation of cell volume 
and IGF-1 dependent cell volume addition.  
As in Chapter 3, these investigations used the NSΔRafER cells. This 
meant lipogenic pathways could be studied in Raf kinase activated cells, where 
mass is added in the absence of an increase in cell volume, as well as in IGF-1 
treated cells, where cells are adding mass and volume. It was hoped this would 
help discern whether there is a specific role for lipogenesis in the regulation of 
cell volume during Schwann cell growth. The basic experimental protocol was 
also as in Chapter 3, except where specified in the text. Briefly: cells were cell 
cycle arrested, using aphidicolin, in normal Schwann cell medium (3% FCS) for 
24hrs before being transferred to Minimal Medium plus aphidicolin for a further 
24 hours and then treated with IGF-1 or Tmx (to activate the Raf kinase 
construct).  
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5.1 IGF-1, but not Raf Kinase Activation, Induces Expression of Genes that 
Drive Fatty Acid and Sterol Synthesis 
The defined cell culture medium (Minimal Medium) used in these studies 
is essentially free from exogenous lipids, which means any increase in the 
amount of cellular lipids must result from de novo lipogenesis, i.e. synthesis of 
lipids from non-lipid sources (Section 1.5.2). As stated above, the master 
regulators of de novo lipogenesis are the SREBP family of bHLH-zip 
transcription factors (Section 1.5.2). To determine whether IGF-1 was regulating 
SREBP expression in the Schwann cell, as it has been shown to do in other 
systems, western blot analysis was performed against the SREBPs.  
There are three SREBP proteins encoded by two genes: SREBP-1a and 
-1c (encoded by SREBP1) and SREBP-2 (encoded by SREBP2). As described 
in the Introduction (Section 1.5.2), the SREBPs are synthesised as inactive 
precursors (~125 kDa) that are retained in the endoplasmic reticulum until an 
activation signal drives their translocation to the Golgi where they are cleaved to 
release the N-terminal active transcription factor (~68 kDa), which enters the 
nucleus and can activate transcription.  
 The antibodies used in this study recognise epitopes in the N-termini of 
the proteins and therefore recognise both the precursor and mature SREBPs. 
The SREBP-1 antibody recognises both the SREBP-1a and -1c isoform and 
therefore the two were not distinguished in these analyses. Cells were collected 
1 and 4 hours +/- IGF-1 treatment or Raf kinase activation (Tmx) and 
cytoplasmic and nuclear fractions extracted for Western blot analysis. As can be 
seen in Figure 5.1, by 1 hour post-factor addition, IGF-1 treatment drove an 
increase in the level of mature, nuclear SREBP-2 (~1.5-fold), compared to 
control and Raf kinase activated cells and, by 4 hours post-factor addition, this 
was also seen for SREBP-1 (~1.7-fold). These results suggested that IGF-1 
was activating the SREBP pathway. The timings are consistent with the findings 
of other studies, which have shown that IGF-1 and/ or Akt can induce 
accumulation of nuclear SREBPs within 2 hours (Du et al., 2006, Luu et al., 
2012, Porstmann et al., 2008). The different kinetics of SREBP-1 and -2 
activation may indicate their activation is- at least in part- via distinct 
mechanisms. There also appeared to be a small, transient increase in the level 
of mature, nuclear SREBP-2 downstream of Raf kinase activation compared to 
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control, however this was not sustained (Figure 5.1- 1 hour). SREBP-1c and 
SREBP-2 are themselves SREBP target genes; consistent with an increase in 
the mature proteins, there is an increase in the precursor proteins downstream 
of, in particular, IGF-1. 
It is interesting to note the multiple bands of the mature SREBP-2- 
particularly in the IGF-1 treated cells. The SREBPs can be modified in a number 
of ways (phosphorylation, sumoylation, acetylation and ubiquitination), which 
can positively and negatively regulate their transcriptional activity and stability 
(Introduction Section 1.5.2) (Giandomenico et al., 2003, Hirano et al., 2003, 
Kotzka et al., 2004, Kotzka et al., 2000, Roth et al., 2000, Sundqvist et al., 
2005). Given that the ratio between the bands is particularly affected in the IGF-
1 treated cells it is interesting to speculate whether IGF-1 drives such post-
translational modifications. 
To analyse the transcriptional activity of the SREBPs, the mRNA 
expression levels of two SREBP target genes, Fatty Acid Synthase (FASN) and 
HMGCoA Reductase (HMGCoR), were quantified by RT-qPCR. FASN and 
HMGCoR are rate-limiting enzymes for fatty acid and sterol synthesis, 
respectively, and whose expression is regulated in large part at the level of 
transcription. Consistent with the increase in the level of mature SREBP protein 
downstream of IGF-1, IGF-1 treatment increased the mRNA expression of both 
FASN (~3.5-fold) and HMGCoR (~1.8-fold) 6 hours post-factor addition, 
compared to control cells (Figure 5.2, EtOH+/IGF-1+). This was not seen 
downstream of Raf kinase activation, although there was a trend for the mRNA 
expression of HMGCoR- the classic SREBP-2 target- to be slightly increased 
compared to control (Figure 5.2 B Tmx+/IGF-1-). This suggests the slight 
increase in SREBP-2 downstream of Raf kinase has no significant effect on the 
expression of these downstream target genes. Together, these results 
demonstrate that IGF-1 activates a transcriptional program leading to the 
expression of genes that drive de novo fatty acid and sterol synthesis. However, 
it was important to determine whether IGF-1 dependent expression of these 
genes has a functional effect on these processes.  
 
 
Figure 5.1 IGF-1 increases the amount of cytoplasmic precursor and nuclear 
mature SREBP proteins
Aphidicolin arrested NSΔRafER cells were treated as indicated. Cells were then collected 
and cytoplasmic and nuclear extracts separated and lysed before western blot analysis was 
performed against SREBP-1 and SREBP-1. mSin3a and GAPDH were used as nuclear and 
cytoplasmic loading controls, respectively. The cytoplasmic and nuclear extracts were from the
same experiment for each timepoint. Quantifications show the mean fold-change to control
(-Tmx, -IGF-1), normalised to the loading control, from 2-5  experiments.
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Figure 5.2 IGF-1 increases the mRNA expression of key SREBP target genes 
that drive de novo fatty acid and sterol synthesis
Aphidicolin arrested NSΔRafER cells were treated as indicated for 6hrs before total RNA was 
extracted. mRNA levels of the indicated genes was analysed by RT-qPCR and normalised to 
B2M as a loading control; mRNA expression levels are expressed relative to time 0hrs. 
A) FASN mRNA expression levels.
B) HMGCoR mRNA expression levels.
Bar charts show mean +SEM of A) and B) 6 experiments. One-Way Repeated Measures 
ANOVA, A) and B) p<0.01. Select post-hoc Newman-Keuls as indicated on the graphs.
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The main extracellular precursors for de novo lipogenesis present in the 
Schwann cell medium are glucose, glutamine and pyruvate. To indicate the rate 
of de novo lipogenesis from extracellular substrates, the incorporation of 
radiolabelled pyruvate into cellular lipids was quantified, as follows: Cells were 
treated with IGF-1 or Tmx, to activate Raf kinase, for 4 hours before [2-14C] 
pyruvate (2.5µCi/well) was added to the cell culture medium for a further 4 
hours. Cellular lipids were then extracted and the amount of radioactivity 
incorporated into the lipid fraction was quantified by scintillation counting. This 
value was normalised to the cell number of cells from parallel cell culture dishes 
to determine incorporation per cell. The rate of pyruvate incorporation into lipid 
was assayed between 4 & 8 hours post-factor addition because by 4 hours 
post-factor addition there is accumulation of both SREBP-1 and -2 in the 
nucleus downstream of IGF-1 (Figure 5.1) and, importantly, the nuclear SREBP 
appears to be active, as indicated by the induction of SREBP targets critical for 
de novo lipogenesis (Figure 5.2). Therefore it was hypothesised that if the rate 
de novo lipogenesis increases downstream of this, then it would be increased 
between 4 and 8 hours post-factor addition. As can be seen in Figure 5.3, IGF-1 
(EtOH+/IGF-1+) drove a 3-fold increase in the incorporation of radiolabel into 
cellular lipids, compared to control (EtOH+/IGF-1-) and Raf kinase activated 
(Tmx+/IGF-1-) cells. Moreover, there was no significant difference in 
incorporation between Raf kinase and control conditions, consistent with the 
lack of significant increase in the mRNA expression of the SREBP targets 
FASN and HMGCoR that are required for de novo lipogenesis (Figure 5.2).  
Although the contribution of the different extracellular substrates to de 
novo lipogenesis (e.g. pyruvate, glucose, glutamine and acetate) does not 
always change co-ordinately in response to activation of distinct signalling 
pathways, the results presented here are consistent with the findings of other 
studies that have shown that IGF-1 and/ or Akt/mTORC1 (activated in response 
to IGF-1 in the Schwann cell and required for IGF-1 driven Schwann cell volume 
addition, Figure 3.7, 3.8 & 3.9) increase the incorporation of glucose, glutamine 
and acetate into cellular lipids (Hagiwara et al., 2012, Porstmann et al., 2008, 
Smith et al., 2008, Wise et al., 2008).  
 
 
Figure 5.3 IGF-1 increases de novo lipogenesis from extracellular pyruvate
Aphidicolin arrested NSΔRafER cells were treated as indicated for 4hrs before [2-14C] pyruvate 
was added to the cell culture medium. Cells were left for a further 4hrs before cell lipids were  
extracted and the incorporation of radiolabel into cellular lipids measured by scintillation 
counting. Bar chart shows 14C incorporation into the lipid phase (as Disintegrations per Minute 
(DPM)) normalised to cell number and shows the mean +SEM of 3 experiments. One-Way 
Repeated Measures ANOVA, p<0.05, post-hoc Newman-Keuls as indicated on the graph.
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In conclusion: IGF-1 drives expression of the mature nuclear forms of 
SREBP-1 and SREBP-2 and their downstream targets FASN and HMGCoR, 
rate limiting enzymes in de novo lipogenesis. This is consistent with published 
findings from other groups (Du et al., 2006, Luu et al., 2012, Smith et al., 2008). 
Although Raf kinase drives a slight increase in mature nuclear SREBP-2, there 
is no significant effect of downstream mRNA expression of FASN and 
HMGCoR. Consistent with this, IGF-1, and not Raf kinase activation, increased 
the incorporation of extracellular radiolabeled pyruvate, a precursor substrate 
for de novo lipogenesis, into cellular lipids. These findings correlate with the 
IGF-1 specific increase in cell volume and suggest de novo lipogenesis might 
be required for IGF-1 dependent cell volume addition.  
 
5.2 IGF-1 Dependent Cell Volume Addition Requires SREBP-2 and is 
Inhibited by Inhibitors of De Novo Lipogenesis  
To investigate a functional role for the SREBPs in the regulation of cell 
volume, siRNAs were used to knock down SREBP-1 and SREBP-2 prior to IGF-
1 treatment/ Raf kinase activation. Transfection complexes were applied for 18 
hours to cells seeded in normal Schwann cell medium (containing 3% FCS). 
The cells were then medium changed into Minimal Medium plus aphidicolin for 
24 hours before factors (IGF-1 or Tmx) were added in fresh Minimal Medium 
plus aphidicolin. Cell volume was quantified using the Coulter Counter after a 
further 24 hours. RNA was collected at the end of the assay to quantify 
knockdown efficiency by RT-qPCR (Materials & Methods 2.3). The two SREBP-
1 isoforms (SREBP-1a and -1c) were not individually targeted in this study; the 
siRNAs silence both isoforms. Two distinct oligos that recognise opposite ends 
of each SREBP mRNAs were used to reduce the chance of drawing 
conclusions based on off-target effects.  
As can be seen in Figure 5.4 A, silencing SREBP-2 significantly inhibited 
cell volume addition downstream of IGF-1 and also reduced the volume of 
control (EtOH+/IGF-1-) and Raf kinase activated cells (Tmx+/IGF-1-). This 
suggests SREBP-2 is required for the maintenance and IGF-1 dependent 
addition of cell volume. Figure 5.4 B i demonstrates SREBP-2 mRNA 
expression was reduced to ~20% of the scrambled control for all three 
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conditions, using either oligo. Confirming that the siRNAs were not also non-
specifically silencing SREBP-1, the mRNA expression of SREBP-1a was not 
reduced by the SREBP-2 siRNA oligo’s (Figure 5.4 B ii). Consistent with a role 
for de novo lipogenesis in the regulation of cell volume downstream of SREBP-
2, silencing SREBP-2 using either siRNA oligo inhibited mRNA expression of 
HMGCoR in all three conditions (Figure 5.5 A). The mRNA levels of FASN were 
also reduced by both siRNA oligo’s in IGF-1 treated cells (Figure 5.5 B, 
EtOH+/IGF-1+), suggesting that SREBP-2 is required for FASN expression 
downstream of IGF-1. Given that cell volume was reduced in all three 
conditions, this may suggest sterol synthesis has a more significant role than 
fatty acid synthesis in the maintenance of cell volume. Differences in the extent 
to which target gene mRNA is reduced after SREBP-2 silencing between the 
different growth factor conditions (control, Raf kinase activation and IGF-1 
treatment) and the two siRNA oligos may reflect differences in SREBP-2 activity 
between the growth factor conditions and/ or efficacy of SREBP-2 knockdown. 
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Figure 5.4 siRNA knockdown of SREBP-2 blocks IGF-1 dependent cell volume 
addition and reduces the volume of control (no factor) and Raf kinase activated 
cells
NSΔRafER cells were transfected with siRNAs as indicated in normal (3% FCS) Schwann cell 
medium for 18hrs then transferred into defined (no factor) conditions plus aphidicolin for 24hrs 
before factors (Tmx or IGF-1) were added as indicated for a further 24hrs. Final cell volume was 
quantified using a Coulter Counter. 
A) Quantification of mean cell volume. Bar chart shows mean +SEM of 3 experiments. Two-Way 
ANOVA, siRNA p<0.001. Post hoc Bonferroni compared to Scrambled control, for each growth 
factor condition, as indicated on the graph.
B) i) SREBP-2 and ii) SREBP-1a mRNA expression level analysed by RT-qPCR and normalised 
to B2M as a loading control. Total RNA was collected at the end of the assay when cell volume 
was quantified.
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Figure 5.5 mRNA levels of the SREBP targets FASN & HMGCoR after siRNA knockdown 
of SREBP-2
NSΔRafER cells were transfected with siRNAs as indicated in normal (3% FCS) Schwann cell 
medium for 18hrs then transferred into defined (no factor) conditions plus aphidicolin for 24hrs 
before factors (Tmx or IGF-1) were added as indicated for a further 24hrs before total RNA was 
extracted. mRNA levels of the indicated genes were analysed by RT-qPCR and normalised to 
B2M as a loading control. Bar charts show mean mRNA expression level as % of the 
Scrambled control. Dashed line represents 100%, i.e. expression in the Scrambled control.
A) FASN mRNA.
B) HMGCoR mRNA.
Bar charts show mean +SEM of 3 experiments. 
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In contrast to SREBP-2, siRNAs targeting SREBP-1 had no significant 
effect on IGF-1 dependent cell volume addition, or the cell volume of control 
(EtOH+/IGF-1-) or Raf kinase activated cells (Tmx+/IGF-1-) (Figure 5.6 A). 
Silencing SREBP-1 reduced SREBP-1a mRNA expression to ~20-60% and 
SREBP-1c to ~10-50% of the scrambled controls (Figure 5.6 B). Similarly, 
knockdown of SREBP-1 did not reduce the mRNA expression levels of FASN or 
HMGCoR (Figure 5.7). The increases in FASN and HMGCoR mRNA 
expression seen in some growth factor conditions and/ or one or other siRNA 
oligo may reflect differences in the efficacy of SREBP-1 knockdown combined 
with compensation by SREBP-2 activity. Together, these results may suggest 
SREBP-1 is dispensable for the regulation of Schwann cell volume. This is not 
implausible, given that the different isoforms have been shown to be 
differentially regulated and to differentially regulate target genes in different cell 
types (Amemiya-Kudo et al., 2002, Horton et al., 2002, Horton et al., 2003a, 
Shimano et al., 1997a). In adipocytes, for example, SREBP-1c does not drive 
lipogenic gene expression (Sekiya et al., 2007, Shimomura et al., 1998). 
However it is possible there was not sufficient knockdown of SREBP-1 at the 
protein level. The amount of cell material required for the SREBPs to be 
detected at the protein level limited this investigation- it is not clear whether this 
is due to low levels of SREBP-1 expression, or poor antibody quality. This 
analysis is required to conclude whether SREBP-1 is non-essential for cell 
volume regulation in the Schwann cell. It is also possible the loss of one or 
other SREBP-1 isoform was compensated by the enhanced activity of SREBP-
2- as occurs in the liver of mice that have lost functional SREBP-1a and -1c 
(Shimano et al., 1997b). 
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Figure 5.6 siRNA knockdown of SREBP-1 does not inhibit cell volume
NSΔRafER cells were transfected with siRNAs as indicated in normal (3% FCS) Schwann cell 
medium for 18hrs then transferred into defined (no factor) conditions plus aphidicolin for 24hrs 
before factors (Tmx or IGF-1) were added as indicated for a further 24hrs. Final cell volume was 
quantified using a Coulter Counter. 
A) Quantification of mean cell volume. Bar chart shows mean +SEM of 3 experiments. 
Two-Way ANOVA, Growth Factor p<0.001. Post hoc Bonferroni compared to Scrambled control, 
for each growth factor condition, as indicated on the graph.
B) i) SREBP-1a and ii) SREBP-1c mRNA expression level analysed by RT-qPCR and 
normalised to B2M as a loading control. Total RNA was collected at the end of the assay when 
cell volume was quantified.
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Figure 5.7 mRNA levels of the SREBP targets FASN & HMGCoR after siRNA knockdown 
of SREBP-1
NSΔRafER cells were transfected with siRNAs as indicated in normal (3% FCS) Schwann cell 
medium for 18hrs then transferred into defined (no factor) conditions plus aphidicolin for 24hrs 
before factors (Tmx or IGF-1) were added as indicated for a further 24hrs before total RNA was 
extracted. mRNA levels of the indicated genes were analysed by RT-qPCR and normalised to 
B2M as a loading control. Bar charts show mean mRNA expression level as % of the 
Scrambled control. Dashed line represents 100%, i.e. expression in the Scrambled control.
A) FASN mRNA.
B) HMGCoR mRNA.
Bar charts show mean +SEM of 3 experiments. 
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HMGCoR catalyses the rate limiting step of sterol synthesis- the 
production of mevalonate. Other isoprenoids can also be synthesised from 
mevalonate, which have roles including being used for post-translational protein 
modification (prenylation). To investigate more directly a role for HMGCoR in 
the regulation of cell volume, the HMGCoR inhibitor simvastatin was used. 
Simvastatin (5µm) was added to cells 30 minutes prior to the addition of factors 
(IGF-1 or Tmx) and cell volume was assayed after a further 24 hours. As shown 
in Figure 5.8 A, simvastatin significantly inhibited IGF-1 (EtOH+/IGF-1+) 
dependent cell volume addition and reduced the volume of control (EtOH+/IGF-
1-) and Raf kinase activated (Tmx+/IGF-1-) cells, suggesting that HMGCoR is 
indeed required both to maintain and add cell volume.  
To try to determine whether there is also a role for de novo fatty acid 
synthesis in the regulation of cell volume in these conditions, the effect of two 
inhibitors of this pathway were also analysed: Cerulenin (7.5µg/ml), which 
inhibits FASN and HMGCoR to block both fatty acid and sterol/ isoprenoid 
synthesis, and C75 (3µg/ml), which inhibits FASN to specifically block fatty acid 
synthesis. Reassuringly, like simvastatin, cerulenin significantly blocked IGF-1 
dependent cell volume addition (Figure 5.8 B). Cerulenin also appeared to 
reduce the volume of control (EtOH+/IGF-1) and Raf kinase activated 
(Tmx+/IGF-1-) cells, but these reductions are not statistically significant. IGF-1 
dependent cell volume addition was also slightly but significantly blocked using 
C75, but the volume of control or Raf kinase activated cells was unaffected 
(Figure 5.8 C). These results are consistent with a role for de novo lipogenesis 
in the regulation of Schwann cell volume, although it must be noted that the 
efficacy of the inhibitors was not tested.  
The results using cerulenin and C75 are also difficult to interpret because 
these inhibitors made the cells incredibly unhealthy- this was apparent when 
cell protein mass was quantified using the fluorescent S. Ester label (Section 
3.1); cells treated with cerulenin and, in particular, C75 were highly vacuolar 
with ‘strings’ of labelling through the cell (Figure 5.9). Although this may be a 
direct consequence of blocking fatty acid synthesis, it also raised the concern 
these inhibitors were having indirect toxic side effects. Cells treated with 
simvastatin showed protein staining and morphology similar to the control cells. 
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Figure 5.8 Addition of volume is blocked by inhibitors that block fatty acid and/ 
or sterol synthesis
Aphidicolin arrested NSΔRafER cells were treated as indicated +/- inhibitors for 24hrs before 
cell volume was quantified using a Coulter Counter. Bargraphs show mean cell volume +SEM.
A) +/- Simvastatin (5μM), an inhibitor of HMGCoR.
B) +/- Cerulenin (5μg/ml), an inhibitor of FASN and HMGCoR.
C) +/- C75 (3μg/ml), an inhibitor of FASN.
Bar charts show mean +SEM of A) and C) 4 and B) 5 experiments. Repeated Measures 
Two-Way ANOVA A) DMSO vs Inhibitor p<0.001, Interaction p<0.001, B) DMSO vs Inhibitor 
p<0.001, Interaction p<0.05 and C) DMSO vs Inhibitor p<0.05. Post hoc Bonferroni as indicated 
on the graphs.
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Figure 5.9 Cells look unhealthy in the presence of fatty acid synthesis 
inhibitors
Aphidicolin arrested NSΔRafER cells were treated +/- inhibitors as indicated for 24hrs +IGF-1 before 
being fixed and labelled with AlexaFlour647-succinimidyl ester. Total fluorescence intensity per 
cell was then quantified and taken to represent mean amount of protein per cell (a.u.).
Representative widefield microscopy images of labelled cells. Scale bar = 25μm.
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When cell protein mass was quantified from S. Ester labelling, it was 
found that cerulenin and C75 treatment significantly inhibited Raf kinase 
dependent addition of protein mass (Figure 5.10 B & C, Tmx+/IGF-1-). 
Cerulenin also significantly inhibited the addition of protein mass in the 
presence of IGF-1 (Figure 5.10 B, EtOH+/IGF-1+). Although C75 appeared to 
block IGF-1 dependent addition of protein mass, this was not statistically 
significant (Figure 5.10 C, EtOH+/IGF-1+). It is possible that de novo fatty acid 
synthesis is linked to the addition of cell protein mass as well as cell volume; for 
example, de novo lipogenesis may be required to maintain proper organelle 
membranes and is therefore indirectly required for the addition of protein mass 
during cell growth. However, non-specific toxic side effects of the inhibitors may 
also block cell protein mass. 
In contrast to cerulenin and C75, simvastatin had no effect on protein 
mass (Figure 5.10 A). The finding that simvastatin blocked IGF-1 dependent cell 
volume addition, yet did not prevent IGF-1 dependent addition of protein mass, 
demonstrates once again that the addition of cell mass and volume can be 
uncoupled and therefore regulated independently during cell growth. 
To summarise: SREBP-2 is required for the maintenance (control and 
Raf kinase activated cells) and IGF-1 dependent addition of Schwann cell 
volume. Consistent with this, chemically inhibiting HMGCoR also blocks the 
maintenance and IGF-1 dependent addition of Schwann cell volume. In 
contrast, SREBP-1 appears to be dispensable for the regulation of Schwann 
cell volume- however further investigations are required to confirm these 
results. It is possible that the regulation of protein mass is linked to fatty acid 
synthesis, but these findings require more careful investigation. 
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Figure 5.10 Addition of protein mass is blocked by inhibitors that block fatty acid 
synthesis
Aphidicolin arrested NSΔRafER cells were treated as indicated +/-inhibitors for 24hrs before 
being fixed and labelled with AlexaFlour647-succinimidyl ester. Total fluorescence intensity per 
cell was then quantified and taken to represent mean amount of protein per cell (a.u.).
A) +/- Simvastatin (5μM), an inhibitor of HMGCoR.
B) +/- Cerulenin (5μg/ml), an inhibitor of FASN and HMGCoR.
C) +/- C75 (3μg/ml), an inhibitor of FASN.
Bar charts show mean +SEM of 5 experiments, minimum 50 cells quantified per condition per 
experiment. Repeated Measures Two-Way ANOVA A) Growth Factor p<0.001, B) Growth Factor 
p<0.001, DMSO vs Inhibitor p<0.05, Interaction p<0.001 and C) Growth Factor p<0.05, DMSO 
vs Inhibitor p<0.001. Post hoc Bonferroni as indicated on the graphs.
n.s.
n.s.n.s.n.s.
n.s.n.s.
250
 	   251	  
5.3 Expression of Constitutively Active SREBP-2 or SREBP-1a is not 
Sufficient to Drive Addition of Cell Volume 
 The above results demonstrate that SREBP-2 is necessary for IGF-1 
dependent cell volume addition. This raised the question of whether driving 
SREBP activity is sufficient to drive cell volume addition- either in the absence 
of any growth factor signalling, or in the presence of Raf kinase activation 
where certain biogenic pathways are already activated (those leading to the 
addition of protein mass). 
 Although this study did not find a role for SREBP-1 in the addition or 
maintenance of Schwann cell volume, this may because SREBP-1 (1a and -1c) 
were not sufficiently knocked down. In addition, even if there is not a role for 
endogenous SREBP-1 in the regulation of Schwann cell volume, this does not 
mean driving sustained activation of the protein would not have an effect. 
Moreover, SREBP-1a is the most potent transcriptional activator of the three 
SREBPs (Bengoechea-Alonso and Ericsson, 2007, Shimano et al., 1997a). 
Therefore, the response of Schwann cells to activation of both SREBP-1a and 
SREBP-2 with or without simultaneous activation of Raf kinase and/ or IGF-1 
activation was investigated. 
 To do this, stable cell lines expressing a 4-hydroxytamoxifen (Tmx) 
inducible form of the mature SREBP-1a or SREBP-2 protein were generated in 
both normal Schwann cells and the NSΔRafER cells. The constructs were 
generated by the Schulze laboratory (London Research Institute) and contain 
the N-terminal domain of human SREBP-1a or SREBP-2 fused to a modified 
hormone-binding domain of the oestrogen receptor- the modification means the 
domain selectively binds to Tmx and does not bind it’s natural ligand, 17β-
oestradiol (Figure 5.11) (Littlewood et al., 1995). Stable cell lines were 
generated by retroviral transduction. The nomenclature that will be used to 
describe these cell lines throughout this section is as follows: Normal Schwann 
cells expressing the constructs are ‘NS’ and the NSΔRafER cells are ‘NR’ and 
these descriptions will be followed by ER.mSREBP1a or ER.mSREBP2 as 
appropriate. Expression of the SREBP fusion constructs in the NR cells means 
that upon Tmx addition, both Raf kinase and the expressed SREBP are 
activated. 
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Figure 5.11 Schematic of the ER.mSREBP-1a and -2 fusion constructs
Schematics showing:
A) The full-length SREBP protein with the major domains highlighted. Amino acid numbers 
correspond to those in the human SREBP-1a protein.
B) The fusion protein constructs; the N-terminus of SREBP-1a or -2 (mature SREBP) is fused 
via a 20bp linker to a modified hormone-binding domain of the murine oestrogen receptor (ER). 
The modified ER domain has a point mutation (G>R at amino acid 525) that renders it unable to 
bind its native ligand, oestrogen, but still able to bind and be conformationally altered by 
4-hydroxytamoxifen (Tmx) (Littlewood et al 1995). Mature SREBPs (mSREBPs) are active, 
nuclear localised transcription factors. The fusion proteins (ER.mSREBP-1a or -2) therefore 
enable Tmx dependent activation of mSREBP dependent transcription.
C) Activation of the ER.mSREBP proteins: The ER.mSREBPs are constitutively expressed. In 
the absence of tamoxifen the ER domain complexes with heatshock protein 90 (HSP90) 
molecules rendering the ER.mSREBP inactive. Binding of tamoxifen to the ER domain induces 
a conformational change that leads to dissociation of the HSP90 molecules and activation of 
the ER.mSREBP (i.e. activation of the mSREBP transcription factor function).
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 Western blot analyses were performed against the modified oestrogen 
receptor (anti-ERα) to confirm expression of the ER.mSREBP fusion proteins 
(Figure 5.12). The ER.mSREBP construct is ~80kDa, therefore in the NR 
ER.mSREBP cell lines the upper band represents the SREBP construct and the 
lower band represents the ~60kDa RafER construct (Figure 5.12 C & D). Tmx 
stabilises the RafER fusion protein and, because the ER.mSREBP band was so 
much stronger than the RafER band, the RafER ERα band was essentially only 
visible after Tmx treatment. Interestingly, simultaneous activation of the 
SREBPs and Raf kinase (i.e. +Tmx in the NR ER.mSREBP cells) also 
increased expression of the SREBP construct over time (Figure 5.12 C & D). 
Unlike the RafER, it is unlikely Tmx induced stabilisation of the protein, as 
activation of ER.mSREBP1a and 2 in the absence of Raf kinase activation (i.e. 
+Tmx to the NS ER.mSREBP cells) decreased the expression of the SREBP 
fusion protein (Figure 5.12 A & B). The SREBPs undergo activity dependent 
degradation, which may explain the latter observation (Hirano et al., 2001, 
Punga et al., 2006, Sundqvist et al., 2005, Sundqvist and Ericsson, 2003). 
These results suggest Raf/ ERK signalling specifically stabilises the construct; 
perhaps via activation of the transcriptional co-activator p300, which is an ERK 
target and is known to acetylate and stabilise the SREBPs (Giandomenico et 
al., 2003, Meissner et al., 2011, Wang et al., 2006). It may also reflect 
increased activity of the retroviral promoter. Reassuringly, strong induction of 
pERK was seen upon Tmx treatment of the NR cells expressing either construct 
(Figure 5.12 C & D), further demonstrating that cells continued to express the 
Tmx inducible Raf kinase construct.  
There was a progressive band shift of the ER.mSREBP1a protein over 
time in the presence of simultaneous Raf kinase activation, which may suggest 
post-translational modification of the protein (Figure 5.12 C). Both SREBP-1a 
and -2 can be targets for ERK dependent phosphorylation, which enhances 
their transcriptional activity and this may be responsible for the observed 
mobility shift of the ER.mSREBP1a protein (Kotzka et al., 2004, Kotzka et al., 
2000, Roth et al., 2000). Consistent with this hypothesis, no band shift was 
observed upon activation of the construct in the absence of a sustained Raf 
kinase signal (i.e. in the NS ER.mSREBP1a cells) (Figure 5.12 A). A similar 
band shift was not observed for ER.mSREBP2 upon simultaneous Raf kinase 
activation, however (Figure 5.12 D).  
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Figure 5.12 Expression of ER.mSREBP -1a and ER.mSREBP-2 in Normal 
Schwann (NS) and NSΔRafER (NR) cells
Cells were retrovirally transduced with ER.mSREBP -1a or ER.mSREBP-2 constructs. The 
ER.mSREBP expressing cell lines and the non-expressing controls were aphidicolin arrested 
before being treated with Tmx for times as indicated and cell lysates collected. Western blot 
analysis was performed against the ER domain of the constructs, using an anti-ERα antibody. 
Continued activity of the RafER construct in the NR cells was confirmed by western blot 
analysis against pERK1/2 (Thr202/Thr183).
A) NS.ERmSREBP1a cells and NS cell controls.
B) NS.ERmSREBP2 cells and NS cell controls.
C) NR.ERmSREBP1a cells and NR cell controls.
D) NR.ERmSREBP2 cells and NR cell controls.
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 The Western blot analyses demonstrated that at least some cells in the 
population express the SREBP fusion constructs. However, for an SREBP 
dependent change in cell volume to be observed by Coulter Counter analyses, 
a large proportion of the population must express the protein and therefore be 
subject to the induced change in cell volume. To determine the proportion of 
cells that expressed the SREBP fusion construct anti-ERα immunofluorescence 
analyses were performed, cells cultured in normal Schwann cell medium (3% 
FCS) were treated with Tmx or the control solvent ethanol (EtOH) and fixed and 
immunostained after 24 hours.  
ERα labelling was visible in cells expressing the constructs as intense 
nuclear staining after Tmx treatment (Figure 5.13 A i & B i). Although in the NR 
cells both the RafER and ER.mSREBP fusion proteins would have been 
detected by the antibody, intense nuclear staining after Tmx treatment was 
seen only in NR ER.mSREBP cells (Figure 5.13 B i). The proportion of ERα 
positive nuclei after Tmx treatment was quantified and taken to represent the 
proportion of ER.mSREBP expressing cells in each cell line. These analyses 
showed that ~60% of the NS ER.mSREBP-1a and NS ER.mSREBP-2 
populations (Figure 5.13 A ii), >85% of the NR ER.mSREBP1a and >60% of the 
NR ER.mSREBP2 populations (Figure 5.13 B ii) were positive for nuclear ERα.  
 To confirm the ERα staining in the NR ER.mSREBP cells, where there 
was the potential confounding effect of the simultaneous RafER expression, 
anti-SREBP-1 and anti-SREBP-2 immunofluorescence analyses were also 
performed. Strong nuclear staining was observed in both NR ER.mSREBP cell 
lines after Tmx treatment and labelling with the corresponding SREBP antibody, 
but not in NR cells lacking the construct (Figure 5.14). As for the anti-ERα 
immunofluorescence, over 50% of the NR ER.mSREBP-1a and -2 populations 
showed positive nuclear staining with their corresponding antibody (Figure 5.14 
A ii & B ii, respectively). These values should be sufficient for any SREBP 
dependent change in cell volume to be detected in Coulter Counter analyses of 
these populations. 
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Figure 5.13 Anti-ERα immunofluorescence demonstrates the proportion of 
cells expressing the ER.mSREBP-1a or -2 construct
NSΔRafER (NR) or normal Schwann (NS) cells that had been transduced with retroviral 
ER.mSREBP -1a or -2 constructs, as indicated, were treated +/-Tmx in 3%FCS for 24hrs before 
being processed for anti-ERα immunofluorescence to label the expressed ER.mSREBP 
constructs. 
A) Representative widefield microscopy images of labelled cells +/- Tmx i) Normal Schwann 
(NS) cells and ii) NSΔRafER (NR) cells.
B) Quantification of the proportion of cells positive for nuclear anti-ERα labelling, i) Normal 
Schwann (NS) cells and ii) NSΔRafER (NR) cells. Bar charts show mean +SEM of 3 
experiments. 
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Figure 5.14 Anti-SREBP immunofluorescence demonstrates the proportion of 
cells expressing the ER.mSREBP-1a or -2 construct
NSΔRafER (NR) cells that had/ not been transduced with retroviral ER.mSREBP -1a or -2 
constructs, as indicated, were treated +/-Tmx in 3%FCS for 24hrs before being processed for 
immunofluorescence to label the expressed ER.mSREBP constructs, as indicated. 
A) Anti-SREBP-1 immunofluorescence i) Representative widefield microscopy images of 
labelled cells and ii) Quantification of the proportion of NR ER.mSREBP1a cells positive for 
nuclear anti-SREBP1 labelling. Bar chart shows mean +SEM of 3 experiments.
B) Anti-SREBP-2 immunofluorescence i) Representative widefield microscopy images of 
labelled cells and ii) Quantification of the proportion of NR ER.mSREBP-2 cells positive for 
nuclear anti-SREBP1 labelling. Bar chart shows mean +SEM of 3 experiments.
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To confirm the constructs are active, the mRNA levels of the SREBP 
target genes FASN and HMGCoR were analysed by RT-qPCR after addition of 
Tmx to activate the constructs (Figure 5.15 & 5.16). These experiments 
reverted back to the standard cell culture protocol: cells were seeded and then 
cell-cycle arrested using aphidicolin in normal Schwann cell medium for 24 
hours before being transferred into Minimal Medium plus aphidicolin for 24 
hours. Cells were then treated with factors (IGF-1 and/ or Tmx) for 6 hours 
before total RNA was collected for analysis by RT-qPCR. Tmx treatment 
induced FASN mRNA expression in all 4 cell lines, indicating that the constructs 
are active (Figure 5.15 Tmx+/IGF-1- & EtOH+/IGF-1+). This induction was ~ 
equivalent to IGF-1 treatment. In 3 of the 4 cell lines SREBP activation also 
induced HMGCoR mRNA expression to a level ~equivalent to IGF-1 treatment 
(Figure 5.16). The reason HMGCoR mRNA expression was not increased 
compared to control in Tmx treated NS ER.mSREBP-1a cells is not clear- it 
may suggest that (in the absence of simultaneous Raf kinase activation) 
SREBP-1a does not act strongly on the HMGCoR promoter in Schwann cells 
(Figure 5.16 A i). Interestingly, there seemed to be an additive effect of 
combined IGF-1 treatment and SREBP activation on FASN and HMGCoR 
expression, in both the presence and absence of simultaneous Raf kinase 
activation (Figure 5.15 & 5.16, Tmx+/ IGF-1+). Quantifying the mRNA 
expression of FASN in normal Schwann cells +/- Tmx treatment and/ or IGF-1 
stimulation confirmed the increase in mRNA levels of SREBP target genes was 
not an artefact of Tmx treatment (Figure 5.17). 
 
 
 
 
 
 
 
 
Figure 5.15 Activation of ER.mSREBP-1a or -2 induces the mRNA expression of 
FASN, a key SREBP target gene
Aphidicolin arrested NS ER.mSREBP cells were treated as indicated for 6hrs before total RNA 
was extracted. mRNA levels were analysed by RT-qPCR and normalised to 
B2M as a loading control; FASN mRNA levels are expressed relative to EtOH+/IGF-1-. 
A) NS i) ER.mSREBP-1a cells and ii) ER.mSREBP-2 cells. 
B) NR i) ER.mSREBP-1a cells and ii) ER.mSREBP-2 cells.
Bar charts show mean +SEM of 3 experiments.
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Figure 5.16 Activation of ER.mSREBP-1a or -2 can induce the mRNA expression 
of HMGCoR, a key SREBP target gene
Aphidicolin arrested NS & NR ER.mSREBP cells were treated as indicated for 6hrs before total 
RNA was extracted. mRNA levels were analysed by RT-qPCR and normalised to B2M as a 
loading control; HMGCoR mRNA levels are expressed relative to EtOH+/IGF-1-. 
A) NS i) ER.mSREBP-1a cells and ii) ER.mSREBP-2 cells.
B) NR i) ER.mSREBP-1a cells and ii) ER.mSREBP-2 cells.
Bar charts show mean +SEM of 3 experiments.
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Figure 5.17 Tmx does not induce the mRNA expression of FASN, a key 
SREBP target gene 
Aphidicolin arrested NS cells were treated as indicated for 6hrs before total RNA was 
extracted. FASN mRNA levels were analysed by RT-qPCR and normalised to 
B2M as a loading control; mRNA levels are normalised to EtOH+/IGF-1-. Bar charts show 
mean +SEM of 3 experiments. 
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 Having demonstrated that the SREBP fusion proteins are expressed and 
can activate target gene expression, the effect of inducing SREBP activation on 
cell volume addition was assayed. NS ER.mSREBP and NR ER.mSREBP were 
treated according to the standard protocol, i.e. factors (Tmx and/ or IGF-1) were 
added to cells that were cell cycle arrested and in defined conditions (Minimal 
Medium). Cell volume was quantified by Coulter Counter analysis after 24 
hours. Activation of SREBP-1a (Figure 5.18 A) or SREBP-2 (Figure 5.18 B) 
alone was not sufficient to drive addition of cell volume (Tmx+/IGF-1-) and did 
not synergise with IGF-1 to drive further addition of cell volume than the 
addition of IGF-1 alone (Tmx+/IGF-1+). Similarly, combined activation of Raf 
kinase and SREBP-1a (Figure 5.19 A) or SREBP-2 (Figure 5.19 B) was not 
sufficient to drive addition of cell volume (Tmx+/IGF-1-) and also did not 
synergise with IGF-1 to drive further addition of cell volume than the addition of 
IGF-1 alone (Tmx+/IGF-1+).  
 In conclusion, although IGF-1 dependent addition of cell volume and the 
maintenance of cell volume in the presence or absence of Raf kinase activation 
is dependent on SREBP-2 and HMGCoR (Section 5.2), activation of SREBP-1a 
or SREBP-2 does not seem to be sufficient to drive addition of cell volume- 
alone or in combination with Raf kinase activation- and does not synergise with 
IGF-1 to enhance IGF-1 dependent addition of cell volume. This suggests other 
factors also limit cell volume addition. 
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Figure 5.18 Activation of SREBP-1a or -2 has no effect on Schwann cell 
volume 
Aphidicolin arrested NS ER.mSREBP -1a or -2 cells were treated as indicated before cell 
volume was quantified using a Coulter Counter. Bar charts show mean cell volume +SEM.
A) NS ER.mSREBP1a cells.
B) NS ER.mSREBP2 cells.
Bar charts show mean +SEM of 3 experiments. Repeated Measures One-Way ANOVA 
A) and B) p<0.001. Select post hoc Tukey’s as indicated on the graphs.
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Figure 5.19 Activation of Raf kinase and SREBP-1a or -2 has no effect on 
Schwann cell volume 
Aphidicolin arrested NR ER.mSREBP -1a or -2 cells were treated as indicated before cell 
volume was quantified using a Coulter Counter. Bar charts show mean cell volume +SEM.
A) NR ER.mSREBP1a cells.
B) NR ER.mSREBP2 cells.
Bar charts show mean +SEM of 3 experiments. Repeated Measures One-Way ANOVA 
A) and B)  p<0.001. Select post hoc Tukey’s as indicated on the graphs.
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5.4 Addition of Fatty Acids and Cholesterol to the Cell Culture Medium (in 
a Chemically Defined Supplement) Does not Drive Cell Volume Addition 
 In the presence of growth factors, cells in vivo and in vitro will 
preferentially take up extracellular lipids to provide the substrates for new lipid 
synthesis, rather than undergo de novo lipogenesis (Goldstein and Brown, 
1977, Bailey et al., 1972). De novo lipogenesis is metabolically expensive and 
preferential use of extracellular lipids is likely to preserve cell resources. 
Although there are essentially no exogenous lipids in the defined cell culture 
medium used in these studies, trace fatty acids will be bound to the bovine 
serum albumin (BSA) used to make the Minimal Medium supplement. This is 
because albumin is a fatty acid carrier protein in vivo and therefore, unless it 
has been delipidated, fatty acids can remain bound to albumin purified from 
animal sera. To determine whether these trace fatty acids have a significant 
effect on Schwann cell volume, the volume of cells cultured in Minimal Medium 
made with delipidated or standard BSA were compared by Coulter Counter 
analysis. As shown in Figure 5.20, the volume of control or IGF-1 treated 
Schwann cells was equivalent in Minimal Medium made using either type of 
BSA, demonstrating that BSA-bound fatty acids have no significant effect on 
Schwann cell volume in these conditions.  
Although the results in the preceding section demonstrate that activating 
SREBP-1a or SREBP-2 (which would be predicted to induce de novo 
lipogenesis) is not sufficient to drive addition of cell volume, it was interesting to 
determine whether providing cells with exogenous lipid is sufficient to increase 
Schwann cell volume- in the presence or absence of Raf kinase activation or 
IGF-1 stimulation. Exogenous lipids were added in the form of a commercially 
available chemically defined lipid concentrate (Gibco) consisting of fatty acids 
and cholesterol in an aqueous mix with surfactants to solubilise the lipids and 
facilitate their uptake by the cell. A chemically defined lipid mixture was used 
because lipids purified from biological sources, such as serum, are potentially 
likely to contain traces of extracellular factors that could independently regulate 
cell volume. The final concentration of fatty acids in the cell culture medium 
after the supplement was added was ~equivalent to medium containing around 
0.7% foetal calf serum (FCS) and the concentration of cholesterol was 
~equivalent to that in 1.4% FCS, although it is not clear whether such a 
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comparison of concentrations is biologically relevant, because lipids in serum 
are found in different forms (bound to albumin for the fatty acids, or in 
lipoproteins for the cholesterol) to the way they are in this supplement (free) 
(Spector et al., 1980). The lipid concentrate was added in the defined (Minimal) 
medium 30 minutes prior to the addition of IGF-1 or Tmx and cell volume was 
quantified using the Coulter Counter after 24 hours. As can be seen in Figure 
5.21 A, addition of the lipid supplement did not drive addition of cell volume in 
the control (EtOH+/IGF-1-) or Raf kinase activated (Tmx+/IGF-1-) conditions 
and had no effect on cell volume addition downstream of IGF-1.  
 Although the lipid supplement contains surfactants to optimise lipid entry 
into the cell, it may be that the supplement had no effect on cell volume 
because the cells could not take up and utilise the added lipids. As uptake of 
extracellular lipids represses de novo lipogenesis, the mRNA levels of FASN 
and HMGCoR were quantified by RT-qPCR 6 hours +/- the supplement, to 
indicate whether the cells were utilising the supplement’s lipids. The presence 
of exogenous lipids significantly reduced the mRNA expression of both FASN 
and HMGCoR downstream of IGF-1, suggesting the lipids were utilised by IGF-
1 treated cells (Figure 5.21 B). These results, together with the fact 
overexpression of the SREBPs did not affect Schwann cell volume (Section 
5.3), indicate that factors other than lipid availability also limit IGF-1 volume 
addition. 
FASN and HMGCoR expression was not reduced in control (EtOH+/IGF-
1-) or Raf kinase activated (Tmx+/IGF-1-) cells, which may suggest the 
supplement was not utilised by these cells. However, it could also be that, in the 
absence of a direct block to their transcription, FASN and HMGCoR expression 
is already at basal levels in these cells and therefore will not be reduced even if 
extracellular lipids are taken up and utilised.  
In conclusion, the addition of exogenous lipids in a chemically defined 
lipid concentrate (containing free fatty acids and cholesterol) is not sufficient to 
drive addition of Schwann cell volume in the presence or absence of Raf kinase 
activation or IGF-1 treatment, although the supplement does appear to be 
utilised in IGF-1 treated cells at least. It cannot be excluded that alternative 
lipids, higher concentrations of lipid and/ or lipids delivered in a more 
physiological manner, would increase cell volume.  
AFigure 5.20 IGF-1 drives an increase in cell volume independent of residual 
fatty acids on the bovine serum albumin (BSA) used in the cell culture medium
Aphidicolin arrested NSΔRafER cells were treated as indicated for 24hrs before cell volume 
was quantified using a Coulter Counter.
A) Representative frequency distribution of cell volumes in the measured populations (μmᶟ). 
B) Quantification of mean cell volume (μmᶟ). Bar chart shows mean + standard error of the 
mean (SEM) of 3 experiments, performed in duplicate per condition per experiment. Repeated 
Measures Two-Way ANOVA, Minimal Medium vs IGF-1 p<0.05.
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Figure 5.21 Supplementing the cell culture medium with a chemically defined 
mixture of fatty acids and cholesterol does not drive cell volume addition, 
although IGF-1 induced FASN and HMGCoR mRNA expression is inhibited
Aphidicolin arrested NSΔRafER cells were treated as indicated for: 
A) 24hrs before cell volume was quantified using a Coulter Counter. Bar chart shows 
quantification of mean cell volume (μmᶟ).
B) 8hrs before RNA was extracted and mRNA expression of SREBP target genes i) HMGCoR 
and ii) FASN was analysed by RT-qPCR. mRNA levels of target genes were normalised to B2M 
as a loading control. 
Bar charts show mean +SEM of A) 3 experiments performed in duplicate and B)i) 4 and ii) 5 
experiments. Repeated Measures Two-Way ANOVA  A) Growth Factor p<0.001 B) i) Lipid 
p<0.01, Interaction p<0.05 and ii) Lipid p<0.05. Post hoc Bonferroni as indicated on the graphs.
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5.5 Addition of Fatty Acids and Cholesterol to the Cell Culture Medium 
Does not Rescue Cell Volume Addition After SREBP-2 siRNA Knockdown 
or Chemical Inhibition of Sterol Synthesis 
Although the lipid supplement had no effect on Schwann cell volume in 
the experiments described above, because the FASN and HMGCoR mRNA 
expression data suggested the lipids were utilised in the IGF-1 treated cells at 
least, this suggested the lipid supplement might rescue the inhibition of cell 
volume if de novo lipogenesis is inhibited, i.e. as is predicted to occur after 
SREBP-2 silencing, or chemical inhibition of HMGCoR (Section 5.2, Figure 5.4 
& 5.8). Extracellular lipid supplementation can partially rescue the loss of 
myelination, i.e. the synthesis of extensive lipid membranes, caused by 
inhibiting SREBP dependent lipogenesis in vitro (Verheijen et al., 2009). To test 
this hypothesis, as in the previous assays, the lipid supplement was added 30 
minutes before the factors (IGF-1 or Tmx) to cells treated either with 
simvastastin (to inhibit sterol synthesis) or after siRNA knockdown of SREBP-2 
(all as described in Section 5.2 and Materials & Methods 2.1). As previously, 
cell volume was quantified using the Coulter Counter 24 hours after factor 
addition. The additional two inhibitors used to block de novo lipogenesis in 
Section 5.2 (cerulenin and C75) were not assayed because of the concern that 
the drugs may be having non-specific toxic effects (as described in Section 5.2).  
The addition of the lipid supplement did not rescue the inhibition of cell 
volume downstream of SREBP-2 silencing (Figure 5.22) or simvastatin 
treatment (Figure 5.23). As described in the preceding section, it was not clear 
whether the control and Raf kinase activated cells utilised the lipid supplement 
and this may be the reason for the lack of volume rescue in these experiments. 
Alternatively, the blocks to de novo lipogenesis (SREBP-2 silencing or 
simvastatin treatment) may reduce the cell’s lipid supply to a greater degree 
than can be rescued by the lipid supplement and this may be why cell volume 
was not rescued. It is also possible that there must be a basal flux through the 
SREBP/ de novo lipogenic pathway to sustain cell volume and/ or the lipid 
supplement does not contain the composition of lipids necessary to sustain cell 
volume. 
 
**
Figure 5.22 Supplementing the cell culture medium with a chemically defined 
mixture of fatty acids and cholesterol does not rescue the cell volume inhibition 
downstream of SREBP-2 knockdown (siRNA).
NSΔRafER cells were transfected with siRNAs as indicated in normal (3% FCS) Schwann cell 
medium for 18hrs then transferred into defined (no factor) conditions plus aphidicolin for 24hrs 
before lipid supplement and/ or factors (Tmx or IGF-1) were added as indicated for a further 
24hrs. Final cell volume was quantified using a Coulter Counter. Bar chart shows mean cell 
volume +SEM of 3 experiments. Repeated Measures Two-Way ANOVA, siRNA/Lipid effect 
p<0.001. Select post hoc Bonferroni as indicated on the graph.
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Figure 5.23 Supplementing the cell culture medium with a chemically defined 
mixture of fatty acids and cholesterol does not rescue the cell volume inhibition 
downstream of simvastatin.
Aphidicolin arrested NSΔRafER cells were treated +/- Simvastatin (5μM) and +/- lipid 
supplement, as indicated, for 24hrs before cell volume was quantified using a Coulter Counter. 
Bar chart shows mean +SEM of 3 experiments. Repeated Measures Two-Way ANOVA, 
Inhibitor/ Lipid effect p<0.001. Select post hoc Bonferroni as indicated on the graph.
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In conclusion, although the addition of chemically defined lipids (free fatty 
acids and cholesterol) suppressed mRNA expression of genes required for de 
novo lipogenesis in IGF-1 treated cells, it was not sufficient to rescue cell 
volume inhibition downstream of a likely block to de novo lipogenesis resulting 
from siRNA silencing of SREBP-2, or chemical inhibition of HMGCoR. 
 
5.6 Chapter 5: Summary 
The findings described in this chapter can be summarised as follows: 
• IGF-1, but not Raf kinase activation, activates the master transcription 
factor regulators of de novo lipogenesis, SREBP-1 and -2, to drive 
SREBP dependent transcription and de novo lipogenesis. This 
phenotype correlates with the IGF-1 specific increase in cell volume. 
• SREBP-2 and de novo sterol/ isoprenoid synthesis appear to be 
necessary for the addition and maintenance of cell volume. The role of 
SREBP-1 and de novo fatty acid synthesis requires further investigation.  
• However, expression of constitutively active SREBP-1a or SREBP-2 is 
not sufficient to drive addition of cell volume and does not cooperate with 
IGF-1 to increase IGF-1 driven addition of cell volume. 
• Similarly, addition of exogenous fatty acids and cholesterol in a 
chemically defined lipid supplement (Gibco) is not sufficient to drive 
addition of cell volume and does not cooperate with IGF-1 to increase 
IGF-1 driven addition of cell volume. 
• The addition of this lipid supplement is also not sufficient to rescue the 
inhibition of cell volume induced by silencing SREBP-2 or chemical 
inhibitors of fatty acid and sterol synthesis. 
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5.7 Chapter 5: Discussion 
5.7.1 SREBP-2 and De Novo Lipogenesis are Required for the Addition and 
Maintenance of Schwann Cell Volume 
 The work in this study shows that not only the addition, but also the 
maintenance of Schwann cell volume requires SREBP-2 and de novo 
lipogenesis, demonstrating that lipogenesis is critical to the regulation of cell 
volume. As the SREBP pathway is activated downstream of IGF-1 in the 
Schwann cell and is required for the IGF-1 dependent addition of cell volume, 
this suggests it has an active role in the addition of cell volume. However, 
although necessary, the findings of this study suggest that SREBP activation is 
not the only factor downstream of IGF-1 required for the addition of cell volume, 
because activating SREBP in the absence of IGF-1 is not sufficient to drive an 
increase in cell volume. 
A role for the SREBPs and de novo lipogenesis in the regulation of cell 
volume is consistent with the findings of other studies in vitro.  Combined 
silencing of SREBP-1 and -2 inhibited Akt driven cell volume addition in 
conditions with limited exogenous lipid in vitro (1% lipoprotein-deprived serum 
(LPDS)) (Porstmann et al., 2008). Moreover, at the highest siRNA 
concentrations where SREBP knockdown was most efficient, Porstmann et al 
found that the volume of control cells also seemed to be reduced, consistent 
with our findings. Silencing SREBP-1 also reduced the volume of senescent 
cells, where senescence was induced by stress (immortalised human 
hepatocytes) or replicative senescence (human diploid fibroblasts), in vitro (Kim 
et al., 2010). Moreover, lipogenesis is required for the rapid growth of a number 
of tumour cell models (Bauer et al., 2005, Brusselmans et al., 2005, 
Hatzivassiliou et al., 2005, Kim et al., 2010, Kuhajda et al., 2000, Menendez 
and Lupu, 2007, Porstmann et al., 2005, Porstmann et al., 2008). 
The role of the SREBPs in the regulation of cell volume and cell growth 
in vivo is not as clear. SREBPs appear to be expressed, at least at a low level, 
across a number of tissues in vivo (Shimomura et al., 1997b, de Preux et al., 
2007). However, it is not yet clear whether all tissues require a certain level of 
de novo lipogenesis, regulated by SREBP activity, or whether the SREBPs are 
expressed only to be retained inactive in the ER in case a shortage occurs in 
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the supply of exogenous lipid. In vivo, mice lacking SREBP-2, or all three 
isoforms, are embryonic lethal, precluding studies of the role of SREBPs in cell 
and tissue growth during later development (Horton et al., 2002, Mitchell et al., 
2001, Shimano et al., 1997b). At the time of lethality, however, the embryos 
appeared phenotypically normal suggesting that the SREBPs are not required 
for gross embryonic growth to this point, although the findings do not preclude 
changes in intracellular structure and composition. Between 15-45% of mice 
lacking SREBP-1 (SREBP-1a and -1c) survive and develop apparently 
normally, without reduced body size (Shimano et al., 1997b). However, SREBP-
2 is upregulated and this appears to compensate for the loss of SREBP-1. 
Therefore it cannot be excluded that SREBP-1 normally functions in cell growth 
during development. The proper development of particular tissues has been 
shown to require the SREBPs and de novo lipogenesis. SREBP and target 
gene expression peaks during Schwann cell myelination, which is when these 
cells are synthesising massive amounts of lipid membrane to produce the 
extensive myelin sheath and, perhaps unsurprisingly, formation of the myelin 
sheath has been shown to require SREBPs and de novo cholesterol 
biosynthesis (Chrast et al., 2011, de Preux et al., 2007, Leblanc et al., 2005, 
Verheijen et al., 2009). Loss of the SREBP escort protein, SCAP (the SREBP 
escort protein required for SREBP processing) in myelinating Schwann cells 
blocked SREBP and target gene expression and mice exhibited severe 
hypomyelination- the myelin that did form required extracellular lipids (Verheijen 
et al., 2009). Similarly, loss of squalene synthase, an enzyme required for 
cholesterol synthesis also resulted in hypomyelination (Chrast et al., 2011). 
Myelinating Schwann cells are a highly specialised cell type, with a dramatically 
exaggerated requirement for membrane, however consistent with a role for the 
SREBPs in cell growth during development, Porstmann et al showed that loss 
of dSREBP during development reduces cell and organ size in Drosophila 
(Porstmann et al., 2008). These examples demonstrate that the SREBPs and 
de novo lipogenesis have a physiologically role in the growth of at least certain 
cell types.  
It seems inevitable that the addition of cell volume during cell growth will 
require lipogenesis for the biogenesis of membranous organelles and the 
plasma membrane. It may initially seem less obvious why the maintenance of 
cell volume would also require lipogensis. However, even cells that are 
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maintaining a constant cell size must continually turnover of macromolecules 
and organelles in order to replace those that are worn out and damaged and 
this includes replacing damaged and degraded lipids and membranes. If the 
replacement of these lipids is blocked, for example because lipid synthesis is 
blocked, then damaged organelle membranes and the plasma membrane 
cannot be replaced and it does not seem unreasonable to assume they will 
shrink/ be lost and the cell will shrink and lose volume. So, it can be seen how 
SREBP and the de novo lipogenic pathway could be required for both the 
addition and maintenance of cell volume. 
In addition to the structural role outlined above, the product of HMGCoR 
activity (inhibited by the use of simvastatin, which reduced cell volume)- 
mevalonate- is also used for the synthesis of isoprenoids that post-
translationally modify proteins in a process called prenylation (Goldstein and 
Brown, 1990). Prenylation affects the localisation (membrane targeting) and 
function of a number of proteins, including signalling and structural proteins 
such as Ras and nuclear lamins, respectively (Schafer and Rine, 1992). It is 
possible that loss of prenylation upon loss of SREBP-2/ inhibition of HMGCoR 
may also contribute to the block to cell volume by causing the mislocalisation of 
signalling proteins required to regulate cellular processes required for cell 
volume regulation and/ or structural proteins required for cell volume addition.  
Further work is required to clarify the role of the SREBPs and de novo 
lipogenesis in the Schwann cell system used in this study. It is important to 
determine whether SREBP-1 is dispensable for the regulation of Schwann cell 
volume, perhaps because SREBP-2 is able to compensate, as can occur in 
vivo. If siRNA knockdown is not effectively silencing SREBP-1 then alternative 
strategies should be tested- perhaps stable inducible shRNAs, or dominant 
negative SREBP proteins. It will also be important to clarify the role of de novo 
fatty acid and sterol synthesis, which could be investigated using siRNAs 
targeting enzymes in each of these pathways, including FASN and HMGCoR. 
Finally, it is necessary to establish whether SREBP-2 silencing is blocking either 
fatty acid and/ or sterol synthesis; in other words, to determine whether de novo 
lipogenesis is the pathway downstream of SREBP-2 that is critical for the 
regulation of cell volume. In addition to de novo lipogenesis, the SREBPs also 
regulate other metabolic pathways- including the One Carbon Cycle (1CC) and 
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the Pentose Phosphate Pathway (PPP) (Duvel et al., 2010, Liang et al., 2002, 
Shimano et al., 1999, Walker et al., 2011). These pathways are linked to de 
novo lipogenesis- flux through the PPP produces NADPH that can be used for 
de novo lipogenesis, for example. However, they also participate in wider cell 
metabolism and it would be interesting to determine whether these pathways 
have a role in the regulation of Schwann cell volume downstream of SREBP 
signalling. 
The IGF-1 dependent addition of protein mass did not require the 
addition of cell volume, demonstrated by the finding that simvastatin inhibited 
IGF-1 driven addition of cell volume, but not protein mass. Thus, not only can 
IGF-1 drive an increase in volume in the absence of an increase in protein 
mass (as demonstrated in Chapter 3, using the MEK inhibitor), but can also 
drive an increase in protein mass in the absence of an increase in volume. This 
finding further emphasising that cell protein mass and volume can be separately 
and independently regulated. This suggests that, at least at the gross level, the 
coupled addition of protein and lipid is not required.  
As an aside: considering membrane biogenesis, it is noteworthy that Raf 
kinase activation did not significantly increase SREBP target gene mRNA 
expression or the incorporation of extracellular radiolabelled pyruvate into lipid. 
However, Raf kinase appears to drive a significant increase in the amount of 
two highly membranous organelles- the mitochondria and the endoplasmic 
reticulum (Chapter 3). It might have been predicted this would require an 
increase in the rate of de novo lipogenesis. The rate of de novo lipogenesis 
from lipogenic precursors other than extracellular pyruvate (e.g. glucose or 
glutamine) may be increased downstream of Raf kinase, which was not 
assayed in this study. If so, this may have been driven by altered post-
translational modification of lipogenic enzymes such as FASN and HMGCoR, 
rather than an increase in their transcription (Jin et al., 2010, Parker et al., 
1986). Alternatively, lipolysis may be reduced and/ or intracellular lipid stores 
(i.e. in lipid droplets) may be sufficient to fuel any membrane biogenesis. It is 
also possible that the amount of de novo lipogenesis required for the synthesis 
of these membranes represents a minor fraction of total de novo lipogenesis 
and so was not detected in this study. 
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5.7.2 Inducing SREBP Activity is not Sufficient to Drive Cell Volume Addition 
 Although the results of this study indicate that SREBP-2 is required for 
the addition and maintenance of Schwann cell volume, activation of either 
SREBP-1a or SREBP-2 was not sufficient to drive addition of cell volume in the 
presence or absence of Raf kinase activation and did not enhance cell volume 
addition downstream of IGF-1. This suggests that activation of the de novo 
lipogenic pathway does not appear to be sufficient to drive the addition of cell 
volume and therefore other factors also limit cell volume addition. In other 
systems in vitro and in vivo, the response to overexpressing active SREBPs is 
variable and depends on cell type and SREBP isoform (the latter highlighting 
that the different SREBP isoforms regulate different although overlapping 
subsets of genes) (Amemiya-Kudo et al., 2002, Horton et al., 2002, Horton et 
al., 2003a, Shimano et al., 1997a). This highlights that the cellular response 
depends on both the specific activity of the cell type in question, as well as the 
specific activity of the SREBP isoform introduced.  
For example, liver and adipose tissue- tissues that store and mobilise 
lipids in response to whole body nutrition- might be predicted to have 
hypertrophic responses to activation of the lipogenic pathway. However, even in 
these tissues the response to overexpressing mature SREBP depends of the 
SREBP isoform. Expression of mature SREBP-1a induces adipocyte 
hypertrophy, whereas expression of mature SREBP-1c inhibits adipocyte 
differentiation and fails to induce lipogenic gene expression (Horton et al., 
2003a, Sekiya et al., 2007, Shimomura et al., 1998). In the liver, overexpressing 
mature SERBP-1a or -1c induces hypertrophy, associated with excessive 
accumulation of triglycerides, whereas mature SREBP-2 does not, although 
hepatic cholesterol and triglyceride levels increase (Horton et al., 1998, Kotzka 
et al., 2012, Shimano et al., 1996, Shimano et al., 1997a). Interestingly, 
although the livers of the SREBP-1a transgenic mice are hypertrophic, they fail 
to regenerate after hepatectomy and this is associated with a cell cycle arrest, 
highlighting how blocking proliferation can limit tissue growth (Nakakuki et al., 
2007). It is worthwhile to note that, in each of the above examples, SREBP 
expression was altered constitutively and throughout development. Therefore 
the phenotypes may reflect longer term, compensatory and/ or indirect effects 
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of altering the de novo lipogenic pathway, rather than immediate effects, as 
would have been observed with the inducible system used in this study.  
Interestingly, activating drosophila SREBP (mdSREBP) in the Drosophila 
wing disc during development inhibits wing growth (Porstmann et al., 2008). In 
mammalian cells, high levels of SREBP-1a can induce G1 cell-cycle arrest in 
some conditions and Porstmann et al hypothesise this is the cause of the 
growth arrest in the Drosophila wing (Inoue et al., 2005, Nakakuki et al., 2007, 
Porstmann et al., 2008). Although cell-cycle arrest does not necessarily inhibit 
cell growth, it will limit tissue growth and patterning. This is because there will 
be an upper limit to the size an individual cell can grow to. Therefore, where 
cell-cycle arrest limits the number of cells in a tissue, so this limits the maximum 
size to which the tissue can grow. This finding highlights that, in vivo, tissue 
growth is more complex than simple cell growth and suggests that there may be 
pleiotropic effects of changes in gene expression and activity, i.e. in this case, 
SREBP activity. 
From a mechanistic perspective and in the context of this Schwann cell 
study: it is possible that SREBP activation and the resulting increase in 
lipogenic target gene expression did not drive cell volume addition because de 
novo lipogenesis was not induced (which was not investigated, although the 
mRNA expression of genes rate limiting for de novo fatty acid and sterol 
synthesis, FASN and HMGCoR respectively, increased). This could occur if, for 
example, negative regulators of the process were also activated- for example 
the protein kinase AMPK, which is activated in conditions of low cell energy 
(energetic stress).  Active AMPK supresses most anabolic processes within the 
cell, in order to conserve energy (Hardie, 2011). This includes de novo fatty 
acid and sterol synthesis- AMPK phosphorylates and inhibits HMGCoR, ACC 
(Acetyl-CoA carboxylase) and SREBP-1 (Carling et al., 1987, Li et al., 2011, 
Sato et al., 1993). As demonstrated in Chapter 4, cells in the absence of growth 
factors/ growth factor activated signalling (IGF-1/ Raf kinase activation) are 
autophagic and slowly lose volume- likely because they cannot utilise sufficient 
extracellular nutrients. Therefore it is tempting to speculate whether, in this 
condition at least, activating the SREBPs and, initially, de novo lipogenesis 
induces energetic stress, AMPK activation and inhibition of further de novo 
lipogenesis. An important next step in these studies will be to determine if there 
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is sustained de novo lipogenesis after activation of the SREBP constructs, by 
assaying the incorporation of radiolabelled precursors into lipid.  
Alternatively, if sustained de novo lipogenesis is induced after SREBP 
activation, this demonstrates that simply driving lipogenesis is insufficient to 
drive cell volume addition. This could be consistent with the finding that the 
addition of a chemically defined exogenous lipid supplement had no effect of 
Schwann cell volume. Why might driving lipogenesis be insufficient to induce 
volume addition? One possibility is that the ability to utilise the synthesised 
lipids may be limiting. In other words, additional pathways are needed to direct 
the use of the synthesised lipids into structures/ functions that increase cell 
volume. Organelle biogenesis is metabolically expensive, requiring the 
coordinated synthesis of many protein and lipid species, and is therefore 
carefully regulated according to need. Therefore it would perhaps not be 
surprising that, in the absence of appropriate biogenic stimuli, such as specific 
growth factors, cells do not self-assemble the lipid into functional membranous 
organelles that might be required for volume addition. Linked to this, it would be 
interesting to quantify lipid droplet and peroxisome number following SREBP 
activation, as both have roles in cell lipid metabolism and correlate with the 
induction of the SREBP pathway and cell volume downstream of IGF-1 
(Chapter 3). In addition to the ability to utilise lipids, other factors/ signals may 
also be required to add cell volume. For example, as cells add volume during 
cell growth the cell cortex (actin cytoskeleton) must expand. The actin 
cytoskeleton is carefully controlled to control cell shape and size and therefore it 
seems likely that signals to add volume might specifically regulate the 
remodelling of this structure. Other functions of cytoskeletal structures may also 
be required for cell volume addition. For example, trafficking along microtubules 
may be required to transport vesicles containing plasma membrane to the cell 
surface for plasma membrane expansion, or to transport substrates between 
organelles for their growth and functioning. 
It was striking to note that even in IGF-1 treated cells that are already 
adding volume, inducing exogenous SREBP activation did not augment volume 
addition. Although the IGF-1 concentration used is saturating for growth 
downstream of this factor, IGF-1 treated cells are not at the physiological limit of 
Schwann cell volume as more potent growth factors (including serum) can 
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induce larger increases in cell volume. Therefore even in this condition, other 
factors must limit cell volume addition. In this regard, it is interesting that IGF-1 
treatment causes an increase in the number and total volume of lipid droplets 
per cell, compared to control and Raf kinase activated cells. A major role of this 
organelle is as a storage site for excess lipids, which might suggest IGF-1 alone 
drives lipogenesis in excess of any required for IGF-1 dependent volume 
addition.  
5.7.3 Other Factors can Limit Cell Volume  
 The results presented in this Chapter, indicate that factors other than the 
SREBPs and, potentially, lipogenesis are required to add cell volume. As 
discussed, this may include the ability to utilise synthesised lipids, or the size of 
the actin cytoskeleton. Another factor that has the potential to limit increases in 
cell volume is the addition of cell water. Approximately 70% of the weight of the 
cell is water and water can move rapidly into and out of the cell. Given that this 
movement is carefully regulated to prevent inappropriate changes in cell 
volume, this may be one additional factor that limits cell volume addition. It 
seems inevitable that increases during cell growth must be accompanied by, 
and at least partially the result of, water uptake. However, whilst much attention 
has been paid to how water movement is regulated to maintain a constant cell 
volume, there has been a distinct lack of attention to the role of water uptake 
during mammalian cell growth.  
 Water uptake during cell growth may occur simply as an indirect passive 
‘by-product’ of other aspects of cell growth. It has been proposed that cells 
regulate water movement to maintain a constant cell volume by sensing 
deviations in plasma membrane tension from a set point (Lang, 2007, Lang et 
al., 1998). Changes in cell volume, result in changes in tension on the plasma 
membrane. The tension-mediated hypothesis states that changes in plasma 
membrane tension are sensed by the cell, which then induces the appropriate 
change in the direction of net water transport into/ out of the cell to reverse the 
change in cell volume. If the plasma membrane expands during cell growth, this 
could reduce plasma membrane tension and induce water uptake to restore 
membrane tension- resulting in an increase in cell volume. As an aside: as 
discussed at the end of Chapter 4, it has also been proposed that plasma 
membrane size is controlled by plasma membrane tension. If membrane 
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tension drives plasma membrane expansion during cell growth then cell volume 
must increase before the plasma membrane expands. Therefore, clearly, the 
tension hypothesis is mutually exclusive for water uptake and plasma 
membrane expansion. It remains to be determined which process, if either, 
tension regulates. 
 An alternative mechanism is that growth factors might actively regulate 
cell surface water channels (Aquaporins) and actively increase intracellular 
osmolarity to drive water uptake (Burg, 2000, Burg and Ferraris, 2008, King et 
al., 2004, Lang, 2007, Lang et al., 1998, Verkman, 2011). Intracellular 
osmolarity is controlled by regulating the uptake and secretion of inorganic ions 
and organic osmolytes (e.g. myo-inositol, sorbitol, amino acids and betaine), as 
well as the synthesis and degradation of the latter (Burg and Ferraris, 2008, 
Lang et al., 1998). High intracellular ion concentrations are toxic because they 
can disrupt the structure and function of molecules including proteins and DNA, 
therefore if growth stimuli drive an increase in intracellular osmolarity to drive 
water uptake it might be most likely that this is through driving the accumulation 
of organic osmolytes (Lang et al., 1998). In this regard, it would be very 
interesting to investigate whether growth factor signalling activates the 
transcription factor NFAT5 (Also known as TonEBP/ OREBP) during cell 
growth. NFAT5 drives expression of Aquaporin2 and organic osmolyte 
transporters and synthetic enzymes and PI3K has been shown to activate 
NFAT5 in response to hypoxia, high intracellular sodium chloride levels and 
DNA damage (Burg and Ferraris, 2008, Hasler et al., 2006, Irarrazabal et al., 
2006, Villanueva et al., 2012). 
 Intriguingly, mice deficient in the adipose specific Aquaporin- 7 (AQP7) 
develop adipocyte hypertrophy and obesity (Hara-Chikuma et al., 2005, Hibuse 
et al., 2005). However AQP7 is an aquaglyceroporin that also transports small, 
uncharged solutes such as glycerol and it transpires that inhibiting glycerol 
export out of adipocytes is sufficient to drive hypertrophy and therefore explain 
the phenotype. It must be noted, however, that a role for water transport was 
not investigated in the study. 
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5.7.4 Conclusion 
 This study demonstrates that SREBP-2 and the de novo lipogenic 
pathway is required not only for the IGF-1 dependent addition of Schwann cell 
volume, but also to maintain the volume of control and Raf kinase activated 
cells. Lipids are critical structural components of cell membranes, therefore it 
seems inevitable that the requirement for cellular lipids is, at least in part, 
because they are required both to maintain and to drive the expansion of 
organelle membranes and the plasma membrane. However, given that inducing 
SREBP activity is not sufficient to increase cell volume, this highlights that 
additional factors must also be required. These may include the ability to utilise 
synthesised lipids, e.g. assemble them into functional organelle membranes, or 
it may be a factor largely independent of cellular lipids, such as the regulation of 
cell water uptake. In order to fully understand how cell volume is regulated 
during cell growth, it is absolutely necessary to understand the additional 
mechanisms that can limit cell volume. 
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Chapter 6: Final Discussion 
The findings presented in this thesis both demonstrate the complexity of 
cell growth and cell size regulation and highlight that our understanding of how 
these processes are regulated remains, for the most part, poor. This study has 
shown that cell mass and volume can be separately and independently 
regulated. Although the ability to uncouple mass and volume- and, linked to 
this, differentially regulate organelle content downstream of distinct biogenic 
stimuli- can help generate the diversity in cell size, morphology and organelle 
content observed in vivo, it presents a complex regulatory challenge. Multiple 
layers of cell regulatory control will be necessary so that cell protein, lipid and 
organelle biogenesis can be separately and independently regulated and these 
control mechanisms remain poorly understood. The complexity of regulating cell 
biogenesis is further highlighted by the finding in this study that the plasma 
membrane, despite maintaining a constant barrier between the cytosol and 
extracellular environment, is incredibly dynamic and is internalised between 2-4 
times per hour. This finding was particularly remarkable because the rapid rate 
of turnover is maintained in starved cells. These cells are maintaining a 
constant plasma membrane size, which means these cells must be able to 
control the rapid processes of plasma membrane removal and delivery with 
enough precision to maintain a constant membrane area. This demonstrates 
that all cells, whether they are growing or not, maintain active and tight control 
of the rapid turnover of cell material.  
Technological advances have made high throughput confocal 
microscopy image based screens feasible and this is an attractive approach to 
begin to address these questions, as such screens have the potential to yield a 
wealth of unbiased and informative data. Using a primary growth factor 
receptive cell such as the Schwann cell it should be possible to perform siRNA 
screens to identify genes that regulate the addition of cell mass and/ or volume 
downstream of growth factors such as serum and IGF-1. Protein mass could be 
quantified from the fluorescence intensity per cell after Succinimidyl Ester 
labelling, as used in these studies, and cell volume from image stacks through 
the depth of labelled cells. If organelles were also labelled, e.g. by 
immunofluorescence, organelle size could be correlated with effects on cell 
mass/ volume, which could then be followed up with functional investigations. 
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As this type of screen, although powerful, provides only snapshots of the 
outputs of biogenesis, alternative techniques must be used in parallel to 
understand the dynamic regulation of cell macromolecules and organelles by 
biogenic stimuli- i.e. the control of their synthesis and degradation. It is only by 
understanding both the biosynthetic processes driving cell growth and the 
resulting outputs of biogenesis, i.e. the ‘snapshot’, that we will have a complete 
understanding of the mechanisms that control cell growth. 
The proper control of cell growth is absolutely necessary for the correct 
development and maintenance of all organisms. Understanding how organelle 
biogenesis links to driving mass and/ or volume addition will both advance our 
understanding of how cell growth is normally regulated, as well as the ways in 
which it can become deregulated leading to disease. This will be critical to 
understanding how deregulated cell growth could be targeted therapeutically in 
a range of diseases, such as cancer, cardiac hypertrophy and autistic spectrum 
disorders, in which it plays a fundamental role.  
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